"Rank","Title","Status","Study Results","Conditions","Interventions","Sponsor/Collaborators","Other IDs","First Posted","Locations","URL"
1,"[18F] F-GLN by PET/CT in Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Drug: Fluoroglutamine [18F]F-GLN","University of Pennsylvania","831804","March 5, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03863457"
2,"Individualizing Surveillance Mammography for Older Breast Cancer Survivors","Active, not recruiting","No Results Available","Breast Cancer","Other: Communication Tool","Dana-Farber Cancer Institute|National Institutes of Health (NIH)|National Cancer Institute (NCI)","19-001|1R21CA227615-01A1","March 7, 2019","Dana-Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT03865654"
3,"Elevate! : An Elderly Breast Cancer Cohort Study","Recruiting","No Results Available","Breast Cancer","Behavioral: Observational cohort","Dana-Farber Cancer Institute|Susan G. Komen Breast Cancer Foundation","18-634","January 28, 2019","Brigham and Women Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT03818087"
4,"Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot","Active, not recruiting","No Results Available","Breast Cancer","Other: YES portal","Dana-Farber Cancer Institute|Breast Cancer Research Foundation","18-641","April 12, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT03913936"
5,"Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.","Recruiting","No Results Available","Breast Cancer","Drug: Talazoparib|Drug: Sacituzumab Govitecan","Massachusetts General Hospital|Pfizer","19-239","July 31, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04039230"
6,"Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial","Recruiting","No Results Available","Breast Cancer","Drug: Talazoparib","Massachusetts General Hospital|Pfizer","19-188","June 19, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT03990896"
7,"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)","Recruiting","No Results Available","Breast Cancer","Drug: Ipatasertib|Drug: Fulvestrant|Drug: Aromatase Inhibitor|Drug: Palbociclib","Massachusetts General Hospital|Genentech, Inc.","19-086","May 22, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT03959891"
8,"Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: oral vinorelbine|Drug: Capecitabine|Drug: Gemcitabine 1250 mg/m²|Drug: Gemcitabine 1000 mg/m²|Drug: Paclitaxel|Drug: Docetaxel","Pierre Fabre Medicament","PM0259CA223B0","March 22, 2019",,"https://ClinicalTrials.gov/show/NCT03887130"
9,"Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening","Recruiting","No Results Available","Breast Cancer","Other: Breast Cancer-Related Lymphedema Measurements","Massachusetts General Hospital|Heinz Family Foundation","18-181","March 5, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT03861975"
10,"Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: 5-FU, epirubicin and cyclophosphamide","Henrik Lindman|Scandinavian Breast Group|Danish Breast Cancer Cooperative Group|Swedish Cancer Society|Swedish Cancer Foundation|Pharmacia Pharmaceutical Company|Swedish Breast Cancer Group|Uppsala University Hospital","SBG 2000-1","March 25, 2019",,"https://ClinicalTrials.gov/show/NCT03888677"
11,"Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )","Recruiting","No Results Available","Breast Cancer|HER2-positive Breast Cancer","Drug: Pyrotinib Plus Fulvestrant","Chinese Academy of Medical Sciences","NCC2018M-042","July 25, 2019","Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04033172"
12,"Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Endostar|Drug: Chemotherapy","Zhejiang Cancer Hospital","ZJCHBC008","April 8, 2019","Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China","https://ClinicalTrials.gov/show/NCT03907098"
13,"Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer Stage","Drug: nab-paclitaxel","Jilin University","CSPC-KAL-BC-12","May 22, 2019","the first hospital of Jilin University, Jilin, Changchun, China","https://ClinicalTrials.gov/show/NCT03959397"
14,"COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer|Estrogen Receptor-positive Breast Cancer","Drug: Aspirin|Drug: Tamoxifen Pill|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel","University of Virginia","21822","July 30, 2019","University of Virginia, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT04038489"
15,"Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation","Not yet recruiting","No Results Available","Breast Cancer Female","Drug: Pembrolizumab + Tamoxifen","Mediclinic Middle East","AN.MCME.CR.12|MISP # 55574","March 18, 2019","Mediclinic City Hospital, Dubai, United Arab Emirates","https://ClinicalTrials.gov/show/NCT03879174"
16,"99mTc-ADAPT6-based HER2 Imaging in Breast Cancer","Enrolling by invitation","No Results Available","Breast Cancer","Diagnostic Test: SPECT","Tomsk National Research Medical Center of the Russian Academy of Sciences|KTH Royal Institute of Technology|Uppsala University","99mTc-ADAPT6|99mTc-ADAPT6 [TomskNRMC]","June 19, 2019","TomskNRMC, Tomsk, Russian Federation","https://ClinicalTrials.gov/show/NCT03991260"
17,"Hypofractionated Radiation Therapy in Patients With Breast Cancer","Enrolling by invitation","No Results Available","Breast Cancer","Radiation: Hypofractionated Radiation therapy","Postgraduate Institute of Medical Education and Research","HRBC","August 30, 2019","Dr Budhi Singh Yadav, Chandigarh, N/A = Not Applicable, India","https://ClinicalTrials.gov/show/NCT04075058"
18,"The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Tamoxifen Citrate|Drug: Letrozole|Drug: Exemestane|Diagnostic Test: Blueprint|Diagnostic Test: Mammaprint","Johns Hopkins University|Agendia","IRB00130428","October 16, 2019","Johns Hopkins Bayview Hospital, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT04129216"
19,"Study on Bisphosphonates Targeting Triple-negative Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Zoledronic Acid","Shengjing Hospital|Liaoning Tumor Hospital & Institute|The People's Hospital of Liaoning Province","Shengjing_001","August 5, 2019","Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|Liaoning Tumor Hospital & Institute, Shenyang, Liaoning, China|People's Hospital of Liaoning Province, Shenyang, Liaoning, China","https://ClinicalTrials.gov/show/NCT04045522"
20,"Breast Cancer and Its Relationship With the Microbiota","Recruiting","No Results Available","Breast Cancer",,"Universidad de Granada","PI-0538-2017","March 21, 2019","Unit of Mammary Pathology, General Surgery Service, University Hospital Campus de la Salud, Granada, Spain","https://ClinicalTrials.gov/show/NCT03885648"
21,"Randomized Clinical Trial Comparing Rehabilitation Robotic Versus Conventional After Breast Cancer Surgery","Not yet recruiting","No Results Available","Breast Cancer","Device: Armeo®Power|Other: Conventional rehabilitation protocol","Barretos Cancer Hospital","1563/2018","July 18, 2019",,"https://ClinicalTrials.gov/show/NCT04025112"
22,"Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Apatinib|Drug: Paclitaxel|Drug: Cisplatin|Procedure: Surgery","RenJi Hospital","SHPD005","June 11, 2019","Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT03982485"
23,"Survival Benefits of Statins in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer Female","Drug: statins|Behavioral: Dietary intervention group (control group)","Peking Union Medical College Hospital","PUMCH-SBSBC","June 3, 2019","PUMCH, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03971019"
24,"Personalised Risk-based Breast Cancer Prevention and Screening","Recruiting","No Results Available","Breast Cancer","Diagnostic Test: Mammography outside official screening","Tartu University Hospital|University of Tartu|North Estonia Medical Centre","estPerMed 1, Breast","June 18, 2019","Tartu University Hospital, Tartu, Tartumaa, Estonia|The North Estonia Medical Centre, Tallinn, Estonia","https://ClinicalTrials.gov/show/NCT03989258"
25,"Clinical Application of CTC in Operable Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Procedure: Neoadjuvant chemotherapy before surgery|Procedure: Surgery followed by adjuvant chemotherapy","Peking Union Medical College Hospital","PUMCH-BREAST-CTC","February 15, 2019","Peking Union Medical College Hospital, Beijing, China","https://ClinicalTrials.gov/show/NCT03842176"
26,"TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer","Not yet recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Docetaxel|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Pembrolizumab|Drug: IL-12 gene therapy|Drug: L-NMMA","The Methodist Hospital System|Merck Sharp & Dohme Corp.","Merck IIS","September 19, 2019","Houston Methodist Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04095689"
27,"Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: nab-paclitaxel regimen1|Drug: nab-paclitaxel regimen2","Beijing Cancer Hospital","CABC012","December 10, 2019","BeijingCancerH, Haidian, Beijing, China","https://ClinicalTrials.gov/show/NCT04192331"
28,"NOSTRA-Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer","Recruiting","No Results Available","Breast Cancer","Procedure: Tumour bed core biopsy","University of Birmingham|Roche Pharma AG|Cancer Research UK","RG_16-108","October 8, 2019","Bailsdon Hospital, Basildon, Essex, United Kingdom|Blackpool Teaching Hospitals NHS Trust, Blackpool, United Kingdom|University Hospital of Llandough, Cardiff, United Kingdom|Cheltenham General hospital, Cheltenham, United Kingdom|Borders General Hospital, Melrose, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Peterborough City Hospital, Peterborough, United Kingdom|Poole Hospital, Poole, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Arrowe Park Hospital, Upton, United Kingdom","https://ClinicalTrials.gov/show/NCT04118192"
29,"Comorbidities and Health Care Services Utilisation Among Long-term Breast Cancer Survivors","Completed","No Results Available","Breast Cancer",,"Parc de Salut Mar|Fondo de Investigacion Sanitaria|European Regional Development Fund|Red de Investigación en Servicios de Salud y Enfermedades Crónicas (REDISSEC)","SURBCAN Project","February 20, 2019",,"https://ClinicalTrials.gov/show/NCT03846999"
30,"Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer","Recruiting","No Results Available","Breast Cancer","Biological: ISB 1302 250 ng/kg|Biological: ISB 1302 325 ng/kg|Biological: ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|Biological: ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|Biological: ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|Biological: ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22|Biological: ISB 1302 escalating doses,1200 ng/kg D15,22|Biological: ISB 1302 at the MTD and/or RP2D dose","Ichnos Sciences SA|Glenmark Pharmaceuticals S.A.","ISB 1302-103|IND Number 131316","June 12, 2019","Glenmark Investigational Site 1, Gilbert, Arizona, United States|Glenmark Investigational Site 5, Los Angeles, California, United States|Glenmark Investigational Site 4, Louisville, Kentucky, United States|Glenmark Investigational Site 2, Detroit, Michigan, United States|Glenmark Investigational Site 3, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03983395"
31,"Breast Cancer Liquid Biopsy Stratification","Active, not recruiting","No Results Available","Breast Cancer","Genetic: Nucleosome positioning","Medical University of Graz","BreastctDNA01","June 20, 2019","Medical University of Graz, Graz, Austria","https://ClinicalTrials.gov/show/NCT03992521"
32,"Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.","Not yet recruiting","No Results Available","Breast Cancer",,"Tianjin Medical University Cancer Institute and Hospital|CSPC Ouyi Pharmaceutical Co., Ltd.","CSPC-DMS-BC-13","June 12, 2019","Jin Zhang, Tianjin, China","https://ClinicalTrials.gov/show/NCT03983096"
33,"Evaluating and Following Breast Cancer Patients in a Better Way","Not yet recruiting","No Results Available","Breast Cancer Female","Diagnostic Test: clinical and physical assessment","Centro Hospitalar Lisboa Ocidental|University of Lisbon","CentroHLO_EFBreastCancer","February 5, 2019",,"https://ClinicalTrials.gov/show/NCT03831308"
34,"Evaluation of the Effect of Metformin on Metastatic Breast Cancer as Adjuvant Treatment","Completed","No Results Available","Metastatic Breast Cancer","Drug: Metformin plus chemotherapy|Drug: Chemotherapy","Hager salah el din|Beni-Suef University","FWA00015574/6-01-2019/korany","October 29, 2019","Beni-Seuf University Hospital, Banī Suwayf, Egypt","https://ClinicalTrials.gov/show/NCT04143282"
35,"Effect of a Program of Physical Activity and Nutritional Therapeutic Education in Breast Cancer Patients","Completed","No Results Available","Breast Cancer","Other: APAD","Institut du Cancer de Montpellier - Val d'Aurelle","VA2012/39|2012-A01648-35","September 30, 2019","Institut Sainte Catherine, Avignon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|CH Ambroise Paré, Marseille, France|ICM, Montpellier, France|CH Montélimar, Montélimar, France|Centre Eugène Marquis, Rennes, France|Institut de Cancéologie de l'Ouest, Saint-Herblain, France","https://ClinicalTrials.gov/show/NCT04109326"
36,"A Window-of-opportunity Study of Pelareorep in Early Breast Cancer","Recruiting","No Results Available","Breast Cancer","Biological: Pelareorep|Drug: Letrozole|Drug: Atezolizumab|Drug: Trastuzumab","Oncolytics Biotech|SOLTI Breast Cancer Research Group","REO 027","September 25, 2019","ICO Badalona, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Quirón Dexeus, Barcelona, Spain|Hospital Moisés Broggi, Esplugues De Llobregat, Spain|Hospital Fuenlabrada, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Puerta de Hierro de Majadahonda, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Clínico Universitario Virgen Arrixaca, Murcia, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Consorci Sanitari de Terrassa, Terrassa, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT04102618"
37,"Long-term Effects of Breast Cancer Treatment","Not yet recruiting","No Results Available","Breast Cancer",,"Cancer Registry of Norway|Extrastiftelsen","2019/FO244363","March 15, 2019",,"https://ClinicalTrials.gov/show/NCT03877029"
38,"Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer","Recruiting","No Results Available","Triple Negative Breast Cancer",,"European Institute of Oncology","IEO 0761/","April 19, 2019","Istituto Europeo di Oncologia, Milan, Italy","https://ClinicalTrials.gov/show/NCT03920488"
39,"Automated Method for Breast Cancer Detection","Recruiting","No Results Available","Breast Cancer Diagnosis","Procedure: Fine needle aspiration|Device: Cancer Detection cartridge","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","J18138|IRB00172441","March 5, 2019","Johns Hopkins Hospital Outpatient Center, Baltimore, Maryland, United States|Johns Hopkins Medical Imaging at Green spring Station, Lutherville-Timonium, Maryland, United States","https://ClinicalTrials.gov/show/NCT03863522"
40,"Using Imaging Data and Genomic Data to Predict Metastasis of Breast Cancer After Treatment","Recruiting","No Results Available","Breast Cancer",,"Chinese University of Hong Kong|Department of Electronic and computer engineering, HKUST|Department of clinical oncology, CUHK|Department of Anatomical and Cellular Pathology,PWH|Department of Surgery, North District Hospital","2019.089","May 8, 2019","The Chinese University of Hong Kong, Prince of Wale Hospital, Hong Kong, Shatin, Hong Kong","https://ClinicalTrials.gov/show/NCT03941639"
41,"TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Talazoparib|Drug: Avelumab","Georgetown University|Pfizer","STUDY00000023","May 28, 2019","MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Levine Cancer Institute, Charlotte, North Carolina, United States","https://ClinicalTrials.gov/show/NCT03964532"
42,"Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk","Recruiting","No Results Available","Breast Cancer, Male",,"Spanish Breast Cancer Research Group","GEICAM/2016-04","January 11, 2019","Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain|Hospital Virgen de los Lirios, Alcoy, Alicante, Spain|Hospital Universitario San Agustín, Avilés, Asturias, Spain|Hospital General de Granollers, Granollers, Barcelona, Spain|Instituto Catalán de Oncología de L'Hospitalet, L'Hospitalet De Llobregat, Barcelona, Spain|Consorci Corporació Sànitari Parc Taulí, Sabadell, Barcelona, Spain|Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Basurto, Bilbao, Bizcaia, Spain|Consorcio Hospitalario Provincial de Castellón, Castellón De La Plana, Castellón, Spain|Hospital General La Mancha Centro, Alcázar De San Juan, Ciudad Real, Spain|Hospital Universitario Donostia, Donostia-San Sebastián, Guipúzcoa, Spain|Onkologikoa, Donostia-San Sebastián, Guipúzcoa, Spain|Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Universitario de Getafe, Getafe, Madrid, Spain|Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain|Hospital Universitario de Móstoles, Móstoles, Madrid, Spain|Hospital Universitario Quirónsalud Madrid, Pozuelo De Alarcón, Madrid, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain|Hospital de Tortosa Verge de la Cinta, Tortosa, Tarragona, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Dexeus-Grupo Quirónsalud-Instituto Oncológico Dr. Rosell, Barcelona, Spain|Hospital Universitari Vall D´Hebrón, Barcelona, Spain|IDOC Centre Médic, Barcelona, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Instituto Catalán de Oncología de Girona, Girona, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Juan Ramón Jiménez, Huelva, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas De Gran Canaria, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|GenesisCare Madrid Hospital La Milagrosa, Madrid, Spain|Hospital Central de la Defensa Gómez Ulla, Madrid, Spain|Hospital Quirón Madrid, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario La Zarzuela, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital Regional Universitario, Málaga, Spain|Hospital Universitari Son Espases, Palma De Mallorca, Spain|Hospital Universitario Nuestra Señora De Candelaria, Santa Cruz De Tenerife, Spain|Hospital de Sant Pau i Santa Tecla, Tarragona, Spain|Hospital Virgen de la Salud, Toledo, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Universitario Río Hortega, Valladolid, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Hospital Universitario de Araba, Vitoria-Gasteiz, Álava, Spain","https://ClinicalTrials.gov/show/NCT03800355"
43,"Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer","Recruiting","No Results Available","Early-stage Breast Cancer|HER2-positive Breast Cancer","Drug: Docetaxel|Drug: Carboplatin|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Atezolizumab|Drug: Trastuzumab emtansine","Renske Altena|Karolinska University Hospital","PREDIX II HER2|2018-004457-24","March 28, 2019","Sahlgrenska universitetssjukhuset, Göteborg, Sweden|Skånes universitetssjukhus, Malmö, Sweden|Karolinska universitetssjukhuset, Stockholm, Sweden|Länssjukhuset Sundsvall, Sundsvall, Sweden|Norrlands universitetssjukhus, Umeå, Sweden|Örebro universitetssjukhus, Örebro, Sweden","https://ClinicalTrials.gov/show/NCT03894007"
44,"Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer","Active, not recruiting","No Results Available","Metastatic Breast Cancer","Drug: Proxalutamide","Suzhou Kintor Pharmaceutical Inc,|Beijing Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|Sun Yat-sen University|Ruijin Hospital|The First Affiliated Hospital with Nanjing Medical University|Hebei Medical University Fourth Hospital|Hunan Cancer Hospital","GT0918-CN-2001","September 26, 2019","Beijing Cancer Hospital, Beijing, Beijing, China|Sun-Yat-sen University Cancer center, Guangzhou, Fujian, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Hunan Cancer Hospital, Changsha, Hunan, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China","https://ClinicalTrials.gov/show/NCT04103853"
45,"KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer","Not yet recruiting","No Results Available","HER2-positive Breast Cancer","Biological: KN035|Biological: Trastuzumab|Drug: Docetaxel","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","KN035-TH-HER2","July 26, 2019",,"https://ClinicalTrials.gov/show/NCT04034823"
46,"Clinical Trial of ARV-471 in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: ARV-471","Arvinas Inc","ARV-471-mBC-101","August 28, 2019","UCLA Medical Center, Santa Monica, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Moffitt Cancer Center, Tampa, Florida, United States|Sarah Cannon, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT04072952"
47,"Adjuvant Radiotherapy on Circulating Cells in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Other: blood samples collection","Clinica Luganese Moncucco|Curzio Rüegg, MD, Head of Department, University of Fribourg|Swiss National Science Foundation|Tsoutsou Pelagia MD, Head of Radation Therapy Department","CirculatingCellsBreast-RT","June 28, 2019","Clinica Luganese Moncucco, Lugano, Ticino, Switzerland","https://ClinicalTrials.gov/show/NCT04002570"
48,"Evaluating a Digital Tool for Supporting Breast Cancer Patients","Not yet recruiting","No Results Available","Breast Cancer","Device: OWise","Royal Marsden NHS Foundation Trust|Innovate UK","CCR4965","March 7, 2019",,"https://ClinicalTrials.gov/show/NCT03866655"
49,"TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer","Recruiting","No Results Available","HER2-Positive Breast Cancer","Drug: TCHP","Guangdong Provincial People's Hospital","2018396H","September 19, 2019","Guangdong General Hospital, Guangzhou, China","https://ClinicalTrials.gov/show/NCT04094896"
50,"Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer","Recruiting","No Results Available","Breast Cancer","Diagnostic Test: F-Var3 PET/CT|Other: Blood draw","Memorial Sloan Kettering Cancer Center","19-147","August 13, 2019","Memorial Sloan-Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04054986"
51,"Infrared Imaging for Breast Cancer Modeling","Active, not recruiting","No Results Available","Breast Cancer","Procedure: IR Imaging|Procedure: 3D Scanning","University of Texas Southwestern Medical Center","STU-2018-0370","June 18, 2019","Parkland Memorial Hospital, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT03990012"
52,"Clinico-biological Data Collection Study of Metastatic Breast Cancer","Recruiting","No Results Available","Breast Cancer","Procedure: Metastasis biopsy|Biological: Biomarkers blood, urine and microbiota samples|Behavioral: Patient Reported Outcome (PRO)","Institut Cancerologie de l'Ouest|European Regional Development Fund|AstraZeneca|Novartis|Eli Lilly and Company","ICO-N-2017-12","May 21, 2019","Institut de Cacerologie de l'ouest - site Paul Papin, Angers, France|Institut de cancerologie de l'Ouest, Saint Herblain, France","https://ClinicalTrials.gov/show/NCT03958136"
53,"Analysis of Circulating Epithelial Tumor Cells in Peripheral Blood in Patients With Primary Non-metastatic Breast Cancer Under Adjuvant Radiotherapy","Completed","No Results Available","Breast Cancer Female","Radiation: radiation","University of Jena","CETC 001","May 2, 2019","Department of Radiooncology, Jena, Jena, Germany","https://ClinicalTrials.gov/show/NCT03935802"
54,"Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer","Recruiting","No Results Available","Breast Cancer","Biological: nivolumab|Drug: paclitaxel (PTX)|Other: nivolumab placebo|Drug: anthracycline|Drug: cyclophosphamide|Drug: Endocrine Therapy|Procedure: Surgery","Bristol-Myers Squibb","CA209-7FL","September 30, 2019","Local Institution, Mobile, Alabama, United States|Local Institution, Concord, California, United States|Marin Cancer Care, Inc, Greenbrae, California, United States|Local Institution, Los Angeles, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Local Institution, Stamford, Connecticut, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Miami, Florida, United States|Sacred Heart Medical Group, Pensacola, Florida, United States|Local Institution, Tallahassee, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Northside Hospital,Inc.- Central Research Department, Atlanta, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Local Institution, Louisville, Kentucky, United States|Local Institution, Bethesda, Maryland, United States|Summit Medical Group, Florham Park, New Jersey, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States|Local Institution, Bronx, New York, United States|Local Institution, Durham, North Carolina, United States|Local Institution, Canton, Ohio, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Knoxville, Tennessee, United States|Local Institution, Fort Worth, Texas, United States|Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma Beunos Aires, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, La Plata, Buenos Aires, Argentina|Local Institution, Rosario, Santa FE, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, La Rioja, Argentina|Local Institution, Viedma, Argentina|Mater Hospital, North Sydney, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Calvary Central Districts Hospital, Elizabeth Vale, South Australia, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Ballarat Base Hospital, North Ballarat, Victoria, Australia|Local Institution, Graz, Austria|Local Institution, Innsbruck, Austria|Landeskrankenhaus-Universitaetsklinik fuer Innere Medizin III, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Charleroi, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Liege, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Santo Andre, SP, Brazil|Local Institution, Port Alegre, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Kingston, Ontario, Canada|Local Institution, Thunder Bay, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Local Institution, Santiago de Chile, Metropolitana, Chile|Local Institution, Vina del Mar, Valparaiso, Chile|Local Institution, La Serena, Chile|Local Institution, Santiago Region Metropolitana, Chile|Local Institution, Colombia, Bogota, Colombia|Local Institution, Bogota, Colombia|Local Institution, Cali, Colombia|Local Institution, Floridablanca, Colombia|Local Institution, Monteria, Colombia|Local Institution, Rionegro, Antioquia, Colombia|Local Institution, Chomutov, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Novy Jicin, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Aarhus N, Denmark|Local Institution, Herlev, Denmark|Local Institution, Kobenhavn O, Denmark|Local Institution, Naestved, Denmark|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Bayonne, France|Local Institution, Besancon, France|Local Institution, Brest, France|Local Institution, Clermont-ferrand, France|Local Institution, Le Mans Cedex 2, France|Local Institution, Lyon, France|Local Institution, Paris, France|Local Institution, Plerin, France|Local Institution, Saint Herblain Cedex, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Local Institution, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Homburg, Germany|Local Institution, Koeln, Germany|Local Institution, Leipzig, Germany|Evang. Krankenhaus Bethesda, Moenchengladbach, Germany|Local Institution, Muenchen, Germany|Local Institution, Rostock, Germany|Local Institution, Saarbruecken, Germany|MVZ-Onkologie Velbert GbR, Velbert, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Bergamo, Italy|Local Institution, Catania, Italy|Local Institution, Catanzaro, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Pavia, Italy|Local Institution, Prato, Italy|Local Institution, Roma, Italy|Local Institution, Rozzano MI, Italy|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, Colima, Mexico|Local Institution, Oaxaca, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Deventer, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Koszalin, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Opole, Poland|Local Institution, Warszawa, Poland|Local Institution, Lisboa, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Ponce Medical School Foundation, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Bucharest, Romania|Local Institution, Bucuresti, Romania|Local Institution, Craiova, Romania|Local Institution, Floresti, Romania|Local Institution, Suceava, Romania|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Elche (alicante), Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Sevilla, Spain|Local Institution, Basel, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Thun, Switzerland|Local Institution, Swansea, Glamorgan, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Coventry, United Kingdom|Local Institution, Headington, United Kingdom|Local Institution, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04109066"
55,"Fibrotic Focus in Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Diagnostic Test: Immunohistochemistry","Chinese University of Hong Kong","2019.444","October 10, 2019",,"https://ClinicalTrials.gov/show/NCT04122131"
56,"Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer","Recruiting","No Results Available","Breast Cancer",,"Libbs Farmacêutica LTDA","LB1802","March 27, 2019","William Hiromi Fuzita, Manaus, Amazonas, Brazil|Daniel Fontes Santos de Teive e Argolo, Salvador, Bahia, Brazil|Márcia Cristina Colares Régis de Araújo, Fortaleza, Ceará, Brazil|João Paulo Vendas Villalba, Campo Grande, MS, Brazil|Sâmio Pimentel Ferreira, Belém, Pará, Brazil|Cláudio Rocha, Teresina, Piaui, Brazil|Danielli de Almeida Matias, Natal, Rio Grande Do Norte, Brazil|Tomás Reinert, Caxias Do Sul, Rio Grande Do Sul, Brazil|Giuliano Santos Borges, Itajaí, Santa Catarina, Brazil|Raquel Pedro Moreira, Araraquara, São Paulo, Brazil|Daniel Grabarz, Mogi Das Cruzes, São Paulo, Brazil|Monique Celeste Tavares, São Paulo, Brazil","https://ClinicalTrials.gov/show/NCT03892655"
57,"A Pilot Study on Use of Liquid Crystal Contact Thermography to Detect Early Breast Cancer","Completed","No Results Available","Breast Cancer","Device: Thermographic breast examination performed by Braster device","Braster S.A.|Clinmark Clinical Research","ThermaAlg","March 1, 2019",,"https://ClinicalTrials.gov/show/NCT03858738"
58,"Tw HER2 Positive Breast Cancer Productivity & Utility Study","Recruiting","No Results Available","HER2-positive Breast Cancer",,"Taiwan Epidemiology Association","ML40952","July 8, 2019","National Taiwan University hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT04011085"
59,"FErtility, PrEgnancy, contRaceptIon After Breast Cancer in France","Recruiting","No Results Available","Breast Cancer Female","Other: questionnaires","Institut Curie|seintinelles network","IC 2016-07","March 21, 2019","Seintinelles.Com, Paris, France","https://ClinicalTrials.gov/show/NCT03884413"
60,"Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer|Triple Negative Breast Cancer","Drug: Durvalumab|Radiation: Radiation Therapy|Drug: Carboplatin|Drug: Paclitaxel","Cedars-Sinai Medical Center|AstraZeneca","IIT2018-17-McArthur-TCDRT","March 13, 2019","Cedars Sinai Medical Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT03872505"
61,"Exercise Study for Breast Cancer Survivors","Active, not recruiting","No Results Available","Breast Cancer","Other: Exercise Intervention","San Diego Biomedical Research Institute|California Breast Cancer Research Program|Arizona State University|Tri-City Wellness & Fitness Center|We Support U","25IB-0023","December 23, 2019","Aditi Narsale, San Diego, California, United States","https://ClinicalTrials.gov/show/NCT04208074"
62,"Coping Together After Breast Cancer","Recruiting","No Results Available","Breast Cancer","Behavioral: Intimacy Enhancement|Behavioral: Living Healthy Together","Fox Chase Cancer Center|National Cancer Institute (NCI)","18-1025|1R01CA222124-01A1","April 29, 2019","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03930797"
63,"Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Ribociclib|Drug: Letrozole or Anastrozole|Drug: Goserelin","Novartis Pharmaceuticals|Novartis","CLEE011A2207|2018-004234-15","January 30, 2019","Southern Cancer Center PC, Mobile, Alabama, United States|Marin Cancer Care, Greenbrae, California, United States|Rocky Mountain Cancer Centers Rocky Mountain Cancer Ctr (50), Greenwood Village, Colorado, United States|Mid Florida Hematology and Oncology Center, Orange City, Florida, United States|Florida Retina Institute, Orlando, Florida, United States|Emory University School of Medicine/Winship Cancer Institute, Atlanta, Georgia, United States|Weinberg Cancer Institute at Franklin Square Hospital, Baltimore, Maryland, United States|Nebraska Hematology-Oncology, P.C., Lincoln, Nebraska, United States|Nebraska Cancer Specialists Oncology Hematology West, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada CCC of Nevada Henderson (4), Las Vegas, Nevada, United States|New York Oncology Hematology SC, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai School of Medicine CFTY720D2306, New York, New York, United States|US Oncology Central Monitoring Regulatory - 2, Dallas, Texas, United States|Millennium Oncology, Houston, Texas, United States|Texas Oncology, McAllen, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Community Cancer Trials of Utah, Ogden, Utah, United States|Northwest Medical Specialties Dept.ofNW Med. Specialties, Tacoma, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, San Juan, Argentina|Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Ottignies, Belgium|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Natal, RN, Brazil|Novartis Investigative Site, Florianopolis, Santa Catarina, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Jose Do Rico Preto, Brazil|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Sudbury, Ontario, Canada|Novartis Investigative Site, Valledupar, Cesar, Colombia|Novartis Investigative Site, Ibague, Tolima, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Praha 5, Czechia|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Besancon Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Clermont-Ferrand, France|Novartis Investigative Site, Lyon Cedex 08, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Valenciennes, France|Novartis Investigative Site, Muenchen, Bavaria, Germany|Novartis Investigative Site, Langen, Hessen, Germany|Novartis Investigative Site, Velbert, Nordhein-Westfalen, Germany|Novartis Investigative Site, Luebeck, Schleswig-holstein, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Weiden, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Tamil Nadu, Chennai, India|Novartis Investigative Site, Raipur, Chhattisgarh, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Bhubaneshwar, Orissa, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Kaunas, LTU, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, Arequipa, Peru|Novartis Investigative Site, Lisbon, Portugal|Novartis Investigative Site, Loures, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Vaxjo, Sweden|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand","https://ClinicalTrials.gov/show/NCT03822468"
64,"Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery","Recruiting","No Results Available","Breast Cancer","Other: Rehabilitation after breast cancer surgery","Universidade Federal de Sao Carlos","154/2019","October 4, 2019","Catholic University of Maule, Talca, Maule, Chile","https://ClinicalTrials.gov/show/NCT04116281"
65,"Artificial Intelligence in Mammography-Based Breast Cancer Screening","Not yet recruiting","No Results Available","Breast Cancer","Other: mammography","Chinese University of Hong Kong|IBM China/Hong Kong Limited","NTEC-2019-0655","November 8, 2019",,"https://ClinicalTrials.gov/show/NCT04156880"
66,"Immunopheresis Alone or In Combination With Chemotherapy Versus Chemotherapy Alone in Advanced Triple Negative Breast Cancer (TNBC)","Recruiting","No Results Available","Advanced Triple Negative Breast Cancer","Other: Plasma soluble TNF receptor pulldown|Other: Plasma soluble TNF receptor pulldown + chemotherapy|Drug: Chemotherapy Drugs, Cancer","Immunicom Inc","CP7-005","July 2, 2019","Katedra i Klinika Onkologii UJ CM, Kraków, Małopolskie, Poland","https://ClinicalTrials.gov/show/NCT04004910"
67,"Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Paclitaxel|Drug: Carboplatin|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Docetaxel","Fudan University","2018-68-1461","December 10, 2019","Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04193059"
68,"Clinical Outcome and Toxicity Data in Patients With Advanced Breast Cancer Treated With CDK Inhibitors Combined With Endocrine Therapy","Active, not recruiting","No Results Available","Breast Cancer Stage IV",,"Hellenic Cooperative Oncology Group","CDK-HeCOG-2019","October 21, 2019","Hellenic Oncology Cooperative Group, Athens, Greece","https://ClinicalTrials.gov/show/NCT04133207"
69,"Exercise Programming in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Other: Exercise","University of Hawaii","Fukui-2019-1","July 9, 2019","University of Hawaii Cancer Center, Honolulu, Hawaii, United States","https://ClinicalTrials.gov/show/NCT04013568"
70,"Breast Cancer Screening With Diffusion-weighted MRI in Women at High Risk for Breast Cancer","Recruiting","No Results Available","Breast Cancer",,"Seoul National University Hospital","Breast Screening with DWI","February 11, 2019","Seoul National University Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT03835897"
71,"A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer","Recruiting","No Results Available","Breast Cancer","Drug: Ribociclib","Universitaire Ziekenhuizen Leuven","s61033","May 21, 2019","UZ Gasthuisberg Leuven, Leuven, Belgium","https://ClinicalTrials.gov/show/NCT03956654"
72,"SEINIOR:Quality of Life and Breast Cancer in Older Women","Recruiting","No Results Available","Breast Cancer","Other: Determination of acceptance and / or rejection of mastectomy","Central Hospital Saint Quentin","2016-A00286-45","July 31, 2019","Centre Hospitalier de Saint-Quentin;, Saint-Quentin, Aisne, France","https://ClinicalTrials.gov/show/NCT04038606"
73,"Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Drug: Eribulin","MedSIR","MedOPP167","January 7, 2019","Hospital de Jaén, Jaen, Jaén, Spain|Hospital Quiron Dexeus, Barcelona, Please Select, Spain|Institut Català d'Oncologia, Girona, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario La Paz,, Madrid, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Universitario Dr Peset, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT03795012"
74,"Implementing Patients´ Competence in Oral Breast Cancer Therapy","Not yet recruiting","No Results Available","Metastatic Breast Cancer|Advanced Breast Cancer",,"Onco Medical Consult GmbH|Eli Lilly and Company|Institut fuer Frauengesundheit","OMC2018/01","July 24, 2019",,"https://ClinicalTrials.gov/show/NCT04030728"
75,"Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey","Not yet recruiting","No Results Available","Breast Cancer","Other: Patient Reported Outcome Measure Survey result feedback","University of Colorado, Denver|National Cancer Institute (NCI)","18-2562.cc|P30CA046934","June 21, 2019",,"https://ClinicalTrials.gov/show/NCT03995082"
76,"ExclUsive endocRine Therapy Or Partial Breast Irradiation for Women Aged ≥70 Years With Luminal-A Early Stage Breast Cancer (EUROPA)","Not yet recruiting","No Results Available","Breast Cancer","Radiation: Partial Breast Irradiation (PBI)|Drug: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen","Azienda Ospedaliero-Universitaria Careggi|Institut Curie|University of Florence","EUROPA","October 22, 2019",,"https://ClinicalTrials.gov/show/NCT04134598"
77,"Converting HR+ Breast Cancer Into an Individualized Vaccine","Active, not recruiting","No Results Available","Breast Cancer","Radiation: Focal Radiation therapy|Drug: Pembrolizumab (200mg IV for 30 minutes|Biological: CDX-301","Weill Medical College of Cornell University","1808019498","January 15, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States|Icahn School of Medicine at Mt Sinai, New York, New York, United States|Weill Cornell Medicine New York Presbyterian Hospital, New York, New York, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Houston Methodist Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03804944"
78,"The Breast Cancer Personalized Nutrition Study","Recruiting","No Results Available","Breast Cancer","Other: Nutrition intervention","Sheba Medical Center|Weizmann Institute of Science","SMC- 5725-18","September 6, 2019","Sheba Medical Center, Ramat Gan, Israel","https://ClinicalTrials.gov/show/NCT04079270"
79,"Minimal Invasive Breast Cancer Excision Using Vacuum Assisted Biopsy Under Ultrasound Guidance","Not yet recruiting","No Results Available","Breast Cancer","Procedure: Vacuum assisted biopsy|Procedure: conventional lumpectomy","Radboud University|Canisius-Wilhelmina Hospital|The Netherlands Cancer Institute|St. Antonius Hospital","NL68820.091.19","September 27, 2019",,"https://ClinicalTrials.gov/show/NCT04107636"
80,"Advanced MR Techniques for Breast Cancer Detection","Not yet recruiting","No Results Available","Breast Cancer","Other: MRI sequence","Assistance Publique - Hôpitaux de Paris|GE Healthcare","K180603J|2018-A01647-48","July 16, 2019","Service de Radiologie Hôpital Tenon (APHP), Paris, France","https://ClinicalTrials.gov/show/NCT04020523"
81,"Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells","Recruiting","No Results Available","Breast Cancer|Triple Negative Breast Cancer","Biological: Neo-antigen pulsed Dendritic cell","Universidad Nacional de Colombia|Fundación Salud de los Andes","TEBICA002","September 26, 2019","Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia","https://ClinicalTrials.gov/show/NCT04105582"
82,"Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China","Not yet recruiting","No Results Available","Breast Cancer",,"Fengxi Su|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","BCSCO003","September 3, 2019","Guangdong Province Hospital of Chinese Medicine, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Cancer Hospital OF Shantou University Medical College, Shantou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China","https://ClinicalTrials.gov/show/NCT04076111"
83,"Effect of Preoperative Curcumin in Breast Cancer Patients","Active, not recruiting","No Results Available","Breast Cancer","Dietary Supplement: Curcumin|Other: Placebo","University of Malaya","20149-582","February 20, 2019","University of Malaya Medical Center, Kuala Lumpur, Malaysia","https://ClinicalTrials.gov/show/NCT03847623"
84,"Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Nivolumab","Seoul National University Hospital|Seoul National University Bundang Hospital|Korean Cancer Study Group (KCSG)|Eisai Korea Inc.|Ono pharmaceutical Korea","KCSG BR18-16","August 20, 2019","Seoul National University Bundang Hospital, Seongnam, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04061863"
85,"XIST Gene Deletion in Breast Cancer Therapy","Not yet recruiting","No Results Available","Breast Cancer","Genetic: XIST gene deletion","Assiut University","Xist","September 18, 2019",,"https://ClinicalTrials.gov/show/NCT04093609"
86,"Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Other: Specimen collection","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","OSU-09142","July 17, 2019","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT04022616"
87,"A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)","Not yet recruiting","No Results Available","Breast Cancer","Drug: Pembrolizumab|Drug: Trastuzumab Biosimilar ABP 980|Drug: Pertuzumab","West German Study Group|Merck Sharp & Dohme Corp.|Amgen|NanoString Technologies, Inc.","WSG-AM09|2018-003996-37","June 17, 2019",,"https://ClinicalTrials.gov/show/NCT03988036"
88,"Clinical Application of ctDNA in Early Screening of Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Diagnostic Test: Low depth whole genome sequencing","Peking Union Medical College Hospital","PUMCH-BREAST-ctDNA screening","June 4, 2019",,"https://ClinicalTrials.gov/show/NCT03973034"
89,"Follow-up in Early and Locally Advanced Breast Cancer Patients","Not yet recruiting","No Results Available","Breast Cancer",,"European Organisation for Research and Treatment of Cancer - EORTC","EORTC-1617-QLG-BCG","March 1, 2019",,"https://ClinicalTrials.gov/show/NCT03859453"
90,"Correlation Between TILs and Blood Cell Counts in Triple Negative Breast Cancer Patients","Recruiting","No Results Available","Triple Negative Breast Cancer","Other: Blood sample","Centre Jean Perrin","2019-A01861-56","August 28, 2019","Centre Jean PERRIN, Clermont-Ferrand, Please Select, France","https://ClinicalTrials.gov/show/NCT04068623"
91,"Corellation of Mutations, TILs and Age in Breast Cancer","Completed","No Results Available","Breast Cancer","Genetic: Corellation of Mutations, TILs and Age in Breast Cancer","Hellenic Cooperative Oncology Group","HE10/mut","July 26, 2019",,"https://ClinicalTrials.gov/show/NCT04033965"
92,"Nab-Paclitaxel in Patients With ER+/HER2- Recurrent Metastatic Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: nab-paclitaxel","Chinese Academy of Medical Sciences","NCC2129","December 11, 2019",,"https://ClinicalTrials.gov/show/NCT04194684"
93,"Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer","Recruiting","No Results Available","Breast Cancer","Radiation: intraoperative radiotherapy|Radiation: whole breast irradiation","University Hospital Heidelberg","COSMOPOLITAN","February 12, 2019","University Hospital of Heidelberg, Radiation Oncology, Heidelberg, Germany","https://ClinicalTrials.gov/show/NCT03838419"
94,"CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: CFI-400945|Drug: Durvalumab","Canadian Cancer Trials Group|AstraZeneca|University Health Network, Toronto","I239","November 25, 2019",,"https://ClinicalTrials.gov/show/NCT04176848"
95,"Assessment of Feasibility and Acceptability of Personalized Breast Cancer Screening","Recruiting","No Results Available","Breast Cancer","Other: Risk based screening","Institut de Recerca Biomèdica de Lleida|Institut Català de la Salut|Catalan Health Service","PI17/00834","January 2, 2019","Institut de Recerca Biomèdica de Lleida, Lleida, Spain","https://ClinicalTrials.gov/show/NCT03791008"
96,"Prospective Cohort Study of Breast Cancer Patients Treated With Radiotherapy","Enrolling by invitation","No Results Available","Breast Cancer",,"National Cancer Center, Korea","NCC2019-0142","December 18, 2019","National Cancer Center Korea, Goyang, Gyeonggi, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04203849"
97,"HER2 Expression Detection in Breast Cancer Using Anti-HER2 sdAb SPECT/CT","Recruiting","No Results Available","Breast Cancer","Drug: 99m-Tc-NM-02 Injection","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|NanoMab","2019/52","August 1, 2019","Shanghai General Hospital, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04040686"
98,"T-DM1 in HER2-positive Metastatic/Relapsed Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer",,"Samsung Medical Center|Health Insurance Review & Assessment Service|Korean Cancer Study Group","KCSG BR19-15","December 17, 2019","Korea University Ansan Hospital, Ansan, Korea, Republic of|Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of|Soonchunhyang University Bucheon Hospital, Bucheon, Korea, Republic of|The Catholic University of Korea, Bucheon ST. Mary's Hospital, Bucheon, Korea, Republic of|Dongnam Institute of Radiological&Medical Sciences, Busan, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Gyeongsang National University Changwon Hospital, Changwon, Korea, Republic of|Dankook University Hospital, Cheonan, Korea, Republic of|Soonchunhyang University Cheonan Hospital, Cheonan, Korea, Republic of|Chungbuk National University Hospital, Cheonju, Korea, Republic of|Daegu Fatima Hospital., Daegu, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Daegu Catholic University Medical Center, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|The Catholic University of Korea Daejeon ST. Mary's Hospital, Daejeon, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Daejeon Eulji Medical Center, Eulji University., Daejeon, Korea, Republic of|Konyang University Hospital, Daejeon, Korea, Republic of|Gangneung Asan Hospital, Gangneung, Korea, Republic of|National Cancer Center, Goyang, Korea, Republic of|Chosun University Hospital, Gwangju, Korea, Republic of|Dongguk University Gyeongju Hospital., Gyeongju, Korea, Republic of|Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of|Dongguk University Ilsan Hospital, Ilsan, Korea, Republic of|nje University Ilsan Paik Hospital, Ilsan, Korea, Republic of|The Catholic University of Korea Incheon ST. Mary's Hospital, Incheon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Gyeongsang National University Hospital, Jinju, Korea, Republic of|Cha University Bundang Medical Center, Seongnam, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Korea Cancer Hospital of Korea Institute of Radiological and Medical Sciences, Seoul, Korea, Republic of|Nowon Eulji Medical Center, Eulji University, Seoul, Korea, Republic of|Kangdong Kyung Hee University Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Soonchunhyang University Seoul Hospital, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul ST. Mary's Hospital, Seoul, Korea, Republic of|ChungAng University Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Yeouido ST. Mary's Hospital, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|The Catholic University of Korea ST. Mary's Hospital, Suwon, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|The Catholic University of Korea Uijeongbu ST. Mary's Hospital, Uijeongbu, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04202328"
99,"Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","Recruiting","No Results Available","Breast Cancer","Combination Product: Docetaxel / Capecitabine|Combination Product: Capecitabine / Vinorelbine|Combination Product: Paclitaxel / Gemcitabine|Drug: Ribociclib|Drug: Letrozole OR Anastrozole|Drug: Goserelin","Novartis Pharmaceuticals|Novartis","CLEE011A3201C","February 15, 2019","Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Giza, Egypt|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Johor Bahru, Johor, Malaysia|Novartis Investigative Site, Kota Kinabalu, Sabah, Malaysia|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Cankaya Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kecioren Ankara, Turkey|Novartis Investigative Site, Malatya, Turkey|Novartis Investigative Site, Hanoi, Vietnam","https://ClinicalTrials.gov/show/NCT03839823"
100,"MRI-guided Single Dose Preoperative Radiotherapy in Low-risk Breast Cancer","Recruiting","No Results Available","Breast Cancer","Radiation: MR-guided single dose preoperative PBI","UMC Utrecht","NL63209 041 18","March 5, 2019","UMC Utrecht, Utrecht, Netherlands","https://ClinicalTrials.gov/show/NCT03863301"
101,"A Study of ZN-c5 in Participants With Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: ZN-c5","Zeno Alpha Inc.","ZN-c5-002","November 25, 2019","Site 3, Tucson, Arizona, United States|Site 2, New York, New York, United States|Site 4, Nashville, Tennessee, United States|Site 1, Houston, Texas, United States|Site 5, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04176757"
102,"Implementing Exercise Into Clinical Practice in Breast Cancer Care","Not yet recruiting","No Results Available","Breast Cancer","Behavioral: Exercise|Behavioral: Self-Management|Behavioral: Booster Sessions","Hamilton Health Sciences Corporation","NEXT-BRCA","September 30, 2019",,"https://ClinicalTrials.gov/show/NCT04109274"
103,"Dose Escalation Study of Single Fraction Early Stage Breast Cancer","Recruiting","No Results Available","Breast Cancer","Radiation: Radiomics on MRI","University of Texas Southwestern Medical Center","2019-1183","July 31, 2019","University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT04040569"
104,"the New Geneswell BCT in Vitro Diagnosis of Breast Cancer Prognosis","Not yet recruiting","No Results Available","Breast Cancer","Diagnostic Test: Geneswell BCT","Second Affiliated Hospital, School of Medicine, Zhejiang University|The Affiliated Hospital of Hangzhou Normal University|Korea University","YANWQ002","November 27, 2019",,"https://ClinicalTrials.gov/show/NCT04179318"
105,"Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin","Recruiting","No Results Available","Breast Cancer","Drug: Vitamin D","Damanhour University","919PP17","November 18, 2019","Damnhour university, Beheira, Egypt","https://ClinicalTrials.gov/show/NCT04166253"
106,"A ""Window Trial"" on Curcumin for Invasive Breast Cancer Primary Tumors","Recruiting","No Results Available","Breast Cancer","Drug: Curcumin","Medical University of South Carolina","103089","June 10, 2019","Medical University of South Carolina, Charleston, South Carolina, United States","https://ClinicalTrials.gov/show/NCT03980509"
107,"Regularity of Lymphatic Drainage and Surgical Treatment of Breast Cancer","Recruiting","No Results Available","Breast Cancer","Procedure: Participants receive SLNB as well as non SLNs resection","Shandong University","HECT004","February 28, 2019","Qifeng Yang, Jinan, Shandong, China","https://ClinicalTrials.gov/show/NCT03857932"
108,"Diet Restriction and Exercise-induced Adaptations in Metastatic Breast Cancer","Enrolling by invitation","No Results Available","Breast Cancer","Behavioral: Short-term diet and exercise intervention","University of Alberta|Canadian Cancer Society Research Institute (CCSRI)|Canadian Institutes of Health Research (CIHR)","HREBA.CC-18-0657","January 7, 2019","University of Alberta, Edmonton, Alberta, Canada","https://ClinicalTrials.gov/show/NCT03795493"
109,"A First-in-human Clinical Evaluation of SN132D in Patients With Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: SN132D","Spago Nanomedical AB|CTC Clinical Trial Consultants AB|Antaros Medical AB","SN132D CSP final version 3.0|2018-002193-41","September 6, 2019","Gothia Forum Clinical Trial Center, Gothenburg, Sweden|CTC Clinical Trial Consultants AB, Uppsala, Sweden","https://ClinicalTrials.gov/show/NCT04080024"
110,"Evaluating New Surgical Technique in Management of Female Patients With Operable Multifocal Breast Cancer","Active, not recruiting","Has Results","Breast Cancer","Procedure: oncoplastic breast surgery","Alexandria University","multifocal breast cancer2018","April 3, 2019","Faculty of medicine ,Alexandria university, Alexandria, Egypt","https://ClinicalTrials.gov/show/NCT03900299"
111,"Reliability and Reproducibility of Bandaging in Breast Cancer","Recruiting","No Results Available","Breast Cancer","Other: functional compressive bandage","Elaine Caldeira de Oliveira Guirro|University of Sao Paulo","000001","September 3, 2019","University of São Paulo, Ribeirão Preto, São Paulo, Brazil","https://ClinicalTrials.gov/show/NCT04076033"
112,"Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT","Not yet recruiting","No Results Available","Breast Cancer","Drug: nab-Paclitaxel+carboplatin|Drug: Paclitaxel+carboplatin","Shengjing Hospital","Shengjing-LCG004","October 24, 2019","Shengjing Hospital of China Medical University, Shenyang, Liaoning, China","https://ClinicalTrials.gov/show/NCT04137653"
113,"Docosahexaenoic Acid (DHA) for Women With Breast Cancer in the Neoadjuvant Setting","Recruiting","No Results Available","Breast Cancer","Dietary Supplement: Docosahexaenoic acid (DHA)|Drug: Placebo oral capsule","AHS Cancer Control Alberta|Canadian Institutes of Health Research (CIHR)|University of Alberta","IIT-0005","February 5, 2019","Cross Cancer Institute, Edmonton, Alberta, Canada","https://ClinicalTrials.gov/show/NCT03831178"
114,"Individualized Exercise Oncology Program for Newly Diagnosed Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Other: Supervised, individualized exercise oncology program|Other: Current standard of care","Karen Wonders|Kettering Health Network","Maple Tree Exercise","September 27, 2019","Maple Tree Cancer Alliance, Dayton, Ohio, United States","https://ClinicalTrials.gov/show/NCT04106609"
115,"EMDR Psychotherapy for Anxious-depressive Symptoms in Breast Cancer Patient","Active, not recruiting","No Results Available","Breast Cancer Female","Behavioral: EMDR psychotherapy|Behavioral: support psychotherapy","Centre Hospitalier Régional Metz-Thionville|University of Lorraine|Central Hospital, Nancy, France","2018-A01128-47","April 2, 2019","CHR Metz-Thionville, Metz, France","https://ClinicalTrials.gov/show/NCT03898453"
116,"A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: Avelumab|Drug: Aspirin|Drug: Lansoprazole","The Christie NHS Foundation Trust|University of Manchester","CFT / sp123|2018-004121-80|017NovCC107","December 5, 2019",,"https://ClinicalTrials.gov/show/NCT04188119"
117,"Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer","Recruiting","No Results Available","Breast Cancer Recurrent","Drug: Palbociclib 125mg|Drug: Standard endocrine therapy","International Breast Cancer Study Group|Pfizer","IBCSG 59-19|2018-003553-19|BIG 18-02|WI239003","January 29, 2019","Medizinische Universität Graz (MUG), Graz, Austria|Medizinische Universität Innsbruck - Univ.-Klinik f. Frauenheilkunde, Innsbruck, Austria|Uniklinikum Salzburg, Salzburg, Austria|MUW - Universitätsklinik für Innere Medizin, Vienna, Austria|Institut Sainte Catherine, Avignon, France|Polyclinique Bordeaux Nord, Bordeaux, France|Centre Francois Baclesse, Caen, France|Cêntre Hospitaler de Cholet, Cholet, France|Centre Georges François Leclerc, Dijon, France|Centre Hospitalier Universitaire de Limoges, Limoges, France|ICM Val d'Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Institut Claudius Regaud, Toulouse, France|Gustave Roussy, Villejuif, France|National Institute of Oncology, Budapest, Hungary|Cro Irccs, Aviano, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|PO Antonio Perrino Brindisi, Brindisi, Italy|Istituto scientifico Romagnolo per lo studio e la cura, Meldola, Italy|Istituto Europeo di Oncologia, Milan, Italy|AOU Maggiore Della Carita, University of Eastern Piedmont, Novara, Italy|Azienda Ospedaliero-Universitaria di Parma, Parma, Italy|Istituti Clinici Scientifici Maugeri, Pavia, Italy|Ospedale S. Stefano, Prato, Italy|U.O. Oncologia, Ospedale Infermi, Rimini, Italy|Hospital Universitario de Canarias, San Cristóbal de La Laguna, Tenerife, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario Vall d´Hebrón, Barcelona, Spain|Instituto Catalan de Oncologia L´Hospitalet, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|HU Ramón y Cajal, Madrid, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Instituto Valenciano de Oncología (IVO), Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Kantonsspital Baden, Baden, Switzerland|Brustzentrum Basel Bethesda Spital, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Centre du Sein Fribourg, Fribourg, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Brust-Zentrum AG Zürich, Zürich, Switzerland","https://ClinicalTrials.gov/show/NCT03820830"
118,"Use of Quantitative Ultrasound to Guide Adaptive Chemotherapy Among Women With Breast Cancer","Recruiting","No Results Available","Breast Cancer","Other: Imaging","Sunnybrook Health Sciences Centre","308-2017","August 8, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04050228"
119,"Molecular Profiling in Young (<50 Years of Age) Patients With Metastatic Breast Cancer","Enrolling by invitation","No Results Available","Breast Cancer","Genetic: FoundationOne CDx","Seoul National University Hospital","SNUH_FMI","September 23, 2019","Seoul National University Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04098640"
120,"Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT","Active, not recruiting","No Results Available","Breast Cancer","Drug: Imaging Drug FluorThanatrace (FTT)","University of Pennsylvania","832165","February 19, 2019","University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03846167"
121,"Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO","Recruiting","No Results Available","Breast Cancer","Drug: Nivolumab|Drug: Doxorubicin","The Netherlands Cancer Institute|Bristol-Myers Squibb","M18BEL","January 24, 2019","NKI-AVL, Amsterdam, Netherlands","https://ClinicalTrials.gov/show/NCT03815890"
122,"Real-world Study for the Safety of Albumin-Bound Paclitaxel in Recurrent or Metastatic Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Other: Observational study","CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","CSPC-KAL-AE-01","August 19, 2019","Anhui Cancer Hospital, Hefei, Anhui, China|Anhui Provincial Hospital, Hefei, Anhui, China|Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Inner Mongolia Autonomous Region Cancer Hospital, Hohhot, Inner Mongolia Autonomous Region, China|Liaoning Cancer Hospital, Shenyang, Liaoning, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China","https://ClinicalTrials.gov/show/NCT04060290"
123,"Real World Study of Lapatinib Among Metastatic Breast Cancer Patients","Active, not recruiting","No Results Available","Breast Cancer",,"Fudan University","YOUNGBC-6","March 28, 2019","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT03894410"
124,"Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors","Completed","No Results Available","Breast Cancer","Behavioral: Joint Loosening Yoga","AshtaYoga, LLC|Columbia University|Swami Vivekananda Yoga Anusandhana Samsthana","AI Yoga Study on Facebook - 1","August 2, 2019","Columbia University Medical Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04042870"
125,"Enabling the Study of Metabolism in Breast Cancer Through Collection of Fresh-tissue Biopsies","Not yet recruiting","No Results Available","Breast Cancer","Procedure: Research Biopsy","University College, London","17/0765","March 19, 2019",,"https://ClinicalTrials.gov/show/NCT03880097"
126,"Sodium (23Na) MRI for Tumour Characterisation and Assessment of Therapy Response in Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Other: MRI|Other: PET/MRI","Cambridge University Hospitals NHS Foundation Trust","260281","May 7, 2019","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom","https://ClinicalTrials.gov/show/NCT03940092"
127,"Single Pre-Operative Radiation Therapy - With Delayed Surgery for Low Risk Breast Cancer","Recruiting","No Results Available","Breast Cancer","Radiation: Single Pre-Operative Radiation Therapy - with Delayed Surgery","Michael Yassa|Maisonneuve-Rosemont Hospital","SPORT-DS","April 17, 2019","Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT03917498"
128,"Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Palbociclib + Letrozole|Drug: Letrozole","Shengjing Hospital","Shengjing_002","August 7, 2019","Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China|Liaoning Provincial People's Hospital, Shenyang, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China","https://ClinicalTrials.gov/show/NCT04047758"
129,"Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: nab-paclitaxel followed by anthracycline and cyclophosphamide|Drug: Docetaxel followed by anthracycline and cyclophosphamide","Xijing Hospital","KY20192081-F-1","December 2, 2019","Xijing hospital, Xi'an, Shaanxi, China","https://ClinicalTrials.gov/show/NCT04182568"
130,"Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers","Not yet recruiting","No Results Available","Breast Cancer","Diagnostic Test: Intervention 1|Diagnostic Test: Intervention 2","British Columbia Cancer Agency|Genomic Health®, Inc.","H18-02581","January 2, 2019",,"https://ClinicalTrials.gov/show/NCT03790813"
131,"Evaluation of the Impact of a Pharmaceutical Interview on the Adherence to Hormonotherapy in Women With Breast Cancer","Recruiting","No Results Available","Breast Cancer","Other: interview","Centre Georges Francois Leclerc","HORMONOVILLE","October 29, 2019","Centre Georges Francois Leclerc, Dijon, France","https://ClinicalTrials.gov/show/NCT04142476"
132,"A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2-Breast Cancer That Has Spread","Recruiting","No Results Available","Breast Cancer","Drug: nivolumab|Drug: ipilimumab|Drug: nab-paclitaxel","Bristol-Myers Squibb","CA048-001","October 21, 2019","Local Institution, Los Angeles, California, United States|Local Institution, Newport Beach, California, United States|Local Institution, Sacramento, California, United States|Local Institution, San Francisco, California, United States|Local Institution, Aurora, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Chicago, Illinois, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Local Institution, New York, New York, United States|Local Institution, Uniondale, New York, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Dallas, Texas, United States|Local Institution, San Antonio, Texas, United States|Local Institution, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT04132817"
133,"Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Pyrotinib|Drug: Etoposide","Chinese Academy of Medical Sciences","LQ007","April 22, 2019","Cancer Hospital, ChineseAMS, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03923179"
134,"Simultaneous Integrated Boost With Volumetric Arc Radiotherapy in Patients With Breast Cancer","Recruiting","No Results Available","Breast Cancer","Radiation: Radiotherapy","Postgraduate Institute of Medical Education and Research","INT/IEC/2017/127","August 28, 2019","Dr Budhi Singh Yadav, Chandigarh, India","https://ClinicalTrials.gov/show/NCT04072718"
135,"Promoting Early Detection of Breast Cancer in Rural Rwanda: Impact of Community Health Worker and Nurse Training","Completed","No Results Available","Breast Cancer","Other: Experimental: Training, Phase 1|Other: Experimental: Training, Phase 2","Brigham and Women's Hospital|Breast Cancer Research Foundation|University of Pennsylvania|Partners in Health|Ministry of Health, Rwanda","2014P002688","April 18, 2019",,"https://ClinicalTrials.gov/show/NCT03919682"
136,"The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors","Active, not recruiting","No Results Available","Breast Cancer","Behavioral: Education|Behavioral: Values","University of Colorado, Boulder|National Cancer Institute (NCI)","18-0234","June 10, 2019","Rocky Mountain Cancer Centers, Greenwood Village, Colorado, United States","https://ClinicalTrials.gov/show/NCT03980093"
137,"Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe","Completed","No Results Available","Breast Cancer","Drug: Palbociclib","Fernando Moreno Antón|Hospital San Carlos, Madrid","PALBOCOMP","September 30, 2019","Fernando Moreno, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04109261"
138,"A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer","Recruiting","No Results Available","HR+ Metastatic Breast Cancer|Breast Cancer|Breast Cancer Metastatic","Drug: GMI-1359","GlycoMimetics Incorporated","GMI-1359-210","December 13, 2019","Duke University Medical Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04197999"
139,"Effects of Progressive Relaxation Training in Breast Cancer Survivors Receiving Aromatatase Inhibitor Therapy","Active, not recruiting","No Results Available","Breast Cancer","Other: Progressive relaxation exercises","Hacettepe University","PREBCA","November 15, 2019","Florence Nightingale Hospital, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04163692"
140,"Targeting PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: Enzalutamide","SOLTI Breast Cancer Research Group","ARIANNA (SOLTI-1502)|2019-002806-28","October 29, 2019","ICO Badalona, Badalona, Barcelona, Spain|Institut Català d'Oncologia Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitari Vall d' Hebrón, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Fundación de Alcorcón, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04142060"
141,"Is Lipid Mapping an Effective Early Detection Tool for Breast Cancer in High-risk Populations?","Recruiting","No Results Available","Breast Cancer","Procedure: Magnetic resonance imaging (MRI)","University of Aberdeen|NHS Grampian","2-025-19","May 14, 2019","Aberdeen Biomedical Imaging Centre, Aberdeen, Aberdeenshire, United Kingdom","https://ClinicalTrials.gov/show/NCT03949946"
142,"Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Durvalumab|Drug: Trastuzumab|Drug: Pertuzumab","Jenny C. Chang, MD|AstraZeneca|The Methodist Hospital System","Pro00020917","January 29, 2019","Houston Methodist Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03820141"
143,"Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study","Recruiting","No Results Available","Breast Cancer","Drug: PTC-Pz","Borstkanker Onderzoek Groep|Roche Pharma AG|BOOG Study Center","BOOG 2018-01","January 29, 2019","Noordwest Ziekenhuisgroep, Alkmaar, Netherlands|Ziekenhuisgroep Twente, Almelo, Netherlands|Meander Medisch Centrum, Amersfoort, Netherlands|Ziekenhuis Amstelland, Amstelveen, Netherlands|NKI-AVL, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|Gelre ziekenhuizen, Apeldoorn, Netherlands|Rijnstate, Arnhem, Netherlands|Rode Kruis Ziekenhuis, Beverwijk, Netherlands|Alexander Monro ziekenhuis, Bilthoven, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Groep, Delft, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Haaglanden MC, Den Haag, Netherlands|Haga Ziekenhuis, Den Haag, Netherlands|Deventer ziekenhuis, Deventer, Netherlands|van Weel Bethesda, Dirksland, Netherlands|Nij Smellinghe, Drachten, Netherlands|Ziekenhuisvoorziening Gelderse Vallei, Ede, Netherlands|Catharina ziekenhuis, Eindhoven, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Sint Annaziekenhuis, Geldrop, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Martini ziekenhuis, Groningen, Netherlands|Ziekenhuis St. Jansdal, Harderwijk, Netherlands|Tjongerschans, Heerenveen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Elkerliek ziekenhuis, Helmond, Netherlands|Tergooi, Hilversum, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|MUMC, Maastricht, Netherlands|Sint Antonius ziekenhuis, Nieuwegein, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Bernhoven, Oss, Netherlands|Stichting ziekenhuizen West-Friesland en Waterland, Purmerend, Netherlands|Erasmus MC, Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands|Franciscus Gasthuis en Vlietland, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands|Maasstadziekenhuis, Rotterdam, Netherlands|ZorgSaam, Terneuzen, Netherlands|Rivierenland Ziekenhuis, Tiel, Netherlands|Elisabeth TweeSteden ziekenhuis, Tilburg, Netherlands|Diakonessenhuis Utrecht, Utrecht, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|VieCurie Medisch Centrum voor Noord-Limburg, Venlo, Netherlands|SKB Ziekenhuis Winterswijk, Winterswijk, Netherlands|Zaans Medisch Centrum, Zaandam, Netherlands|Isala Klinieken, Zwolle, Netherlands","https://ClinicalTrials.gov/show/NCT03820063"
144,"Quality of Life and Sexuality of Patients Over 65 Years Undergoing Adjuvant Treatment for Breast Cancer","Recruiting","No Results Available","Breast Cancer","Other: self questionnaires","Centre Henri Becquerel","CHB18.04","May 10, 2019","CHU Amiens, Amiens, France|Centre François Baclesse, Caen, France|Centre Henri Becquerel, Rouen, France","https://ClinicalTrials.gov/show/NCT03946579"
145,"Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Breast Cancer","Recruiting","No Results Available","Breast Cancer",,"Peking Union Medical College Hospital","PUMCH-BC500","October 31, 2019","Peking Union Medical College Hospital, Beijing, China","https://ClinicalTrials.gov/show/NCT04145960"
146,"Application of Deep-learning and Ultrasound Elastography in Opportunistic Screening of Breast Cancer","Recruiting","No Results Available","Breast Cancer",,"Peking Union Medical College Hospital|Peking University Third Hospital|Beijing Hospital|Beijing Chao Yang Hospital|Beijing Zhongguancun Hospital|Peking University Aerospace Centre Hospital|Beijing Anzhen Community Health Service Center|First Hospital of Tsinghua University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|The First Affiliated Hospital of Zhengzhou University|Henan Provincial People's Hospital|Third Affiliated Hospital of Zhengzhou University|Xinxiang Central Hospital|Henan Cancer Hospital|First Hospital of China Medical University|Shengjing Hospital|Liaoning Cancer Hospital & Institute|West China Hospital|Sichuan Provincial People's Hospital|Yan'an Hospital of Kunming City|Xi'an Central Hospital|Ningxia Medical University|First Hospital of Shijiazhuang City|Chengde Central Hospital|Qinghai Province Cancer Hospital|Gansu Cancer Hospital|Shanghai Zhongshan Hospital|Ruijin Hospital|The Affiliated Hospital of Qingdao University|Qingdao Central Hospital|Shandong Jining No.1 People's Hospital|Linyi Tumour Hospital|The First Affiliated Hospital of Shanxi Medical University|The Second Affiliated Hospital of Harbin Medical University|Second Hospital of Jilin University|The Second Hospital of the West Coast New Area of Qingdao|Fudan University|Tongji Hospital|The First Affiliated Hospital with Nanjing Medical University|Peking University Shougang Hospital|Gansu Jiugang Hospital","S-detect 2019","February 22, 2019","Peking Union Medical College Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03851497"
147,"Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China","Recruiting","No Results Available","Breast Cancer","Other: detect gene mutations of ctDNA and ctRNA","Beijing Cancer Hospital|Predicine (Shanghai) Medical Technology Co., Ltd.","2017KT40","January 3, 2019","Beijing Cancer Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03792529"
148,"Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: Onapristone","SOLTI Breast Cancer Research Group","ONAWA (SOLTI-1802)|2019-001433-13","October 29, 2019","Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Sant Joan de Reus, Tarragona, Spain","https://ClinicalTrials.gov/show/NCT04142892"
149,"A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer","Withdrawn","No Results Available","Breast Cancer","Drug: Avelumab|Drug: Aspirin|Drug: Lansoprazole (Proton Pump Inhibitor)","The Christie NHS Foundation Trust|University of Manchester","CFT/sp123|2018-004121-80|16_DOG02_289|017NovCC1079","January 7, 2019",,"https://ClinicalTrials.gov/show/NCT03794596"
150,"Role of Adding Metformin to Neoadjuvant Chemotherapy in Patients With Breast Cancer (METNEO)","Recruiting","No Results Available","Breast Cancer Female","Drug: Metformin Hydrochloride 850 mg Tablets|Drug: AC-T chemotherapy regimen","Damanhour University|Alexandria University","919PP18","November 20, 2019","Damanhour University, Beheira, Egypt","https://ClinicalTrials.gov/show/NCT04170465"
151,"Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: Albumin-bound paclitaxel combined with carboplatin|Drug: Epirubicin combined with docetaxel","Shengjing Hospital","Shengjing-LCG005","October 23, 2019","Cancer Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China|The Second Hospital of Jilin University, Changchun, Jilin, China|Dalian Municipal Central Hospital, Dalian, Liaoning, China|Panjin Liaohe Oilfield Gem Flower Hospital, Panjin, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China|Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China","https://ClinicalTrials.gov/show/NCT04136782"
152,"Pyrotinib Combined With Capecitabine Metronomic Therapy in HER2-postitive Advanced Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Pyrotinib|Drug: capecitabine","Chinese Academy of Medical Sciences","LQ006","April 22, 2019","Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03923166"
153,"A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer","Diagnostic Test: Left Ventricular Ejection Fraction","Memorial Sloan Kettering Cancer Center","19-045","June 12, 2019","Memorial Sloan Kettering Cancer Center @ BaskingRidge (Consent and follow-up only), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (Consent and Follow up), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Consent and follow-up only), Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Commack (Consent and Follow up), Commack, New York, United States|Memoral Sloan Kettering Westchester (Consent and Follow-up), Harrison, New York, United States|Memorial Sloan - Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau (Consent and Follow-up), Rockville Centre, New York, United States","https://ClinicalTrials.gov/show/NCT03983382"
154,"Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: Pembrolizumab|Drug: Paclitaxel","Queen Mary University of London|Merck Sharp & Dohme Corp.|European Institute of Oncology","012342QM|2018-000188-10","February 15, 2019",,"https://ClinicalTrials.gov/show/NCT03841747"
155,"Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer","Recruiting","No Results Available","Breast Cancer","Biological: Talimogene laherparepvec|Drug: Atezolizumab","SOLTI Breast Cancer Research Group|Amgen|Roche Pharma AG","SOLTI-1503|2018-001300-10","January 14, 2019","Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Clínico universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT03802604"
156,"Use of Ultrasound Imaging and Spectroscopy as Early Indicators of Locally- Advanced Breast Cancer Response to Neoadjuvant Treatment","Recruiting","No Results Available","Breast Cancer",,"Sunnybrook Health Sciences Centre","301-2014","October 22, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04134780"
157,"A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America","Recruiting","No Results Available","Breast Cancer","Drug: Bevacizumab|Drug: Trastuzumab|Drug: Ado-trastuzumab emtamsine|Drug: Pertuzumab|Drug: Atezolizumab|Drug: Capecitabine","Hoffmann-La Roche|Latin American Cooperative Oncology Group","MO39485","November 8, 2019","Instituto Alexander Fleming, Buenos Aires, Argentina|Instituto Oncologico De Cordoba; Oncology, Cordoba, Argentina|Hospital Privado Centro Medico de Cordoba, Córdoba, Argentina|Hospital de Morón, Moron, Argentina|Instituto de Oncología de Rosario, Rosario, Argentina|Sanatorio de la Mujer, Rosario, Argentina|Crio - Centro Regional Integrado de Oncologia, Fortaleza, CE, Brazil|Hospital do Câncer de Londrina, Londrina, PR, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital Jardim Amália, Volta Redonda, RJ, Brazil|Inst. de Vita, Caxias do Sul, RS, Brazil|Hospital Moinhos de Vento, Porto Alegre, RS, Brazil|Centro de Pesquisa em Oncologia, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, Brazil|Instituto Brasileiro De Controle Do Câncer - IBCC; Laboratório De Patologia, São Paulo, SP, Brazil|Clinica Las Condes, Santiago, Chile|Instituto Nacional del Cancer, Santiago, Chile|Hospital Dr. Hernan Henriquez Aravena, Temuco, Chile|Organización Clínica Bonnadona Prevenir S.A.S, Barranquilla, Colombia|Inst. Nacional de Cancerologia; Clinica de Seno, Bogota, Colombia|Centro Medico Imbanaco, Cali, Colombia|Fundacion Cardiovascular de Colombia - Instituto del Corazón, Floridablanca, Colombia|Hospital San Juan de Dios, San Jose, Costa Rica|Hospital Hermanos Ameijeiras, La Habana, Cuba|Instituto de Oncologia Dr. Heriberto Pieter, Santo Domingo, Dominican Republic|Hospital Solca Quito; Oncologia, Quito, Ecuador|Consultorio Privado Dr. Muñoz, Quito, Ecuador|Grupo Angeles, Guatemala City, Guatemala|Hospital Zambrano Hellion TecSalud, Monterrey, Nuevo LEON, Mexico|Instituto Nacional de Cancerologia, Mexico City, Mexico|Centro Oncologico Estatal ISSEMYM, Toluca, Mexico|Instituto Regional de Enfermedades Neoplásicas del Sur; Centro de Inv. de Medicina Oncológica, Arequipa, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Internacional, Sede San Borja; Unidad de Investigacion de Clínica Internacional, Lima, Peru|Hospital Pereira Rossell; Oncology Department, Montevideo, Uruguay|Sanatorio CASMU; Oncología, Montevideo, Uruguay","https://ClinicalTrials.gov/show/NCT04158258"
158,"Management of Cognitive Difficulties After Cancer Treatments in Women Treated for Breast Cancer: Feasibility Study (Step 1 of the Cog-Stim Protocol)","Recruiting","No Results Available","Breast Cancer","Other: Cognitive stimulation sessions coupled with Adapted Physical Activity sessions.","Centre Francois Baclesse|National Cancer Institute, France|Ligue contre le cancer, France","2019-A02500-57","December 30, 2019","centre François Baclesse, Caen, France","https://ClinicalTrials.gov/show/NCT04213365"
159,"Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer","Recruiting","No Results Available","Breast Cancer","Radiation: Hypofractionated|Radiation: Conventional","Fudan University","FDRT-BC008","February 27, 2019","Suzhou Municipal hospital, Suzhou, Jiangsu, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Huangpu Branch, Shanghai ninth people's hospital, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT03856372"
160,"Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer","Other: Mathematical modeling to predict response to chemotherapy","New Mexico Cancer Care Alliance","INST 1411","June 12, 2019","University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States","https://ClinicalTrials.gov/show/NCT03983538"
161,"Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)","Completed","No Results Available","Breast Cancer","Drug: Paclitaxel|Drug: Carboplatin|Drug: Epirubicin|Drug: Cyclophosphamide|Drug: 5-fluorouracil|Drug: Docetaxel","Fudan University","PATTERN","July 24, 2019",,"https://ClinicalTrials.gov/show/NCT04031703"
162,"Breast Cancer Treatment Based on Organ-like Culture","Enrolling by invitation","No Results Available","Breast Cancer Organoids","Drug: Trastuzumab|Drug: Doxorubicin Hydrochloride|Drug: Epirubicin hydrochloride|Drug: Fluorouracil|Drug: Paclitaxel|Drug: Gemcitabine|Drug: Cisplatin|Drug: Recombinant Human Endostatin|Drug: Pirarubicin hydrochloride|Drug: Pyrrolidine|Drug: Ixabepilone|Drug: Tamoxifen citrate|Drug: Vinorelbine tartrate|Drug: Carboplatin|Drug: Methotrexate|Drug: Eribulin mesylate|Drug: Toremifene citrate|Drug: Anastrozole|Drug: Letrozole|Drug: Exemestane|Drug: Fulvestrant|Drug: Olaparib|Drug: Bevacizumab|Drug: Apatinib mesylate|Drug: Pattozumab|Drug: Capecitabine|Drug: Ear particles|Drug: Aidi Injection|Drug: Cyclophosphamide","Xijing Hospital","KY20182079-F-1","April 24, 2019","JingSu, Xi'an, Shaanxi, China","https://ClinicalTrials.gov/show/NCT03925233"
163,"KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: Hydrogen Peroxide","Institute of Cancer Research, United Kingdom|Kortuc Inc.","CCR5119|2019-001709-25","May 10, 2019",,"https://ClinicalTrials.gov/show/NCT03946202"
164,"Health-Related Quality of Life Coupled With Therapeutic Information on Compliance to Endocrine Therapy in Breast Cancer (COMPLIANCE)","Not yet recruiting","No Results Available","Breast Cancer","Other: Routine Assessment of HRQoL coupled with Therapeutic Information","Centre Georges Francois Leclerc","2019-A01323-54","November 25, 2019",,"https://ClinicalTrials.gov/show/NCT04176809"
165,"Phase 2 Window Study of SAR439859 Versus Letrozole in ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (AMEERA-4)","Recruiting","No Results Available","Breast Cancer","Drug: SAR439859|Drug: letrozole","Sanofi","ACT16106|2019-002015-26|U1111-1228-9473","December 9, 2019","Investigational Site Number 8400003, Bakersfield, California, United States|Investigational Site Number 8400001, Columbus, Georgia, United States|Investigational Site Number 8400004, Chicago, Illinois, United States|Investigational Site Number 8400018, Fort Wayne, Indiana, United States|Investigational Site Number 8400005, Lincoln, Nebraska, United States|Investigational Site Number 8400006, Fort Worth, Texas, United States|Investigational Site Number 8400008, The Woodlands, Texas, United States|Investigational Site Number 8400012, Tacoma, Washington, United States|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800003, Rozzano, Italy|Investigational Site Number 8400007, Hato Rey, Puerto Rico|Investigational Site Number 6430002, Saint -Petersburg, Russian Federation|Investigational Site Number 6430003, Saint-Petersburg, Russian Federation|Investigational Site Number 7240003, Córdoba, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240002, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04191382"
166,"Follow-up of Sequential Chemotherapy and Stimulation for Fertility Preservation in Young Patients With Breast Cancer","Recruiting","No Results Available","Breast Cancer","Procedure: Consultation|Biological: Biological Test|Procedure: Pelvic Ultrasound","Centre Oscar Lambret","KSF2-1707","January 7, 2019","Centre Oscar Lambret, Lille, France","https://ClinicalTrials.gov/show/NCT03795246"
167,"A Study to Evaluate the Safety and Clinical Outcome of Using FR-Mask in Breast Cancer Patients With Radiation-irritated Skin After Radiotherapy","Recruiting","No Results Available","Breast Cancer","Other: FR-Mask","China Medical University Hospital","CMUH108-REC3-090","December 9, 2019","China Medical University Hospital, Taichung, Taiwan","https://ClinicalTrials.gov/show/NCT04190381"
168,"Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer","Terminated","No Results Available","Breast Cancer","Drug: Pyrotinib|Drug: nab-Paclitaxel|Drug: Trastuzumab|Drug: EC chemotherapy|Procedure: Surgery","Shanghai Jiao Tong University School of Medicine|Jiangsu HengRui Medicine Co., Ltd.","RJBC1901","August 26, 2019","Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04066790"
169,"Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Pegylated Liposomal Doxorubicin|Drug: Albumin-bound paclitaxel|Drug: Trastuzumab","Peking Union Medical College|CSPC Ouyi Pharmaceutical Co., Ltd.","CSPC-DMS-BC-17","June 21, 2019","Fei Ma, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03994107"
170,"PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate","Recruiting","No Results Available","Breast Cancer","Drug: Leuprorelin acetate|Drug: Letrozole|Genetic: MammaPrint","Seoul National University Hospital","PLATO study","April 3, 2019","Seoul National University Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT03900637"
171,"A Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: GDC-9545|Procedure: Surgery","Genentech, Inc.","GO40987|2018-003798-85","April 16, 2019","University of Colorado, Aurora, Colorado, United States|University of Colorado Health Lone Tree Medical Center, Lone Tree, Colorado, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Peter MacCallum Cancer Centre-Box Hill, East Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Fiona Stanley Hospital; Investigational Drugs, Pharmacy Department, Murdoch, Western Australia, Australia|Clinique Edith Cavell; Pharmacie, Auderghem, Belgium|UZ Antwerpen, Edegem, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|Clinique Sainte-Elisabeth; Oncologie, Namur, Belgium|GasthuisZusters Antwerpen, Wilrijk, Belgium|Centre Oscar Lambret, Lille, France|Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer, Rennes, France|Centre Rene Gauducheau, Saint Herblain, France|HOPITAL RENE HUGUENIN- Institut Curie, Saint-Cloud, France|Institut Claudius Régaud, Toulouse, France|Onkologikoa - Instituto Oncológico de Donostia, San Sebastian, Guipuzcoa, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Ruber Internacional;Servicio de Oncologia, Madrid, Spain|HM Sanchinarro - CIOCC, Madrid, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Clatterbridge Cancer Centre Liverpool, Liverpool, United Kingdom|Barts Health NHS Trust; William Harvey Heart Centre, QMUL School of Medicine & Dentistry, London, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT03916744"
172,"Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment","Recruiting","No Results Available","Breast Cancer","Radiation: Hypofractionated radiotherapy|Radiation: Conventional radiotherapy","Ruijin Hospital|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai 10th People's Hospital|RenJi Hospital|The First Affiliated Hospital of the Fourth Military Medical University|First Affiliated Hospital of Chongqing Medical University","RJBC-HFRNI","February 4, 2019","Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT03829553"
173,"A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Drug: Pyrotinib|Drug: Placebo","Jiangsu HengRui Medicine Co., Ltd.","HR-BLTN-III-EBC","June 10, 2019",,"https://ClinicalTrials.gov/show/NCT03980054"
174,"Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer|Luminal B","Other: Exercise|Other: Stretching","Spanish Breast Cancer Research Group|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Faculty of Physical Activity and Sport Sciences (INEF)","GEICAM/2014-09","March 4, 2019","Hospital General Universitario Gregorio Marañón, Madrid, Spain","https://ClinicalTrials.gov/show/NCT03860740"
175,"Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy","Recruiting","No Results Available","Breast Cancer","Procedure: Hyperbaric Oxygen Therapy|Drug: Trental Pill|Dietary Supplement: Vitamin E","Legacy Health System","HBO001","April 16, 2019","Legacy Emanuel Medical Center, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT03916068"
176,"Red Clover and Lifestyle Changes to Contrast Menopausal Symptoms in Premenopausal Breast Cancer Patients Given Tamoxifen","Completed","No Results Available","Breast Cancer","Drug: Promensil|Drug: Placebo Oral Tablet","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","INT 101/11","February 18, 2019","Cristina Ferraris, Milan, Italy","https://ClinicalTrials.gov/show/NCT03844685"
177,"Capecitabine in the Treatment of Breast Cancer With Low-hormone Receptor Expression After Neoadjuvant Chemotherapy","Not yet recruiting","No Results Available","Breast Cancer","Drug: Capecitabine|Drug: Placebos","Zhejiang Cancer Hospital","CALORIE","January 29, 2019",,"https://ClinicalTrials.gov/show/NCT03821454"
178,"Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients With rCR and pCR in the Breast After NAST","Not yet recruiting","No Results Available","Breast Cancer Female|Breast Cancer","Procedure: omission of SLNB","Toralf Reimer, MD PhD|European Breast Cancer Reseach Association of Surgical Trialists|University Medicine Rostock, Rostock, Germany (sponsor)|Else Kröner-Fresenius-Stiftung (funding)|University of Rostock","EUBREAST-01","September 24, 2019",,"https://ClinicalTrials.gov/show/NCT04101851"
179,"Telephone Support for Metastatic Breast Cancer Patients","Recruiting","No Results Available","Metastatic Breast Cancer","Behavioral: Acceptance and Commitment Therapy|Behavioral: Education/Support","Indiana University|National Cancer Institute (NCI)|Eskenazi Health","1812850942|R01CA230542","June 26, 2019","Indiana University Simon Cancer Center, Indianapolis, Indiana, United States","https://ClinicalTrials.gov/show/NCT03998618"
180,"A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer","Withdrawn","No Results Available","Advanced Breast Cancer|HER2-positive Breast Cancer","Drug: Trastuzumab|Drug: Pertuzumab|Drug: Vinorelbine|Drug: Docetaxel","iOMEDICO AG|Arbeitsgemeinschaft fur Internistische Onkologie|Amgen","iOM-110383|2017-004749-25","January 22, 2019","iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany","https://ClinicalTrials.gov/show/NCT03811418"
181,"HERPET- A Novel PET Imaging Study of HER2 in Breast Cancer","Recruiting","No Results Available","Breast Cancer","Radiation: [18F]GE-226","Imperial College London|Medical Research Council|University of Cambridge","2015‐004027‐31","February 1, 2019","Imperial College Healthcare NHS Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT03827317"
182,"Prospective Cohort Study of Traditional Chinese Medicine for Survival of Patients With Early Breast Cancer","Recruiting","No Results Available","Early-stage Breast Cancer","Combination Product: Chinese herbal medicine","Chang Gung Memorial Hospital","201801559A3","January 9, 2019","Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan","https://ClinicalTrials.gov/show/NCT03797248"
183,"Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Docetaxel|Drug: Cyclophosphamide","Fudan University","CLOVER","April 24, 2019","Chongqing Cancer Hospital, Chongqing, Chongqing, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, China|Sun Yet-Sen Memorial Hospital, Sun Yet-Sen University, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|The First Bethune Hospital of Jilin University (The First Hospital of Jilin University), Changchun, Jilin, China|The Second Hospital of Dalian Medical University, Dalian, Liaoning, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|OB/GYN Hospital of Fudan University, Shanghai, Shanghai, China|Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China|The First Affiliated Hospital, ZheJiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hanzhou, Zhejiang, China","https://ClinicalTrials.gov/show/NCT03926091"
184,"Evaluating Whether Integration of Prognostic and Predictive Algorithms Into Routine Clinical Practice Effect Whether Oncologists Order Multigene Assays in Patients With Early Stage Breast Cancer","Recruiting","No Results Available","Breast Cancer",,"Ottawa Hospital Research Institute","REaCT-Algorithm","October 18, 2019","Ottawa Hospital Research Institute, Ottawa, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04131933"
185,"Evaluation of Orally Administered SAR439859 in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)","Recruiting","No Results Available","Breast Cancer","Drug: SAR439859","Sanofi","TED15954|U1111-1217-2758","January 25, 2019","Investigational Site Number 3920002, Chuo-Ku, Japan|Investigational Site Number 3920001, Kashiwa-Shi, Japan|Investigational Site Number 3920003, Nagoya-Shi, Japan","https://ClinicalTrials.gov/show/NCT03816839"
186,"A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Ipatasertib|Drug: Placebo|Drug: Palbociclib|Drug: Fulvestrant","Hoffmann-La Roche","CO41012|2019-001072-11","August 19, 2019","Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States|USC Norris Cancer Center, Los Angeles, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|Christina Care Institutional Review Board, Newark, Delaware, United States|Orlando Health Inc., Orlando, Florida, United States|Atlanta Cancer Care, Alpharetta, Georgia, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Mercy Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute; GYN Oncology, Boston, Massachusetts, United States|Minnesota Oncology Minneapolis, Minneapolis, Minnesota, United States|Summit Medical Group; MD Anderson Cancer Center, Florham Park, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Duke Cancer Center, Durham, North Carolina, United States|Northwest Cancer Specialists, Portland, Oregon, United States|Faris Research, Greenville, South Carolina, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Ashford Cancer Centre, Ashford SA, South Australia, Australia|Cabrini Medical Centre; Oncology, Malvern, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit, Bull Creek, Western Australia, Australia|St John of God Hospital; Bendat Cancer Centre, Subiaco, Western Australia, Australia|LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie, Innsbruck, Austria|Klinikum Klagenfurt; Abt. f. Hämatologie u. internistische Onkologie, Klagenfurt, Austria|Ordensklinikum Linz Barmherzige Schwestern; Abt. fur Innere Medizin 1, Linz, Austria|Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU, Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I, Wien, Austria|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Juravinski Cancer Clinic; Clinical Trials Department, Hamilton, Ontario, Canada|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Università degli Studi della Campania Luigi Vanvitelli; Divsione Di Oncologia Medica, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS, Reggio Emilia, Emilia-Romagna, Italy|Ospedale San Raffaele S.r.l., Milano, Lombardia, Italy|ASST DI MONZA; Oncologia Medica, Monza, Lombardia, Italy|Istituto Clinico Humanitas, Rozzano (MI), Lombardia, Italy|Ospedale San Vincenzo Taormina :Divisione di Oncologia Medica, Taormina, Sicilia, Italy|Ospedale Civile - Livorno, Livorno, Toscana, Italy|Fondazione del Piemonte per l'Oncologia (IRCCS), Candiolo, Trentino-Alto Adige, Italy|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Ajou University Medical Center, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|China Medical University Hospital; Surgery, Taichung, Taiwan|National Cheng Kung Uni Hospital; Dept of Hematology and Oncology, Tainan, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|National Taiwan Uni Hospital; Dept of Oncology, Taipei, Taiwan|Mackay Memorial Hospital; Dept of Surgery, Taipei, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Srinagarind Hospital; Medical Oncology Unit, Khon Kaen, Thailand|The Royal Marsden Hospital; Dept of Medicine, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Royal Marsden Hosp NHS Fnd; Medicine - Breast Unit, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT04060862"
187,"Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer","Recruiting","No Results Available","Breast Cancer Female","Drug: Pyrotinib","RenJi Hospital","KY2019-023","October 15, 2019","Renji Hospital, Shanghai, China","https://ClinicalTrials.gov/show/NCT04126525"
188,"A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Ipatasertib|Drug: Paclitaxel|Drug: Atezolizumab|Drug: Nab-Paclitaxel|Drug: AC","Hoffmann-La Roche","CO40151|2017-001957-15","January 11, 2019","Pacific Shores Medical Group, Long Beach, California, United States|Northwest Medical Specialties, Tacoma, Washington, United States|St Vincents Hospital; Cardiopulmonary transplant Ambulatory Care Dept, Darlinghurst, New South Wales, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Center, Melbourne, Victoria, Australia|Institut de Cancerologie de l Ouest, Angers, France|Institut Bergonie, Bordeaux, France|Centre Georges Francois Leclerc, Dijon, France|Institut Curie, Paris, France|Gustave Roussy, Villejuif CEDEX, France|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz., Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Barts Cancer Institute, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT03800836"
189,"Evaluation of Prognostic Monitoring for Young Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer Female",,"Peking Union Medical College Hospital","PUMCH-BC503","October 31, 2019","Peking Union Medical College Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04145986"
190,"Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer","Recruiting","No Results Available","Breast Cancer Female|Hormone Receptor Positive Malignant Neoplasm of Breast","Drug: Palbociclib|Drug: Endocrine therapy","Kyoto Breast Cancer Research Network|Pfizer","OOTR-N016/KBCRN-B-003/HT-PAB","May 31, 2019","Monash Health, Clayton, Australia|Peter MacCallum Cancer Centre, Melbourne, Australia|UNIMED Medical Institute, Hong Kong, Hong Kong|Amagasaki General Medical Center, Amagasaki, Hyogo, Japan|University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan|Kyushu Cancer Center, Fukuoka, Japan|Sagara Hospital, Kagoshima, Japan|Kobe City Medical Center General Hospital, Kobe, Japan|Kyoto University Hospital, Kyoto, Japan|Aichi Cancer Center, Nagoya, Japan|Tazuke Kofukai, Medical Research Institute, Kitano Hospital, Osaka, Japan|Saitama Cancer Center, Saitama, Japan|Toranomon Hospital, Tokyo, Japan|Tokyo Metropolitan Komagome Hospital, Tokyo, Japan|Cancer Institute Hospital Of JFCR, Tokyo, Japan|Kyorin University Hospital, Tokyo, Japan|Kanagawa Cancer Center, Yokohama, Japan|National Cancer Center, Korea, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Korea Cancer Center Hospital, Seoul, Korea, Republic of|Seoul National University College of Medicine, Seoul, Korea, Republic of|Soonchunhyang University Hospital, Seoul, Korea, Republic of|Aju University Hospital, Suwon, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Sun Yat-Sen Cancer Center, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT03969121"
191,"A Study Evaluating the Efficacy and Safety of GDC-0077 + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: GDC-0077|Drug: Placebo|Drug: Palbociclib|Drug: Fulvestrant","Hoffmann-La Roche","WO41554|2019-002455-42","December 9, 2019","Beverly Hills Cancer Center, Beverly Hills, California, United States|Kaiser Permanente;Clinical Trials Department, Denver, Colorado, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States|South Broward Hospital District; Memorial Division Of Cancer Institute, Pembroke Pines, Florida, United States|Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), Saint Petersburg, Florida, United States|SCRI Florida Cancer Specialists PAN, Tallahassee, Florida, United States|SCRI Florida Cancer Specialists East, West Palm Beach, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|Univ of Chicago, Chicago, Illinois, United States|Massachusetts General Hospital., Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|HCA Midwest Division, Kansas City, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Providence Portland Medical Center; Providence Oncology and Hematology Clinic Westside, Portland, Oregon, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Tech University Health Sciences Center; Department of Neurology, El Paso, Texas, United States|The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|USOR - Texas Oncology - San Antonio Northeast, San Antonio, Texas, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Southern Medical Day Care Centre, Wollongong, New South Wales, Australia|Mater Adult Hospital; Oncology, South Brisbane, Queensland, Australia|Townsville Hospital; Haematology and Oncology, Townsville, Queensland, Australia|Princess Alexandra Hospital; Cancer Trials Unit, Woolloongabba, Queensland, Australia|Western Health, Fitzroy, Victoria, Australia|Peninsula and South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|Austin Health; Cancer Clinical Trial Centre, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia|Universitätsklinikum St. Pölten; Klinische Abteilung für Innere Medizin 1, St. Pölten, Austria|AKH - Medizinische Universität Wien; Department of Oncology, Vienna, Austria|Cliniques Universitaires St-Luc, Bruxelles, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|UZ Antwerpen, Edegem, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Fraser Valley Centre British Columbia Cancer Agency, Surrey, British Columbia, Canada|Royal Victoria Hospital, Barrie, Ontario, Canada|London Regional Cancer Program, London Health Sciences Centre, Baines Centre, London, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Jewish General Hospital; Research Unit, Montréal, Quebec, Canada|CHU de Québec - Hôpital du Saint-Sacrement, Quebec City, Quebec, Canada|Centre de sante et de services sociaux Rimouski Neigette, Rimouski, Quebec, Canada|Herlev Hospital; Afdeling for Kræftbehandling, Herlev, Denmark|Vejle Sygehus; Onkologisk Afdeling, Vejle, Denmark|Centre Oscar Lambret; Senologie, Lille, France|Institut régional du Cancer Montpellier, Montpellier, France|Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France|Vivantes Klinikum Am Urban Klinik für Innere Medizin Hämatologie und Onkologie, Berlin, Germany|Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters, Berlin, Germany|Gynäkologisches Zentrum Bonn, Bonn, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany|Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany|St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe, Koeln, Germany|Zentrum für ambulante gynäkologische Onkologie (ZAGO), Krefeld, Germany|Universitätsklinikum Leipzig; Klinik und Poliklinik für Frauenheilkunde, Leipzig, Germany|Universitätsklinikum Mannheim; Frauenklinik, Mannheim, Germany|Klinik & Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt, München, Germany|St. Vincenz-Krankenhaus Paderborn; Haus 3 Frauenklinik, Paderborn, Germany|Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie, Recklinghausen, Germany|Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie, Trier, Germany|Universitätsfrauenklinik Ulm; Abteilung Gynäkologie, Ulm, Germany|Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine, Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|Metropolitan Hospital; Dept. of Oncology, Pireaus, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Prince of Wales Hospital; Department of Clinical Onocology, Shatin, Hong Kong|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, Hungary|Uzsoki Utcai Korhaz; Onkoradiológiai Osztály, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont ; Department of Oncology, Debrecen, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet; Megyei Onkologiai Kozpont, Szolnok, Hungary|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|A.O. Universitaria Di Parma, Parma, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|Azienda Ospedaliera Univ di Udine; Oncologia Medica, Udine, Friuli-Venezia Giulia, Italy|Policlinico Universitario ""Agostino Gemelli""; U.O.C. Oncologia Medica, Roma, Lazio, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|Ospedale Santa Maria Annunziata; Oncologia, Bagno a Ripoli, Toscana, Italy|Azienda Ospedaliero Universitaria Pisana; Unita Operativa Oncologia Medica 2, Pisa, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Pusan National University Hospital, Busan, Korea, Republic of|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Kyungpook National University Medical Center, Daegu, Korea, Republic of|Soon Chun Hyang University Cheonan Hospital, Dongnam-gu, Cheonan-si, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Borame Medical Center, Seoul, Korea, Republic of|Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Auckland City Hospital; Clinical Oncology, Auckland, New Zealand|Christchurch Hospital NZ, Christchurch, New Zealand|Waikato Hospital; Dept of Medical Oncology, Hamilton, New Zealand|Palmerston North Hospital; Regional Cancer Treatment Service, Palmerston North, New Zealand|Centrum Onkologii im. Prof. Franciszka Łukaszczyka; Ambulatorium Chemioterapii, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|Narodowy Instytut Onkologii Odział w Gliwicach; Centrum Diagnostyki i Leczenia Chorób Piersi, Gliwice, Poland|Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, Poland|Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina, Klinika Onkologii, Otwock, Poland|Wojewódzki Szpital Zespolony im.L.Rydygiera; Oddzial Chemioterapii Nowotworów, Toruń, Poland|Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr, Warszawa, Poland|Wojskowy Instytut Medyczny; Klinika Onkologii, Warszawa, Poland|Dolnośląskie Centrum Onkologii; Oddział Onkologii Klinicznej i Chemioterapii, Wrocław, Poland|Centro Clinico Champalimaud; Oncologia Medica, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Centro Hospitalar do Porto - Hospital de Santo António; Oncologia, Porto, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Moscow Clinical Scientific Center, Moscow, Moskovskaja Oblast, Russian Federation|MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy, Moscow, Moskovskaja Oblast, Russian Federation|Medical Clinic ""AB Medical group"", Saint Petersburg, Sankt Petersburg, Russian Federation|Blokhin Cancer Research Center; Out-Patients Dept, Moscow, Russian Federation|Regional Oncology Dispensary; Dept of Chemotherapy, Novgorod Veliky, Russian Federation|Volgograd Regional Clinical Oncology Dispensary, Volgograd, Russian Federation|Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clinic Provincial;Medical Oncology, Barcelona, Spain|Insituto Catalán de Oncologia (ICO), Barcelona, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Clinica Universidad de Navarra-Madrid, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Kaohsiung Medical Uni Chung-Ho Hospital; Dept of Surgery, Kaohsiung, Taiwan|Chi-Mei Medical Centre; Hematology & Oncology, Tainan, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Tri-Service General Hospital, Division of General Surgery, Taipei, Taiwan|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial, Chiang Mai, Thailand|Chulabhorn Hospital; Medical Oncology, Lak Si, Thailand|Songklanagarind Hospital; Department of Oncology, Songkhla, Thailand|SI Institute of general&urgent surgery n/a Zaytseva V.T NAMSU; Purulent Surgery department, Kharkiv, Kharkiv Governorate, Ukraine|Municipal Institution SubCarpathian Clinical Oncological Centre; Surgical department#2, Ivano-Frankivsk, KIEV Governorate, Ukraine|Uzhhorod Central City Clinical Hospital, Uzhhorod, KIEV Governorate, Ukraine|City Clinical Hospital #4, Dnipropetrovsk, Ukraine|ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department, Kryvyi Rih, Ukraine|Kyiv City Clinical Oncological Center, Kyiv, Ukraine|RCI Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|Bristol Royal Infirmary, Bristol, United Kingdom|Princess Alexandra Hospital; Oncology Department, Harlow, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|Barts Health NHS Trust; Cancer Research Delivery Group, London, United Kingdom|St Georges University Hospitals NHS Foundation Trust, London, United Kingdom|Royal Marsden Hospital - Fulham; Oncology Department, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Maidstone Hospital; Kent Oncology Centre, Maidstone, United Kingdom|Christie Foundation Trust, Manchester, United Kingdom|Mount Vernon Hospital; Mount Vernon Cancer Centre, Northwood, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Churchill Hospital; Department of Oncology, Oxford, United Kingdom|Peterborough City Hospital, Edith Cavell Campus; Oncology Department, Peterborough, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Marsden Hosp NHS Fnd; Medicine - Breast Unit, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT04191499"
192,"Optimizing Functional Recovery of Breast Cancer Survivors","Recruiting","No Results Available","Breast Cancer Female","Behavioral: The Behavioral Activation/ Problem Solving Intervention|Behavioral: Attention Control Condition","Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI)","D18167|1R01CA225792-01A1","April 16, 2019","Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States","https://ClinicalTrials.gov/show/NCT03915548"
193,"Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women With Breast Cancer","Recruiting","No Results Available","Breast Cancer Female","Dietary Supplement: Tocotrienol-rich Fraction (TRF)","Nur Aishah Mohd Taib|Malaysia Palm Oil Board|University of Malaya","853.4","February 26, 2019","University of Malaya Medical Center, Kuala Lumpur, Malaysia","https://ClinicalTrials.gov/show/NCT03855423"
194,"Acupuncture for Breast Cancer Related Lymphedema","Not yet recruiting","No Results Available","Breast Cancer Lymphedema","Other: acupuncture|Other: sham acupuncture","Tianjin University of Traditional Chinese Medicine|Baokang Hospital Affiliated to Tianjin University of Traditional Chinese Medicine|Tianjin Medical University Cancer Institute and Hospital|Gansu Provincial Cancer Hospital|The Second Affiliated Hospital of Baotou Medical College","2014CB543202-03","November 8, 2019",,"https://ClinicalTrials.gov/show/NCT04158193"
195,"Facial Skin Health Tracking Feasibility in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer Female","Other: Skin health assessment","University of Colorado, Denver|National Cancer Institute (NCI)","18-2444.cc|P30CA046934","July 29, 2019","University of Colorado Hospital, Aurora, Colorado, United States","https://ClinicalTrials.gov/show/NCT04035408"
196,"ModraDoc006/r in Patients With Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer|Recurrent Breast Cancer","Drug: ModraDoc006/r","Modra Pharmaceuticals","M18DMB","March 26, 2019","Institut Jules Bordet, Brussels, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Odense University Hospital, Odense, Denmark","https://ClinicalTrials.gov/show/NCT03890744"
197,"Trial Comparing 3 Schedules of Hypofractionated Whole Breast Irradiation in Females With Early Stage Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer Female","Other: Whole Breast Irradiation","National Cancer Institute, Egypt","201617090.3","November 1, 2019","NCI. Cairo University, Cairo, Egypt","https://ClinicalTrials.gov/show/NCT04148586"
198,"Acupuncture for Joint Symptoms in Patients With Breast Cancer","Recruiting","No Results Available","Female Breast Cancer","Device: Acupuncture","The Hong Kong Polytechnic University|The Affiliated Hospital Of Southwest Medical University","HSEARS20180509004","February 11, 2019","Xianliang Liu, Luzhou, China","https://ClinicalTrials.gov/show/NCT03836872"
199,"Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy for Breast Cancer","Recruiting","No Results Available","Breast Cancer Female","Device: Robotic assisted nipple sparing mastectomy (R-NSM)|Procedure: conventional nipple sparing mastectomy (C-NSM)|Procedure: Endoscopic assisted nipple sparing mastectomy (E-NSM)","Changhua Christian Hospital|Ministry of Science and Technology, Taiwan|Intuitive Surgical","CCH-IRB-190414-R|MOST 108-2314-B-371-006-","August 8, 2019","European Institute of Oncology, Milan, Italy|Severance Hospital, Seoul, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Shuang-Ho Hospital - Taipei Medical University, Taipei county, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan|Taipei Municipal Wan Fang Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan","https://ClinicalTrials.gov/show/NCT04049305"
200,"A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: ZEN003694|Drug: Talazoparib","Zenith Epigenetics|Pfizer","ZEN003694-004|2018-003906-26","April 3, 2019","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Tennessee Oncology (Sarah Cannon), Nashville, Tennessee, United States|MD Anderson, Houston, Texas, United States|Institut Jules Bordet, Brussels, Belgium|UZ Leuven, Leuven, Belgium|Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain|START Madrid, Madrid, Spain","https://ClinicalTrials.gov/show/NCT03901469"
201,"Breast Cancer Screening for Underserved Women: Comparing Outcomes and Lowering Recall Rates With 3D- vs. 2D-mammography","Recruiting","No Results Available","Breast Cancer Screening","Other: Routine Screening Mammogram (3D + 2D)|Other: Routine Screening Mammogram (2D)|Other: No Screening Mammogram","New Mexico Cancer Care Alliance","INST UNM 1525","June 7, 2019","University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States","https://ClinicalTrials.gov/show/NCT03979729"
202,"Effects of Exercise in Patients With Metastatic Breast Cancer","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Behavioral: Supervised exercise","UMC Utrecht|German Cancer Research Center|Australian Catholic University|Karolinska Institutet|The Netherlands Cancer Institute|Medical University of Gdansk|Fundación Onkologikoa Fundazioa|Europa Donna|German Sport University, Cologne|University Hospital Heidelberg|Nurogames GmbH, Cologne","19-524|NL69600.041.19","October 9, 2019",,"https://ClinicalTrials.gov/show/NCT04120298"
203,"Xenografts Development From Surgical Tumor Samples of Patients With Triple Negative or Luminal B Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer Female","Biological: blood samples collection","Centre Jean Perrin","2020-A00398-31","October 21, 2019",,"https://ClinicalTrials.gov/show/NCT04133077"
204,"FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer","Recruiting","No Results Available","Breast Cancer","Drug: Ribociclib|Drug: Aromatase Inhibitors, non steroideal|Drug: LHRH agonist","Fondazione Sandro Pitigliani|Novartis","FACILE","May 9, 2019","Hospital of Prato, Prato, Please Select:, Italy","https://ClinicalTrials.gov/show/NCT03944434"
205,"Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy in the Management of Breast Cancer-Prospective Study","Recruiting","No Results Available","Breast Cancer Female","Device: robotic assisted nipple sparing mastectomy|Procedure: Endoscopic assisted nipple sparing mastectomy|Procedure: Conventional nipple sparing mastectomy","Changhua Christian Hospital|Intuitive Surgical|Ministry of Science and Technology, Taiwan","CCH-IRB-190414-P|108-2314-B-371-006-","July 30, 2019","Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan|Shuang-Ho Hospital - Taipei Medical University, Taipei, Taiwan|Taipei Municipal Wan Fang Hospital, Tawian, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan, Taoyuan, Taiwan","https://ClinicalTrials.gov/show/NCT04037852"
206,"Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer","Active, not recruiting","No Results Available","Metastatic Breast Cancer","Behavioral: Lifestyle Intervention","Medical College of Wisconsin|Loyola University Chicago","27600","January 31, 2019","Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03824145"
207,"Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer","Recruiting","No Results Available","Triple-negative Breast Cancer","Biological: AE37 Peptide vaccine|Biological: Pembrolizumab","Antigen Express, Inc|Merck Sharp & Dohme Corp.|NSABP Foundation Inc","NSABP FB-14|MK3475 KN 548","July 18, 2019","Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Cancer Care Specialists of Central Illinois-Swansea, Swansea, Illinois, United States|West Virginia University, Morgantown, West Virginia, United States","https://ClinicalTrials.gov/show/NCT04024800"
208,"A Novel Method of Clipped Axillary Lymph Node Localization Post Neoadjuvant Chemotherapy in Breast Cancer Patients .","Active, not recruiting","No Results Available","Breast Cancer Female","Procedure: skin marking of clip axillary lymph node for localisation","KK Women's and Children's Hospital","2017/2037","March 18, 2019","KK Women's and Children's Hospital, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT03878017"
209,"Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Drug: Vinorelbine|Drug: Gemcitabine|Drug: Carboplatin","Shandong Cancer Hospital and Institute","Shandong CHI-10","October 30, 2019",,"https://ClinicalTrials.gov/show/NCT04143906"
210,"Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer","Suspended","No Results Available","Resistant Breast Cancer|Non-metastatic Invasive Breast Cancer","Drug: Capecitabine|Radiation: Radiotherapy","A Bapsi Chakravarthy, MD|Vanderbilt-Ingram Cancer Center","VICC BREP 1898|NCI-2019-03276","May 22, 2019","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT03958721"
211,"Living Better With Advanced Breast Cancer: Feasibility Evaluation of an Online Supportive Intervention.","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Other: LIBERATE website","University of Leeds|Breast Cancer Now","NOV2016PhD818","November 22, 2019",,"https://ClinicalTrials.gov/show/NCT04173897"
212,"ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Hormonal therapy-based treatments","National Taiwan University Hospital|Novartis","201703138RIPD","December 27, 2019","National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT04212702"
213,"Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Device: Epicutaneous cryoimmunotherapy|Drug: Topical imiquimod|Drug: Pembrolizumab|Other: Dermatologic Quality of Life Index|Other: Functional Assessment of Cancer Therapy|Drug: Intra-lesional GM-CSF|Device: Cry-AC|Procedure: Cutaneous tumor biopsy|Procedure: Peripheral blood draw for research","Washington University School of Medicine|Merck Sharp & Dohme Corp.","201911047","June 11, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT03982004"
214,"Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Nivolumab|Drug: Cisplatin|Drug: Low dose doxorubicin","The Netherlands Cancer Institute|Bristol-Myers Squibb","N19TON","November 12, 2019","Antoni van Leeuwenhoek, Amsterdam, Netherlands","https://ClinicalTrials.gov/show/NCT04159818"
215,"Specialist Recommendation on FBC (Familial Breast Cancer) Chemoprevention Prescribing","Active, not recruiting","No Results Available","Familial Breast Cancer","Other: Survey Administration","University of Nottingham|University of Oxford","19049","August 15, 2019","University of Nottingham, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT04058418"
216,"Taxane Induced Peripheral Neuropathy in Chinese Patients With Breast Cancer","Recruiting","No Results Available","Breast Cancer","Other: Patient Questionnaires|Other: Blood Collection","Cancer Institute and Hospital, Chinese Academy of Medical Sciences","TIPN in China","August 28, 2019","Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04068090"
217,"Study of KN026 Monotherapy or Combined With Chemotherapy in Patients With Metastatic Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: KN026 combination|Drug: KN026 monotherapy","Jiangsu Alphamab Biopharmaceuticals Co., Ltd","KN026-201","November 18, 2019","Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China","https://ClinicalTrials.gov/show/NCT04165993"
218,"A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.","Recruiting","No Results Available","Triple-Negative Breast Cancer","Drug: Atezolizumab|Drug: Ipatasertib|Drug: Paclitaxel|Drug: Placebo for Atezolizumab|Drug: Placebo for Ipatasertib","Hoffmann-La Roche","CO41101|2019-000810-12","November 26, 2019","USA Mitchell Cancer Institute, Mobile, Alabama, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|CBCC Global Research Inc., at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Community Cancer Institute (CCI), Fresno, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|TMPN/ Cancer Care Associates, Redondo Beach, California, United States|Kaiser Permanente-SCPMG; Oncology Research, San Diego, California, United States|Stanford Cancer Center, Stanford, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|Kaiser Permanente - Franklin, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Stamford Hospital; BCC, MOHR, Stamford, Connecticut, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Memorial Healthcare System - Memorial Regional Hospital, Hollywood, Florida, United States|Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Nancy N. and J.C. Lewis Cancer & Research Pavillion -St. Josephs / Candler Health System-CCD PRIME, Savannah, Georgia, United States|Rush University, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Ochsner Health System, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Medstar Franklin Square Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|St. Joseph Mercy Hospital; Cancer Care Center., Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States|CHI Health Saint Francis; Oncology, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack Univ Med Ctr, Hackensack, New Jersey, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Kaiser Permanente - Portland, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Charleston Oncology, P .A, Charleston, South Carolina, United States|Greenville Health System; Cancer Center, Greenville, South Carolina, United States|Roper St. Francis Healthcare, North Charleston, South Carolina, United States|The West Clinic; West Cancer Center, Germantown, Tennessee, United States|Vanderbilt Univ Medical Ctr, Nashville, Tennessee, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Inst. Angel Roffo; Haematology, Buenos Aires, Argentina|Hospital Britanico, Ciudad Autonoma Bs As, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Fundación Scherbovsky, Mendoza, Argentina|Mid North Coast Cancer Institute, Port Macquarie, New South Wales, Australia|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|Macquarie University Hospital, Sydney, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Monash Health Monash Medical Centre, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia|Sunshine Hospital; Oncology Research, St Albans, Victoria, Australia|St John of God Hospital; Bendat Cancer Centre, Subiaco, Western Australia, Australia|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie, Innsbruck, Austria|Ordensklinikum Linz Barmherzige Schwestern; Interne 1 - Hämato-Onkologie, Linz, Austria|Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU, Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I, Wien, Austria|Cliniques Universitaires St-Luc, Bruxelles, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|AZ Maria Middelares, Gent, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|Hospital Sao Rafael - HSR, Salvador, BA, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hospital Sirio Libanes; Centro de Oncologia - Unidade Brasilia, Brasilia, SP, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Inst. Brasileiro de Controle Ao Cancer; Oncologia Clinica / Quimioterapia, Sao Paulo, SP, Brazil|MHAT Serdika, Sofia, Bulgaria|MHAT Nadezhda, Sofia, Bulgaria|National Hospital in Oncology; Medical Oncology, Sofia, Bulgaria|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Fraser Valley Centre British Columbia Cancer Agency, Surrey, British Columbia, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Royal Victoria Hospital, Barrie, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Centre de Sante & de Services Sociaux de Chicoutimi; Recherche Clinique Oncologie, Chicoutimi, Quebec, Canada|Centre Hospitalier De St-Mary, Montreal, Quebec, Canada|McGill University; Glen Site; Oncology, Montreal, Quebec, Canada|Jewish General Hospital; Research Unit, Montréal, Quebec, Canada|St-Jerome Medical Research Inc, St. Jerome, Quebec, Canada|Saskatoon Cancer Centre; Uni of Saskatoon Campus, Saskatoon, Saskatchewan, Canada|CHAUQ Hospital St Sacrement, Quebec, Canada|Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China|Beijing Cancer Hospital, Beijing, China|Jilin Cancer Hospital, Changchun, China|the First Hospital of Jilin University, Changchun, China|Hunan Cancer Hospital, Changsha City, China|West China Hospital, Sichuan University; Department of Breast, Chengdu, China|The First Affiliated Hospital, Chongqing Medical University, Chongqing, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Guangdong Provincial Traditional Chinese Medicine Hospital, Guangzhou, China|Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China|Jiangsu Cancer Hospital, Nanjing, China|Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai City, China|Liaoning cancer Hospital & Institute, Shenyang, China|Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province), Shijiazhuang, China|Tianjin Medical University Cancer Institute & Hospital, Tianjing, China|Zhejiang Cancer Hospital, Zhejiang, China|Clinica del Country, Bogota, Colombia|Instituto Cancerologia Medellin; Clinica Las Americas, Medellin, Colombia|Oncomedica S.A., Monteria, Colombia|Oncólogos de Occidente, Pereira, Colombia|Clinica CIMCA, San Jose, Costa Rica|ICIMED Instituto de Investigación en Ciencias Médicas, San Jose, Costa Rica|Oncotech S.A., San José, Costa Rica|Masarykův onkologický ústav; Klinika komplexní onkologické péče, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Aarhus Universitetshospital Skejby ; Kræftafdelingen, Klinik A, Aarhus, Denmark|Herlev Hospital; Afdeling for Kræftbehandling, Herlev, Denmark|Rigshospitalet; Onkologisk Klinik, København Ø, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|Vejle Sygehus; Onkologisk Afdeling, Vejle, Denmark|Docrates Cance Center, Helsinki, Finland|KYS Sadesairaala; Syopatautien poliklinikka, Kuopio, Finland|VAASAN KESKUSSAIRAALA; Onkologian poliklinikka, Vaasa, Finland|Centre Oncologie Du Pays Basque, Bayonne, France|Institut Bergonie; Oncologie, Bordeaux, France|Centre Jean Perrin, Clermont Ferrand, France|Chu Grenoble - Hopital Albert Michallon; Departement de Cancero-Hematologie, Grenoble, France|CHD Vendée, La Roche Sur Yon, France|Centre Oscar Lambret; Senologie, Lille, France|Centre Leon Berard, Lyon, France|Clinique Clementville; Hopital De Jour, Montpellier, France|Centre D'Oncologie de Gentilly; Oncology, Nancy, France|Centre Hospitalier Uni Ire Caremeau; Radiotherapie & Oncologie, Nimes, France|Institut Curie; Oncologie Medicale, Paris, France|Clinique Armoricaine Radiologie; Hopital de Jour, Plerin, France|Centre Eugene Marquis; Service d'oncologie, Rennes, France|Institut Curie - Hopital Rene Huguenin, Saint-Cloud, France|Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France|Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept., Kifisia, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Tuen Mun Hospital; Clinical Onc, Hong Kong, Hong Kong|Prince of Wales Hospital; Department of Clinical Onocology, Shatin, Hong Kong|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, Hungary|Uzsoki Utcai Korhaz; Onkoradiológiai Osztály, Budapest, Hungary|Pécsi Tudományegyetem; Klinikai Központ Onkoterápiás Intézet, Pécs, Hungary|Komarom-Esztergom Megyei Onkormanyzat Szent Borbala Korhaz; Haematologiai Osztaly, Tatabánya, Hungary|Indraprastha Apollo Hospitals, New Delhi, Delhi, India|Max Super Speciality Hospital; Medical Oncology, North WEST Delhi, Delhi, India|Marthwada Regional Cancer Center & Research Institute, Aurangabad, Maharashtra, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Sahyadri Super Specialty Hospital Hadapsar, Pune, Maharashtra, India|TATA Medical Centre; Medical Oncology, Kolkata, WEST Bengal, India|Shatabdi Superspeciality Hospital, Nasik, India|Grant Medical Foundation, Ruby Hall Clinic, Pune, India|St Vincent'S Uni Hospital; Medical Oncology, Dublin, Ireland|Mater Misericordiae Uni Hospital; Oncology, Dublin, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|University Hospital Waterford, Pharmacy Department, Waterford, Ireland|Rambam Health Care Campus; Oncology, Haifa, Israel|Hadassah University Hospital - Ein Kerem; Oncology, Jerusaelm, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Sheba Medical Center, Ramat Gan, Israel|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|ASU FC S. M. DELLA MISERICORDIA; Oncologia, Udine, Friuli-Venezia Giulia, Italy|ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica, Brescia, Lombardia, Italy|ASST DI LECCO; Oncologia Medica, Lecco, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1, Milano, Lombardia, Italy|IRCCS Istituto Clinico Humanitas; Oncologia, Rozzano, Lombardia, Italy|Ospedale Civile; Unita Operativa Di Oncologia Medica, Livorno, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Aichi Cancer Center Hospital, Aichi, Japan|Chiba Cancer Center, Chiba, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Gunma Prefectural Cancer Center, Gunma, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Hiroshima University Hospital, Hiroshima, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan|Hyogo College of Medicine Hospital, Hyogo, Japan|St. Marianna University School of Medicine Hospital, Kanagawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Kumamoto Shinto General Hospital, Kumamoto, Japan|Okayama University Hospital, Okayama, Japan|Naha-nishi Clinic, Okinawa, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan|Saitama Cancer Center, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|St. Luke's International Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Showa University Hospital, Tokyo, Japan|Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan|Kyungpook National University Medical Center, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Ajou University Medical Center, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Investigacion Oncofarmaceutica, La Paz, BAJA California SUR, Mexico|Consultorio Privado (José Luis González Trujillo), Leon, Guanajuato, Mexico|Health Pharma Professional Research, CD Mexico, Mexico CITY (federal District), Mexico|Christus Muguerza Clinica Vidriera, Monterrey, Nuevo LEON, Mexico|Cuidados oncologicos, Querétaro, Queretaro, Mexico|Centro Medico Dalinde, Mexico City, Mexico|Auckland City Hospital, Cancer and Blood Research, Auckland, New Zealand|Christchurch Hospital NZ, Christchurch, New Zealand|Tauranga Hospital, Clinical Trials Unit; BOP Clinical School, Tauranga, New Zealand|Wellington Regional Hospital; Clinical Trials Unit, Wellington, New Zealand|Centro Medico Monte Carmelo, Arequipa, Peru|Instituto Regional de Enfermedades Neoplasicas, Arequipa, Peru|Unidad de Investigación Oncologica; Hospital Nacional Daniel Alcides Carrion, Lima, Peru|Hospital Nacional Edgardo Rebagliati Martins; Oncologia, Lima, Peru|Clínica San Gabriel; Unidad de Investigación Oncológica de la Clínica San Gabriel, Lima, Peru|Hospital Arzobispo Loayza, Lima, Peru|Oncosalud Sac; Oncología, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Hospital De Alta Complejidad Virgen De La Puerta - Essalud; Oncology, Trujillo, Peru|Instituto Regional de Enfermedades Neoplasicas - IREN Norte, Trujillo, Peru|Bialostockie Centrum Onkologi, Bialystok, Poland|Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice; Centr.Diagn.i Lecz.Chor.Piersi, Gliwice, Poland|Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii, Kraków, Poland|Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii, Lublin, Poland|SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie, Olsztyn, Poland|Wielkopolskie Centrum Onkologii, Poznan, Poland|Centralny Szpital Kliniczny MSW w Warszawie, Warszawa, Poland|Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Nowotworow Piersi i Chirurgii Rekonstr, Warszawa, Poland|Instyt. Centrum Zdrowia Matki Polki; Klinika Chirurgii Onk. Chorób Piersi z Podod. Onko Klinicznej, Łódź, Poland|Hospital da Luz; Departamento de Oncologia Medica, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Hospital Beatriz Angelo; Departamento de Oncologia, Loures, Portugal|Centro Hospitalar do Porto - Hospital de Santo António; Oncologia, Porto, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|""Filantropia"" Clinical Hospital; Gynecological Oncology, Bucharest, Romania|Institute of Oncology ""Prof. Dr. I. Chiricuta"", Cluj-Napoca, Romania|Oncology Center Sf. Nectarie, Craiova, Romania|Centrul de Oncologie Oncohelp, Timisoara, Romania|University сlinic of headaches, Moscow, Moskovskaja Oblast, Russian Federation|SBIH ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"", Moskva, Moskovskaja Oblast, Russian Federation|Fed State Budgetary Inst ""N.N. Blokhin Med Center of Oncology"" MHRF, Moskva, Moskovskaja Oblast, Russian Federation|FSAI Treatment and rehabilitation Centre Ministry of Health; Clinical research and chemotherapy., Moskva, Moskovskaja Oblast, Russian Federation|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|P.A. Gertsen Cancer Research Inst. ; Chemotherapy Dept, Moscow, Russian Federation|Limited Liability Company ""RC Medical"", Novosibirsk, Russian Federation|Rostov Scientific Research Inst. of Oncology; Chemotherapy, Rostov-na-donu, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Institute for Onc/Rad Serbia, Belgrade, Serbia|Clinical Center Bezanijska Kosa, Belgrade, Serbia|Clinical Center Kragujevac;Center for Hematology, Kragujevac, Serbia|Clinical Centre Nis, Clinic for Oncology, Nis, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, Serbia|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|National Hospital; Oncotherapy Dept, Bloemfontein, South Africa|Life Vincent Pallotti Oncology Centre, Bothasig, South Africa|Cancercare, George, South Africa|Wits Clinical Research, Johannesberg, South Africa|Groote Schuur Hospital Radiation Oncology Department, Observatory, South Africa|Cancercare, Port Elizabeth, South Africa|Wilgers Oncology Centre, Pretoria, South Africa|Mary Potter Oncology Centre, Pretoria, South Africa|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon de La Plana, Castellon, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Oncologia, La Coruna, LA Coruña, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|Universitätsspital Basel; Frauenklinik, Basel, Switzerland|China Medical University Hospital; Surgery, Taichung, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Chang Gung Memorial Hosipital at Linkou, Taoyuan Hsien, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial, Chiang Mai, Thailand|Khonkaen Hospital, Khonkaen, Thailand|Songklanagarind Hospital; Department of Oncology, Songkhla, Thailand|Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology, Adana, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Ankara, Turkey|Ankara City Hospital, Ankara, Turkey|Memorial Ankara Hastanesi, Ankara, Turkey|Memorial Antalya Hospital, Antalya, Turkey|Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji, Bakirkoy / Istanbul, Turkey|Pamukkale University School Of Medicine; Oncology Department, Denizli, Turkey|Dicle University Faculty of Medicine, Diyarbakir, Turkey|Kartal Training and Research Hospital;Medical Oncology Department, Istanbul, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Katip Celebi University Ataturk Training and Research Hospital; Oncology, Izmir, Turkey|Namik Kemal Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, 100, Tekirdag, Turkey|SI Institute of general&urgent surgery n/a Zaytseva V.T NAMSU; Purulent Surgery department, Kharkiv, Kharkiv Governorate, Ukraine|Municipal Institution SubCarpathian Clinical Oncological Centre; Surgical department#2, Ivano-Frankivsk, KIEV Governorate, Ukraine|Regional Oncology Center; Department of Mammology, Chernigiv, Ukraine|CI Dnipropetrovsk CMCH 4 of Dnipropetrovsk RC Dept of Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, Ukraine|ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department, Kryvyi Rih, Ukraine|Kyiv City Clinical Oncological Center, Kyiv, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine|RCI Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|Uzhgorod Central City Clinical Hospital, Uzhhorod, Ukraine|Royal Bournemouth Hospital; Oncology, Bournemouth, United Kingdom|University Hospital Bristol, Bristol, United Kingdom|Velindre Hospital, Dept Clinical Trials, Cardiff, United Kingdom|Colchester General Hospital, Colchester, Essex, United Kingdom|BEATSON WEST OF SCOTLAND CANCER CENTRE; Clinical Research Unit - Level 1, Glasgow, United Kingdom|Royal Lancaster Infirmary, Morecambe Bay Hospitals Nhs Trust, Lancaster, United Kingdom|Barts, London, United Kingdom|Guys ST Thomas Hospital, London, United Kingdom|The Royal Marsden Hospital, Fulham, London, United Kingdom|Sarah Cannon Research Institute, London, United Kingdom|Maidstone & Tonbridge Wells Hospital; Kent Oncology Center, Maidstone, United Kingdom|Christie Hospital, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Peterborough City Hospital, Peterborough, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Poole General Hospital; Oncology Research Park View House, Poole, United Kingdom|Musgrove Park Hospital; Department Clinical Research, Beacon Centre, Somerset, United Kingdom|Royal Marsden Hospital; Institute of Cancer Research, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT04177108"
219,"Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer|Triple Negative Breast Cancer","Drug: PMD-026","Phoenix Molecular Designs","PMD-026-1-001","October 4, 2019","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|The University of Arizona Cancer Center, Tucson, Arizona, United States|Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT04115306"
220,"Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)","Recruiting","No Results Available","Early Breast Cancer","Drug: PLD|Drug: CTX|Drug: Docetaxel|Drug: Paclitaxel|Drug: Doxorubicin","Fudan University","CSPC -DMS- BC-08","May 14, 2019","Fudan University affiliated cancer hospital, Shanghai, China","https://ClinicalTrials.gov/show/NCT03949634"
221,"Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Pyrotinib combined with capecitabine","Fudan University|Jiangsu HengRui Medicine Co., Ltd.","HR-BLTN-003","June 28, 2019","Fudan University Shanghai Cancer Center, Shanghai, China","https://ClinicalTrials.gov/show/NCT04001621"
222,"Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)","Recruiting","No Results Available","Metastatic Breast Cancer","Biological: huMNC2-CAR44 CAR T cells|Biological: huMNC2-CAR44 CAR T cells @ RP2D","Minerva Biotechnologies Corporation|Fred Hutchinson Cancer Research Center","10038","July 16, 2019","Fred Hutchinson Cancer Research Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04020575"
223,"Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)","Recruiting","No Results Available","Breast Cancer Metastatic","Drug: SAR439859|Drug: Endocrine monotherapy as per physician choice","Sanofi","ACT16105|2018-004593-98","August 16, 2019","Investigational Site Number 8400008, Birmingham, Alabama, United States|Investigational Site Number 8400018, Bakersfield, California, United States|Investigational Site Number 8400024, Santa Monica, California, United States|Investigational Site Number 8400019, Woodland, California, United States|Investigational Site Number 8400029, Fort Lauderdale, Florida, United States|Investigational Site Number 8400017, Chicago, Illinois, United States|Investigational Site Number 8400005, Chicago, Illinois, United States|Investigational Site Number 8400012, Tinley Park, Illinois, United States|Investigational Site Number 8400031, Urbana, Illinois, United States|Investigational Site Number 8400027, Fairway, Kansas, United States|Investigational Site Number 8400020, Baton Rouge, Louisiana, United States|Investigational Site Number 8400036, Silver Spring, Maryland, United States|Investigational Site Number 8400015, Boston, Massachusetts, United States|Investigational Site Number 8400032, Kansas City, Missouri, United States|Investigational Site Number 8400003, Billings, Montana, United States|Investigational Site Number 8400013, Lebanon, New Hampshire, United States|Investigational Site Number 8400025, Hackensack, New Jersey, United States|Investigational Site Number 8400009, Jamaica, New York, United States|Investigational Site Number 8400030, Pinehurst, North Carolina, United States|Investigational Site Number 8400006, Canton, Ohio, United States|Investigational Site Number 8400014, Tulsa, Oklahoma, United States|Investigational Site Number 8400001, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400023, Pittsburgh, Pennsylvania, United States|Investigational Site Number 8400022, Fort Worth, Texas, United States|Investigational Site Number 8400026, Burlington, Vermont, United States|Investigational Site Number 8400016, Madison, Wisconsin, United States|Investigational Site Number 0320003, Buenos Aires, Argentina|Investigational Site Number 0320006, Buenos Aires, Argentina|Investigational Site Number 0320004, La Rioja, Argentina|Investigational Site Number 0320005, Rosario, Argentina|Investigational Site Number 0320002, Salta, Argentina|Investigational Site Number 0360001, Nedlands, Australia|Investigational Site Number 0360003, South Brisbane, Australia|Investigational Site Number 0360002, Woolloongabba, Australia|Investigational Site Number 0560002, Charleroi, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 0560003, Namur, Belgium|Investigational Site Number 0760005, Goiania, Brazil|Investigational Site Number 0760001, Porto Alegre, Brazil|Investigational Site Number 0760002, Porto Alegre, Brazil|Investigational Site Number 0760006, Sao Paulo, Brazil|Investigational Site Number 0760003, São José Do Rio Preto, Brazil|Investigational Site Number 1240004, Calgary, Canada|Investigational Site Number 1240002, Cambridge, Canada|Investigational Site Number 1240003, London, Canada|Investigational Site Number 1240006, Montreal, Canada|Investigational Site Number 2030002, Brno, Czechia|Investigational Site Number 2030003, Novy Jicin, Czechia|Investigational Site Number 2030004, Praha 4, Czechia|Investigational Site Number 2500008, Angers Cedex 9, France|Investigational Site Number 2500006, Creteil Cedex, France|Investigational Site Number 2500007, Marseille, France|Investigational Site Number 2500005, Paris Cedex 10, France|Investigational Site Number 2500002, Saint-Herblain, France|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 3760002, Jerusalem, Israel|Investigational Site Number 3800001, Candiolo, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Prato, Italy|Investigational Site Number 3920007, Chiba-Shi, Japan|Investigational Site Number 3920004, Chuo-Ku, Japan|Investigational Site Number 3920001, Kashiwa-Shi, Japan|Investigational Site Number 3920008, Koto-Ku, Japan|Investigational Site Number 3920002, Nagoya-Shi, Japan|Investigational Site Number 3920003, Osaka-Shi, Japan|Investigational Site Number 3920006, Yokohama-Shi, Japan|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100004, Seoul, Korea, Republic of|Investigational Site Number 4100003, Seoul, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 4840005, Mexico, Mexico|Investigational Site Number 4840002, Monterrey, Mexico|Investigational Site Number 4840006, Veracruz, Mexico|Investigational Site Number 6160004, Pila, Poland|Investigational Site Number 6160003, Poznan, Poland|Investigational Site Number 8400028, Ponce De Leon, Puerto Rico|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Saint -Petersburg, Russian Federation|Investigational Site Number 6430004, Saint-Petersburg, Russian Federation|Investigational Site Number 7240006, Barcelona, Spain|Investigational Site Number 1580002, Taichung, Taiwan|Investigational Site Number 1580003, Tainan, Taiwan|Investigational Site Number 1580001, Taipei, Taiwan|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920002, Edirne, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920003, Istanbul, Turkey|Investigational Site Number 8040004, Odesa, Ukraine","https://ClinicalTrials.gov/show/NCT04059484"
224,"Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)","Recruiting","No Results Available","Advanced Breast Cancer",,"Spanish Breast Cancer Research Group|Roche Farma, S.A","GEICAM/2017-04","February 4, 2019","Hospital Universitario Virgen Macarena, Sevilla, Andalucía, Spain|Hospital del Mar, Barcelona, Cataluña, Spain|Hospital Clínico Universitario ""Virgen de la Arrixaca"", El Palmar, Murcia, Spain|Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain|ICO L´Hospitalet, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hopsital Clínico San Carlos, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT03829306"
225,"Pilot Study of a an App to Improve Medication Adherence in Breast Cancer Survivors Receiving AIs","Not yet recruiting","No Results Available","Breast Cancer|DCIS","Device: LifeExtend-AI","Indiana University","CTO-IUSCC-0715","November 20, 2019",,"https://ClinicalTrials.gov/show/NCT04170920"
226,"Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive，HR-Positive Metastatic Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Pyrotinib combined with fulvestrant","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","2019-KY-049","July 26, 2019","Sun Yat-Sen University Cancer Center, Guangyuan, China|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, China","https://ClinicalTrials.gov/show/NCT04034589"
227,"A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body","Completed","No Results Available","Metastatic Breast Cancer","Drug: LY3295668 Erbumine|Drug: Endocrine therapy|Drug: Midazolam","Eli Lilly and Company","17249|J1O-MC-JZHC|2018-004183-61","May 20, 2019","City of Hope National Medical Center, Duarte, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium","https://ClinicalTrials.gov/show/NCT03955939"
228,"Cyberknife for Early Stage Breast Cancer","Active, not recruiting","No Results Available","Early Stage Breast Cancer","Radiation: Cyberknife for Early Stage Breast Cancer","NYU Langone Health","18-01721","May 13, 2019","NYU Langone Health, New York, New York, United States","https://ClinicalTrials.gov/show/NCT03946683"
229,"Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated or Homologous Recombination Deficient (HRD) Advanced Breast Cancer","Recruiting","No Results Available","Advanced Breast Cancer","Drug: Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]","MedSIR","MedOPP168","April 30, 2019","Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Reina Sofía, Cordoba, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional y Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Fundación Onkologikoa, San Sebastián, Spain|Hospital Clínico Universitario de Santiago -CHUS, Santiago De Compostela, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Arnau de Vilanova de Valencia, Valencia, Spain|Complejo Asistencial de Àvila Hospital Ntra. Sra. de Sonsoles, Ávila, Spain","https://ClinicalTrials.gov/show/NCT03931551"
230,"Effects of Manual Therapy on Chronic Pain and Functionality of Breast Cancer Survivors","Recruiting","No Results Available","Breast Cancer","Other: Kinesiotherapy Protocol|Other: Manual Therapy Protocol|Other: Traditional Massage","University of the State of Santa Catarina","Manual Therapy BCS","September 10, 2019","Santa Catarina State University, Florianópolis, Santa Catarina, Brazil","https://ClinicalTrials.gov/show/NCT04084600"
231,"Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Drug: Pyrotinib combine with SHR6390","Sun Yat-sen University|Jiangsu HengRui Medicine Co., Ltd.","HR-BLTN-014","June 21, 2019",,"https://ClinicalTrials.gov/show/NCT03993964"
232,"A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","Not yet recruiting","No Results Available","Advanced Breast Cancer","Drug: SHR6390|Drug: Placebo|Drug: Fulvestrant","Jiangsu HengRui Medicine Co., Ltd.","SHR6390-III-301","April 25, 2019",,"https://ClinicalTrials.gov/show/NCT03927456"
233,"A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer","Withdrawn","No Results Available","Metastatic Breast Cancer","Drug: Abemaciclib|Drug: Nonsteroidal Aromatase Inhibitor (NSAI)","Eli Lilly and Company","17395|I3Y-MC-JPCX|2019-001781-16","June 17, 2019","Southern Cancer Center, P.C., Daphne, Alabama, United States|Arizona Oncology Associates, P.C., Tempe, Arizona, United States|Compassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States|California Cancer Associates Research and Excellence (cCARE), Fresno, California, United States|Beaver Medical Group, Highland, California, United States|Pacific Cancer Care, Monterey, California, United States|St. Joseph Hospital, Orange, California, United States|Comprehensive Cancer Centers of the Desert, Palm Springs, California, United States|California Cancer Associates in Research and Excellence, San Marcos, California, United States|Cancer Center of Santa Barbara with Sansum Clinic, Santa Barbara, California, United States|UCLA Medical Center, Torrance, California, United States|Memorial Hospital, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Center, Lone Tree, Colorado, United States|Medical Oncology Hematology Consultants, PA, Newark, Delaware, United States|BayCare Medical Group, Clearwater, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Woodlands Medical Specialists, Pensacola, Florida, United States|Cancer Specialists of North Florida -St Augustine, Saint Augustine, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Tallahassee, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Cleveland Clinic of Florida, Weston, Florida, United States|Summit Cancer Care, Savannah, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Community Health Network, Indianapolis, Indiana, United States|Central Maine Medical Center, Lewiston, Maine, United States|York Hospital, York, Maine, United States|HCA Midwest, Kansas City, Missouri, United States|Oncology Hematology West, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Valley Health System, Paramus, New Jersey, United States|Broome Oncology LLC, Johnson City, New York, United States|Abington Hematology Oncology Associates, Horsham, Pennsylvania, United States|Charleston Hematology Oncology Associates, Charleston, South Carolina, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Texas Oncology - Abilene, Abilene, Texas, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology-Arlington South, Arlington, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Texas Oncology - Bedford, Bedford, Texas, United States|Texas Oncology P.A., Dallas, Texas, United States|Texas Oncology - Medical City Dallas, Dallas, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Marnie McFadden Ward Cancer Center, Dallas, Texas, United States|Texas Oncology P.A., El Paso, Texas, United States|Texas Oncology Flower Mound, Flower Mound, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Texas Oncology-Memorial City, Houston, Texas, United States|Renovatio Clinical, Houston, Texas, United States|Texas Oncology - McAllen, McAllen, Texas, United States|Texas Oncology-McKinney, McKinney, Texas, United States|Texas Oncology- Mesquite, Mesquite, Texas, United States|Texas Oncology - Midland Allison Cancer Center, Midland, Texas, United States|Texas Oncology - Paris, Paris, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology-Plano West, Plano, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology-Sherman, Sherman, Texas, United States|US Oncology, The Woodlands, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Texas Oncology-Deke Slayton Cancer Center, Webster, Texas, United States|Texas Oncology-Wichital Falls Texoma Cancer Center, Wichita Falls, Texas, United States|Intermountain Medical Center, Saint George, Utah, United States|Hematology Oncology Associates of Fredericksburg Inc., Fredericksburg, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia Inc, Salem, Virginia, United States|Shenandoah Oncology, P.C., Winchester, Virginia, United States|Centro de Oncologia e Investigacion Buenos Aires, Berazategui, Buenos Aires, Argentina|CEMEDIC, Caba, Buenos Aires, Argentina|CENIT Centro de Neurociencias, Investigación y Tratamiento, Caba, Ciudad Autonoma Buenos Aires, Argentina|Centro Medico San Roque, San Miguel de Tucumán, Tucuman, Argentina|Clinica Adventista de Belgrano, Ciudad Autonoma Buenos Aires, Argentina|Sanatorio Parque, Salta, Argentina|Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan, San Juan, Argentina|Centro para la Atencion Integral del Paciente Oncologico, Tucumain, Argentina|Universitätsklinikum Graz, Graz, Steiermark, Austria|Universitätsklinik Innsbruck, Innsbruck, Tirol, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|AKH, Wien, Austria|Algemeen Ziekenhuis St Jan Brugge, Brugge, Belgium|Hopital De Jolimont, Haine-St.- Paul, Belgium|VZW REgional Ziekenhuis Jan Yperman, Ieper, Belgium|Clinique Saint Pierre Ottignies, Ottignies, Belgium|Núcleo de Oncologia da Bahia, Salvador, Bahia, Brazil|Instituto de Cancer de Londrina, Londrina, Parana, Brazil|Hospital de Caridade Ijui, Ijui, Rio Grande Do Sul, Brazil|Hospital São Lucas - PUCRS - ONCOLOGY, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto COI de Pesquisa Educação e Gestão, Rio de Janeiro, RJ, Brazil|Hospital Bruno Born de Lajeado, Lajeado, RS, Brazil|Fundação PIO XII, Barretos, Sao Paulo, Brazil|Hospital de Base Fac de Medicina de Sao Jose do Rio Preto, Sao Jose Rio Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|Hospital das Clinicas da FMRP, Ribeirao Preto, São Paulo, Brazil|INCA - Instituto Nacional Do Cancer, Rio de Janeiro, Brazil|Fundacao Antonio Prudente-Hosp. do Cancer AC Camargo, Sao Paulo, Brazil|Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology, São Paulo, Brazil|Clin. Pesq.e Centro Estudos Oncologia Ginecológica e Mamária, São Paulo, Brazil|Clinica Onco Star, São Paulo, Brazil|Hämatologisch-Onkologische Praxis Augsburg, Augsburg, Bavaria, Germany|Universität Leipzig - Universitätsklinikum, Leipzig, Sachsen, Germany|St. Vincenz-Krankenhaus GmbH-Frauen- und Kinderklinik St. Louise, Paderborn, Germany|Istituto Tumori Fondazione G. Pascale IRCCS, Napoli, Naples, Italy|Fondazione Piemonte l'Oncologia-Istituto Ricerca Cura Cancro, Candiolo, Torino, Italy|Policlinico S. Orsola Malpighi - Universita di Bologna, Bologna, Italy|Azienda Ospedaliera Universitaria Ospedale San Martino di Genova, Genova, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Istituto Oncologico Veneto, Padova, Italy|Centro di Riferimento Oncologico, Udine, Italy|Puerto Rico Hematology/Oncology Group, Bayamon, Puerto Rico|Ad-Vance Medical Research, Ponce, Puerto Rico|E-DA Cancer Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|MacKay Memorial Hospital, Taipei, Taiwan|Koo Foundation Sun Yan-Sen Cancer Center, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT03988114"
234,"Vitamin D Supplementation to Correct the Vitamin D Deficiency for Breast Cancer","Completed","No Results Available","Breast Cancer","Dietary Supplement: VITAMIN D","Institut du Cancer de Montpellier - Val d'Aurelle","ICM2013/06","September 16, 2019","Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, Montpellier, France","https://ClinicalTrials.gov/show/NCT04091178"
235,"A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","Not yet recruiting","No Results Available","Advanced Breast Cancer","Drug: SHR6390 Tablets|Drug: Placebo Tablets|Drug: Letrozole or Anastrozole Tablets","Jiangsu HengRui Medicine Co., Ltd.","SHR6390-III-302","May 29, 2019",,"https://ClinicalTrials.gov/show/NCT03966898"
236,"A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer|HER2-positive Breast Cancer","Drug: Pyrotinib|Drug: SHR6390|Drug: Letrozole|Drug: Capecitabine","Jinming Yu|Jiangsu HengRui Medicine Co., Ltd.|Shandong Cancer Hospital and Institute","HR-BLTN-010","September 19, 2019","Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China","https://ClinicalTrials.gov/show/NCT04095390"
237,"Evaluation of Prognostic Monitoring for Breast Cancer Patients With Recurrence and Metastasis After Surgery","Recruiting","No Results Available","Breast Cancer",,"Peking Union Medical College Hospital","PUMCH-BC501","October 31, 2019","Peking Union Medical College Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04145973"
238,"A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer","Suspended","No Results Available","Metastatic Breast Cancer","Drug: Abemaciclib|Drug: Fulvestrant|Drug: Standard Chemotherapy","Eli Lilly and Company","17320|I3Y-MC-JPCU","July 24, 2019","Scottsdale Healthcare Hospitals, Avondale, Arizona, United States|University of Arizona Cancer Center, Phoenix, Arizona, United States|Yuma Regional Cancer Center, Yuma, Arizona, United States|CARTI Cancer Center, Little Rock, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Compassionate Cancer Care Medical Group Inc, Corona, California, United States|Chan Soon- Shiong Institute for Medicine, Costa Mesa, California, United States|Chan Soon- Shiong Institute for Medicine, El Segundo, California, United States|Compassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|Scripps Clinic, La Jolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|TRIO - Translational Research in Oncology-US, Inc., Los Angeles, California, United States|Univ of California Irvine College of Medicine, Orange, California, United States|Comprehensive Cancer Centers of the Desert, Palm Springs, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|Emad Ibrahim, MD, INC, Redlands, California, United States|Compassionate Cancer Care Medical Group Inc, Riverside, California, United States|University of California, Davis - Health Systems, Sacramento, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|Banner MD Anderson Cancer Center, Greeley, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|Millennium Oncology, Hollywood, Florida, United States|Ocala Oncology, P.A., Ocala, Florida, United States|Tallahassee Memorial Cancer Center, Tallahassee, Florida, United States|Cleveland Clinic of Florida, Weston, Florida, United States|Candler Medical Oncology Practice, Savannah, Georgia, United States|Tift Regional Health System Anita Stewart Oncology Center, Tifton, Georgia, United States|Kaiser Permanente Center for Health Research, Honolulu, Hawaii, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Touro Infirmary, New Orleans, Louisiana, United States|Willis-Knighton Cancer Center, Shreveport, Louisiana, United States|York Hospital, York, Maine, United States|Reliant Medical Group, Inc., Worcester, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Baptist Cancer Center, Oxford, Mississippi, United States|St. Francis Medical Center, Grand Island, Nebraska, United States|Oncology Hematology West, Omaha, Nebraska, United States|OptumCare Cancer Care, Las Vegas, Nevada, United States|Carol Simon Cancer Center at Overlook Medical Center, Summit, New Jersey, United States|Brooklyn Methodist Hospital, Brooklyn, New York, United States|Weill Cornell Medical College, New York, New York, United States|SUNY At Stony Brook, Stony Brook, New York, United States|White Plains Hospital, White Plains, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cancer Care Associates of York, York, Pennsylvania, United States|Womens and Infants, Providence, Rhode Island, United States|Baptist Cancer Center, Memphis, Tennessee, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Oncology Consultants, P.A., Houston, Texas, United States|Renovatio Clinical, The Woodlands, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Cancer Care Northwest, Spokane, Washington, United States|Centro Integrado de Cancer del Sur, PSC, Coto Laurel, Puerto Rico|Bella Vista Oncology Group, Mayaguez, Puerto Rico|Ponce Medical School, Ponce, Puerto Rico|Centro de Cancer de la Mujer, Ponce, Puerto Rico|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico|Fundacion de Investigacion de Diego, San Juan, Puerto Rico","https://ClinicalTrials.gov/show/NCT04031885"
239,"Hyperventilation and Oxygenation to Prolong Breath Hold in Breast Cancer Irradiation Treatment","Recruiting","No Results Available","Breast Cancer","Device: Optiflow/Ventilator","University Hospital, Ghent","EC2019/0127","September 16, 2019","University Hospital - Radiotherapy Department, Ghent, Belgium","https://ClinicalTrials.gov/show/NCT04091542"
240,"Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Capecitabine plus aromatase inhibitor|Drug: A.I.","Ain Shams University","Combined CTH and HT in MBC","July 9, 2019","Clinical oncology department, Faculty of medicine, Ain Shams University, Cairo, Egypt","https://ClinicalTrials.gov/show/NCT04012918"
241,"Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer","Not yet recruiting","No Results Available","Triple-negative Breast Cancer","Drug: Chidamide combined with Cisplatin","Fudan University","1910208-9","December 10, 2019",,"https://ClinicalTrials.gov/show/NCT04192903"
242,"Pharmacodynamic Study of Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Advanced Breast Cancer","Not yet recruiting","No Results Available","Advanced Breast Cancer","Drug: Goserelin acetate 3.6 mg Injection|Drug: ZOLADEX® 3.6mg Injection","Eurofarma Laboratorios S.A.","EF 160","May 3, 2019",,"https://ClinicalTrials.gov/show/NCT03936933"
243,"Adipose-Induced Regeneration of Breast Skin to Treat Post-Mastectomy Radiation Injury in Breast Cancer Patients","Not yet recruiting","No Results Available","Breast Cancer","Procedure: Fat grafting","Mayo Clinic","19-002792","June 11, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States","https://ClinicalTrials.gov/show/NCT03981718"
244,"Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Positive Tumor","Drug: Talazoparib|Drug: ASTX727","Kathy Miller|Pfizer|Astex Pharmaceuticals, Inc.|Van Andel Institute Stand Up to Cancer Team|Indiana University","CTO-IUSCC-0684","October 22, 2019","Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States","https://ClinicalTrials.gov/show/NCT04134884"
245,"A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Drug: Pyrotinib|Drug: Treatment of physician's choice|Drug: vinorelbine","Sun Yat-sen University|Jiangsu HengRui Medicine Co., Ltd.","HR-BLTN-002","June 25, 2019",,"https://ClinicalTrials.gov/show/NCT03997539"
246,"Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)","Completed","No Results Available","Primary Breast Cancer","Drug: Paclitaxel|Drug: Docetaxel|Drug: Cyclophosphamide|Drug: Epirubicin|Drug: 5-fluorouracil","Fudan University","MASTER","October 15, 2019",,"https://ClinicalTrials.gov/show/NCT04127019"
247,"Breast Cancer: Axillary Conservation After Neoadjuvant Chemotherapy in Micro Metastatic Sentinel Lymph Nodes.","Recruiting","No Results Available","Breast Cancer","Procedure: Omission of Axillary dissection|Procedure: Axillary dissection","Istituto Clinico Humanitas","651","July 15, 2019","Istituto Clinico Humanitas, Rozzano, MI, Italy","https://ClinicalTrials.gov/show/NCT04019678"
248,"SHR-1210 Combined With Albumin-bound Paclitaxel and Epirubicin Neoadjuvant for Triple Negative Breast Cancer","Not yet recruiting","No Results Available","Triple-negative Breast Cancer","Drug: SHR-1210+Albumin-bound paclitaxel + epirubicin","Henan Cancer Hospital","HR-TNBC-HN100","December 30, 2019",,"https://ClinicalTrials.gov/show/NCT04213898"
249,"Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients","Recruiting","No Results Available","Triple Negative Breast Cancer",,"Peking Union Medical College Hospital","PUMCH-BC502","October 31, 2019","Peking Union Medical College Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04145947"
250,"The Impact of the Gene Recurrence Score on Chemotherapy Prescribing in ER Positive, Lymph Node Positive Early Stage Breast Cancer","Recruiting","No Results Available","Breast Cancer",,"Cancer Trials Ireland","CTRIAL-IE 15-34","February 18, 2019","Letterkenny University Hospital, Letterkenny, Co. Donegal, Ireland|St Vincent's University Hospital, Dublin, Dublin 4, Ireland|Mater Misericordiae University Hospital & Mater Private Hospital, Dublin, Dublin 7, Ireland|Beaumont Hospital, Dublin, Dublin 9, Ireland|Bon Secour Cork, Cork, Ireland|Cork University Hospital, Cork, Ireland|St James' Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|University Hospital Limerick, Limerick, Ireland|University Hospital Waterford, Waterford, Ireland","https://ClinicalTrials.gov/show/NCT03843346"
251,"Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Patients With Stage Ⅳ Breast Cancer","Not yet recruiting","No Results Available","Stage IV Breast Cancer","Combination Product: surgery combined with systemic therapy|Other: systemic therapy","Henan Cancer Hospital","HNCH-BC003","December 16, 2019",,"https://ClinicalTrials.gov/show/NCT04199520"
252,"Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer","Not yet recruiting","No Results Available","HR-positive Breast Cancer","Dietary Supplement: Vitamin B12|Other: Blood collection|Other: Brief Pain Inventory - Short Form survey|Other: FACT-ES Trial Outcome Index (Version 4)|Other: Questionnaire to Assess Adherence to Aromatase Inhibitors|Other: Demographics Questionnaire","Case Comprehensive Cancer Center","CASE5119","December 19, 2019","Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT04205786"
253,"Breast Cancer Self-Management Mobile Care Application Intervention in the Quality of Life","Completed","No Results Available","Breast Cancer|Quality of Life","Other: BCSMS App","National Yang Ming University","YM107109E","November 22, 2019","National Yang-Ming University, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT04174248"
254,"Rise Up After Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer|Body Image","Behavioral: Exercise|Behavioral: Art Sculpting Class","University of Alberta","HREBA.CC 19-0363","September 13, 2019","University of Alberta, Edmonton, Alberta, Canada","https://ClinicalTrials.gov/show/NCT04088877"
255,"Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)","Recruiting","No Results Available","Early-stage Breast Cancer","Combination Product: Endocrine Therapy and Radiotherapy","Ottawa Hospital Research Institute","OTT 18-02","May 14, 2019","Ottawa Hospital Research Institute, Ottawa, Ontario, Canada","https://ClinicalTrials.gov/show/NCT03948568"
256,"Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease","Active, not recruiting","No Results Available","Breast Cancer|Triple Negative Breast Neoplasms","Drug: Nivolumab|Drug: Ipilimumab|Drug: Capecitabine","Centre Leon Berard","ET17-093 BreastImmune03","January 28, 2019","Institut de Cancérologie de l'Ouest, Angers, France|Institut Sainte Catherine, Avignon, France|CHRU Besançon, Besançon, France|Centre Francois Baclesse, Caen, France|Hopital Prive Jean Mermoz, Lyon, France|Centre Léon Bérard, Lyon, France|Clinique de la Sauvegarde, Lyon, France|Institut Paoli Calmettes, Marseille, France|Centre Antoine Lacassagne, Nice, France|Institut Curie, Paris, France|Institut Jean Godinot, Reims, France|Institut Curie, Saint Cloud, France|Institut de Cancérologie de l'Ouest, Saint-Herblain, France|Centre Paul Strauss, Strasbourg, France","https://ClinicalTrials.gov/show/NCT03818685"
257,"A Prospective Evaluation of the Peri-operative Hypoxia in Breast Cancer","Recruiting","No Results Available","Breast Cancer Female","Procedure: Intra-operative Tumor Tissue Biopsy","Tata Memorial Hospital","Protocol 254","January 9, 2019","Tata Memorial Center, Mumbai, Maharashtra, India","https://ClinicalTrials.gov/show/NCT03797482"
258,"A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer","Recruiting","No Results Available","Triple-negative Breast Cancer","Biological: KN046|Drug: Nab-paclitaxel","Jiangsu Alphamab Biopharmaceuticals Co., Ltd","KN046-203","March 13, 2019","National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03872791"
259,"Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer","Not yet recruiting","No Results Available","Triple-negative Breast Cancer","Drug: Vinorelbine + placebo|Drug: Vinorelbine + Apatinib","Liaoning Tumor Hospital & Institute","STao-003","April 30, 2019",,"https://ClinicalTrials.gov/show/NCT03932526"
260,"Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Chemotherapeutic Agent","Fudan University","1808189-7","January 10, 2019","Cancer Hospital/ Institute, Fudan University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT03799679"
261,"A Study of Atezolizumab Plus Nab-Paclitaxel or Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer","Recruiting","No Results Available","Triple-Negative Breast Cancer","Drug: Atezolizumab|Drug: Nab-Paclitaxel|Drug: Paclitaxel","Hoffmann-La Roche","MO39874|2019-002488-91","November 4, 2019","Cemic; Oncologia Clinica, Buenos Aires, Argentina|Instituto de Investigaciones Metabolicas (Idim), Ciudad Autonoma de Buenos Aires, Argentina|Sanatorio de la Mujer, Rosario, Argentina|Pontificia Universidad Catolica de Chile; Centro Del Cáncer, Santiago, Chile|Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika, Brno, Czechia|Nemocnice Horovice, NH Hospital a.s.; Oncology Department, Horovice, Czechia|Nemocnice Nový Jicin a.s.; Oddeleni radioterapie a onkologie, Novy Jicin, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|Fakultni nemocnice v Motole; Onkologicka klinika 2. LF UK a FN Motol, Praha 5, Czechia|Nemocnice na Bulovce; Ustav radiacni onkologie, Praha 8, Czechia|Hopital Avicenne; Cancerologie, Bobigny, France|Institut de Cancérologie de Bourgogne; Oncologie Médicale, Dijon, France|Institut Hospitalier Franco-Britannique; Cancerologie, Levallois-Perret, France|CENTRE LEON BERARD; Département d'Hématologie et d'Oncologie, Lyon, France|Institut de cancerologie du Gard, Nimes, France|Chp Saint Gregoire; Cancerologie Radiotherapie, Saint Gregoire, France|Clinique Onco Des Dentellieres; Chimiotherapie Radiotherapie, Valenciennes, France|Departement Medecine; Immunotherapie, Villejuif, France|Debreceni Egyetem Klinikai Kozpont ; Department of Oncology, Debrecen, Hungary|Bacs-Kiskun Megyei Korhaz, SZTE AOK Oktato Korhaza, Onkoradiologiai Kozpont, Kecskemet, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly, Miskolc, Hungary|Komarom-Esztergom Megyei Onkormanyzat Szent Borbala Korhaz; Onkologiai Osztaly, Tatabánya, Hungary|Zala Megyei Korhaz; Dept of Oncology, Zalaegerszeg-Pozva, Hungary|Azienda Universitaria Magna Grecia; Dip. di Medicina Sperimentale e Clinica_U.O. Oncologia Medica, Catanzaro, Calabria, Italy|Azienda Ospedaliera San Giuseppe Moscati, Avellino, Campania, Italy|Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|Irccs Ospedale San Raffaele, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|Ospedale San Gerardo, Monza, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo, Oncologia, Pavia, Lombardia, Italy|Ospedale Di Macerata; Oncologia, Macerata, Marche, Italy|Presidio Ospedaliero di Summa-Perrino; Oncologia Medica, Brindisi, Puglia, Italy|Ospedale Civile; Oncologia Medica, Sassari, Sardegna, Italy|Ospedale Cannizzaro, Oncologia, Catania, Sicilia, Italy|Azienda ospedaliero-universitaria careggi, Sezione di radioterapia del dipartimento di fisiopatolo, Firenze, Toscana, Italy|Ospedale Della Misericordia; U.O. Di Medicina Ia - Oncologia Medica, Grosseto, Toscana, Italy|Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria - Polo Oncologico, Pisa, Toscana, Italy|Nuovo Ospedale di Prato S. Stefano - Azienda USL Toscana Centro, Prato, Toscana, Italy|Clinica Oncologica-Ospedali Riuniti Ancona, Torrette, Toscana, Italy|Fondazione del Piemonte per l'Oncologia (IRCCS), Candiolo, Trentino-Alto Adige, Italy|Ospedale Santa Chiara; Oncologia Medica, Trento, Trentino-Alto Adige, Italy|USL Umbria 1 - Osp. Città di Castello; U.O. di Oncologia, Città Di Castello (PG), Umbria, Italy|AULSS3 - Presidio di Mirano; Dip. di Oncologia, Mirano (VE), Veneto, Italy|Hospital de Oncología Siglo XXI, Ciudad de México, Mexico CITY (federal District), Mexico|Centro Estatal de Cancerologia de Chihuahua; ONCOLOGY, Chihuahua, Mexico|Instituto Nacional de Cancerologia; Oncology, Distrito Federal, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Hospital Central Fap Juan Benavides Dorich; Oncology, Lima, Peru|Hospital Nacional Cayetano Heredia; Hematology - Oncology, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Szpital Specjalistyczny Podkarpacki Ośrodek Onkologiczny, Brzozów, Poland|Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, Poland|Szpital Wojewódzki im. Mikołaja Kopernika; Oddział Dzienny Chemioterapii, Koszalin, Poland|Ars Medical Sp. z o. o., Piła, Poland|MRUKMED Lekarz Beata Madej-Mruk i Partner Spolka Partnerska Oddzial nr 1 w Rzeszowie, Rzeszow, Poland|Hospital Garcia de Orta; Servico de Oncologia Medica, Almada, Portugal|IPO de Coimbra; Servico de Oncologia Medica, Coimbra, Portugal|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, Portugal|Hospital de S. Francisco Xavier; Unidade de Oncologia Medica, Lisboa, Portugal|Hospital Cuf Descobertas; Unidade de Oncologia, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Narodny onkologicky ustav, Bratislava, Slovakia|Vychodoslovensky onkologicky ustav, Košice, Slovakia|POKO Poprad; Department of Oncology, Poprad, Slovakia|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Univerzitetni klinični center Maribor; Oddelek za onkologijo, Maribor, Slovenia|Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, Spain|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital Alvaro Cunqueiro, Vigo, Pontevedra, Spain|Hospital de Basurto; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Hospital Universitario San Cecilio; Servicio de Oncologia, Granada, Spain|Hospital Juan Ramon Jimenez;Servicio de Oncologia, Huelva, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia, Lerida, Spain|Hospital Lucus Augusti; Servicio de Oncologia, Lugo, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia, Murcia, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Hospital General de Segovia; Servicio de Oncologia, Segovia, Spain|Hospital Universitari i Politecnic La Fe; Oncologia, Valencia, Spain|Hosp Clinico Univ Lozano Blesa; División De Oncología Médica, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT04148911"
262,"A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer","Withdrawn","No Results Available","Metastatic Triple Negative Breast Cancer","Drug: Trifluridine/Tipiracil","AHS Cancer Control Alberta|Tom Baker Cancer Centre","OZM-103","November 4, 2019","Tom Baker Cancer Centre, Calgary, Alberta, Canada","https://ClinicalTrials.gov/show/NCT04149444"
263,"Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment","Recruiting","No Results Available","Triple-Negative Breast Cancer","Drug: JS001|Drug: Nab-Paclitaxel|Drug: Placebo","Shanghai Junshi Bioscience Co., Ltd.","JS001-026-III-TNBC","September 11, 2019","The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China|Beijing Hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Peking University People's Hospital, Beijing, Beijing, China|Peking University Shougang Hospital, Beijing, Beijing, China|Affiliated Hospital of Hebei University, Baoding, China|The first affiliated Hospital of Bengbu Medical College, Bengbu, China|Jilin Cancer Hospital, Changchun, China|The First Hospital of Jilin University, Changchun, China|Hunan Cancer Hospital, Changsha, China|Affiliated Hospital of Chengde Medical University, Chengde, China|Sichuan Cancer Hospital, Chengdu, China|Chongqing Cancer Hospital, Chongqing, China|The Second Hospital of Dalian Medical University, Dalian, China|The First People's Hospital of Foshan, Foshan, China|Fujian Medical University Union Hospital, Fuzhou, China|Guangdong General Hospital, Guangzhou, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China|Sun Yat-sen University Cancer Center, Guangzhou, China|The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China|The Women and Children's Hospital of Guangdong Province, Guangzhou, China|The First Affiliated Hospital Zhejiang University, Hangzhou, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Anhui Province Hospital & The First Affiliated Hospital of USTC, Hefei, China|The First Affiliated Hospital of Anhui Medical University, Hefei, China|The Second Hospital of Anhui Medical University, Hefei, China|The Affiliated Hospita of Inner Mongolia Medical University, Hohhot, China|Shandong Cancer Hospital, Jinan, China|Yunnan Cancer Hospital, Kunming, China|Linyi Cancer Hospital, Linyi, China|The Affiliated Hospita of of Southwest Medical University, Luzhou, China|Jiangxi Cancer Hospital, Nanchang, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|The Third Hospital of Nanchang, Nanchang, China|Jiangsu Cancer Hospital, Nanjing, China|Jiangsu Province Hospital, Nanjing, China|The Affiliated Hospital of Qingdao University, Qingdao, China|Changhai Hospital, Shanghai, China|Shanghai General Hospital, Shanghai, China|Liaoning Cancer Hospital&Intitute, Shenyang, China|The First Hospital of China Medical University, Shenyang, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, China|Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, China|Hubei Cancer Hospital, Wuhan, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, China|Affiliated Hospital of Jiangnan University（Wuxi NO.4 People's Hospital）, Wuxi, China|The First Affiliated Hospital of Xiamen University, Xiamen, China|Xiangyang Central Hospital, Xiangyang, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xian, China|The Second Affiliated Hospital of The PLA Air Force Military Medical University, Xian, China|General Hospital of Ningxia Medical University, Yinchuan, China|Henan Provincial People's Hospital, Zheng'zhou, China|Henan Cancer Hospital, Zhengzhou, China","https://ClinicalTrials.gov/show/NCT04085276"
264,"Impact of Recurrence Score on Adjuvant Treatment Decisions in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer Female",,"University Hospital Tuebingen","IRMA","May 23, 2019","Department for Women's Health, Tübingen, BW, Germany","https://ClinicalTrials.gov/show/NCT03961880"
265,"B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer","Recruiting","No Results Available","HER2-positive Breast Cancer","Biological: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.","Shanghai Pharmaceuticals Holding Co., Ltd","B003-101","May 17, 2019","West China Hospital of Sichuan University, Chengdu, Sichuan, China","https://ClinicalTrials.gov/show/NCT03953833"
266,"Assessment of Breast Cancer-Related Arm Lymphedema","Recruiting","No Results Available","Breast Neoplasms","Diagnostic Test: ICG、CM、VM、BIS、self-report","Peking University People's Hospital","PUPH18050101","June 7, 2019","Peking University People's Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03978754"
267,"Radical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis","Recruiting","No Results Available","Breast Cancer|Oligometastasis","Procedure: Radical resection|Radiation: Radical radiotherapy|Other: Palliative treatment","xuexin he|Second Affiliated Hospital, School of Medicine, Zhejiang University","BOMB","November 12, 2019","Institute of Cancer Research and Basic Medical Sciences, CAS Cancer Hospital, University of Chinese Academy of Sciences Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU), Hangzhou, Zhejiang, China|Jiaxing Second Hospital, Jiaxing, Zhejiang, China|The Central Hospital of Lishui, Lishui, Zhejiang, China","https://ClinicalTrials.gov/show/NCT04158843"
268,"Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Carboplatin|Drug: Paclitaxel|Drug: Doxorubicin|Drug: Cyclophosphamide","University of Illinois at Chicago","2019-0550","September 10, 2019","University of Illinois, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04083963"
269,"A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)","Recruiting","No Results Available","Triple-Negative Breast Cancer","Drug: camrelizumab in combination with nab-paclitaxel and famitinib","Fudan University","SCHBCC-N025","October 17, 2019","Zhi-Ming Shao, Shanghai, China","https://ClinicalTrials.gov/show/NCT04129996"
270,"Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer","Not yet recruiting","No Results Available","HER2-positive Breast Cancer","Drug: Pyrotinib|Drug: Trastuzumab","xuexin he|Second Affiliated Hospital, School of Medicine, Zhejiang University","SHERO","November 12, 2019",,"https://ClinicalTrials.gov/show/NCT04158856"
271,"Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer","Recruiting","No Results Available","HER2-positive Breast Cancer","Other: non-interventional","Chinese Academy of Medical Sciences","HR-BLTN-016","November 8, 2019","National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04158505"
272,"Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer","Recruiting","No Results Available","HER2-positive Breast Cancer","Drug: pegylated liposomal doxorubicin","Chinese Academy of Medical Sciences|CSPC Ouyi Pharmaceutical Co., Ltd.","CSPC-DMS-BC-11","May 1, 2019","Peng Yuan, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03933319"
273,"Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study","Not yet recruiting","No Results Available","HER2-positive Breast Cancer","Combination Product: pyrotinib maleate tablets+nab-paclitaxel","Hebei Medical University Fourth Hospital","HBBL-01","April 18, 2019",,"https://ClinicalTrials.gov/show/NCT03919253"
274,"Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation","Not yet recruiting","No Results Available","HER2-Negative Breast Cancer","Drug: Pembrolizumab","University of Malaya|Merck Sharp & Dohme (MSD)|National University Hospital, Singapore|Cancer Research Malaysia","IIT-UM2018001","June 18, 2019","University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia","https://ClinicalTrials.gov/show/NCT03989089"
275,"Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer","Not yet recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8","Biological: Pembrolizumab|Drug: Tamoxifen|Drug: Vorinostat","University of California, San Francisco|Merck Sharp & Dohme Corp.","197520|NCI-2019-07572","December 9, 2019","University of California, San Francisco, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT04190056"
276,"Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer","Recruiting","No Results Available","Metastatic Triple Negative Breast Cancer","Drug: Tumor infiltrating lymphocytes (TIL) LN-145","Yale University|Iovance Biotherapeutics, Inc.","2000025837","October 1, 2019","Yale School of Medicine, New Haven, Connecticut, United States","https://ClinicalTrials.gov/show/NCT04111510"
277,"Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.","Not yet recruiting","No Results Available","HER2 Positive Breast Cancer","Drug: Pyrotinib and Trastuzumab plus Vinorelbine","Henan Cancer Hospital","HR-NeoBC-HN003","May 13, 2019",,"https://ClinicalTrials.gov/show/NCT03947242"
278,"Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer","Not yet recruiting","No Results Available","HER2-positive Breast Cancer","Drug: Pyrotinib+Trastuzumab+Docetaxel+Carboplatin","Shandong University","495573096","February 20, 2019",,"https://ClinicalTrials.gov/show/NCT03847818"
279,"Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer","Recruiting","No Results Available","HER-2 Negative Breast Cancer","Drug: Chemotherapy","Fudan University","1808189-8","January 10, 2019","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai, China","https://ClinicalTrials.gov/show/NCT03799692"
280,"Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients","Not yet recruiting","No Results Available","Breast Cancer|DCIS","Drug: (Z)-Endoxifen supplementation according to genotype|Drug: (Z)-Endoxifen supplementation according to plasma levels","Robert Bosch Gesellschaft für Medizinische Forschung mbH","IKP275 / GBG91|2016-000418-31","April 30, 2019",,"https://ClinicalTrials.gov/show/NCT03931928"
281,"TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery","Not yet recruiting","No Results Available","HER2-positive Breast Cancer","Drug: TAHP and AHP|Drug: TAHP plus AC and AHP","Samsung Medical Center","2019-01-064","March 20, 2019","Samsung Medical Center, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT03881878"
282,"A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients","Recruiting","No Results Available","Triple Negative Breast Cancer|Residual Disease","Drug: Niraparib|Radiation: Radiation Therapy","Massachusetts General Hospital|Tesaro, Inc.","19-055","May 10, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT03945721"
283,"Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors","Recruiting","No Results Available","Breast Cancer|Fatigue","Behavioral: Energy Conservation Work Simplification Education","Ketki Raina|University of Toledo Medical Center|University of Toledo Health Science Campus","UT BCS ECS Study","November 12, 2019","University of Toledo, Toledo, Ohio, United States","https://ClinicalTrials.gov/show/NCT04160182"
284,"A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer","Recruiting","No Results Available","Estrogen Receptor-positive Breast Cancer","Dietary Supplement: 2-Week Ketogenic Diet|Drug: Letrozole","Vanderbilt-Ingram Cancer Center","VICC BRE 18108|NCI-2019-03071","May 24, 2019","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT03962647"
285,"A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer","Recruiting","No Results Available","HER2-positive Breast Cancer","Drug: tucatinib|Drug: placebo|Drug: T-DM1","Seattle Genetics, Inc.","SGNTUC-016","June 5, 2019","University of South Alabama - Mitchell Cancer Institute, Mobile, Alabama, United States|Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States|Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|California Cancer Associates for Research and Excellence Inc (cCARE), Encinitas, California, United States|UCLA Medical Center / David Geffen School of Medicine, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California, United States|University of California Irvine - Newport, Orange, California, United States|University of California Davis, Sacramento, California, United States|Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado, United States|University of Colorado Hospital / University of Colorado, Aurora, Colorado, United States|University of Colorado Health Memorial Hospital, Colorado Springs, Colorado, United States|Cancer Centers of Colorado - Denver, Denver, Colorado, United States|Poudre Valley Health System (PVHS), Fort Collins, Colorado, United States|SCL Health Good Samaritan Medical Center Cancer Centers of Colorado, Lafayette, Colorado, United States|Helen F. Graham Cancer Center / Christiana Care Health Systems, Newark, Delaware, United States|Florida Cancer Specialists - South Region, Fort Myers, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|AdventHealth Cancer Institute, Orlando, Florida, United States|Florida Cancer Specialists - North Region, Saint Petersburg, Florida, United States|Florida Cancer Specialists - East West Palm Beach, FL (SCRI), West Palm Beach, Florida, United States|Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Rush University Medical Center, Chicago, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|CHI Saint Joseph Medical Group Cancer Care Center, Lexington, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center -Weinberg Center, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders/RCCA, Bethesda, Maryland, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Minnesota Oncology Hematology P.A., Minneapolis, Minnesota, United States|North Mississippi Medical Center Hematology Oncology - Tupelo, Tupelo, Mississippi, United States|Saint Luke's Cancer Institute LLC, Kansas City, Missouri, United States|HCA Midwest Health Kansas City, Kansas City, Missouri, United States|Washington University in St Louis, Saint Louis, Missouri, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Summit Medical Group, Florham Park, New Jersey, United States|Rutgers Cancer Institute of New Jersey / Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States|Stony Brook University Cancer Center, Stony Brook, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Tigard, Oregon, United States|Brig Center for Cancer Care and Survivorship, Knoxville, Tennessee, United States|Tennessee Oncology - Nashville, Nashville, Tennessee, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology - Austin Central, Austin, Texas, United States|Texas Oncology - Medical City Dallas, Dallas, Texas, United States|Texas Oncology - Baylor Sammons Cancer Center, Dallas, Texas, United States|The Center for Cancer and Blood Disorders: Fortworth, Fort Worth, Texas, United States|Texas Oncology - Houston Memorial City, Houston, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care, Blacksburg, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Saint Francis Hospital / Bon Secours - Virginia, Midlothian, Virginia, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Swedish Cancer Institute - Edmonds, Edmonds, Washington, United States|Swedish Cancer Institute - Issaquah, Issaquah, Washington, United States|Swedish Cancer Institute, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT03975647"
286,"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation","Not yet recruiting","No Results Available","Advanced HER2+Breast Cancer","Drug: Alpelisib|Drug: Alpelisib matching Placebo|Drug: Trastuzumab|Drug: Pertuzumab","Novartis Pharmaceuticals|Novartis","CBYL719G12301|2019-002741-37","December 23, 2019",,"https://ClinicalTrials.gov/show/NCT04208178"
287,"Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR","Recruiting","No Results Available","Recurrent or Metastatic Breast Cancer","Diagnostic Test: cfDNA was detected by dPCR","Chinese Academy of Medical Sciences|Questgenomics","NCC1824","May 13, 2019","Chinese Academy of Medical Sciences, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03947736"
288,"A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)","Recruiting","No Results Available","Triple Negative Breast Cancer (TNBC)","Drug: TQB2450 Injection and Anlotinib Hydrochioride Capsules","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","TQB2450-Ib-07","February 26, 2019","Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03855358"
289,"A Study of TAS-120 in Patients With Metastatic Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer|FGFR2 Amplification","Drug: TAS-120|Drug: Fulvestrant","Taiho Oncology, Inc.","FOENIX-MBC2 TAS-120-201|2019-001164-30","July 18, 2019","UT Southwestern, Dallas, Texas, United States|MD Anderson, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04024436"
290,"Metastatic Breast Cancer in Austria","Recruiting","No Results Available","Breast Cancer|Breast Carcinoma|Breast Tumor",,"Arbeitsgemeinschaft medikamentoese Tumortherapie|Hoffmann-La Roche|Pfizer","AGMT_MBC-Registry","March 12, 2019","BHS Linz, Linz, Oberösterreich, Austria|Kepler Universitätsklinikum, Linz, Oberösterreich, Austria|LKH Steyr, Steyr, Oberösterreich, Austria|Klinikum Wels Grieskirchen, Wels, Oberösterreich, Austria|LKH-Univ. Klinikum Graz, Graz, Steiermark, Austria|Universitätsklinik für Frauenheilkunde Innsbruck, Innsbruck, Tirol, Austria|BKH Kufstein, Kufstein, Tirol, Austria|LKH Feldkirch, Feldkirch, Vorarlberg, Austria|Universitätsklinik für Innere Medizin III Salzburg, Salzburg, Austria|AKH Wien, Universitätsklinik für Frauenheilkunde, Wien, Austria","https://ClinicalTrials.gov/show/NCT03870620"
291,"Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer","Recruiting","No Results Available","TN ER-/PR-/HER2- Breast Cancer|Triple Negative Breast Cancer|HER2-positive Breast Cancer|ERany/PRany/HER2+ Breast Cancer","Radiation: Standard Trimodality Breast Imaging","Masonic Cancer Center, University of Minnesota","2018NTLS176","June 11, 2019","University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT03981705"
292,"Alpha-Lipoic Acid in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer|Chemotherapeutic Toxicity","Dietary Supplement: Alpha-lipoic acid|Drug: Chemotherapy","Damanhour University","Alpha-Lipoic Acid","April 9, 2019","Ayadi AL-Mostakbal Oncology Center, Alexandria, Egypt","https://ClinicalTrials.gov/show/NCT03908528"
293,"Technology-Supported Physical Activity Intervention for Metastatic Breast Cancer Survivors: Fit2ThriveMB","Enrolling by invitation","No Results Available","Metastatic Breast Cancer|Obesity","Behavioral: Fit2ThriveMB App|Behavioral: Fitbit|Behavioral: Physical Activity Coaching Calls|Behavioral: Healthy Living Coaching Calls|Behavioral: Cancer.net app","Northwestern University|National Cancer Institute (NCI)","SP00049673|R21CA239130","October 16, 2019","Northwestern University, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04129346"
294,"Exercise Treatment With Standard Therapy for Metastatic Breast Cancer","Recruiting","No Results Available","Hormone Receptor Positive Metastatic Breast Cancer","Other: Exercise Treatment","Memorial Sloan Kettering Cancer Center","19-113","June 17, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT03988595"
295,"Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers","Recruiting","No Results Available","TNBC - Triple-Negative Breast Cancer","Drug: Gedatolisib|Drug: Talazoparib","Kari Wisinski|Pfizer|Big Ten Cancer Research Consortium","BTCRC-BRE18-337","April 11, 2019","Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|University of Wisconsin, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03911973"
296,"The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer","Active, not recruiting","No Results Available","HER2-positive Advanced Breast Cancer","Biological: BAT8001 for injection|Drug: Lapatinib|Drug: Capecitabine","Bio-Thera Solutions","BAT-8001-002-CR","December 4, 2019","The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China|Anhui Provincial Hospital, Hefei, Anhui, China|Beijing Hospital, Beijing, Beijing, China|Beijing Shijitan Hospital, Beijing, Beijing, China|Peking union medical college hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Peking, Beijing, China|Chongqing Cancer Hospital, Chongqing, Chongqing, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|Foshan City No. 1 People's Hospital, Foshan, Guangdong, China|Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital. SYSU, Guangzhou, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Peking University Shenzhen Hospital, Shenzhen, Guangdong, China|Shenzhen People's Hospital, Shenzhen, Guangdong, China|The First Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China|The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai, Guangdong, China|Liuzhou workers hospital, Liuzhou, Guangxi, China|The First Affiliated Hospital of Hainan Medical College, Haikou, Hainan, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of science and technology, Luoyang, Henan, China|The First Affiliated Hospital of Xixiang Medical College, Xinxiang, Henan, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Tongji Hospital of Tongji Medical College of HUST, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Yichang Central Hospital, Yichang, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Jiangsu Cancer Hospital, Nanning, Jiangsu, China|Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China|Yancheng City No. 1 People's Hospital, Yancheng, Jiangsu, China|Jiangxi Cancer Hospital, Nanchang, Jiangxi, China|The Third Hospital of Nanchang, Nanchang, Jiangxi, China|Jilin Cancer Hospital, Chang chun, Jilin, China|The First Bethune Hospital of Jilin University, Changchun, Jilin, China|Jinzhou Central Hospital, Jinzhou, Liaoning, China|Liaoning Cancer Hospital, Shenyang, Liaoning, China|General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|Shandong Cancer Hospital, Jinan, Shandong, China|Linyi Cancer Hospital, Linyi, Shandong, China|Weifang People's Hospital, Weifang, Shandong, China|Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China|Shanghai General Hospital, Shanghai, Shanghai, China|Shanghai Sixth People's Hospital, Shanghai, Shanghai, China|The Second Hospital of Anhui Medical University, Shanghai, Shanghai, China|Shanxi Cancer Hospital, Xi'an, Shanxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Yunnan Cancer Hospital, Kunming, Yunnan, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Taizhou Hispotal of Zhejiang Province, Taizhou, Zhejiang, China","https://ClinicalTrials.gov/show/NCT04185649"
297,"A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer","Recruiting","No Results Available","HER2-positive Early Breast Cancer","Drug: SIBP-01|Drug: Herceptin|Drug: Docetaxel|Drug: Carboplatin","Shanghai Institute Of Biological Products|Fudan University","SIBP-01-3","June 18, 2019","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT03989037"
298,"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer","Recruiting","No Results Available","Breast Cancer|Triple-negative Breast Cancer|Nab-paclitaxel","Drug: Nab-paclitaxel + Carboplatin|Drug: Nab-paclitaxel + Epirubicin","Hebei Medical University Fourth Hospital|The fifth medical center of PLA general hospital|CSPC Ouyi Pharmaceutical Co., Ltd.","CSPC-KAL-BC-11","October 24, 2019","The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China","https://ClinicalTrials.gov/show/NCT04138719"
299,"A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer","Recruiting","No Results Available","Hormone Receptor Positive Advanced Breast Cancer","Drug: fluvestrant + oral vinorelbine","Chinese Academy of Medical Sciences","NCC1564","May 7, 2019","National Cacner Center/ Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03939871"
300,"Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors","Recruiting","No Results Available","Breast Cancer","Drug: Rucaparib","University of Arizona","30388|1903397220","April 11, 2019","University of Arizona Cancer Center, Tucson, Arizona, United States","https://ClinicalTrials.gov/show/NCT03911453"
301,"A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer","Recruiting","No Results Available","Breast Cancer|Cancer","Biological: Nivolumab|Drug: Anastrozole|Drug: Palbociclib","Bristol-Myers Squibb","CA209-7A8","September 3, 2019","Local Institution, Greenbrae, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Miami, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Northside Hospital,Inc.- Central Research Department, Atlanta, Georgia, United States|Local Institution, Louisville, Kentucky, United States|Local Institution, Boston, Massachusetts, United States|Summit Medical Group, Florham Park, New Jersey, United States|Local Institution, Hackensack, New Jersey, United States|Local Institution, Bronx, New York, United States|Local Institution, Cleveland, Ohio, United States|Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg, Virginia, United States|Peninsula Cancer Center Riverside Cancer Care Center, Newport News, Virginia, United States|Local Institution, Richmond, Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Rosario, Santa FE, Argentina|Local Institution, Caba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, North Sydney, New South Wales, Australia|Calvary Central Districts Hospital, Elizabeth Vale, South Australia, Australia|Local Institution, Bendigo, Victoria, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Geelong, Victoria, Australia|Breast Cancer Research Centre - WA, Nedlands, Western Australia, Australia|Local Institution, Charleroi, Belgium|Local Institution, Leuven, Belgium|Local Institution, Liege, Belgium|Local Institution, Namur, Belgium|Local Institution, Wilrijk, Belgium|Local Institution, Victoria, British Columbia, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Gatineau, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Bordeaux, France|Local Institution, Creteil Cedex, France|Local Institution, La Roche-sur-yon Cedex 9, France|Centre Leon Berard, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Montpellier, France|Local Institution, TOULOUSE Cedex 9, France|Local Institution, Berlin, Germany|Gynaekologisches Zentrum Bonn, Bonn, Germany|Local Institution, Erlangen, Germany|Klinik Essen-Mitte, Essen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Koeln, Germany|Local Institution, Leipzig, Germany|Evang. Krankenhaus Bethesda, Moenchengladbach, Germany|CaritasKlinikum Saarbruecken., Saarbruecken, Germany|Ponce Medical School Foundation, Ponce, Puerto Rico|Clinical Research Puerto Rico, San Juan, Puerto Rico|Fundacion De Investigacion, San Juan, Puerto Rico|H. Univ. Vall dHebron, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Santiago De Compostela, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04075604"
302,"Tucatinib + Abemaciclib + Herceptin for HER2+ MBC","Not yet recruiting","No Results Available","Breast Cancer","Drug: Tucatinib|Drug: Abemaciclib|Drug: Trastuzumab|Drug: Aromatase Inhibitor","Dana-Farber Cancer Institute|Eli Lilly and Company","18-621","February 19, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|The Broad Institute of MIT, Cambridge, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT03846583"
303,"Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis","Recruiting","No Results Available","Breast Tumors","Drug: DS-8201a","UNICANCER|Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","UC-0105/1815|2018-004868-57","October 21, 2019","Institut de Cancérologie de l'Ouest - Site Paul Papin, Angers, France|Institut Bergonié, Bordeaux, France|Centre François Baclesse, Caen, France|Sasu Roc 37, Chambray Les Tours, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Oscar Lambret, Lille, France|Centre Hospitalier Universitaire Dupuytren, Limoges, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes, Marseille, France|Institut Régional du Cancer Montpellier (ICM), Montpellier, France|Centre Antoine Lacassagne, Nice, France|Institut Curie, Paris, France|Institut Jean Godinot, Reims, France|Centre Eugène Marquis, Rennes, France|Institut Curie - Hôpital Huguenin, Saint-Cloud, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France|Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France|Institut Claudius Regaud, Toulouse, France|Institut de Cancérologie de Lorraine, Vandoeuvre Les Nancy, France|Gustave Roussy, Villejuif, France","https://ClinicalTrials.gov/show/NCT04132960"
304,"Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors","Recruiting","No Results Available","Breast Cancer|Adherence, Medication","Other: STRIDE|Other: Medication Monitoring Control","Massachusetts General Hospital|National Cancer Institute (NCI)","18-603|K07CA211107","February 12, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT03837496"
305,"'ADVANCE' (A Pilot Trial)","Recruiting","No Results Available","Breast Cancer","Drug: Paclitaxel|Drug: Cyclophosphamide|Drug: Carboplatin","Dana-Farber Cancer Institute|Mayo Clinic","19-031","February 28, 2019","City of Hope National Medical Center, Duarte, California, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) at Milford Regional Medical Center, Milford, Massachusetts, United States|Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in Clinical Affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT03858322"
306,"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","Recruiting","No Results Available","HER2-positive Early Breast Cancer","Drug: Pertuzumab IV|Drug: Trastuzumab IV|Drug: FDC of Pertuzumab and Trastuzumab SC|Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Docetaxel|Procedure: Surgery|Radiation: Post-Operative Radiotherapy|Drug: Hormone Therapy","Hoffmann-La Roche","YO41137","July 18, 2019","Peking University People's Hospital, Beijing, China|Beijing Cancer Hospital, Beijing, China|The First Hospital of Jilin University, Changchun City, China|Jilin Cancer Hospital, Changchun, China|West China Hospital, Sichuan University, Chengdu, China|Fuzhou General Hospital, PLA Nanjing Military Area Command, Fuzhou, China|Sun Yet-sen University Cancer Center, Guangzhou, China|Zhejiang Cancer Hospital; Breast Surgery, Hangzhou City, China|The Second Affiliated Hospital, Zhejiang University, Hangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Shandong Cancer Hospital, Jinan, China|Jiangsu Province Hospital, Nanjing, China|The Affiliated Hospital of Medical College Qingdao University, Qingdao, China|Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai City, China|Fudan University Shanghai Cancer Center, Shanghai City, China|Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province), Shijiazhuang, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China|Hubei Cancer Hospital, Wuhan, China|The First Affiliated Hospital of Xian Jiao Tong University, Xi'an City, China","https://ClinicalTrials.gov/show/NCT04024462"
307,"Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer","Recruiting","No Results Available","Breast Neoplasms","Drug: Endocrine therapy","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","2019-KY-051|ChiCTR1900024427","July 17, 2019","Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04023292"
308,"Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer","Recruiting","No Results Available","Breast Cancer|Triple Negative Breast Cancer|HER2-positive Breast Cancer","Drug: Nab-paclitaxel|Drug: Carboplatin|Drug: Herceptin","Ruijin Hospital","RJBC1801","April 9, 2019","Ruijin Hospital, Shanghai, China","https://ClinicalTrials.gov/show/NCT03907800"
309,"Effectiveness of Ear Acupuncture to Improve Insomnia in Women With Breast Cancer","Active, not recruiting","No Results Available","Breast Neoplasm","Procedure: Ear acupuncture|Behavioral: Psychoeducation","Universität Duisburg-Essen|Karl and Veronica Carstens Foundation","18-8214-BO|KVC 0/100/2018","March 14, 2019","Kliniken Essen-Mitte, Essen, NRW, Germany","https://ClinicalTrials.gov/show/NCT03874598"
310,"A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer","Recruiting","No Results Available","Breast Cancer|Brain Metastases","Drug: Pyrotinib Plus Vinorelbine","Chinese Academy of Medical Sciences","NCC1865","May 1, 2019","Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China","https://ClinicalTrials.gov/show/NCT03933982"
311,"Endometrial Changes in Breast Cancer Women With or Without Hormonal Therapies","Completed","No Results Available","Breast Cancer|Endometrial Cancer","Procedure: Diagnostic hysteroscopy and targeted endometrial biopsy","Università degli Studi dell'Insubria","BETA-1","April 2, 2019",,"https://ClinicalTrials.gov/show/NCT03898947"
312,"Mindful-life: Mindfulness Based Intervention vs Cognitive Behavioral Therapy in Patients With Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer|Depressive Symptoms","Behavioral: Mindfulness Based Intervention|Behavioral: Cognitive Behavioral Therapy","University of Turin, Italy","OstacoliMIND&BC","June 3, 2019",,"https://ClinicalTrials.gov/show/NCT03972020"
313,"Lifestyles and Breast Cancer","Not yet recruiting","No Results Available","Malignant Tumor of Breast","Behavioral: Mediterranean diet supplemented with extra-virgin olive oil|Behavioral: Low-fat diet","University of Navarra|Instituto de Salud Carlos III","2019.046","November 22, 2019","University of Cantabria, Santander, Cantabria, Spain|University of Navarra-Instituto de Investigación Sanitaria de Navarra, Pamplona, Navarra, Spain|Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain|University of Jaen, Jaen, Spain","https://ClinicalTrials.gov/show/NCT04174391"
314,"An Innovative Care-improvement Smartphone-based Perioperative Solution for Women Undergoing Breast Cancer Surgery","Recruiting","No Results Available","Breast Cancer Female|Surgery","Other: iCareBreast|Other: Routine care","HE Hong-Gu|KK Women's and Children's Hospital|Buddy Healthcare Ltd OY|National University, Singapore","2019/2632","November 21, 2019","KK Women's and Children's Hospital, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT04172350"
315,"Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer","Recruiting","No Results Available","Neutropenia|Breast Cancer","Drug: Eflapegrastim|Drug: Docetaxel|Drug: Cyclophosphamide","Spectrum Pharmaceuticals, Inc","SPI-GCF-104","December 5, 2019","ACRC/ Arizona Clinical Research Center, Tucson, Arizona, United States|Pacific Cancer Medical Center, Anaheim, California, United States|Pacific Shores Oncology, Long Beach, California, United States|Bond & Steele Clinic, P.A., Winter Haven, Florida, United States|Mercy Health Youngstown, Youngstown, Ohio, United States","https://ClinicalTrials.gov/show/NCT04187898"
316,"Sitravatinib in Metastatic Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer Stage IV|Triple Negative Breast Cancer|Breast Neoplasms|Breast Cancer Metastatic","Drug: Sitravatinib","Maryam Nemati Shafaee|Mirati Therapeutics Inc.|Baylor Breast Care Center","H-43432","October 11, 2019",,"https://ClinicalTrials.gov/show/NCT04123704"
317,"Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease","Recruiting","No Results Available","Breast Cancer|Joint Pain","Dietary Supplement: Curcumin|Other: Placebo|Other: Nanoemulsion|Other: Quality-of-Life Assessment|Behavioral: Questionnaire","City of Hope Medical Center|National Cancer Institute (NCI)","18432|NCI-2018-03787|UG1CA189823","March 7, 2019","City of Hope Medical Center, Duarte, California, United States|City of Hope Rancho Cucamonga, Rancho Cucamonga, California, United States|City of Hope South Pasadena, South Pasadena, California, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT03865992"
318,"RecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer|Radiation","Radiation: regional nodal irradiation|Radiation: WBI|Radiation: chestwall XRT","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Xiaobo Huang","RIGAIN","August 28, 2019","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04069884"
319,"KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer","Recruiting","No Results Available","Breast Cancer|Gastric/Gastroesophageal Junction Cancer","Drug: KN026","Jiangsu Alphamab Biopharmaceuticals Co., Ltd","KN026-US-I-001","February 20, 2019","Greenville Health System Center Institute, Greenville, South Carolina, United States","https://ClinicalTrials.gov/show/NCT03847168"
320,"Effect of Mindful Eating on Weight Management in Breast Cancer Survivors","Completed","No Results Available","Breast Neoplasm Female","Behavioral: Mindful eating intervention","University of Georgia","STUDY00002818","June 3, 2019",,"https://ClinicalTrials.gov/show/NCT03972540"
321,"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer","Recruiting","No Results Available","Triple Negative Breast Cancer|Nab-paclitaxel","Drug: Nab-paclitaxel + Carboplatin|Drug: Nab-paclitaxel + Capecitabine","Hebei Medical University Fourth Hospital|The fifth medical center of PLA general hospital|CSPC Ouyi Pharmaceutical Co., Ltd.","CSPC-KAL-BC-16","November 12, 2019","The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China","https://ClinicalTrials.gov/show/NCT04159142"
322,"Mindfulness-Enhanced Decision Intervention To Aid Treatment Election - Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer|Surgery","Behavioral: Mindfulness Session","NorthShore University HealthSystem|Northwestern University","EH18-203","March 19, 2019","NorthShore University HealthSystem, Evanston, Illinois, United States","https://ClinicalTrials.gov/show/NCT03880799"
323,"Highly Accelerated Dose-Integrated Radiotherapy in 5 Fractions in Breast Cancer","Completed","No Results Available","Breast Cancer|Radiotherapy","Radiation: Dose-integrated accelerated EBRT in pN0 breast cancer|Radiation: Dose-integrated accelerated EBRT in pN+ breast cancer","University Hospital, Ghent","EC/2014/1167","September 23, 2019","University Hospital - Radiotherapy Department, Ghent, Belgium","https://ClinicalTrials.gov/show/NCT04098926"
324,"Effects of Mediterranean Diet Based Intervention in Breast Cancer Patients","Not yet recruiting","No Results Available","Breast Cancer|Obesity","Behavioral: Mediterranean diet","Gangnam Severance Hospital","3-2019-0140","August 5, 2019",,"https://ClinicalTrials.gov/show/NCT04045392"
325,"Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer|Chest Wall Tumor","Drug: Pembrolizumab","European Institute of Oncology","IEO 675","June 3, 2019",,"https://ClinicalTrials.gov/show/NCT03971045"
326,"Sentinel Lymph Node Biopsy in Early Breast Cancer: a Real-world Multicenter Cross-sectional Study (CABS001 Study)","Recruiting","No Results Available","Breast Cancer|Sentinel Lymph Node","Diagnostic Test: mapping agent|Procedure: neoadjuvant chemotherapy","Xijing Hospital","KY20192114-C-1","November 8, 2019","Xijing hospital, Xi'an, Shaanxi, China","https://ClinicalTrials.gov/show/NCT04156841"
327,"The Consistency of Drug Screening in Vitro and Neoadjuvant Chemotherapy Results in Breast Cancer Patients","Completed","No Results Available","Breast Cancer|Drug Effect",,"Peking University People's Hospital|Peking University","PKUPH10B002","October 18, 2019","Peking University People'S Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04131881"
328,"Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer","Recruiting","No Results Available","Breast Cancer|Hormone Receptor Positive Tumor","Drug: Durvalumab|Drug: Anastrozole 1mg|Drug: Letrozole 2.5mg|Drug: Exemestane 25 MG","H. Lee Moffitt Cancer Center and Research Institute|AstraZeneca","MCC-19803|ESR-17-13182","March 14, 2019","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","https://ClinicalTrials.gov/show/NCT03874325"
329,"Mechanical Stimulation on Pain Level and Functional Discomfort After Breast Cancer Surgery","Not yet recruiting","No Results Available","Breast Cancer","Procedure: Mechanical Stimulation|Procedure: Massages","Centre Oscar Lambret","PRESSODOU-1809","December 17, 2019","Centre Oscar Lambret, Lille, Hauts-de- France, France","https://ClinicalTrials.gov/show/NCT04202640"
330,"Real-time Interactive Digital Healthcare System in Post Operation Patients With Breast Cancer; Pilot Study","Completed","No Results Available","Breast Cancer|Rehabilitation","Device: Uincare","JongIn Lee|Seoul St. Mary's Hospital","KC19EESI0325","November 5, 2019","Seoul St Mary's Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04152590"
331,"The Effect of Hyperbaric OxygeN Therapy on brEast Cancer Patients With Late Radiation toxicitY - UMBRELLA HONEY Trial","Recruiting","No Results Available","Breast Cancer|Radiation Toxicity","Drug: Hyperbaric oxygen therapy","UMC Utrecht|The Netherlands Cancer Institute","NL69081.041.19","December 10, 2019","University Medical Center Utrecht, Utrecht, Netherlands","https://ClinicalTrials.gov/show/NCT04193722"
332,"Comparison of Erector Spinae Plane Block With PECS II Block in Patients Undergoing Breast Cancer Surgery","Recruiting","No Results Available","Breast Cancer|Anesthesia, Local","Procedure: ESP BLOCK|Procedure: PECS BLOCK","University of Padova","ESPvsPECS/AOP","January 22, 2019","University of Padova, Padova, Veneto, Italy","https://ClinicalTrials.gov/show/NCT03811262"
333,"Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients","Not yet recruiting","No Results Available","HER2-positive Breast Cancer|Postmenopausal|Metastatic Breast Cancer","Drug: Ribociclib, Trastuzumab, Letrozole","Yonsei University","4-2018-0765","April 12, 2019","Yonsei Cancer Center at Yonsei University Health System, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT03913234"
334,"A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.","Recruiting","No Results Available","Early-stage Breast Cancer|Hormone Receptor Positive Tumor","Drug: Letrozole|Drug: Letrozole and Prometrium|Drug: Tamoxifen and Prometrium","St. Vincent's Hospital-Manhattan","ACTRN1261000928213","April 8, 2019","St Vincent's Hospital, Sydney, New South Wales, Australia","https://ClinicalTrials.gov/show/NCT03906669"
335,"Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Breast Cancer","Recruiting","No Results Available","Breast Cancer|Quality of Life",,"Helios University Hospital Wuppertal|Medical University of Graz|Université Catholique de Louvain|Hospital de Câncer de Barretos|University Hospital Rijeka|Evangelische Kliniken Gelsenkirchen, Germany|University Medical Center Freiburg|University Hospital Regensburg|Sheba Medical Center|Instituto Nazionale Tumori Fondazione Pascale|Istituto Oncologico Veneto IRCCS|Oslo University Hospital|Jagiellonian University|Oncology Department Hospital of Navarre|University of Leeds|The Netherlands Cancer Institute|Tumor- und Brust­zentrum ZeTuP St. Gallen|National Taiwan University|Taipei Veterans General Hospital, Taiwan|National Center for Global Health and Medicine, Japan|King Hussein Cancer Center","EORTC QLQ BR45","July 12, 2019","Helios Universitiätsklinikum Wuppertal, Universität Witten/Herdecke, Wuppertal, Germany","https://ClinicalTrials.gov/show/NCT04018235"
336,"Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer","Recruiting","No Results Available","Breast Cancer|Solid Tumor","Drug: OBT076, a CD205-directed antibody-drug conjugate","Oxford BioTherapeutics Ltd","OBT076-001","August 21, 2019","Cedars-Sinai, Los Angeles, California, United States|UCLA, Santa Monica, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Quantum Santa Fe, Santa Fe, New Mexico, United States|Columbia University Medical Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04064359"
337,"Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients","Recruiting","No Results Available","Fertility Preservation|Breast Cancer","Other: No hormone|Other: hCG|Other: GnRH a","Hôpital Jean Verdier","2014-A00819-38","May 17, 2019","Hôpital Jean Verdier, Bondy, France","https://ClinicalTrials.gov/show/NCT03954197"
338,"Light Emitting Diode for theTreatment of Genitourinary Syndrome of Menopause Associated With Breast Cancer Treatment","Recruiting","No Results Available","Atrophy;Vaginal|Breast Cancer","Procedure: Experimental: LED group|Procedure: Sham Comparator: Control","Centro de Atenção ao Assoalho Pélvico","CAAP CA","February 7, 2019","Centro de Atenção ao Assoalho Pelvico, Salvador, Ba, Brazil","https://ClinicalTrials.gov/show/NCT03833726"
339,"Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment","Enrolling by invitation","No Results Available","Fertility Preservation|Breast Cancer","Behavioral: web-based questionnaire","Memorial Sloan Kettering Cancer Center","18-461","January 28, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT03817814"
340,"Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases","Recruiting","No Results Available","Metastatic Breast Cancer|Brain Metastases","Drug: Nivolumab|Radiation: Stereotactic Radiosurgery","H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb","MCC-19765|CA209-8NK","January 17, 2019","H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States","https://ClinicalTrials.gov/show/NCT03807765"
341,"Lymphedema Prevention in Breast Cancer","Completed","No Results Available","Breast Cancer|Lymphedema","Procedure: 14 sessions of manual lymphatic drainage technique|Other: the health education","University of Castilla-La Mancha|Castilla-La Mancha Health Service","ECA-DLM-5","October 2, 2019","Provincial Hospital, Toledo, Spain","https://ClinicalTrials.gov/show/NCT04112966"
342,"Prospective Breast Cancer Biospecimen Collection","Recruiting","No Results Available","Breast Cancer|Invasive Breast Cancer|Carcinoma in Situ of the Breast","Procedure: Tissue Sample collection|Other: Blood Sample Collection|Other: Rectal Swab","Thomas Jefferson University","16D.674","August 30, 2019","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04074720"
343,"Analgesic Effect of Adding Thoracic Paravertebral Nerve Blocks to Modified PEC Block in Breast Cancer Surgery","Recruiting","No Results Available","Breast Cancer Female|Pain, Postoperative","Procedure: Thoracic paravertebral block under ultrasound guidance|Procedure: Intraoperative modified PEC block|Procedure: GA with ETT","Mahidol University","SI 475/2019","August 14, 2019","Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok Noi, Bangkok, Thailand","https://ClinicalTrials.gov/show/NCT04056676"
344,"WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor","Recruiting","No Results Available","Metastatic Breast Cancer|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Hormone Receptor Positive Breast Cancer","Drug: Palbociclib|Drug: Bosutinib|Drug: Fulvestrant","Georgetown University|Pfizer","STUDY00000057","February 26, 2019","Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States","https://ClinicalTrials.gov/show/NCT03854903"
345,"Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Local Advanced or Metastatic, HER2 Positive Breast Cancer.","Not yet recruiting","No Results Available","Solid Tumor|Breast Cancer","Drug: FS-1502","Shanghai Fosun Pharmaceutical Development Co, Ltd.","FS-CY1502-Ph1-01","May 9, 2019",,"https://ClinicalTrials.gov/show/NCT03944499"
346,"Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis","Recruiting","No Results Available","Breast Cancer|Lymph Node Metastases",,"Peking University People's Hospital","Luminal A sirt1","October 24, 2019","Peking university people's hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04137406"
347,"Genetic Markers of Circulating Tumor DNA for Monitoring Breast Cancer Patients in Costa Rica","Recruiting","No Results Available","Metastatic Breast Cancer|Mutation, Point",,"Universidad de Costa Rica","R018-SABI-00193|B9316","November 14, 2019","Hospital San Juan de Dios, San José, Costa Rica","https://ClinicalTrials.gov/show/NCT04163159"
348,"Limited Versus No-limited Shoulder Movement in Breast Cancer Surgery","Completed","No Results Available","Breast Neoplasms","Other: No limited movement after surgery","Instituto Nacional de Cancer, Brazil","Shoulder exercise cancer","January 8, 2019","Clarice Gomes Chagas Teodozio, Rio de Janeiro, RJ, Brazil","https://ClinicalTrials.gov/show/NCT03796845"
349,"FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer","Suspended","No Results Available","ERα+ Breast Cancer|ESR1 Gene Mutation","Drug: Tamoxifen|Diagnostic Test: FES PET/CT","University of Wisconsin, Madison","UW19046|2019-0935|A534260|SMPH/MEDICINE/MEDICINE|Protocol Version 10/17/2019","November 22, 2019","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Wisconsin Oncology Network (WONIX) sites, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT04174352"
350,"A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer","Not yet recruiting","No Results Available","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Drug: Oral NVB Metronomic|Drug: Oral NVB Weekly","Chinese Academy of Medical Sciences","BC2","February 26, 2019",,"https://ClinicalTrials.gov/show/NCT03854617"
351,"Photobiomodulation Therapy for the Prevention of Acute Radiodermatitis in Breast Cancer Patients Undergoing Radiotherapy","Recruiting","No Results Available","Radiodermatitis|Breast Cancer","Device: Photobiomodulation therapy (PBMT)|Device: Sham laser","Hasselt University|Jessa Hospital|Ziekenhuis Oost-Limburg","75","April 23, 2019","Ziekenhuis Oost-Limburg Campus St.-Jan, Genk, Limburg, Belgium|Jessa Ziekenhuis, Hasselt, Belgium","https://ClinicalTrials.gov/show/NCT03924011"
352,"CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer","Recruiting","No Results Available","Breast Neoplasms","Drug: Taxanes or/and anthracycline-based therapy","Shengjing Hospital","Shengjing-LJY03","August 16, 2019","Shengjing Hospital of China Medical University, Shenyang, Liaoning, China","https://ClinicalTrials.gov/show/NCT04059003"
353,"Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer Female|Hormone Receptor Positive Tumor","Drug: Tamoxifen Citrate","British Columbia Cancer Agency|Canadian Cancer Society Research Institute (CCSRI)|NanoString Technologies, Inc.","LA LEAST","April 16, 2019",,"https://ClinicalTrials.gov/show/NCT03917082"
354,"BAriaTric Surgery After Breast Cancer Treatment (BATS)","Not yet recruiting","No Results Available","Early-stage Breast Cancer|Obesity","Procedure: Bariatric Surgery with Sleeve Gastrectomy|Behavioral: Lifestyle Intervention","Masonic Cancer Center, University of Minnesota","2018LS148","May 10, 2019",,"https://ClinicalTrials.gov/show/NCT03946423"
355,"Circulating Tumor DNA as Marker of Therapeutic Efficacy in Breast Cancer Patients","Recruiting","No Results Available","Breast Neoplasms","Other: ctDNA level during neoadjuant chemotherapy","First Affiliated Hospital Xi'an Jiaotong University","XJTU1AF-CRF-2018-001","March 19, 2019","First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shaanxi, China","https://ClinicalTrials.gov/show/NCT03881384"
356,"16α-18F-fluor-17β-estradiol PET/CT for Visualisation of Estrogen Receptor Positive Liver Metastases From Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer","Radiation: 16α-18F-fluor-17β-estradiol","University of Aarhus|GCP-unit at Aarhus University Hospital, Aarhus, Denmark|REDCap","2020FES","November 5, 2019",,"https://ClinicalTrials.gov/show/NCT04150731"
357,"MACSSI (MAstectomie Cellules Souches Surveillance Immunitaire)","Not yet recruiting","No Results Available","Breast Cancer","Other: Characterization of breast stem & immune system cells infiltrated in the mammary gland","Centre Leon Berard","ET18-150 - MACSSI","March 12, 2019","Centre Léon Bérard, Lyon, France","https://ClinicalTrials.gov/show/NCT03870802"
358,"IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)","Completed","No Results Available","Breast Cancer|BRCA1 Mutation|BRCA2 Mutation","Genetic: BRCA mutation","Centre Hospitalier Universitaire de Besancon","P/2016/291","July 9, 2019","University Hospital Jean Minjoz, Besançon, Franche-Comté, France","https://ClinicalTrials.gov/show/NCT04012229"
359,"A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy","Recruiting","No Results Available","Breast Cancer","Device: DBT-TOBI|Device: MRI-TOBI","Massachusetts General Hospital|National Cancer Institute (NCI)","18-333|1R01CA187595","January 30, 2019","Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT03822312"
360,"Association of Hepatitis C Virus With Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer|Hepatitis C",,"Mansoura University","R.18.02.34.R1.R2","September 16, 2019","Mansoura University Oncology Center, Mansourah, DK, Egypt","https://ClinicalTrials.gov/show/NCT04090164"
361,"Evaluation of Sexual Quality of Life for Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer|Cancer|Quality of Life","Other: Quality of life","Institut du Cancer de Montpellier - Val d'Aurelle","PROICM 2019-16-BCU","December 16, 2019","Institut régional du Cancer de Montpellier, Montpellier, France","https://ClinicalTrials.gov/show/NCT04200001"
362,"Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer","Recruiting","No Results Available","Breast Carcinoma","Other: Best Practice|Other: Medical Chart Review|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Procedure: Supportive Care","M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.","2018-0473|NCI-2019-03897|P30CA016672","July 17, 2019","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04022772"
363,"Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients","Not yet recruiting","No Results Available","Breast Cancer|Chronic Pain Due to Malignancy (Finding)","Drug: Sulfasalazine|Drug: Placebos","University of Arizona","1605576856","February 20, 2019","Banner University Medical Center South, Tucson, Arizona, United States","https://ClinicalTrials.gov/show/NCT03847311"
364,"Patients' Preferences for Adjuvant Endocrine Therapy in Early Breast Cancer","Recruiting","No Results Available","Breast Cancer|Endocrine Breast Diseases","Other: Completion of questionnaires","European Institute of Oncology","IEO 0837/","May 6, 2019","European Institute of Oncology, Milan, Italy","https://ClinicalTrials.gov/show/NCT03939156"
365,"Establishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast Cancer","Recruiting","No Results Available","Breast Cancer|Breast Neoplasms|Hormone Receptor Positive Tumor","Diagnostic Test: Multi-parameter tests","Oslo University Hospital|KLINBEFORSK|Norwegian Cancer Society","Protocol EMIT-1","April 5, 2019","Drammen Hospital - Vestre Viken, Drammen, Buskerud, Norway|Østfold Hospital, Sarpsborg, Kalnes, Norway|Telemark Hospital, Skien, Ulefossveien 55, Norway|Haukeland University Hospital, Bergen, Norway|Oslo University Hospital, Oslo, Norway","https://ClinicalTrials.gov/show/NCT03904173"
366,"Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer","Recruiting","No Results Available","Breast Neoplasm Female","Drug: Venetoclax|Drug: Palbociclib|Drug: Letrozole","Peter MacCallum Cancer Centre, Australia","18/028","April 3, 2019","Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Austin Health, Melbourne, Victoria, Australia","https://ClinicalTrials.gov/show/NCT03900884"
367,"Effects of Computer-Assisted Cognitive Rehabilitation Programs With Breast Cancer Survivors","Recruiting","No Results Available","Cognitive Impairment|Breast Cancer","Behavioral: computer-assisted rehabilitation","Texas Woman's University","19959","July 22, 2019","Texas Woman's University, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04027400"
368,"Eurythmy Therapy (ERYT) as a Treatment Option for Fatigue in Metastatic Breast Cancer Patients","Recruiting","No Results Available","Fatigue|Breast Cancer","Other: Eurythmy therapy|Other: CoordiFit","University of Bern|Breast Cancer Research Foundation","123123","July 18, 2019","University Hospital Bern, Bern, Switzerland","https://ClinicalTrials.gov/show/NCT04024267"
369,"Sleep and Activity Patterns in Pre-menopausal Breast Cancer Patients on Tamoxifen Using a Wrist-worn Internet of Things Device","Recruiting","No Results Available","Sleep Disorder|Breast Cancer","Drug: Tamoxifen Oral Tablet","Samsung Medical Center","SMC 2018-07-014-011","October 7, 2019","Samsung Medical Center, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04116827"
370,"Stress Reactivity Among African American Breast Cancer Survivors","Recruiting","No Results Available","Breast Cancer Female|Stress Reaction",,"Medical University of South Carolina","AABCSR","March 19, 2019","Medical University of South Carolina, Charleston, South Carolina, United States","https://ClinicalTrials.gov/show/NCT03881085"
371,"Light-CT in the Diagnosis of Breast Tumor and Lymph Node","Recruiting","No Results Available","Breast Neoplasms","Diagnostic Test: Light-CT","Peking University People's Hospital","LightCT-PKUPH","January 3, 2019","Breast Center, Peking University People's Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03791853"
372,"Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases","Recruiting","No Results Available","Breast Cancer Metastatic|Bone Metastases","Other: Bone metastasis|Other: Breast cancer metastatic to bone","Istituto Ortopedico Galeazzi","BC-BOMET","November 19, 2019","IRCCS Istituto Ortopedico Galeazzi, Milan, Italy","https://ClinicalTrials.gov/show/NCT04167605"
373,"Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer|Neutropenia","Drug: PEG-rhG-CSF","Peking University","BC-P26","July 8, 2019",,"https://ClinicalTrials.gov/show/NCT04009941"
374,"Effectiveness of Stellate Ganglion Block in Breast Cancer Related Lymphedema","Enrolling by invitation","No Results Available","Lymphedema of Upper Limb|Breast Cancer Related Lymphedema","Combination Product: bupivacaine and triamcinolone","Marmara University","09.2019.984","November 18, 2019","Canan Şanal-Toprak, İstanbul, Turkey","https://ClinicalTrials.gov/show/NCT04165512"
375,"Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer Female|Locally Advanced Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast","Drug: Abemaciclib, durvalumab and aromatase inhibitor","Alison Stopeck|Eli Lilly and Company|AstraZeneca|Stony Brook University","2019-00174 Neoadj Breast Pilot","September 12, 2019","Stony Brook University Cancer Center, Stony Brook, New York, United States","https://ClinicalTrials.gov/show/NCT04088032"
376,"ATRA Trial - ACTIVITY OF ATRA IN COMBINATION WITH ANASTROZOLE IN PRE-OPERATIVE PHASE OF OPERABLE HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER eBC ATRA TRIAL","Recruiting","No Results Available","Breast Neoplasm Female","Drug: all-trans retinoic acid|Drug: Anastrozole 1mg","Mario Negri Institute for Pharmacological Research","RF-2016-02362383","October 3, 2019","ASST Papa Giovanni XXIII, Bergamo, Italy","https://ClinicalTrials.gov/show/NCT04113863"
377,"Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC","Recruiting","No Results Available","Breast Cancer","Drug: Ribociclib|Other: Mono-chemotherapy|Other: Endocrine-Therapy","Swiss Group for Clinical Cancer Research|The Belgian Society of Medical Oncology","SAKK 21/18|2018-003648-22","April 5, 2019","Kantonsspital Baden, Baden, Switzerland|Kantonsspital Baden, Baden, Switzerland|Universitaetsspital-Basel, Basel, Switzerland|Brustzentrum Basel - Praxis für ambulante Tumortherapie, Basel, Switzerland|Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Clinique des Grangettes, Chêne-Bougeries, Switzerland|Hôpital neuchâtelois, La Chaux-de-Fonds, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Kantonsspital Liestal, Liestal, Switzerland|Kantonsspital Luzern, Luzern, Switzerland|Hirslanden Klinik St. Anna Luzern, Luzern, Switzerland|Onkologie Zentrum Spital Männedorf, Männedorf, Switzerland|Kantonsspital Olten, Olten, Switzerland|Hôpital de Sion, Sion, Switzerland|Brustzentrum Ostschweiz, St. Gallen, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland|Spital STS AG, Thun, Switzerland|Kantonsspital Winterthur, Brustzentrum, Winterthur, Switzerland|Onkologie Bellevue, Zurich, Switzerland|OnkoZentrum Zürich AG - Klinik im Park, Zürich, Switzerland|Universitäts Spital Zürich, Zürich, Switzerland","https://ClinicalTrials.gov/show/NCT03905343"
378,"Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer","Recruiting","No Results Available","Invasive Breast Carcinoma","Other: Interview|Other: Medical Chart Review|Behavioral: Questionnaire","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","2018-1133|NCI-2019-05917|P30CA016672","September 12, 2019","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04087057"
379,"Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer","Recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8","Drug: Atezolizumab|Drug: Capecitabine|Drug: Carboplatin|Drug: Ipatasertib|Drug: Paclitaxel|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","City of Hope Medical Center|National Cancer Institute (NCI)","18496|NCI-2019-00465","February 26, 2019","City of Hope Medical Center, Duarte, California, United States","https://ClinicalTrials.gov/show/NCT03853707"
380,"Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer|Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III","Device: PAXMAN Scalp Cooler","Memorial Sloan Kettering Cancer Center","19-277","November 27, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04180579"
381,"FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients.","Not yet recruiting","No Results Available","Breast Neoplasms","Other: Prospective data and sample collection","Universitaire Ziekenhuizen Leuven|KU Leuven","S63330","December 16, 2019","UZ Leuven, Leuven, Belgium","https://ClinicalTrials.gov/show/NCT04200768"
382,"Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania","Recruiting","No Results Available","Breast Cancer Female|Breast Cancer|Breast Neoplasms|Neoplasms","Device: Contrast-enhanced mammogram","Wendie Berg|Breast Cancer Research Foundation|University of Pittsburgh","STUDY19060359","September 11, 2019","Magee Womancare Passavant Cranberry, Cranberry Township, Pennsylvania, United States|Magee Womancare Monroeville, Monroeville, Pennsylvania, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04085510"
383,"FSRT in Breast Cancer Patients With Brain Metastases","Recruiting","No Results Available","Breast Cancer|Brain Metastases","Radiation: Fractionated stereotactic radiotherapy(FSRT)","Fudan University","FDRT-BC009","August 19, 2019","Fudan University Shanghai Cancer Center, Shanghai, China","https://ClinicalTrials.gov/show/NCT04061408"
384,"Intravenous Chemotherapy and Plant-based Dietary Supplements","Recruiting","No Results Available","Breast Cancer","Other: dietary supplements questionary","Institut Cancerologie de l'Ouest","ICO-N-2018-12|2018-A02460-55","May 22, 2019","Institut de Cancerologie de L'Ouest, Saint Herblain, France","https://ClinicalTrials.gov/show/NCT03959618"
385,"BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases","Recruiting","No Results Available","Breast Cancer|Liver Metastases","Procedure: Surgical intervention|Drug: Control","Umeå University|Uppsala University|Karolinska Institutet|Linkoeping University|Lund University|Göteborg University","BreCLIM-2018-116-31M","September 6, 2019","Umeå University Hospital, Umeå, Sweden","https://ClinicalTrials.gov/show/NCT04079049"
386,"Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer","Recruiting","No Results Available","Breast Neoplasms","Procedure: PET-CT examination|Procedure: Peripheral blood detection","Shengjing Hospital","Shengjing-LJY04","August 22, 2019","Shengjing Hospital of China Medical University, Shenyang, Liaoning, China","https://ClinicalTrials.gov/show/NCT04065321"
387,"Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC","Not yet recruiting","No Results Available","Metastatic Breast Cancer","Drug: Pyrotinib Maleate combine with Docetaxel","Zhejiang Cancer Hospital|Jiangsu HengRui Medicine Co., Ltd.","HR-BLTN-001","March 15, 2019","Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China","https://ClinicalTrials.gov/show/NCT03876587"
388,"Feasibility Study: Yoga Educational Project","Completed","No Results Available","Breast Cancer","Behavioral: educational yoga program","Institut du Cancer de Montpellier - Val d'Aurelle","PROICM 2018-02 SKY|2018-A00208-47","June 28, 2019","Institut du Cancer de Montpellier, Montpellier, France","https://ClinicalTrials.gov/show/NCT04001751"
389,"Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy","Active, not recruiting","No Results Available","Breast Cancer","Drug: Palbociclib + an aromatase inhibitor|Drug: Palbociclib + Letrozole|Drug: Letrozole","Pfizer","A5481122","November 25, 2019","Pfizer, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04176354"
390,"Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)","Recruiting","No Results Available","Triple Negative Breast Neoplasms","Biological: Pembrolizumab|Drug: Olaparib|Drug: Carboplatin|Drug: Gemcitabine","Merck Sharp & Dohme Corp.","7339-009|2019-001892-35|MK-7339-009|KEYLYNK-009|195082","December 9, 2019","Pacific Cancer Care ( Site 0142), Monterey, California, United States|John Wayne Cancer Institute ( Site 0111), Santa Monica, California, United States|St. Joseph Heritage Healthcare ( Site 0104), Santa Rosa, California, United States|Virginia Piper Cancer Institute ( Site 0157), Minneapolis, Minnesota, United States|The Center For Cancer And Blood Disorders ( Site 0151), Fort Worth, Texas, United States|Renovatio Clinical ( Site 0117), The Woodlands, Texas, United States|YVMH dba Vrigina Mason Memorial/North Star Lodge Cancer Center ( Site 0128), Yakima, Washington, United States|Princess Margaret Cancer Centre ( Site 0005), Toronto, Ontario, Canada|McGill University Health Centre ( Site 0002), Montreal, Quebec, Canada|Sociedad de Investigaciones Medicas Limitadas ( Site 0510), Temuco, Araucania, Chile|IC La Serena Research ( Site 0511), La Serena, Coquimbo, Chile|Fundacion Arturo Lopez Perez ( Site 0500), Santiago, Region Metropolitana De Santiago, Chile|Pontificia Universidad Catolica de Chile ( Site 0501), Santiago, Region Metropolitana De Santiago, Chile|Oncocentro ( Site 0502), Vina del Mar, Valparaiso, Chile|Fundacion Colombiana de Cancerologia Clinica Vida ( Site 0601), Medellin, Antioquia, Colombia|Clinica de la Costa Ltda. ( Site 0600), Barranquilla, Atlantico, Colombia|Organizacion Clinica Bonnadona-Prevenir S.A.S. ( Site 0609), Barranquilla, Atlantico, Colombia|Oncomedica S.A. ( Site 0606), Monteria, Cordoba, Colombia|Hemato Oncologos S.A. ( Site 0603), Cali, Valle Del Cauca, Colombia|Fundacion Valle del Lili ( Site 0602), Cali, Villa Del Cauca, Colombia|CHU-Jean Minjoz ( Site 1013), Besancon, Doubs, France|Institut Claudius Regaud IUCT Oncopole ( Site 1001), Toulouse, Haute-Garonne, France|Centre Jean Perrin ( Site 1003), Clermont-Ferrand Cedex 01, Puy-de-Dome, France|Centre Henri Becquerel ( Site 1020), Rouen, Seine-Maritime, France|CHU Amiens Hopital Sud ( Site 1023), Amiens, Somme, France|Gynaekologisches Zentrum-Schwerpunkt Gyn. Onkologie ( Site 1205), Bonn, Nordrhein-Westfalen, Germany|Universitaetsklinikum Carl Gustav Carus ( Site 1203), Dresden, Sachsen, Germany|Bacs-Kiskun Megyei Korhaz ( Site 1608), Kecskemet, Bacs-Kiskun, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 1607), Pecs, Baranya, Hungary|Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 1601), Szolnok, Jasz-Nagykun-Szolnok, Hungary|Orszagos Onkologiai Intezet ( Site 1602), Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont ( Site 1600), Debrecen, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 1604), Kaposvar, Hungary|Zala Megyei Szent Rafael Korhaz ( Site 1605), Zalaegerszeg, Hungary|Aichi Cancer Center Hospital ( Site 2202), Nagoya, Aichi, Japan|Hyogo College of Medicine Hospital ( Site 2203), Nishinomiya, Hyogo, Japan|Fukushima Medical University Hospital ( Site 2201), Fukushima, Japan|Hiroshima City Hiroshima Citizens Hospital ( Site 2204), Hiroshima, Japan|National Hospital Organization Osaka National Hospital ( Site 2200), Osaka, Japan|Gachon University Gil Medical Center ( Site 2408), Incheon, Incheon-gwangyeoksi [Incheon], Korea, Republic of|National Cancer Center ( Site 2406), Goyang-si, Kyonggi-do, Korea, Republic of|Seoul National University Bundang Hospital ( Site 2409), Seongnam-si, Kyonggi-do, Korea, Republic of|Ajou University Hospital ( Site 2407), Suwon-si, Kyonggi-do, Korea, Republic of|Seoul National University Hospital ( Site 2403), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 2401), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Asan Medical Center ( Site 2404), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Samsung Medical Center ( Site 2405), Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Kyungpook National University Chilgok Hospital ( Site 2402), Daegu, Taegu-Kwangyokshi, Korea, Republic of|Regionalny Szpital Specjalistyczny Latawiec ( Site 1917), Swidnica, Dolnoslaskie, Poland|Pratia MCM Krakow ( Site 1919), Krakow, Malopolskie, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1908), Warszawa, Mazowieckie, Poland|Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 1913), Gdynia, Pomorskie, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1912), Gliwice, Slaskie, Poland|Pleszewskie Centrum Medyczne w Pleszewie Sp. z o.o. ( Site 1909), Pleszew, Wielkopolskie, Poland|Instituto Oncologico Baselga.Hospital Quiron. ( Site 0707), Barcelona, Barcelona [Barcelona], Spain|Hospital Universitari Vall d Hebron ( Site 0701), Barcelona, Barcelona [Barcelona], Spain|Hospital Clinic I Provincial de Barcelona ( Site 0702), Barcelona, Barcelona [Barcelona], Spain|Hospital General Arnau de Vilanova de Valencia ( Site 0706), Valencia, Valenciana, Comunitat, Spain|Hospital Universitario Reina Sofia ( Site 0705), Cordoba, Spain|Clinica Universitaria Navarra - Madrid ( Site 0700), Madrid, Spain|Kaohsiung Chang Gung Memorial Hospital ( Site 2304), Kaohsiung, Taiwan|National Cheng Kung University Hospital ( Site 2303), Tainan, Taiwan|MacKay Memorial Hospital ( Site 2301), Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center ( Site 2300), Taipei, Taiwan|China Medical University Hospital ( Site 2302), Taipei, Taiwan|Dnipropetrovsk City Multidiscipline Clinical Hosp. 4 of DRC ( Site 1502), Dnipro, Dnipropetrovska Oblast, Ukraine|CI Krivorizhskiy oncology dispensery ( Site 1504), Kryviy Rih, Dnipropetrovska Oblast, Ukraine|MI Precarpathian Clinical Oncology Center ( Site 1506), Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine|SI-Zaytsev institute of general and urgent surgery-NAMS ( Site 1518), Kharkiv, Kharkivska Oblast, Ukraine|Medical Center Verum ( Site 1501), Kyiv, Kyivska Oblast, Ukraine|Medical Centre Consilium Medical ( Site 1514), Kyiv, Kyivska Oblast, Ukraine|Zhytomyr Regional Oncology Center ( Site 1515), Zhytomyr, Zhytomyrska Oblast, Ukraine|Raigmore Hospital ( Site 0915), Inverness, Highland, United Kingdom","https://ClinicalTrials.gov/show/NCT04191135"
391,"Does Type of Anesthesia Influence Inflammation Change After Breast Surgery?","Recruiting","No Results Available","Breast Cancer Female","Drug: Midazolam|Procedure: PECS|Procedure: Opioid-free general anesthesia|Procedure: General anesthesia|Procedure: Postoperative analgesia","Centro di Riferimento Oncologico - Aviano","CRO-2019-26","November 21, 2019","Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, PN, Italy","https://ClinicalTrials.gov/show/NCT04172220"
392,"Ashwagandha for Cognitive Dysfunction","Not yet recruiting","No Results Available","Breast Cancer","Drug: Ashwagandha|Drug: Placebo","Sutter Health","SIMR_onc19_IIS_D'Andre_Ashwaga","September 17, 2019","Sutter Cancer Center, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT04092647"
393,"Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy","Not yet recruiting","No Results Available","Breast Cancer|Sentinel Lymph Node|Neoplasm, Breast","Procedure: Axillary lymph node dissection|Radiation: Axillary radiotherapy|Radiation: Breast or chest wall radiotherapy","University Hospitals of Derby and Burton NHS Foundation Trust","NIHR 128311","September 30, 2019",,"https://ClinicalTrials.gov/show/NCT04109079"
394,"A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2","Not yet recruiting","No Results Available","HER2 Positive Breast Carcinoma",,"Anhui Provincial Hospital","AnhuiPH","April 9, 2019",,"https://ClinicalTrials.gov/show/NCT03908749"
395,"Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.","Recruiting","No Results Available","ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer|a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status","Drug: Durvalumab|Drug: Olaparib|Drug: Fulvestrant","UNICANCER|ARCAGY/ GINECO GROUP|SOLTI Breast Cancer Research Group","UC-0140/1812","August 12, 2019","Institut de Cancerologie de Montpellier, Montpellier, France|Centre Henri-Becquerel, Rouen, France","https://ClinicalTrials.gov/show/NCT04053322"
396,"Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer|Invasive Ductal Breast Carcinoma|Invasive Lobular Breast Carcinoma","Diagnostic Test: Radiomic, pathomic, and clinical markers","Sunnybrook Health Sciences Centre","270-2018","July 16, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04021069"
397,"Efficacy Study of Mepitel Film the Prophylaxis of Radiation-Induced Skin Reactions in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer|Radiation Dermatitis","Other: Mepitel Film","Sunnybrook Health Sciences Centre","294-2018","April 10, 2019","Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT03910595"
398,"Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.","Not yet recruiting","No Results Available","Breast Cancer|Leptomeningeal Metastasis","Procedure: Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment|Procedure: Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""Lack of evidence"" according to EANO-ESMO classification|Procedure: Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are ""confirmed"", ""probable"" or ""possible"", leading to leptomeningeal metastase specific treatment","Centre Oscar Lambret","Exo-LCR-1807|2018-A02358-47","June 4, 2019","Centre Oscar Lambret, Lille, Hauts-de- France, France|Centre Hospitalier Régional Universitaire de Lille, Lille, Hauts-de-France, France","https://ClinicalTrials.gov/show/NCT03974204"
399,"Study of the Utility of the BOMET-QOL Questionnaire Patients With Breast Cancer and Bone Metastasis","Completed","No Results Available","Breast Carcinoma Metastatic to the Bone","Diagnostic Test: BOMET-QoL questionnaire","Spanish Breast Cancer Research Group|Novartis Pharmaceuticals","Mabomet","February 20, 2019","Hospital Universitario Virgen Del Rocío, Sevilla, Andalucia, Spain|Hospital General de Guadalajara, Guadalajara, Castilla-La Mancha, Spain|ICO Badalona Hospital Universitari Germans Trias I Pujol, Badalona, Cataluña, Spain|Hospital Universitari Clinic I Provincial, Barcelona, Cataluña, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Cataluña, Spain|Hospital Mutua de Terrassa, Barcelona, Cataluña, Spain|ICO Girona Hospital Dr. Josep Trueta, Gerona, Cataluña, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Cataluña, Spain|Fundació Althaia, Xarxa Assistencial de Manresa, Manresa, Cataluña, Spain|Hospital General Universitario de Alicante, Alicante, Cominidad Valenciana, Spain|Hospital Clínico Universitario de Valencia, Valencia, Comunidad Valenciana, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Galicia, Spain|Centro Oncologico de Galicia, A Coruña, Galicia, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Galicia, Spain|Hospital de Barbastro, Barbastro, Huesca, Spain","https://ClinicalTrials.gov/show/NCT03847220"
400,"Brief Intervention for Tobacco and Alcohol Risk Reduction for Couple During Breast Cancer Treatment.","Not yet recruiting","No Results Available","Breast Cancer|Smoking Cessation|Alcohol Use, Unspecified","Behavioral: Brief motivational interview on tobacco/alcohol risk reduction","Institut Bergonié|Ligue contre le cancer, France","IB 2017-05|2017-A03315-48","July 5, 2019","Institut Bergonie, Bordeaux, France","https://ClinicalTrials.gov/show/NCT04007549"
401,"Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC","Recruiting","No Results Available","Breast Cancer","Drug: Tesetaxel|Drug: Capecitabine","Odonate Therapeutics, Inc.","ODO-TE-B201","March 1, 2019","Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Center, Lakewood, Colorado, United States|Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|New York Cancer and Blood Specialists, East Setauket, New York, United States|West Cancer Center, Germantown, Tennessee, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Border Medical Oncology, Albury, New South Wales, Australia|Hopital Maisonneuve-Rosemont, Montréal, Canada|Center Hospitalier de Montreal CHUM McPeak Sirois, Montréal, Canada|CIUSSS de Centre-Ouest-de-l'Île-de-Montréal Jewish General Hospital, Montréal, Canada|McGill University Health Center, Montréal, Canada|CHU de Quebec-University Laval, Québec, Canada|Centre Hospitalier Universitaire de Sherbrooke CIUSSS de lEstrie CHUS patyre, Sherbrooke, Canada|Kyungpook National University Hospital, Daegu, Korea, Republic of|National Cancer Center, Goyang, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Hospital Teresa Herrera Materno-Infantil (CHUAC), A Coruña, Spain|Fundacion Jimenez Diaz, Madrid, Spain|National Taiwan University Hospital, Taipei City, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT03858972"
402,"Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)","Recruiting","No Results Available","Breast Cancer|Renal Cell Carcinoma","Drug: IPI-549|Drug: Atezolizumab|Drug: nab-paclitaxel|Drug: Bevacizumab","Infinity Pharmaceuticals, Inc.|Roche Pharma AG","IPI-549-03","May 23, 2019","Arizona Oncology Associates, Tucson, Arizona, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|Pacific Cancer Care, Monterey, California, United States|Sharp Memorial Hospital, San Diego, California, United States|UCLA, Santa Monica, California, United States|University of Colorado, Aurora, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Tennessee Oncology, Nashville, Tennessee, United States|UT Health East Texas HOPE Cancer Center, Tyler, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT03961698"
403,"Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer|Breast Neoplasms|Triple Negative Breast Cancer|HER2-positive Breast Cancer","Drug: Parsaclisib","UNC Lineberger Comprehensive Cancer Center|Incyte Corporation","LCCC1820","October 29, 2019",,"https://ClinicalTrials.gov/show/NCT04142554"
404,"Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -","Completed","No Results Available","Breast Cancer","Drug: Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Drug: Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib","MedSIR|Pfizer","MedOPP199","January 28, 2019","Hospital da Luz, Lisboa, Portugal|Hospital Fernando Fonseca, Lisboa, Portugal|Portuguese Institute of Oncology of Oporto, Oporto, Portugal|ICO Badalona, Badalona, Barcelona, Spain|ICO l'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital de Jaén, Jaen, Jaén, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, Spain|H. Vall Hebrón, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Onkologikoa, Donostia, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Instituto Valenciano de Oncologia, Valencia, Spain|Hospital Arnau de Vilanova de Valencia, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain","https://ClinicalTrials.gov/show/NCT03819010"
405,"A Web-Based Tool to Improve Breast Cancer Survivorship","Recruiting","No Results Available","Breast Cancer|Hormone Dependent Neoplasms|Adherence to Hormone Therapy","Behavioral: ""OncoTool"" Intervention (MBSR + HT education)|Behavioral: ""Oncotool"" Control (health +HT education)","Northwestern University","STU00206180","February 21, 2019","Northwestern University, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT03849573"
406,"Acupuncture for Insomnia in Breast Cancer Patients Undergoing Chemotherapy","Recruiting","No Results Available","Insomnia, Secondary|Breast Cancer Female|Chemotherapy","Procedure: Electroacupuncture (EA) and Auricular Acupressure (AA)|Procedure: Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)","The University of Hong Kong","UW 19-045","October 30, 2019","Department of Clinical Oncology, Queen Mary Hospital, Hong Kong, Hong Kong|Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong","https://ClinicalTrials.gov/show/NCT04144309"
407,"REJOIN Trial for Older Breast Cancer Survivors","Recruiting","No Results Available","Breast Cancer Female","Behavioral: Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)","Milton S. Hershey Medical Center|American Cancer Society, Inc.","STUDY00010776","May 20, 2019","Penn State Cancer Institute, Hershey, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03955627"
408,"A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone","Recruiting","No Results Available","HER2-positive Breast Cancer|Brain Metastases","Drug: Afatinib|Drug: T-DM1","xuexin he|Second Affiliated Hospital, School of Medicine, Zhejiang University","HER2BAT","November 12, 2019","Peking University International Hospital, Beijing, Beijing, China|Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, Guangdong, China|Kiang Wu Hospital, Macao, Macao, China|The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU), Hangzhou, Zhejiang, China","https://ClinicalTrials.gov/show/NCT04158947"
409,"Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery","Recruiting","No Results Available","Breast Cancer Patient","Drug: Capsaicin|Drug: Pregabalin","Institut Cancerologie de l'Ouest|Grünenthal GmbH","ICO-A-2018-10","January 7, 2019","Institut de Cancerologie de L'Ouest, Angers, France|Chu Grenoble, Grenoble, France|Chd Vendee, La Roche-sur-Yon, France|Centre Oscar Lambret, Lille, France|Hopital Saitn Vincent de Paul, Lille, France|Centre Leon Berard, Lyon, France|CHU NICE, Nice, France|Institut Jean Godinot, Reims, France|Institut Curie, Saint-Cloud, France|Iuct Oncopole, Toulouse, France|Ch Valenciennes, Valenciennes, France","https://ClinicalTrials.gov/show/NCT03794388"
410,"Late-term Effects of Hypofractionated Chest Wall and Regional Nodal Irradiation in Patients With Breast Cancer","Completed","No Results Available","Late Effects of Hypofractionated Radiotherapy in Breast Cancer","Radiation: Hypofractionated radiotherapy","Postgraduate Institute of Medical Education and Research","LEHR","November 25, 2019",,"https://ClinicalTrials.gov/show/NCT04175821"
411,"Effects of a Physical Exercise Program in Quality of Life of Breast Cancer Survivors","Recruiting","No Results Available","Breast Cancer|Quality of Life|Physical Exercise","Other: Physical exercise program","Associacao de Investigacao de Cuidados de Suporte em Oncologia|Centro Hospitalar de Vila Nova de Gaia/Espinho|Aveiro University|University Institute of Maia","MAMA_MOVE_Gaia After Treatment","July 18, 2019","Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Oporto, Portugal","https://ClinicalTrials.gov/show/NCT04024280"
412,"Effects of Bariatric Surgery on Breast Density Improvement and Impact on Breast Cancer Risk in Severe Obese Patients","Not yet recruiting","No Results Available","Breast Cancer|Morbid Obesity|Bariatric Surgery Candidate","Procedure: Bariatric surgery","The Cleveland Clinic","FLA 18-057","November 20, 2019",,"https://ClinicalTrials.gov/show/NCT04170335"
413,"Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","Recruiting","No Results Available","HER2-positive Breast Cancer|Metastatic Breast Cancer|Locally Advanced Breast Cancer|Unresectable Breast Cancer","Drug: Copanlisib|Drug: Trastuzumab emtansine","Cancer Trials Ireland","CTRIAL-IE 17-13","August 1, 2019","Cancer Trials Ireland Investigative Site, Cork, Ireland|Cancer Trials Ireland Investigative Site, Dublin 4, Ireland|Cancer Trials Ireland Investigative Site, Dublin 9, Ireland|Cancer Trials Ireland Investigative Site, Seville, Spain","https://ClinicalTrials.gov/show/NCT04042051"
414,"Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer","Suspended","No Results Available","Breast Cancer|DCIS|LCIS","Radiation: MRIdian Radiation Treatment Unit","University of Wisconsin, Madison","UW18099|2019-0322|SMPH\HUMAN ONCO\HUMAN ONCO|A533300|NCI-2019-03111|Protocol Version 3/10/2020","May 3, 2019","University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03936478"
415,"Impact of Intensive Follow-up for Bone Metastasis on Characteristics and Prognosis of Chinese Breast Cancer Patients","Completed","No Results Available","Breast Cancer|Bone Metastases","Diagnostic Test: Intensive screening / routine screening","Peking University People's Hospital|Fudan University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|Harbin Medical University","20160504","April 23, 2019","Peking University People's Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03924609"
416,"Safety and Performance of the Multi-Modal UltraSound Tomography (MUST) Device in Breast Cancer Screening","Recruiting","No Results Available","Breast Cancer Screening","Device: MUST device","Transonic Imaging, Inc.","MUST-02-001","September 25, 2019","Beth Israel Deaconess Medical Center BreastCare Center, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04102722"
417,"PET/MR in Surgical Planning for Breast CA Treated With Neoadj Chemo","Terminated","Has Results","Breast Cancer","Diagnostic Test: PET/MR","UNC Lineberger Comprehensive Cancer Center","LCCC 1716","November 4, 2019","UNC- Chapel Hill, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04149353"
418,"Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer","Recruiting","No Results Available","Breast Cancer|Adherence, Medication|Side Effect","Behavioral: BETA-Text text messaging intervention","Yale University","2000024495","May 14, 2019","Yale Cancer Center, New Haven, Connecticut, United States","https://ClinicalTrials.gov/show/NCT03949270"
419,"LASER and Radiofrequency for Treatment of Vaginal Vulvar Atrophy (VVA) in Women Treated for Breast Cancer (EPMLARF-arm2)","Recruiting","No Results Available","Vaginal Atrophy|Vulva; Atrophy|Breast Cancer","Procedure: LASER|Procedure: Micro Ablative Radiofrequency|Drug: Promestriene","Federal University of São Paulo|Fundação de Amparo à Pesquisa do Estado de São Paulo","CEP0431/2018 arm 2","September 9, 2019","Federal University of Sao Paulo - Unifesp, São Paulo, SP, Brazil","https://ClinicalTrials.gov/show/NCT04081805"
420,"Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer","Recruiting","No Results Available","Breast Cancer|HER2 Positive|Combination Chemotherapy","Drug: Pyrotinib Maleate Tablets|Drug: Albumin Paclitaxel|Drug: Trastuzumab","West China Hospital|Jiangsu HengRui Medicine Co., Ltd.","BLTN-NeoBC1115","November 5, 2019","West China Hospital, Sichuan University, Chengdu, Chengdu, Sichuan, China, China","https://ClinicalTrials.gov/show/NCT04152057"
421,"68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer","Recruiting","No Results Available","Breast Carcinoma|Estrogen Receptor Positive","Drug: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Procedure: Magnetic Resonance Imaging|Procedure: Positron Emission Tomography|Device: Investigational software and coils in PET/MR scan","Andrei Iagaru|General Electric|Stanford University","IRB-48150|NCI-2019-00237|BRS0098","February 6, 2019","Stanford Cancer Institute Palo Alto, Palo Alto, California, United States","https://ClinicalTrials.gov/show/NCT03831711"
422,"Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC","Recruiting","No Results Available","Breast Cancer Female","Drug: Ribociclib 200Mg Oral Tablet","West German Study Group|Novartis|Genomic Health®, Inc.","WSG-AM08","August 13, 2019","Klinikum der Universität München Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Brustzentrum, Munich, Bavaria, Germany|Universitätsklinikum Aachen, Frauenklinik - Senologie, Aachen, NRW, Germany|Kliniken Essen-Mitte, Klinik für Senologie/Interdisziplinäres Brustzentrum, Essen, NRW, Germany|Praxis für gynäkologische Onkologie am Ev. Krankenhaus Bethesda, Moenchengladbach, NRW, Germany","https://ClinicalTrials.gov/show/NCT04055493"
423,"Omitting Biopsy of SEntinel Lymph Node With Radiation After Neoadjuvant Chemotherapy in Breast Cancer (OBSERB) Trial","Not yet recruiting","No Results Available","Breast Neoplasm Female|Lymphatic Metastasis","Procedure: Radiotherapy","Kyungpook National University Chilgok Hospital|Korean Breast Cancer Study Group","2019-09-023","October 4, 2019",,"https://ClinicalTrials.gov/show/NCT04116125"
424,"Photoacoustic Lymph Node Imaging","Enrolling by invitation","No Results Available","Breast Cancer","Diagnostic Test: Spectroscopic photoacoustic imaging","Geoff Luke|Dartmouth College|Dartmouth-Hitchcock Medical Center","D18155","April 30, 2019","Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States","https://ClinicalTrials.gov/show/NCT03931655"
425,"The SONImage Study","Recruiting","No Results Available","Breast Cancer","Other: FES-PET scan, and possibly one additional visit for an FDG-PET","University Medical Center Groningen|Dutch Cancer Society|BOOG Study Center","201900572","October 14, 2019","VU Medical Center, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands","https://ClinicalTrials.gov/show/NCT04125277"
426,"Proton Accelerated Partial Breast Irradiation","Enrolling by invitation","No Results Available","Breast Cancer","Radiation: Proton Accelerated Partial Breast Irradiation","University of Cincinnati","2019-0088","May 7, 2019","University of Cincinnati, Cincinnati, Ohio, United States","https://ClinicalTrials.gov/show/NCT03940248"
427,"A Pilot Trial of Preoperative Oral Microbiota-based Investigational New Drug","Not yet recruiting","No Results Available","Breast Cancer","Biological: RBX7455","Mayo Clinic|Rebiotix Inc.","19-004024","October 25, 2019",,"https://ClinicalTrials.gov/show/NCT04139993"
428,"Continuous Serrates Plane Block in Axillary Dissection","Recruiting","No Results Available","Breast Cancer","Procedure: Continuous serratus plane block","Arcispedale Santa Maria Nuova-IRCCS","CIMPAX BREAST","June 20, 2019","Ausl-Irccs Reggio Emilia, Reggio Emilia, RE, Italy","https://ClinicalTrials.gov/show/NCT03992859"
429,"Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC","Active, not recruiting","No Results Available","Breast Cancer",,"Fudan University","YOUNGBC-8","June 28, 2019","Biyun Wang, MD, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04001634"
430,"Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer","Recruiting","No Results Available","Invasive Ductal Breast Carcinoma","Drug: Degarelix injection(s)","Assistance Publique - Hôpitaux de Paris","P170407J|2018-000049-38","May 13, 2019","Hôpital Antoine Béclère, Clamart, France","https://ClinicalTrials.gov/show/NCT03947151"
431,"Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer","Recruiting","No Results Available","Breast Neoplasms|HER-2 Gene Amplification",,"University Hospital, Brest","EPTTCSM (239BRC18.0129)","June 7, 2019","CHRU de Brest, Brest, France","https://ClinicalTrials.gov/show/NCT03979911"
432,"18F-FES PET/CT's Additional Clinical Value in ER+ BC","Completed","No Results Available","Breast Cancer",,"Fudan University","YOUNGBC-7","July 5, 2019","Biyun Wang, MD, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04006626"
433,"Neo-RT: A Study Investigating Whether Changing the Sequence of Treatments (Starting Radiotherapy Followed by Hormone Therapy Before Surgery) is Feasible","Recruiting","No Results Available","Breast Cancer","Radiation: Intensity modulated radiotherapy (IMRT)|Drug: Endocrine therapy|Procedure: Breast conserving surgery","CCTU- Cancer Theme|Breast Cancer Now|CRUK Cambridge Institute|Cambridge University Hospitals NHS Foundation Trust","Neo-RT","January 28, 2019","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom","https://ClinicalTrials.gov/show/NCT03818100"
434,"A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Pyrotinib, Trastuzumab, Docetaxel|Drug: Placebo, Trastuzumab, Docetaxel","Jiangsu HengRui Medicine Co., Ltd.","HR-BLTN-III-MBC-C","March 5, 2019","Cancer Institute and Hospital,Chinese Academy of Medical Science, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03863223"
435,"Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy","Not yet recruiting","No Results Available","Breast Cancer","Drug: palbociclib combined with letrozole|Drug: epirubicin combined with cyclophosphamide and sequential docetaxel","Shengjing Hospital","Shengjing-LCG003","October 24, 2019","Shengjing Hospital of China Medical University, Shenyang, Liaoning, China","https://ClinicalTrials.gov/show/NCT04137640"
436,"Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients","Recruiting","No Results Available","Metastatic Breast Carcinoma|Locally Advanced Breast Cancer","Drug: 68GaNOTA-Anti-HER2 VHH1","Universitair Ziekenhuis Brussel|Kom op tegen Kanker (Stand-up-to-Cancer), the Flemish cancer society|Agentschap voor Innovatie door Wetenschap en Technologie, Project Toegepast Biomedisch onderzoek met een primair Maatschappelijke finaliteit.","UZBRU_VHH1_3|2016-002164-13","April 23, 2019","Uz Brussel, Brussels, Brussel, Belgium","https://ClinicalTrials.gov/show/NCT03924466"
437,"Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer","Active, not recruiting","No Results Available","Breast Cancer|Breast Cancer Female|HER2-positive Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III","Drug: Docetaxel|Drug: Herceptin|Drug: FEC|Drug: Tamoxifen|Drug: Letrozole|Drug: LHRH agonist","University of Chicago","IRB18-1178","March 19, 2019","University College Hospital, Ibadan, Nigeria, Ibadan, Nigeria","https://ClinicalTrials.gov/show/NCT03879577"
438,"Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients","Suspended","No Results Available","Breast Cancer Stage IV|Radiotherapy|Surgery","Drug: Palbociclib|Other: locoregional treatment","UNICANCER|Pfizer","UC-0140/1814|2019-A00570-57","March 12, 2019","Institut de Cancérologie de l'Ouest-Site Paul Papin, Angers, France|Centre Hospitalier de Beauvais, Beauvais, France|Centre François Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre George François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Hôpital St Joseph, Marseille, France|Institut Paoli Calmettes, Marseille, France|ICM Val d'Aurelle, Montpellier, France|Polyclinique de Gentilly, Nancy, France|Centre Antoine Lacassagne, Nice, France|Institut Curie Site Paris, Paris, France|Hôpital Saint Louis APHP, Paris, France|Hôpital St Joseph, Paris, France|Hôpital Tenon, Paris, France|Centre Hospitalier de Pau, Pau, France|Institut Jean Godinot, Reims, France|Institut Curie Hôpital René Huguenin, Saint Cloud, France|Hôpitaux Universitaires de Strasbourg, Strasbourg, France|Institut Claudius Regaud, Toulouse, France|Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France|Gustave Roussy, Villejuif, France","https://ClinicalTrials.gov/show/NCT03870919"
439,"Influence of an Intervention on Diet, Physical Exercise and Mindfulness in the Quality of Life of Survivors With Breast Cancer","Completed","No Results Available","Breast Cancer|Nutrition Related Cancer|Physical Activity|Mindfulness","Other: Mediterranean diet, physical exercise and mindfulness workshops","Universidad de Granada|University Hospital Virgen de las Nieves","040907","November 4, 2019",,"https://ClinicalTrials.gov/show/NCT04150484"
440,"Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Sacituzumab Govitecan|Drug: Eribulin|Drug: Capecitabine|Drug: Gemcitabine|Drug: Vinorelbine","Immunomedics, Inc.","IMMU-132-09","April 3, 2019","HonorHealth Research Institute, Avondale, Arizona, United States|Arizona Oncology Associates, PC, Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|University of California, San Diego Moores Cancer Center, La Jolla, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California, United States|University of California, Irvine Medical Center-Chao Family Comprehensive Cancer Center, Orange, California, United States|Southern California Permanente Medical Group, San Diego, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|University of Colorado, Aurora, Colorado, United States|Yale University Cancer Center, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Inc., Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Mercy Medical Center, Medical Oncology & Hematology, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Summit Medical Group, Florham Park, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Laura and Isaac Perlmutter Cancer Center/NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The Ohio State University, Columbus, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|The West Clinic, PC dba West Cancer Center, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States|Texas Oncology-Denton South, Denton, Texas, United States|Houston Methodist Hospital/Houston Methodist Cancer Center, Houston, Texas, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|UT Health San Antonio - Mays Cancer Center, San Antonio, Texas, United States|Virginia Cancer Specialists, Arlington, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology & Hematology Associates of Southwest Virginia, Inc. DBA Blue Ridge Cancer Care, Salem, Virginia, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|Chirec Cancer Institute, Brussels, Belgium|Institut Jules Bordet, Brussels, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|CHU UCL Namur/Site Sainte Elisabeth, Namur, Belgium|Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|Hopital de Mercy, Ars-Laquenexy, France|Institut Sainte Catherine, Avignon, France|Hôpital Jean-Minjoz, Besançon, France|Centre Georges-Francois Leclerc, Dijon, France|Centre Leon Berard, Lyon, France|Institut Régional du Cancer de Montpellier, Montpellier, France|Institut Curie, Paris, France|Hospices Civils de Lyon, Pierre-Bénite, France|Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France|Institut Claudius Regaud, Toulouse, France|HELIOS Klinikum Berlin-Buch, Berlin, Germany|Gynakologisches Zentrum Bonn, Bonn, Germany|Marienhospital Bottrop, Bottrop, Germany|Städtisches Klinikum Dessau, Dessau, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Kliniken Essen-Mitte, Essen, Germany|Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany|Onkologische Schwerpunktpraxis Eppendorf, Hamburg, Germany|Gynakologisch-Onkologische Praxis Hannover, Hannover, Germany|Nationales Centrum für Tumorerkrankungen - Heidelberg, Heidelberg, Germany|Praxisklinik für Hämatologie und Onkologie Koblenz, Koblenz, Germany|Universitätsmedizin Mannheim, Mannheim, Germany|Ospedale di Desio, Desio, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto, Piacenza, Italy|IFO Istituto Nazionale dei Tumori Regina Elena, Rome, Italy|Antoni van Leeuwenhoekziekenhuis, Amsterdam, Netherlands|Maastricht UMC+, Maastricht, Netherlands|Complejo Hospitalario Universitario A Coruna, A Coruña, Spain|Hospital Quirónsalud Barcelona Instituto Oncologico Baselga, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu I Sant Pau, Barcelona, Spain|Hospital Provincial de Castellón, Castillón, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Instituto Oncologico Bureau (IOB), Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario de Santiago de Compostela, Santiago De Compostela, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Royal Cornwall Hospital NHS Trust, Cornwell, United Kingdom|Royal Surrey County Hospital, Guildford, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Barts Health NHS Trust, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|The Royal Marsden NHS Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT03901339"
441,"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","Recruiting","No Results Available","Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer|Endometrial Cancer","Drug: LY3484356|Drug: Abemaciclib","Eli Lilly and Company","17502|J2J-MC-JZLA|2019-003581-41","December 6, 2019","Highlands Oncology Group, Fayetteville, Arkansas, United States|University of California, San Francisco, San Francisco, California, United States|University of Miami School of Medicine, Miami, Florida, United States|Winship Cancer Center Emory University, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Minnesota Oncology/Hematology PA, Minneapolis, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|US Oncology, The Woodlands, Texas, United States|Texas Oncology - Tyler, Tyler, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Inova Dwight and Martha Schar Center Institute, Fairfax, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia Inc, Salem, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Linear Clinical Research Ltd, Nedlands, Western Australia, Australia|Institut Curie, Paris CEDEX 05, France|Hospital Universitari Vall d'Hebron, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04188548"
442,"Uptake of Genetic Counseling Among African American Women","Recruiting","No Results Available","Breast Cancer Risk","Behavioral: Educational video","University of Illinois at Chicago","2016-1219","September 9, 2019","University of Illinois Health System, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04082117"
443,"Functional MRI in Predicting Response to Chemotherapy","Not yet recruiting","No Results Available","Breast Cancer Patients","Device: MRI","Assiut University","MRI in response assesment","May 31, 2019",,"https://ClinicalTrials.gov/show/NCT03969524"
444,"Early Detection of Cardiac Damage With CMR in Women With Breast Cancer","Recruiting","No Results Available","Cardiotoxicity|Breast Cancer|Chemotherapy Induced Systolic Dysfunction","Diagnostic Test: CMR","Radboud University","108818","August 6, 2019","Radboud University Medical Center, Nijmegen, Netherlands","https://ClinicalTrials.gov/show/NCT04046315"
445,"Effect of Quilting Sutures on Post-operative Drainage After Mastectomy and/or Axillary Lymph Node Dissection","Recruiting","No Results Available","Breast Cancer Female","Procedure: quilting|Procedure: conventional suture","Gilles Berclaz, MD PD|University of Bern|StiftungLindenhof|Brustzentrum Bern der Lindenhofgruppe","BZ01/17|17-17-F","April 4, 2019","Brustzentrum Bern, Bern, Switzerland","https://ClinicalTrials.gov/show/NCT03902977"
446,"Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer|Chemotherapy Induced Peripheral Neuropathy|Paclitaxel Induced Neuropathy","Diagnostic Test: Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer","Yale University","2000020709","March 13, 2019","Smilow Cancer Center, New Haven, Connecticut, United States","https://ClinicalTrials.gov/show/NCT03872141"
447,"A Phase I Study of LX-039 Tablets","Enrolling by invitation","No Results Available","Advanced Breast Cancer","Drug: LX-039 tablets","Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","OE861801","September 20, 2019","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04097756"
448,"Health-related Quality of Life-intervention in Breast Cancer Survivors Experiencing Cancer-related Fatigue Using Traditional Chinese Medicine: The HERBAL Trial","Recruiting","No Results Available","Breast Cancer|Fatigue|Cognitive Impairment","Other: Modified Xiang Bei Yangrong Tang|Other: Placebo","National University, Singapore|National Cancer Centre, Singapore|Singapore Thong Chai Medical Institute","CIRB Ref. No: 2019/2135|TCMRG-3-NUS-01","September 26, 2019","National Cancer Centre Singapore, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT04104113"
449,"Nurse AMIE: Addressing Metastatic Individuals Everyday","Recruiting","No Results Available","Metastatic Breast Cancer","Behavioral: Supportive Care","Milton S. Hershey Medical Center","STUDY00011444","June 5, 2019","Penn State Cancer Institute, Hershey, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03975621"
450,"A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics","Not yet recruiting","No Results Available","Advanced Breast Cancer","Drug: TQB3616","Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","TQB3616-I-0001","February 22, 2019",,"https://ClinicalTrials.gov/show/NCT03850873"
451,"CDH1 Germline Mutations in Lobular Breast Cancer","Recruiting","No Results Available","Lobular Breast Carcinoma|CDH1 Gene Inactivation",,"European Institute of Oncology","IEO 0834/","December 20, 2019","European Institute of Oncology, Milan, Italy","https://ClinicalTrials.gov/show/NCT04206891"
452,"Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy","Not yet recruiting","No Results Available","Oncology|Breast Cancer|Chemotherapy-induced Nausea and Vomiting","Drug: Pantoprazole 40mg|Drug: Placebo","University of Auckland, New Zealand","CTNZ-2017-17","May 14, 2019",,"https://ClinicalTrials.gov/show/NCT03948477"
453,"Frequency and Presentations of Chronic Pain Following Breast Cancer Surgery: An Observational Study in a Tertiary Care Hospital of Pakistan","Completed","No Results Available","Breast Cancer Female|Chronic Pain",,"Ali Sarfraz Siddiqui|Aga Khan University","4257-Ane-ERC-16","May 23, 2019",,"https://ClinicalTrials.gov/show/NCT03961269"
454,"Zinc-L-Carnosine Prevents Dysphagia in Breast Cancer Patients Undergoing Adjuvant Radiotherapy","Completed","No Results Available","Breast Cancer Female|Dysphagia|Adjuvant Radiotherapy","Device: Hepilor","Cynthia Aristei|University Of Perugia","003 (Hepilor)","June 25, 2019","University of Perugia, Perugia, Italy","https://ClinicalTrials.gov/show/NCT03997188"
455,"Shared Decision Making With Breast Cancer Patients","Recruiting","No Results Available","Shared Decision Making|Breast Neoplasms|Radiotherapy, Adjuvant","Behavioral: Shared decision making supported by an in-consultation patient decision aid","Vejle Hospital|Danish Breast Cancer Cooperative Group|University of Southern Denmark|Danish Comprehensive Cancer Center","DBCG RT SDM","November 26, 2019","Aalborg Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev University Hospital, Herlev, Denmark|Sjaellands University Hospital, Næstved, Denmark|Odense University Hospital, Odense, Denmark|Vejle Hospital, Vejle, Denmark","https://ClinicalTrials.gov/show/NCT04177628"
456,"MUltimodal Targeted Axillary Surgery","Recruiting","No Results Available","Node-positive Breast Cancer","Diagnostic Test: Systematic axillary ultrasound imaging|Diagnostic Test: Sentinel node|Procedure: Excision of suspicious lymph nodes|Procedure: Two steps axillary node clearance","Parc de Salut Mar|GEICAM","2018/8361/I","July 31, 2019","Hospital del Mar, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04039893"
457,"Circulating Osteocalcin-positive Cells in Breast Cancer Bone Metastasis","Recruiting","No Results Available","Breast Neoplasms|Bone Metastases","Diagnostic Test: Circulating Osteocalcin-positive (cOC) cells","Seoul National University Hospital|National Cancer Center, Korea","SNUH-IRB-1706069859","January 24, 2019","Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT03814811"
458,"FUSCC Refractory TNBC Umbrella (FUTURE)","Recruiting","No Results Available","Triple-negative Breast Cancer","Drug: Pyrotinib with Capecitabine|Drug: AR inhibitor with CDK4/6 inhibitor|Drug: anti PD-1 with nab-paclitaxel|Drug: PARP inhibitor included therapy|Drug: BLIS with anti-VEGFR included therapy|Drug: MES with anti-VEGFR included therapy|Drug: mTOR inhibitor with nab-paclitaxel","Fudan University","1807188-16","January 15, 2019","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT03805399"
459,"Treatment With Oral LY3023414 To Inhibit Homologous Recombination Followed By Prexasertib","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Drug 1: LY3023414; Drug 2: Prexasertib","Baylor Research Institute|Eli Lilly and Company","018-745","July 25, 2019","Baylor Scott and White University Medical Center, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT04032080"
460,"Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Drug: paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide","Hebei Medical University Fourth Hospital","TNBC-NEO","August 26, 2019","Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China","https://ClinicalTrials.gov/show/NCT04067102"
461,"A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: SHR-1210 + Apatinib +Fluzoparib","Jiangsu HengRui Medicine Co., Ltd.","FZPL-Ib-105","May 10, 2019","Beijing Cancer Hosptial, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03945604"
462,"Chronic Pain and Minor Breast Cancer Surgery","Completed","No Results Available","Surgery|Breast Cancer|Pain, Postoperative|Pain, Chronic",,"Institut Claudius Regaud","CNIL-2033408","April 11, 2019","Institut Claudius Regaud - IUCT-Oncopole, Toulouse, Occitanie, France","https://ClinicalTrials.gov/show/NCT03912948"
463,"Anlotinib in Metastatic HER2 Negative Breast Cancer","Recruiting","No Results Available","Breast Neoplasm|Antineoplastic Agents|Anlotinib","Drug: Anlotinib Hydrochloride","Peng Yuan|Chinese Academy of Medical Sciences","NCC1692","June 28, 2019","National Cacner Center/ Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04002284"
464,"Neoadjuvant Database","Recruiting","No Results Available","Neoadjuvant Treatment in Breast Cancer","Drug: Neoadjuvant therapy","Centre Georges Francois Leclerc","AB2009SEIN","July 24, 2019","Methodology, Biostatistics and Data Management Unit, Dijon, France","https://ClinicalTrials.gov/show/NCT04031612"
465,"The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency","Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Epirubicin|Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Carboplatin","Chinese Academy of Medical Sciences","BXu-1839","March 15, 2019","National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03876886"
466,"Needs Assessment After Cancer in Patients Treated for Breast Cancer","Completed","No Results Available","Breast Neoplasm Female|Quality of Life|Fear Cancer",,"Institut Jean-Godinot","2018-A02191-54","April 4, 2019","Institut Jean Godinot, Reims, France","https://ClinicalTrials.gov/show/NCT03902964"
467,"Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer","Recruiting","No Results Available","Breast Cancer|Skin Cancer|Skin Diseases","Drug: Quantum dots coated with veldoreotide|Drug: Topical approved placebo","Al-Azhar University","Qassim QDs-VELD","October 24, 2019","Assiut Clinic, Assiut, Egypt|Buraidah Clinic, Buraidah, Al Qassim, Saudi Arabia|Faculty of Pharmacy, Buraidah, Qassim, Saudi Arabia|Pharmaceutics dept., Faculty of Pharmacy, Qassim University, Buraidah, Qassim, Saudi Arabia","https://ClinicalTrials.gov/show/NCT04138342"
468,"Yoga for Aromatase Inhibitor-related Knee Pain Relief in Breast Cancer Patients","Completed","No Results Available","Breast Cancer|Aromatase Inhibitor|Yoga|Knee Pain","Other: yoga","China Medical University Hospital","CMUH107-REC3-102","May 21, 2019","Ching-Liang Hsieh, Taichung, Taiwan","https://ClinicalTrials.gov/show/NCT03956875"
469,"Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection","Recruiting","No Results Available","HER2-positive Breast Cancer","Biological: GB221,2 mg/kg|Biological: GB221,6 mg/kg|Biological: Herceptin,6 mg/kg|Biological: GB221,8mg/kg|Biological: GB221:2mg/kg and Capecitabi:1000mg/kg|Biological: Herceptin:2mg/kg and Capecitabin:1000mg/kg","Genor Biopharma Co., Ltd.","GENOR GB221-002","November 20, 2019","Affiliated Hospital of Academy of Military Medical Sciences, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04170595"
470,"Pain, Psychological, and Endocannabinoid Responses to Yoga in Breast Cancer Survivors With Chemotherapy-induced Neuropathic Pain","Completed","No Results Available","Breast Cancer|Chemotherapy-induced Peripheral Neuropathy|Neuropathic Pain","Behavioral: Aerobic exercise|Behavioral: Iyengar yoga","University of Wisconsin, Madison|American College of Sports Medicine","2018-1518|A176000|EDUC/KINESIOLOGY/KINESIOLOG|UW18057","August 30, 2019","University of Wisconsin-Madison Natatorium, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT04075097"
471,"Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors","Recruiting","No Results Available","Breast Cancer|Gut Microbiome|Exercise|Fatigue","Other: Aerobic Exercise Training|Other: Attention Control","University of Alabama at Birmingham|National Cancer Institute (NCI)","IRB-30000320|R01CA235598","September 13, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States","https://ClinicalTrials.gov/show/NCT04088708"
472,"Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women","Active, not recruiting","No Results Available","Breast Neoplasm Female|Nutrition Related Cancer|Habits, Diet|Cancer, Breast","Behavioral: Women with recent diagnosis of breast cancer","Instituto de Investigación Hospital Universitario La Paz","PI-2842","April 17, 2019","Institute for Health Research IdiPAZ, Madrid, Spain","https://ClinicalTrials.gov/show/NCT03918668"
473,"Regional Anesthesia for Breast Surgery","Recruiting","No Results Available","Breast Cancer","Procedure: PECSII and paravertebral blocks","Arcispedale Santa Maria Nuova-IRCCS","Breastblock","May 7, 2019","AUSL IRCCS Reggio Emilia, Reggio Emilia, Italy","https://ClinicalTrials.gov/show/NCT03941223"
474,"Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation","Terminated","No Results Available","Breast Cancer|Lymphocele","Procedure: Injection of sandostatine","Institut Cancerologie de l'Ouest","2015-03","January 3, 2019",,"https://ClinicalTrials.gov/show/NCT03791736"
475,"Breast Cancer Diet Intervention Study","Completed","No Results Available","Early-stage Breast Cancer|Carbohydrate Engorgement|Proliferation|Insulin Resistance|Estrogen Receptor-positive Breast Cancer","Dietary Supplement: PreOP","Helse Stavanger HF","59","March 22, 2019",,"https://ClinicalTrials.gov/show/NCT03886389"
476,"Effects of a Traditional Chinese Exercise Program on Symptom Cluster in Breast Cancer Patients","Not yet recruiting","No Results Available","Breast Neoplasm Female|Symptom Cluster|Tai ji","Other: wait list control|Behavioral: tai chi group","Charles Darwin University|The Affiliated Hospital Of Southwest Medical University|The Affiliated Hospital of Putian University|Shenzhen Sixth People's Hospital","H19094","December 9, 2019",,"https://ClinicalTrials.gov/show/NCT04190342"
477,"Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection","Recruiting","No Results Available","HER-2-positive Advanced Breast Cancer","Drug: GB221|Drug: Placebo control","Genor Biopharma Co., Ltd.","GENOR GB221-003；V1.1","November 15, 2019","People's Liberation Army General Hospital The Fifth Medical Center, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04164615"
478,"Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer","Recruiting","No Results Available","Breast Cancer|Breast Cancer, Invasive Ductal|Invasive Mammary Carcinoma|Breast Cancer Stage I|Breast Cancer Stage IIA","Radiation: Intraoperative radiotherapy","University of Louisville","19-0448","September 12, 2019","James Graham Brown Cancer Center at the University of Louisville, Louisville, Kentucky, United States","https://ClinicalTrials.gov/show/NCT04088435"
479,"Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity","Recruiting","No Results Available","Left-Sided Breast Cancer","Diagnostic Test: [1-13C]pyruvate along with MRI imaging","University of Texas Southwestern Medical Center","STU 2019-1099","August 5, 2019","Department of Radiation Oncology; UT Southwestern Medical Center, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT04044872"
480,"Inpatient Screening Mammography for Non-adherent and High Risk Women","Completed","No Results Available","Breast Cancer","Other: Screening mammography","Johns Hopkins University|Maryland Cigarette Restitution Research Grant|EQUIP (Excellence in Quality, Utilization of resources, Integration and Patient- centered Care)","NA_00079826","November 15, 2019",,"https://ClinicalTrials.gov/show/NCT04164251"
481,"Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors","Suspended","No Results Available","Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8","Behavioral: One Diet and Physical Activity Class|Other: Electronic (e) Health (eHealth) Communication Intervention|Behavioral: Six Diet and Physical Activity In-Person Group Classes","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|Breast Cancer Research Foundation","RG1006427|NCI-2019-07643|P30CA015704","December 16, 2019","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04200482"
482,"UK Ibrance Patient Program (IPP) Study","Active, not recruiting","No Results Available","HR+/HER2- Locally Advanced, Metastatic Breast Cancer","Drug: Palbociclib","Pfizer","X9001194|ROIS","April 19, 2019","Brigton and Sussex, Brighton, United Kingdom|Beatson, Glasgow, United Kingdom|Liverpool, Liverpool, United Kingdom|Guys and St Thomas', London, United Kingdom|Maidstone Hospital, Maidstone, United Kingdom|Christie, Manchester, United Kingdom|Newcastle, Newcastle, United Kingdom|Truro, Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT03921866"
483,"Testing the Addition of an Anti-cancer Drug, M6620, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","Recruiting","No Results Available","Bilateral Breast Carcinoma|Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma","Drug: Berzosertib|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Radiation: Radiation Therapy","National Cancer Institute (NCI)","NCI-2019-05187|10291|UM1CA186686","August 12, 2019","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT04052555"
484,"The Value of High-resolution Ultrasound in the Detection of Lymph Node Metastasis: a Proposal of NI-RADS","Recruiting","No Results Available","Breast Neoplasms","Diagnostic Test: Ultrasound evaluation","Peking University People's Hospital","PKUPHUS002","January 3, 2019","Peking University People's Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03791840"
485,"Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences","Recruiting","No Results Available","Metastatic Malignant Neoplasm in the Chest Wall|Recurrent Breast Carcinoma","Drug: Olaparib|Procedure: Hyperthermia Treatment|Other: Questionnaire Administration|Other: Quality-of-Life Assessment","Thomas Jefferson University|AstraZeneca","19P.117","May 20, 2019","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03955640"
486,"Health Belief Model Based Nursing Interventions on Lymphedema Prevention","Completed","No Results Available","Breast Cancer|Breast Cancer Lymphedema|Home Visit","Other: Home visit, health education","Ayse Cal|The Scientific and Technological Research Council of Turkey|Dokuz Eylul University","04.04.2013 970-GOA","September 23, 2019",,"https://ClinicalTrials.gov/show/NCT04098783"
487,"ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer","Recruiting","No Results Available","Solid Tumor|Breast Cancer Metastatic","Drug: Paclitaxel","Orinove, Inc.","ORIN1001-001","May 15, 2019","University of Colorado Anschutz Medical Campus, Denver, Colorado, United States|Gabrail Cancer Center, Canton, Ohio, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Baylor College of Medicine Medical Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03950570"
488,"PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer","Recruiting","No Results Available","Ovarian Cancer|Breast Cancer","Drug: Lynparza","University of Texas Southwestern Medical Center","STU-2019-0769","August 1, 2019","University of Texas Southwestern Medical Center, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT04041128"
489,"Efficacy of Point Of Service Testing in MBC","Recruiting","No Results Available","Metastatic Cancer|Breast Cancer","Other: Point of service delivery model","University of Kansas Medical Center","ePOST","June 12, 2019","The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States","https://ClinicalTrials.gov/show/NCT03983577"
490,"Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:","Active, not recruiting","No Results Available","Luminal B","Drug: Durvalumab|Radiation: Stereotactic Body Radiotherapy|Drug: Oleclumab","Jules Bordet Institute|Institut Curie|AstraZeneca","IJB-LBC-NEOCHECKRAY-2018","March 14, 2019","Institut Jules Bordet, Bruxelles, Belgium","https://ClinicalTrials.gov/show/NCT03875573"
491,"Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer","Recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Refractory Breast Carcinoma","Drug: Alpha-tocopheryloxyacetic Acid|Biological: Trastuzumab","University of Washington|National Cancer Institute (NCI)|Veana Therapeutics, Inc.","RG1004302|NCI-2019-06457|P30CA015704","October 9, 2019","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04120246"
492,"Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx","Active, not recruiting","No Results Available","Hodgkin Lymphoma|Non-hodgkin Lymphoma|Lymphoma|Breast Cancer","Other: Physical Activity Intervention (PAI)|Other: Healthy Living Control","Virginia Commonwealth University","MCC-19-14621","April 22, 2019","Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States","https://ClinicalTrials.gov/show/NCT03923504"
493,"Axillary Reverse Mapping Using Methylene Blue Subcutaneous Injection Can Identify Arm Lymph Nodes and Vessels, Measuring Arm Size for Lymphedema, Histopathological Examination of Arm Lymph Nodes Included With Axillary Lymph Node Dissection","Completed","No Results Available","Arm Lymphedema|Lymphatic Spread of Breast Cancer|Early Breast Cancer","Procedure: AXILLARY REVERSE MAPPING","Zagazig University","hazem nour","October 24, 2019","Zagazig Faculty of Medicine, Zagazig, Sharqya, Egypt","https://ClinicalTrials.gov/show/NCT04137744"
494,"Perioperative Mindfulness Proposal","Recruiting","No Results Available","Breast Cancer|DCIS","Other: Meditation","Hoag Memorial Hospital Presbyterian","173-18-CA","August 8, 2019","Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States","https://ClinicalTrials.gov/show/NCT04049214"
495,"E-Based Technology to Provide Decision Aid on Breast Reconstruction for Women With Breast Cance","Active, not recruiting","No Results Available","Decision Support Technique|Breast Cancer","Other: E-based & personalized breast reconstruction surgery decision aid|Other: Usual care","National Cheng-Kung University Hospital|National Cheng Kung University","B-ER-106-072","December 9, 2019","National Cheng Kung University Hospital, Tainan, Taiwan","https://ClinicalTrials.gov/show/NCT04190992"
496,"Effects of an Integrative Day-care Clinic Program for Breast Cancer Patients During Chemotherapy","Completed","No Results Available","Breast Cancer|Chemotherapy|Mind-Body-Medicine|Acupuncture|Quality of Life","Behavioral: Integrative mind-body-medicine group program","Universität Duisburg-Essen","17-7909-BO","March 11, 2019","Kliniken Essen-Mitte, Essen, NRW, Germany","https://ClinicalTrials.gov/show/NCT03868865"
497,"An Enhanced Artificial Intelligence Breast MRI Interpretation System","Not yet recruiting","No Results Available","Breast Cancer","Diagnostic Test: Breast MRI interpretation","Jamil Kanfoud|Brunel University London|First Option Software Ltd.|Teesside University","4901","February 4, 2019",,"https://ClinicalTrials.gov/show/NCT03829423"
498,"Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer","Recruiting","No Results Available","Breast Cancer|HER2-positive Breast Cancer|Triple Negative Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|Inflammatory Breast Cancer|Metastatic Breast Cancer","Device: MRI","Dana-Farber Cancer Institute|Conquer Cancer Foundation","19-066","July 24, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04030507"
499,"Improvement of Patient Experience and Healthcare Providers' Productivity Using Virtual Reality in the Field of Radiation Therapy","Not yet recruiting","No Results Available","Breast Cancer","Other: Virtual reality","Yonsei University","4-2019-0795","October 28, 2019","Severance Hospital, Seoul, Korea, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04141943"
500,"Magseed Enabled Long-Term Localization of Axillary Lymph Nodes","Recruiting","No Results Available","Breast Cancer|Axillary Lymph Nodes","Device: Magseed Marker","Endomagnetics Inc|M.D. Anderson Cancer Center","US-003","January 8, 2019","Cooper Health, MD Anderson Cancer Center, Camden, New Jersey, United States|MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03796559"
501,"Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer Spread to the Bones","Recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Breast Carcinoma Metastatic in the Bone|Metastatic Breast Carcinoma|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8","Drug: Paclitaxel|Radiation: Radium Ra 223 Dichloride","National Cancer Institute (NCI)","NCI-2019-06088|10302|UM1CA186716","September 16, 2019","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States","https://ClinicalTrials.gov/show/NCT04090398"
502,"Evaluation of NeoNavia® Biopsy System in Axillary Lymph Nodes","Recruiting","No Results Available","Breast Cancer","Device: NeoNavia® Biopsy System","NeoDynamics AB","NEODOC-2021668610-165","June 5, 2019","Klinikum Esslingen, Esslingen, BW, Germany|Universitätsfrauenklinik Tübingen, Tübingen, BW, Germany|Agaplesion Markus Krankenhaus, Frankfurt, HE, Germany|Universitäts-Frauenklinik, Rostock, MV, Germany|HJK Erkelenz, Erkelenz, NRW, Germany|Kliniken Essen-Mitte, Essen, NRW, Germany|Uniklinik Köln, Köln, NRW, Germany","https://ClinicalTrials.gov/show/NCT03975855"
503,"ACH-TH vs EC-TH as Neoadjuvant Therapy for HER2-positive EBC","Recruiting","No Results Available","Breast Cancer|Neoadjuvant Chemotherapy","Drug: Doxorubicin liposome|Drug: Cyclophosphamide|Drug: Trastuzumab|Drug: Docetaxel|Drug: Epirubicin","Sun Yat-sen University|First Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","METIS|SCBCG-023","November 21, 2019","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04172259"
504,"Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer","Recruiting","No Results Available","Breast Carcinoma","Drug: Fingolimod|Drug: Fingolimod Hydrochloride|Other: Questionnaire Administration","Mayo Clinic|National Cancer Institute (NCI)","MC18C1|NCI-2019-02741|P30CA015083","May 8, 2019","Mayo Clinic, Rochester, Minnesota, United States|Virginia Commonwealth University/ Massey Cancer Center, Richmond, Virginia, United States","https://ClinicalTrials.gov/show/NCT03941743"
505,"Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer - Dose-Finding Study","Recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Hormone Receptor Positive Breast Carcinoma|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma","Drug: Abemaciclib|Drug: Copanlisib Hydrochloride|Drug: Fulvestrant","National Cancer Institute (NCI)","NCI-2019-02752|10287|UM1CA186704","May 7, 2019","University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Siteman Cancer Center at Christian Hospital, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT03939897"
506,"OptiBra Study, Optimal Postoperative Bra After Breastcancer Surgery","Recruiting","No Results Available","Bra|Breast Cancer Surgery|Complication|Compression|Symptoms","Other: OptiBra study","Karolinska University Hospital","KarolinskaUD","August 16, 2019","Karolinska University Hospital, Stockholm, Sweden","https://ClinicalTrials.gov/show/NCT04059835"
507,"Physical and Psychological Effects of Different Temperature-controlled Breast Prostheses on Patients With Breast Cancer","Completed","No Results Available","External Breast Prostheses","Other: different temperature-controlled breast prostheses","Fudan University","IRB1403133-2","February 5, 2019",,"https://ClinicalTrials.gov/show/NCT03830294"
508,"Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection","Recruiting","No Results Available","Breast Cancer Stage I|Breast Cancer Stage II|Breast Cancer Stage III","Drug: Isosulfan Blue|Procedure: Axillary Lymph Node Dissection|Procedure: Mapping|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)","A221702|NCI-2018-02445|UG1CA189823","April 25, 2019","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Contra Costa Regional Medical Center, Martinez, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|UF Cancer Center at Orlando Health, Orlando, Florida, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States|University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States|The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States|McLaren Cancer Institute-Bay City, Bay City, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Henry Ford Wyandotte Hospital, Wyandotte, Michigan, United States|Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|University of Cincinnati/Barrett Cancer Center, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|University Pointe, West Chester, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Geisinger South Wilkes-Barre, Wilkes-Barre, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|UTMB Health Angleton Danbury Campus, Angleton, Texas, United States|Parkland Memorial Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|UTMB Cancer Center at Victory Lakes, League City, Texas, United States|Aurora Cancer Care-Grafton, Grafton, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Aurora Sinai Medical Center, Milwaukee, Wisconsin, United States|Aurora West Allis Medical Center, West Allis, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03927027"
509,"Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast","Recruiting","No Results Available","Triple Negative Breast Cancer|Early-stage Breast Cancer|HER2-positive Breast Cancer","Drug: Neratinib","West Cancer Center|Celcuity|Puma Biotechnology, Inc.","2018-002","January 23, 2019","West Cancer Center, Germantown, Tennessee, United States","https://ClinicalTrials.gov/show/NCT03812393"
510,"Utilization of Telehealth to Improve Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients","Recruiting","No Results Available","Estrogen Receptor-positive Breast Cancer|Progesterone Receptor Positive Breast Cancer|Stage 0 Breast Cancer AJCC v6 and v7|Stage I Breast Cancer AJCC v7|Stage IA Breast Cancer AJCC v7|Stage IB Breast Cancer AJCC v7|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7","Other: Telemedicine|Other: Best Practice|Other: Questionnaire Administration|Other: Quality-of-Life Assessment","Thomas Jefferson University","18D.003","August 13, 2019","Thomas Jefefrson University, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04054557"
511,"EndoPredict® Extended Endocrine Trial (EXET)","Recruiting","No Results Available","Breast Cancer",,"Myriad Genetic Laboratories, Inc.","ONC-010","July 12, 2019","Carolina Blood and Cancer Care Associates, Rock Hill, South Carolina, United States","https://ClinicalTrials.gov/show/NCT04016935"
512,"A New Mindfulness Approach Called Swinging Effect Intervention for Women With Breast Cancer","Active, not recruiting","No Results Available","Anxiety|Stress|Self Efficacy|Depression|Breast Cancer Female|Hopefulness","Behavioral: Mindfulness based Swinging Effect Intervention","University of Barcelona","2018/14-01","June 13, 2019","Ozel Oz Psikoloji Aile Danisma Merkezi (Oz Psychology Family Counselling Centre), Izmir, Konak, Turkey|EgeMed Hospital, Aydın, Soke, Turkey","https://ClinicalTrials.gov/show/NCT03985267"
513,"VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)","Recruiting","No Results Available","Stress","Behavioral: R-CBSM|Biological: Influenza vaccine","University of Miami|Florida Department of Health","20160525","May 20, 2019","Flipse Building, Coral Gables, Florida, United States","https://ClinicalTrials.gov/show/NCT03955991"
514,"MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)","Recruiting","No Results Available","Invasive Breast Cancer|Neoadjuvant Chemotherapy|Radiomics|Axillary Lymph Node|Prognosis","Other: No interventions","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|Tungwah Hospital of Sun Yat-Sen University","SYSEC-KY-KS-2019-055-001","July 2, 2019","Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04004559"
515,"Tell us Your Food Story","Active, not recruiting","No Results Available","Breast Neoplasms","Other: no intervention","Medical College of Wisconsin","PRO00034502","October 7, 2019","Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT04117438"
516,"Prevention of Female Cancers by Optimization of Selenium Levels in the Organism.","Recruiting","No Results Available","Breast Neoplasms","Dietary Supplement: Selenium supplementation or placebo treatment|Other: Diet modification|Other: Selenium supplementation or placebo treatment and diet modification","Read-Gene S.A.|National Center for Research and Development, Poland|IQ Pharma S.A.|West Pomeranian University of Technology|Vipharm S.A.","INNOMED/I/16?NCBR/2014","July 10, 2019","Read-Gene S.A., Grzepnica, West Pomerania, Poland","https://ClinicalTrials.gov/show/NCT04014283"
517,"Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01)","Recruiting","No Results Available","Breast Neoplasm Female|Early-stage Breast Cancer|Radiomics|Axillary Lymph Node|Survival, Prosthesis","Other: No interventions","Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Sun Yat-sen University|Tungwah Hospital of Sun Yat-Sen University|Shunde Hospital of Southern Medical University|Zhongshan Ophthalmic Center, Sun Yat-sen University","SYSEC-KY-KS-2019-054-001","July 1, 2019","Tungwah Hospital of Sun Yat-Sen University, Dongguan, Guangdong, China|Shunde hospital of southern medical university, Foshan, Guangdong, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04003558"
518,"Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer","Recruiting","No Results Available","Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Inflammatory Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8","Drug: Indocyanine Green|Procedure: Lymphangiography|Procedure: Lymphovenous Bypass","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","2018-0127|NCI-2019-02320|P30CA016672","May 8, 2019","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03941756"
519,"The Sequelae of Mastectomy and Quadrantectomy Respect to the Reaching Movement in Breast Cancer Survivors","Completed","No Results Available","Breast Cancer|Pain, Chronic|Pain, Postoperative|Mastectomy; Lymphedema","Other: Rehabilitation protocol","University of Roma La Sapienza","URomLS-2019","October 31, 2019","Umberto I Hospital, Rome, Italy","https://ClinicalTrials.gov/show/NCT04145739"
520,"Digoxin Induced Dissolution of CTC Clusters","Not yet recruiting","No Results Available","Breast Cancer|Circulating Tumor Cells (CTCs)","Drug: Digoxin","University Hospital, Basel, Switzerland","2019-00673; sp19Kurzeder","April 26, 2019","Breast Cancer Center, University Hospital Basel, Basel, Switzerland","https://ClinicalTrials.gov/show/NCT03928210"
521,"Enhancing Shared Decision-Making in Breast Cancer","Recruiting","No Results Available","Shared Decision Making","Other: Intervention-specific Carevive questionnaire|Other: Standard of Care questionnaire","University of Alabama at Birmingham|American Cancer Society, Inc.|Carevive Systems, Inc.","427 BC SDM","January 16, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States","https://ClinicalTrials.gov/show/NCT03806738"
522,"Effects of Creatine Supplementation in Breast Cancer Survivors","Not yet recruiting","No Results Available","Breast Cancer|Chemotherapy Effect|Muscle Weakness|Muscle Loss|Exercise","Dietary Supplement: Creatine","The University of Texas Health Science Center at San Antonio","CTMS# 19-0028","December 20, 2019",,"https://ClinicalTrials.gov/show/NCT04207359"
523,"Intestinal Microbiota of Breast Cancer Patients Undergoing Chemotherapy","Recruiting","No Results Available","Microbiota","Drug: cyclophosphamide","First Affiliated Hospital of Harbin Medical University","Yunwei Wei 2019-09-13","October 25, 2019","First affiliated hospital of Harbin medical university, Harbin, Heilongjiang, China","https://ClinicalTrials.gov/show/NCT04138979"
524,"Mindfulness and Self-compassion Focussed Walking","Recruiting","No Results Available","Breast Cancer|Fatigue","Behavioral: Mindfulness and Self-Compassion focussed exercises during walking training|Behavioral: Walking training","Charite University, Berlin, Germany|Sana-Klinikum Lichtenberg|Park-Klinik Berlin Weißensee|Vivantes Klinikum am Urban|Steffen Lohrer Stiftung","MSCW2019","December 10, 2019","Charite Universitätsmedizin Berlin, Berlin, Germany|Sana-Klinikum Lichtenberg, Berlin, Berlin, Germany","https://ClinicalTrials.gov/show/NCT04193644"
525,"Is Dietary Nitrate Effective in Reducing Aerobic Glycolysis in Breast Cancer?","Not yet recruiting","No Results Available","Malignant Breast Tissue Neoplasm","Dietary Supplement: Beetroot juice","University of Aberdeen|NHS Grampian","2-114-18|17/049","May 9, 2019","Aberdeen Biomedical Imaging Centre, Aberdeen, United Kingdom","https://ClinicalTrials.gov/show/NCT03944226"
526,"Randomized Phase III Trial With Mepitel Film for the Prophylaxis of Radiation Dermatitis in Breast Cancer Patients","Recruiting","No Results Available","Breast Cancer|Radiation Dermatitis","Device: Mepitel Film","Sunnybrook Health Sciences Centre","Mepitel RCT","November 18, 2019","Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04166799"
527,"Improving Cognition After Cancer","Recruiting","No Results Available","Breast Cancer Survivors|Cognitive Dysfunction","Behavioral: Exercise|Behavioral: Control","University of California, San Diego","182113","August 8, 2019","Moores UCSD Cancer Center, La Jolla, California, United States","https://ClinicalTrials.gov/show/NCT04049695"
528,"Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC","Recruiting","No Results Available","Breast Cancer","Drug: Tesetaxel|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Atezolizumab","Odonate Therapeutics, Inc.","ODO-TE-B202","May 16, 2019","Sarah Cannon Research Institute - Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States|Florida Cancer Specialists and Research Institute - Panhandle Region, Tallahassee, Florida, United States|Florida Cancer Specialists and Research Institute, West Palm Beach, Florida, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|New York Cancer and Blood Specialists, East Setauket, New York, United States|West Cancer Center, Germantown, Tennessee, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Asan Medical Center, Seoul, Korea, Republic of|John Hopkins Singapore International Medical Centre, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT03952325"
529,"PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)","Recruiting","No Results Available","Breast Cancer|Advanced Breast Cancer|Hormone Receptor Positive Tumor|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Drug: Palbociclib|Drug: Endocrine therapy","MedSIR|Pfizer","MedOPP068","January 18, 2019","Hôpital Jean Minjoz, Besançon, France|Centre Georges François Leclerc, Dijon, France|Chd-Vendee, La Roche-sur-Yon, France|APHP Tenon, Paris, France|George Pompidou European Hospital, Paris, France|Centre Paul Strauss, Strasbourg, France|ICO Badalona, Badalona, Barcelona, Spain|Hospital Provincial de Castellón, Castello, Castelló, Spain|Consorci Sanitari de Terrassa, Terrassa, Terrasa, Spain|Centro Oncológico de Galicia, A Coruña, Spain|Institut Català d'Oncologia Bellvitge, Barcelona, Spain|H. Vall Hebrón, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital de Basurto, Bilbao, Spain|Hospital San Pedro de Alcantara, Cáceres, Spain|Institut Català d'Oncologia, Girona, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Sanchinarro, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Regional Universitario de Malaga, Málaga, Spain|Hospital Universitari Son Espases, Palma De Mallorca, Spain|Hospital Sant Joan, Reus, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Instituto Valenciano de Oncología IVO, Valencia, Spain|Hospital General Universitari de Valencia, Valencia, Spain|Hospital Arnau de Vilanova de Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Hospital Álvaro Cunqueiro, Vigo, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Beatson West of Scotland Cancer Center, Glasgow, United Kingdom|Barts Cancer Institute, London, United Kingdom|Kent Oncology Department, Maidstone, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Royal Cornwall Hospital NHS Trust, Truro, United Kingdom","https://ClinicalTrials.gov/show/NCT03809988"
530,"Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer","Recruiting","No Results Available","Metastatic Triple Negative Breast Cancer|Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Neoplasms|Triple-Negative Breast Cancer|Triple Negative Breast Cancer|Triple-Negative Breast Neoplasm","Drug: Olaparib|Biological: Durvalumib","OHSU Knight Cancer Institute|Oregon Health and Science University","STUDY00018504","January 11, 2019","OHSU Knight Cancer Institute, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT03801369"
531,"Accelerated Partial Irradiation of the Breast: New Altered Fractionation","Recruiting","No Results Available","Breast Cancer",,"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","FIS-APBI-2019-02","September 24, 2019","Hospital Universitario Virgen Macarena, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT04101656"
532,"Photobiomodulation for Breast Cancer Radiodermatitis","Recruiting","No Results Available","Breast Cancer|Radiodermatitis|Radiotherapy Side Effect|Radiation Dermatitis|Radiation Toxicity|Radiation Injuries|Quality of Life|Breast Neoplasms","Device: Photobiomodulation","AC Camargo Cancer Center","2.777.676","August 16, 2019","Universidade do Vale do Itajai - UNIVALI, Itajai, Santa Catarina, Brazil","https://ClinicalTrials.gov/show/NCT04059809"
533,"Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer","Recruiting","No Results Available","Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Triple-Negative Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma","Biological: Therapeutic Estradiol","Mayo Clinic|National Cancer Institute (NCI)","MC1831|NCI-2019-02285|P30CA015083","May 8, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT03941730"
534,"Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC","Recruiting","No Results Available","Triple Negative Breast Neoplasms","Drug: 350 mg leronlimab|Drug: 525 mg leronlimab|Drug: 700 mg leronlimab|Drug: AUC 5 Carboplatin|Drug: Maximum Tolerated Dose (MTD) of leronlimab","CytoDyn, Inc.|Amarex Clinical Research","CD07_TNBC","February 12, 2019","Quest Clinical Research, San Francisco, California, United States|CD07 Investigational Site, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT03838367"
535,"Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer","Recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8","Drug: Nilotinib|Drug: Nilotinib Hydrochloride Monohydrate|Drug: Paclitaxel|Other: Placebo|Other: Questionnaire Administration","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","OSU-18317|NCI-2019-03146|P30CA016058|R01CA238946","December 20, 2019","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT04205903"
536,"Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer","Not yet recruiting","No Results Available","Advanced Breast Carcinoma|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Germline BRCA1 Gene Mutation|Germline BRCA2 Gene Mutation|HER2/Neu Negative|Metastatic Breast Carcinoma|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8","Drug: Cediranib|Drug: Ceralasertib|Drug: Olaparib","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","2018-0062|NCI-2019-04148|P30CA016672","September 16, 2019","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04090567"
537,"Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer","Recruiting","No Results Available","Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma","Biological: Anti-OX40 Antibody PF-04518600|Drug: Avelumab|Drug: Binimetinib|Biological: Utomilumab","Hope Rugo, MD|Translational Breast Cancer Research Consortium|Hoosier Cancer Research Network|Array BioPharma|Pfizer|Breast Cancer Research Foundation|Johns Hopkins University|University of California, San Francisco","187519|NCI-2019-01531|TBCRC 047|BRE16-279","June 3, 2019","University of California, San Francisco, San Francisco, California, United States|Mayo Clinic, Rochester, Minnesota, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT03971409"
538,"Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer","Not yet recruiting","No Results Available","Breast Cancer Female|HER2-positive Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer|Breast Diseases|Hormone Receptor Positive Tumor","Drug: Pyrotinib|Drug: Trastuzumab|Drug: Aromatase Inhibitors","Fuzhou General Hospital","Arise-FJ-B102","September 12, 2019","Fuzhou general hospital, Fuzhou, Fujian, China","https://ClinicalTrials.gov/show/NCT04088110"
539,"Comprehensive Genetic Assessment, Risk and Education in a Mammography Pilot","Enrolling by invitation","No Results Available","Women Age 35+ Qualifies if >15% Lifetime Risk of Breast Cancer as Defined by IBIS Version 8","Genetic: Genetic Testing","Mayo Clinic","19-004343","July 1, 2019","Mayo Clinic in Arizona, Scottsdale, Arizona, United States","https://ClinicalTrials.gov/show/NCT04002986"
540,"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer","Not yet recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|ERBB2 Gene Amplification|HER2 Positive Breast Carcinoma|Metastatic Breast Carcinoma|PIK3CA Gene Mutation|PTEN Gene Mutation","Drug: Copanlisib|Biological: Pertuzumab|Biological: Trastuzumab","National Cancer Institute (NCI)","NCI-2019-06461|10296|UM1CA186688","September 30, 2019",,"https://ClinicalTrials.gov/show/NCT04108858"
541,"Study on Physical Activity's Relationship With Cancer and Cognition","Recruiting","No Results Available","Breast Cancer|Breast Neoplasm Female","Behavioral: Walking","University of Nebraska","IRB091-19","June 10, 2019","University of Nebraska Medical Center, Omaha, Nebraska, United States","https://ClinicalTrials.gov/show/NCT03980626"
542,"Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases","Recruiting","No Results Available","Breast Carcinoma|Metastatic Breast Cancer|Invasive Breast Cancer|Distant Metastases.Pathology","Device: Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)","Alpha Tau Medical LTD.","CTP-BRST-01","June 3, 2019","A. Tsyb Medical Radiological Research Center, Obninsk, Kaluga Region, Russian Federation","https://ClinicalTrials.gov/show/NCT03970967"
543,"Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen","Completed","Has Results","Vasomotor Symptoms (VMS)","Drug: oral capsule of Q-122","Que Oncology","Q-1001","September 6, 2019",,"https://ClinicalTrials.gov/show/NCT04080297"
544,"Responsiveness of Outcome Scales in Breast Cancer Related Lymphedema","Recruiting","No Results Available","Lymphedema of Upper Arm","Other: complex decongestive therapy","Marmara University","09.2019.865","October 24, 2019","Marmara University School of Medicine Department of Physical Medicine and Rehabilitation, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04138667"
545,"Stochastic Modulated Vibrations on Autonomic Nervous System of Breast Cancer Patients During Radiotherapy","Recruiting","No Results Available","Autonomic Nervous System Imbalance|Psychological Distress|Cancer-related Pain|Breast Cancer Lymphedema|Quality of Life","Device: Andullation|Other: Placebo","Universitair Ziekenhuis Brussel","2018/455","October 14, 2019","Universitair Ziekenhuis Brussel, Jette, Brussels, Belgium","https://ClinicalTrials.gov/show/NCT04125953"
546,"Three Fraction Radiation to Induce Immuno-Oncologic Response","Not yet recruiting","No Results Available","High-Risk Cancer|Locally Advanced Breast Cancer","Radiation: Neoadjuvant radiotherapy","Lawson Health Research Institute","112626","June 7, 2019","London Regional Cancer Program, London, Ontario, Canada","https://ClinicalTrials.gov/show/NCT03978663"
547,"TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery","Recruiting","No Results Available","Breast Adenocarcinoma|Stage II Breast Cancer AJCC v6 and v7|Stage IIA Breast Cancer AJCC v6 and v7|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7","Biological: Pertuzumab|Other: Placebo Administration|Biological: Sargramostim|Biological: Trastuzumab|Biological: Trastuzumab Emtansine|Biological: Vaccine Therapy","Mayo Clinic|National Cancer Institute (NCI)","MC1835|NCI-2019-08038|P30CA015083","December 13, 2019","Mayo Clinic Arizona, Phoenix, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT04197687"
548,"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","Suspended","No Results Available","Cancer Metastatic","Drug: Paclitaxel injection|Drug: Capecitabine tablets|Drug: Letrozole 2.5mg|Drug: Anastrozole 1mg|Drug: Fulvestrant Prefilled Syringe|Drug: Abemaciclib","UNICANCER","UC-0140/1901|2019-000260-14","November 8, 2019","Centre Hospitalier Lyon Sud, Pierre Benite, France|Centre Eugène Marquis, Rennes, France","https://ClinicalTrials.gov/show/NCT04158362"
549,"Study of a New Drug Combination, Copanlisib and Fulvestrant, in Postmenopausal Women With Advanced Breast Cancer","Not yet recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Breast Carcinoma Metastatic in the Brain|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Breast Carcinoma|Postmenopausal|Prognostic Stage IV Breast Cancer AJCC v8","Drug: Copanlisib|Drug: Fulvestrant","National Cancer Institute (NCI)","NCI-2019-00048|NCI10195|10195|UM1CA186704","January 15, 2019",,"https://ClinicalTrials.gov/show/NCT03803761"
550,"Assessment of Muscle Strength and Volume Changes in Patients With Breast Cancer- Related Lymphedema","Completed","No Results Available","Lymphedema Arm|Lymphedema; Surgical","Other: Complete Decongestion Therapy","Ege University","LymphHG","May 10, 2019","Ege university school of medicine, Izmir, Turkey","https://ClinicalTrials.gov/show/NCT03945838"
551,"Safety and Pharmacokinetics of ODM-209","Recruiting","No Results Available","Prostate Cancer Metastatic|Advanced Breast Cancer|Castration-resistant Prostate Cancer|Metastatic Breast Cancer","Drug: ODM-209","Orion Corporation, Orion Pharma","3125001","March 18, 2019","Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark|Helsinki University Central Hospital, Helsinki, Finland|Tampere University Hospital, Tampere, Finland|Institut Gustave Roussy, Villejuif, France","https://ClinicalTrials.gov/show/NCT03878823"
552,"Testing a Culturally Adapted Telephone Genetic Counseling Intervention","Recruiting","No Results Available","Breast Cancer|Hereditary Breast Cancer","Behavioral: Telephone Genetic Counseling","Georgetown University|Hackensack Meridian Health","KL2TR001432","May 22, 2019","Capital Breast Care Center, Washington, District of Columbia, United States|Hackensack Meridian Health, Hackensack, New Jersey, United States|Nueva Vida, Alexandria, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States","https://ClinicalTrials.gov/show/NCT03959267"
553,"Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects","Recruiting","No Results Available","Breast Carcinoma|Healthy Subject","Procedure: Photoacoustic Imaging","Roswell Park Cancer Institute|National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation","I 60217|NCI-2019-01356|P30CA016056","April 1, 2019","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT03897270"
554,"Impact of Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery","Recruiting","No Results Available","Breast Carcinoma|Mammoplasty Patient","Other: Diary|Other: Questionnaire Administration","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","PA18-1077|NCI-2019-07463|P30CA016672","November 20, 2019","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04169542"
555,"Study of Nerve Block Pain Management in Patients Undergoing a Double Mastectomy With Immediate Reconstruction","Recruiting","No Results Available","Breast Cancer|Breast Cancer Female","Drug: PVB Protocol|Drug: PECS-1|Drug: Serratus","Memorial Sloan Kettering Cancer Center","19-238","July 11, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04016376"
556,"The Recovery of Reaching Movement in Breast Cancer Survivors: Two Different Rehabilitative Protocols in Comparison","Completed","No Results Available","Breast Cancer|Breast Cancer Lymphedema|Pain|Pain, Postoperative|Pain, Chronic|Mastectomy; Lymphedema|Breast Surgery","Other: Single rehabilitative treatment|Other: Group rehabilitative treatment","University of Roma La Sapienza","URomLS-2019a","November 18, 2019","Umberto I Hospital, Rome, Italy","https://ClinicalTrials.gov/show/NCT04166279"
557,"DFS and QOL After Modified Radical Mastectomy vs. Expanded Mckissock Surgery for EIC of the Breast","Recruiting","No Results Available","Breast Neoplasms","Procedure: Expanded Mckissock surgery|Procedure: Modified radical mastectomy","Shengjing Hospital","Shengjing-LJY02","August 12, 2019","Shengjing Hospital of China Medical University, Shenyang, Liaoning, China","https://ClinicalTrials.gov/show/NCT04052893"
558,"An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction","Recruiting","No Results Available","Breast Carcinoma|Mammoplasty Patient","Procedure: Mammoplasty|Procedure: Vascularized Lymph Node Transfer","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","2018-0528|NCI-2019-03182|P30CA016672","June 19, 2019","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03990610"
559,"Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer","Recruiting","No Results Available","Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Early-Stage Breast Carcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma","Drug: Celecoxib|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Doxorubicin Hydrochloride|Drug: Paclitaxel|Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod","Roswell Park Cancer Institute|National Cancer Institute (NCI)","I 73718|NCI-2019-05299|P30CA016056","September 9, 2019","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT04081389"
560,"An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007","Recruiting","No Results Available","Breastcancer","Drug: Oraxol","Athenex, Inc.|PharmaEssentia","KX-ORAX-008|U1111-1180-5217","November 19, 2019","Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan|Taipei Veterans Generla Hospital, Taipei, Taiwan, 11217, Taiwan","https://ClinicalTrials.gov/show/NCT04168957"
561,"Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy","Recruiting","No Results Available","Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor Negative|HER2/Neu Negative|Inflammatory Breast Carcinoma|Progesterone Receptor Negative|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Stage IIB Breast Cancer AJCC v6 and v7|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Triple-Negative Breast Carcinoma","Drug: Atorvastatin|Drug: Capecitabine","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","2018-0550|NCI-2019-00004|P30CA016672","March 13, 2019","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03872388"
562,"Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted","Recruiting","No Results Available","Anatomic Stage 0 Breast Cancer AJCC v8|Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|HER2/Neu Negative|Invasive Ductal Carcinoma, Not Otherwise Specified|Progesterone Receptor Negative|Prognostic Stage 0 Breast Cancer AJCC v8|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma","Biological: Ipilimumab|Biological: Nivolumab|Biological: Talimogene Laherparepvec","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","18-000427|NCI-2018-01410|Glaspy BMS CA209-9ET Breast|P30CA016042","December 4, 2019","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT04185311"
563,"Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast Cancer","Recruiting","No Results Available","Breast Cancer|Radiotherapy; Adverse Effect, Dermatitis or Eczema|Radiotherapy Side Effect|Radiation Burn|Radiation Dermatitis|Radiotherapy; Complications","Device: Mepitel Film®","Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","2019-185-AGH","November 4, 2019","Allegheny Health Network, Pittsburgh, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04149522"
564,"Treatment of Breast Cancer-related Lymphoedema","Completed","No Results Available","Lymphedema","Device: intermittent pneumatic compression|Procedure: complex decongestive therapy","Aydin Adnan Menderes University","2012/99","June 20, 2019",,"https://ClinicalTrials.gov/show/NCT03992508"
565,"Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab","Recruiting","No Results Available","Cardiotoxicity|Risk Factor, Cardiovascular|Toxicity Due to Chemotherapy|Breast Cancer|Cardiomyopathies|Heart Failure","Drug: Carvedilol","Abramson Cancer Center of the University of Pennsylvania","UPCC12118","July 17, 2019","Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04023110"
566,"Diagnostic Contribution of Ultrasonography in Breast Cancer-Related Lymphedema","Completed","No Results Available","Lymphedema of Upper Arm","Diagnostic Test: ultrasonographic measurement","Dokuz Eylul University","DokuzEUBanuNihan","December 30, 2019","Dokuz eylul university, İzmir, Inciralti, Turkey","https://ClinicalTrials.gov/show/NCT04213001"
567,"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","Recruiting","No Results Available","Triple Negative Breast Neoplasms","Drug: Capivasertib|Drug: Paclitaxel|Drug: Placebo","AstraZeneca","D3614C00001","June 25, 2019","Research Site, Tucson, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Redlands, California, United States|Research Site, Whittier, California, United States|Research Site, Whittier, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Westwood, Kansas, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, East Hills, New York, United States|Research Site, New York, New York, United States|Research Site, Nyack, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Midlothian, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autonoma De Buenos Aire, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Córdoba, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario, Argentina|Research Site, Santa Rosa, Argentina|Research Site, Barretos, Brazil|Research Site, Florianópolis, Brazil|Research Site, Goiania, Brazil|Research Site, Londrina, Brazil|Research Site, Natal, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Chomutov, Czechia|Research Site, Horovice, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jihlava, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Brest Cedex, France|Research Site, Lyon Cedex 08, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nice, France|Research Site, Paris, France|Research Site, Saint Herblain, France|Research Site, Villejuif, France|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Gurgaon, India|Research Site, Hyderabad, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, Madurai, India|Research Site, Mumbai, India|Research Site, Nagpur, India|Research Site, Nasik, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Fukuoka-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Koto-ku, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Ota-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Takasaki-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan-si, Korea, Republic of|Research Site, Cheonan-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Estado de México, Mexico|Research Site, Guadalajara, Mexico|Research Site, Juchitan, Mexico|Research Site, Mexico Distrito Federal, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Tuxtla Gutierrez, Mexico|Research Site, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Bacolod, Philippines|Research Site, Bacolod, Philippines|Research Site, Baguio City, Philippines|Research Site, Baguio City, Philippines|Research Site, Cagayan De Oro City, Philippines|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Iloilo, Philippines|Research Site, Las Pinas, Philippines|Research Site, Legazpi City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, San Juan, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Grudziądz, Poland|Research Site, Konin, Poland|Research Site, Ostrołęka, Poland|Research Site, Poznan, Poland|Research Site, Racibórz, Poland|Research Site, Radom, Poland|Research Site, Tomaszów Mazowiecki, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Guimarães, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Arkhangelsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Ar Riyāḑ, Saudi Arabia|Research Site, Dammam, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Makkah, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Badalona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Hospitalet deLlobregat, Spain|Research Site, Jaén, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Pamplona, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Göteborg, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Sundsvall, Sweden|Research Site, Umeå, Sweden|Research Site, Uppsala, Sweden|Research Site, Changhua, Taiwan|Research Site, Hsinchu, Taiwan|Research Site, Hualien City, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Muang, Thailand|Research Site, Songkla, Thailand|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Mersin, Turkey|Research Site, Edinburgh, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, York, United Kingdom","https://ClinicalTrials.gov/show/NCT03997123"
568,"Use of a Remifentanil-propofol Mixture in Patients Undergoing Breast Cancer Surgery","Completed","No Results Available","Anesthetics|Remifentanil|Propofol","Combination Product: Remifentanil-propofol mixture","Tri-Service General Hospital","2-107-05-079","January 25, 2019","Tri-Service General hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT03817359"
569,"A Breast Cancer Genome Guided Therapy Study","Recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Breast Fibrocystic Change|Ductal Breast Carcinoma In Situ|Estrogen Receptor Negative|HER2/Neu Negative|Invasive Breast Carcinoma|Lobular Breast Carcinoma In Situ|Progesterone Receptor Negative|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Triple-Negative Breast Carcinoma","Drug: Abemaciclib|Procedure: Therapeutic Conventional Surgery","Mayo Clinic|National Cancer Institute (NCI)","MC1734|NCI-2019-03567|P30CA015083","June 7, 2019","Mayo Clinic Arizona, Phoenix, Arizona, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT03979508"
570,"Exploring the Link Between Cancer Genetics and PPSP","Not yet recruiting","No Results Available","Cancer-related Pain|Chronic Post Cancer Surgery Pain|Breast Cancer",,"Institute of Cancer Research, United Kingdom","CCR 5006","July 5, 2019",,"https://ClinicalTrials.gov/show/NCT04007861"
571,"Hypofractionated Versus Conventional Fractionation Radiotherapy","Not yet recruiting","No Results Available","Breast Cancer|Radiation Toxicity","Radiation: Conventional radiotherapy|Radiation: Hypofractionated radiotherapy","Hospital da Baleia","RT 1901","July 11, 2019",,"https://ClinicalTrials.gov/show/NCT04015531"
572,"Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases","Recruiting","No Results Available","Anatomic Stage IV Breast Cancer AJCC v8|Astrocytoma|Breast Carcinoma Metastatic in the Brain|Glioma|Invasive Breast Carcinoma|Oligodendroglioma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Glioma","Other: Best Practice|Drug: Ketoconazole","Wake Forest University Health Sciences|National Cancer Institute (NCI)","IRB00054587|NCI-2018-03087|CCCWFU 91118|P30CA012197","January 8, 2019","Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT03796273"
573,"PILATES METHOD ON THE UPPER LIMBS FUNCTIONALITY","Completed","No Results Available","Breast Neoplasm Female","Other: Pliates method treatment","Universidade Metodista de Piracicaba","2.510.081","February 1, 2019","Raphael Pereira, Belém, PA, Brazil","https://ClinicalTrials.gov/show/NCT03826979"
574,"Magnetic Seed Localisation for Nonpalpable Breast Lesions","Completed","No Results Available","Oncology|Breast Cancer","Device: Preoperative localisation technique","Universitaire Ziekenhuizen Leuven|KU Leuven","S61864","June 17, 2019","University Hospitals Leuven, Leuven, Belgium","https://ClinicalTrials.gov/show/NCT03988777"
575,"Serratus vs. Erector Spinae Fascial Plane Block for Breast and Axillary Surgery","Not yet recruiting","No Results Available","Breast Cancer|Nerve Block|Regional Anesthesia|Neuromuscular Blockade","Procedure: Serratus Block|Procedure: Erector spinae plane block","Women's College Hospital","Serratus vs. ESP block","June 7, 2019","Women's College Hospital, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT03978780"
576,"Comparison to Psychological, Medical and Emotional Influencing Communication and Achievement Factors to Oncogenetics Tests","Completed","No Results Available","Cancer|Colorectal Cancer|Breast Cancer|Ovarian Cancer","Behavioral: Behaviour","University Hospital, Montpellier","8893","March 26, 2019",,"https://ClinicalTrials.gov/show/NCT03889171"
577,"Patient Report Outcome-Reconstruction and Oncoplastic Cohort","Recruiting","No Results Available","Patient Reported Outcome Measures|Breast Reconstruction|Oncoplastic Breast-conserving Surgery|Breast Cancer","Procedure: breast reconstruction|Procedure: oncoplastic breast-conserving surgery","Fudan University|First Affiliated Hospital of Chongqing Medical University|Tianjin Medical University Cancer Institute and Hospital|First Hospital of China Medical University|Guangdong Provincial People's Hospital|The First Affiliated Hospital with Nanjing Medical University|Xijing Hospital, Air Force Medical University|Hunan Province Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|First Affiliated Hospital of Zhejiang University|The First Affiliated Hospital of Xiamen University|First Affiliated Hospital of Xinjiang Medical University|Hubei Cancer Hospital|The Affiliated Hospital of Qingdao University|First People's Hospital of Hangzhou","SCHBCC-N023","July 24, 2019","Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04030845"
578,"Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)","Not yet recruiting","No Results Available","Metastatic Uveal Melanoma|Triple Negative Breast Cancer|Luminal B Breast Cancer|Pediatric Cancer","Behavioral: Questionnaires|Behavioral: Semi-structured individual interviews|Other: Focus Group|Other: DELPHI Consensus Method","Institut Curie","IC 2018-09","October 7, 2019","Institut Curie, Paris, France","https://ClinicalTrials.gov/show/NCT04118062"
579,"MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients With Triple Negative or HER2+ MBC","Recruiting","No Results Available","Breast Neoplasm|Brain Metastases|Triple Negative Breast Cancer|HER2-positive Breast Cancer","Diagnostic Test: MRI screening","Sunnybrook Health Sciences Centre|Harvard University","211-2018","March 19, 2019","Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT03881605"
580,"Evaluation of a New Technique to Fill the Defect Generated After Conservative Surgery in Breast Cancer","Recruiting","No Results Available","Breast Conserving Surgery","Device: Silicone prosthesis|Procedure: Usual practice","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","IIBSP-SIL-2017-70","September 17, 2019","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04092842"
581,"Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast","Not yet recruiting","No Results Available","Cancer Survivor|Ductal Breast Carcinoma In Situ|Invasive Breast Carcinoma","Drug: Afimoxifene|Procedure: Core Biopsy|Other: Questionnaire Administration","Northwestern University|National Cancer Institute (NCI)","NU 18B05|NCI-2019-03771|P30CA060553","July 5, 2019","Northwestern University, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04009044"
582,"Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03","Enrolling by invitation","No Results Available","HER2-positive Breast Cancer|Early-stage Breast Cancer|Breast Cancer|Breast Neoplasms|Stage II Breast Cancer|Stage IIIA Breast Cancer","Biological: TX05 (trastuzumab)|Biological: Herceptin (trastuzumab)","Tanvex BioPharma USA, Inc.","TX05-03E","September 30, 2019","Tanvex Investigational Site 1003E, Gomel, Belarus|Tanvex Investigational Site 1006E, Grodno, Belarus|Tanvex Investigational Site 1008E, Lesnoy, Belarus|Tanvex Investigational Site 1002E, Minsk, Belarus|Tanvex Investigational Site 1001E, Vitebsk, Belarus|Tanvex Investigational Site 4001E, Temuco, Chile|Tanvex Investigational Site 4002E, Vina del Mar, Chile|Tanvex Investigational Site 5006E, Batumi, Georgia|Tanvex Investigational Site 5002E, Batumi, Georgia|Tanvex Investigational Site 5001E, Tbilisi, Georgia|Tanvex Investigational Site 5005E, Tbilisi, Georgia|Tanvex Investigational Site 5010E, Tbilisi, Georgia|Tanvex Investigational Site 6003E, Budapest, Hungary|Tanvex Investigational Site 7031E, Nashik, Maharashtra, India|Tanvex Investigational Site 7019E, Bangalore, India|Tanvex Investigational Site 7001E, Nashik, India|Tanvex Investigational Site 7015E, Pune, India|Tanvex Investigational Site 7017E, Vijayawada, India|Tanvex Investigational Site 2109E, Aguascalientes, Mexico|Tanvex Investigational Site 2103E, Monterrey, Mexico|Tanvex Investigational Site 2106E, Oaxaca, Mexico|Tanvex Investigational Site 2110E, Tequisquiapan, Mexico|Tanvex Investigational Site 2108E, Zapopan, Mexico|Tanvex Investigational Site 1101E, Arequipa, Peru|Tanvex Investigational Site 1107E, Arequipa, Peru|Tanvex Investigational Site 1104E, Chiclayo, Peru|Tanvex Investigational Site 1112E, Lima Cercado, Peru|Tanvex Investigational Site 1108E, San Borja, Peru|Tanvex Investigational Site 1102E, San Isidro, Peru|Tanvex Investigational Site 1109E, Surquillo, Peru|Tanvex Investigational Site 1103E, Trujillo, Peru|Tanvex Investigational Site 1211E, Cebu city, Philippines|Tanvex Investigational Site 1209E, Quezon City, Philippines|Tanvex Investigational Site 1213E, Quezon City, Philippines|Tanvex Invesitgational Site 1210E, Santo Tomas, Philippines|Tanvex Investigational Site 1513E, Sochi, Krasnodar Region, Russian Federation|Tanvex Investigational Site 1535E, Arkhangelsk, Russian Federation|Tanvex Investigational Site 1502E, Kaluga, Russian Federation|Tanvex Investigational Site 1505E, Kislino, Russian Federation|Tanvex Investigational Site 1529E, Krasnodar, Russian Federation|Tanvex Investigational Site 1512E, Krasnoyarsk, Russian Federation|Tanvex Investigational Site 1507E, Moscow, Russian Federation|Tanvex Investigational Site 1511E, Novosibirsk, Russian Federation|Tanvex Investigational Site 1503E, Omsk, Russian Federation|Tanvex Investigational Site 1509E, Omsk, Russian Federation|Tanvex Investigational Site 1537E, Orenburg, Russian Federation|Tanvex Investigational Site 1526E, Pesochnyy, Russian Federation|Tanvex Investigational Site 1510E, Pushkin, Russian Federation|Tanvex Investigational Site 1521E, Rostov-Na-Donu, Russian Federation|Tanvex Investigational Site 1516E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1524E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1525E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1506E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1501E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1523E, Sankt-peterburg, Russian Federation|Tanvex Investigational Site 1508E, Saransk, Russian Federation|Tanvex Investigational Site 1534E, Yaroslavl, Russian Federation|Tanvex Investigational Site 1820E, Antonivka, Ukraine|Tanvex Investigational Site 1803E, Chernihiv, Ukraine|Tanvex Investigational Site 1808E, Chernihiv, Ukraine|Tanvex Investigational Site 1821E, Chernivtsi, Ukraine|Tanvex Investigational Site 1811E, Kiev, Ukraine|Tanvex Investigational Site 1802E, Kiev, Ukraine|Tanvex Investigational Site 1819E, Kropyvnytskyi, Ukraine|Tanvex Investigational Site 1804E, Kryvyi Rih, Ukraine|Tanvex Investigational Site 1815E, Kyiv, Ukraine|Tanvex Investigational Site, Kyiv, Ukraine|Tanvex Investigational Site 1810E, Odesa, Ukraine|Tanvex Investigational Site 1806E, Sumy, Ukraine|Tanvex Investigational Site 1822E, Ternopil, Ukraine|Tanvex Investigational Site 1818E, Vinnytsia, Ukraine|Tanvex Investigational Site 1813E, Zaporizhzhya, Ukraine","https://ClinicalTrials.gov/show/NCT04109391"
583,"Vitamin D Replacement Therapy Can Affects Pathological Response in Neoadjuvant Breast Cancer Treatment","Recruiting","No Results Available","Vitamin D Deficiency|Chemotherapy Effect|Pathology","Drug: Vit D","Florence Nightingale Hospital, Istanbul","2019-40016-06","June 14, 2019","İstanbul Florence Nightingale Hospital Breast Health Center, Istanbul, Şişli, Turkey","https://ClinicalTrials.gov/show/NCT03986268"
584,"Non-mass Enhancement in Breast MRI","Not yet recruiting","No Results Available","Breast Neoplasm","Device: MRI","Assiut University","Breast MRI","September 10, 2019",,"https://ClinicalTrials.gov/show/NCT04083027"
585,"A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer","Recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor Positive Tumor|Progesterone Receptor Positive Tumor|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8","Behavioral: Focus Group|Other: Text Message|Other: Best Practice|Other: Questionnaire Administration","Thomas Jefferson University","19F.265","September 12, 2019","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04086875"
586,"Contrast Enhanced Mammography in Diagnosing Patients With Suspicious Breast Findings","Not yet recruiting","No Results Available","Breast Neoplasms","Procedure: Contrast Enhanced Digital Mammography","Thomas Jefferson University","19D.203","April 29, 2019","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03929783"
587,"Feasibility of Preoperative Tattooing of Percutaneously Biopsied Axillary Lymph Node: A Quasi Experimental Pilot Study","Recruiting","No Results Available","Breast Neoplasm",,"Aga Khan University","2018-0345-1105","May 7, 2019","Aga Khan University, Karachi, Sindh, Pakistan","https://ClinicalTrials.gov/show/NCT03939598"
588,"Breast Cancer Risk After Diagnostic Gene Sequencing","Recruiting","No Results Available","Genetic Predisposition to Disease","Genetic: BRIDGES gene panel testing|Genetic: Breast cancer risk polygenic risk score (PRS)|Behavioral: Questionnaires","Institut Curie","IC 2018-08","October 31, 2019","Institut Curie, Paris, France|University Hospital of Cologne, Cologne, Germany","https://ClinicalTrials.gov/show/NCT04145817"
589,"Continuous Pectoral Nerve Block in Breast Cancer Surgery","Completed","No Results Available","Nerve Blocks|Breast Surgery|Postoperative Pain","Procedure: PECS group|Other: Control group","Antalya Training and Research Hospital","13/21","July 29, 2019","Antalya Training and Research Hospital, Department of Anesthesiology and Reanimation, Antalya, Turkey","https://ClinicalTrials.gov/show/NCT04036370"
590,"Evaluation of the Unconformity of the Hormonal Status of Metastatic Lesions During a First Relapse of Breast Cancer Initially Expressing Estrogen Receptors: a Pilot Study on the Interest of PET With FES","Not yet recruiting","No Results Available","FES TEP in Detection of Estrogen Receptors","Other: FES PET","Centre Georges Francois Leclerc","EstroTEP COMPARE","March 13, 2019","CGFL, Dijon, France","https://ClinicalTrials.gov/show/NCT03873428"
591,"Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer","Recruiting","No Results Available","Invasive Ductal Breast Carcinoma|Invasive Ductal Carcinoma, Breast|DCIS|DCIS Grade 1|DCIS Grade 2|Breast Cancer","Radiation: Accelerated Partial Breast Irradiation","Memorial Sloan Kettering Cancer Center","19-300","September 10, 2019","Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States|Memoral Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States","https://ClinicalTrials.gov/show/NCT04084730"
592,"NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer","Completed","No Results Available","Chemotherapy-induced Nausea and Vomiting","Drug: Netupitant/Palonosetron","Consorzio Oncotech","GIM15-NEPA","March 5, 2019",,"https://ClinicalTrials.gov/show/NCT03862144"
593,"mHealth Behavioral Cancer Pain Intervention for Medically Undeserved Patients","Not yet recruiting","No Results Available","Breast Cancer","Behavioral: Mobile Health Pain Coping Skills Training (mPCST)","Duke University","Pro00103527","November 25, 2019",,"https://ClinicalTrials.gov/show/NCT04175639"
594,"Serratus Plane Plus Pectoral I Block Versus Serratus Plane Block for Perioperative Analgesia in Breast Cancer Surgery","Completed","No Results Available","Postoperative Pain|Postoperative Nausea|Patient Satisfaction|Narcotic Use","Other: Serratus Plane Block|Other: Serratus Plane Block plus Pectoral I Block","Bezmialem Vakif University","71306642-5/24","April 2, 2019","Bezmialem Vakıf University, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT03899545"
595,"Breast Cancer Women on Aromatase Inhibitors Treatment","Recruiting","No Results Available","Osteoporosis|Osteoporosis Fracture|Arthralgia Generalized","Drug: bisphosphonate","Parc de Salut Mar|Instituto de Salud Carlos III","4604010730","January 22, 2019","Xavier Nogues, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT03811509"
596,"Cancer Activity and Lifestyle Measurement Study","Recruiting","No Results Available","Breast Cancer",,"Ohio State University","2017C0165","May 23, 2019","The Ohio State University Clinical Research Center (Davis Medical Research Center), Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT03961685"
597,"Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery","Recruiting","No Results Available","Breast Cancer","Radiation: Hypofractionated Radiotherapy|Radiation: Conventional fractionated Radiotherapy","Fudan University","FDRT-BC007","July 18, 2019","Guizhou Provincial People's Hospital, Guiyang, Guizhou, China|Suzhou Municipal hospital, Suzhou, Jiangsu, China|The Second Hospital of Dalian Medical University, Dalian, Liaoning, China|Shanghai Huangpu District Central Hospital, Shanghai, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04025164"
598,"Sensory Nerve Coaptation in DIEP Flap Breast Reconstruction","Completed","No Results Available","Breast Cancer","Procedure: Sensory nerve coaptation","Maastricht University Medical Center","METC 16 - 4 - 147","September 18, 2019","Maastricht University Medical Center, Maastricht, Limburg, Netherlands","https://ClinicalTrials.gov/show/NCT04093999"
599,"BREADS: Breast Adjuvant Diet Study","Recruiting","No Results Available","Breast Cancer","Other: Carbohydrate restricted dietary intervention|Drug: standard of care aromatase inhibitors","Farin Amersi|Cedars-Sinai Medical Center","IIT2018-21-AMERSI-BREADS","December 6, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT04189263"
600,"Breast Screening - Risk Adaptive Imaging for Density","Recruiting","No Results Available","Breast Cancer","Diagnostic Test: ABUS|Diagnostic Test: CESM|Diagnostic Test: ABB-MRI","University of Cambridge|Cancer Research UK|GE Healthcare|Queen Mary University of London|Public Health England","A095053","September 20, 2019","Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom|Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom|The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT04097366"
601,"TIVA Admnistration and Autologous Fat Transfer in Breast Reconstruction","Recruiting","No Results Available","Breast Cancer","Drug: Propofol","National and Kapodistrian University of Athens|Saint Savvas Anticancer Hospital","2834","September 4, 2019","""Saint Savvas"" Hospital, Athens, Greece","https://ClinicalTrials.gov/show/NCT04077827"
602,"Application of Ultrasound Artificial Intelligence and Elastography in Differential Diagnosis of Breast Nodules","Recruiting","No Results Available","Breast Cancer","Device: Ultrasound diagnosis","Xin-Wu Cui|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Taizhou Hospital|Wuhan Hospital of Traditional Chinese and Western Medicine|Macheng People's Hospital|Huangshi Central Hospital|Affiliated Hospital of Jiangsu University|The First People's Hospital of Yichang|The Second People's Hospital of Yichang|Xiangyang Central Hospital|the Second Affiliated Hospital of Anhui Medical University|Anqing People's Hospital|Huainan People's Hospital|Wenzhou Central Hospital|Xuzhou First People's Hospital|The Central Hospital of Lishui City|Huai'an First People's Hospital|WISCO General Hospital|First People's Hospital of Jiangxia District, Wuhan City|Enshi State Central Hospital|Lianyungang Third People's Hospital|Xiangyang First People's Hospital|Tongji Hospital","2019(S073)","March 25, 2019","Xin-Wu Cui, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT03887598"
603,"Omitting vs. Doing Intraoperative Frozen Section Biopsy for Margin Status in Breast Conserving Surgery","Not yet recruiting","No Results Available","Breast Cancer","Procedure: Omission of intraoperative frozen section biopsy for margin status|Procedure: Frozen section biopsy for margin status","Samsung Medical Center","KC19EEDT0031","June 5, 2019",,"https://ClinicalTrials.gov/show/NCT03975179"
604,"Evaluation of the SmartBx System for Breast Biopsy","Not yet recruiting","No Results Available","Breast Cancer","Device: SmartBx","UC Care, Ltd.","EMC-0124-18","January 17, 2019","Haemek medical center, Afula, North Region, Israel","https://ClinicalTrials.gov/show/NCT03808116"
605,"Nerve Coaptation in LTP Flap Breast Reconstruction","Completed","No Results Available","Breast Cancer","Procedure: Sensory nerve coaptation","Maastricht University Medical Center","METC16-4-147","May 22, 2019","Maastricht University Medical Center, Maastricht, Limburg, Netherlands","https://ClinicalTrials.gov/show/NCT03959943"
606,"A Retrospective Breast Reconstruction Study","Recruiting","No Results Available","Breast Cancer","Other: HADM","Aziyo Biologics, Inc.","CLP-0004","August 16, 2019","Shoals Plastic Surgery, Muscle Shoals, Alabama, United States|Ascension/Seton Institute of Reconstructive Plastic Surgery, Austin, Texas, United States|DHR Health, McAllen, Texas, United States","https://ClinicalTrials.gov/show/NCT04060134"
607,"Investigation of Ultrasound Imaging and Spectroscopy for Characterizing Breast Masses","Recruiting","No Results Available","Breast Cancer",,"Sunnybrook Health Sciences Centre","232-2014","August 8, 2019","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04050423"
608,"Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution","Not yet recruiting","No Results Available","Breast Cancer","Drug: 18F-FDG|Device: Breast-dedicated PET camera","Stanford University","IRB-50877|BRS0102","July 12, 2019","Stanford University, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT04016818"
609,"Study of the Quality of Life in Patients With Standard External Breast Prosthesis Compared to Patients With Custom-made Breast Prosthesis.","Not yet recruiting","No Results Available","Breast Cancer","Device: MEAVANTI prothesis|Device: Standard prothesis","University Hospital, Toulouse","RC31/17/0335","June 10, 2019","CHU Rangueil, Toulouse, France","https://ClinicalTrials.gov/show/NCT03981263"
610,"Patient Satisfaction Survey (PSS) In Breast Clinic","Recruiting","No Results Available","Breast Cancer",,"Tata Memorial Centre","1835","May 24, 2019","Tata Memorial Centre, Mumbai, Maharashtra, India","https://ClinicalTrials.gov/show/NCT03962595"
611,"High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)","Not yet recruiting","No Results Available","Breast Cancer","Diagnostic Test: Contrast-media enhanced breast CT(CE-BCT)|Drug: Iodinated Contrast Agent","University of Arizona|National Institutes of Health (NIH)|National Cancer Institute (NCI)","1903399639|R01CA199044","May 17, 2019","University of Arizona, Tucson, Arizona, United States","https://ClinicalTrials.gov/show/NCT03954431"
612,"Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP)","Recruiting","No Results Available","Breast Cancer","Diagnostic Test: Predictive Model|Diagnostic Test: Breast Imagers","NYU Langone Health","18-00684","April 25, 2019","NYU Langone Health, New York, New York, United States","https://ClinicalTrials.gov/show/NCT03927768"
613,"The Impact of a Web-based Patient Decision Aid for Women Considering Breast Reconstruction","Recruiting","No Results Available","Breast Cancer","Other: online patient decision aid","The Netherlands Cancer Institute|Dutch Cancer Society|UMC Utrecht","NKI 2014-7031|A6C/NKI 2014-7031","January 2, 2019","Meander Medical Center, Amersfoort, Netherlands|Medical Center Slotervaart, Amsterdam, Netherlands|Netherlands Cancer Institute, Amsterdam, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Medical Center Leeuwarden, Leeuwarden, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands","https://ClinicalTrials.gov/show/NCT03791138"
614,"Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications","Suspended","No Results Available","Breast Cancer","Device: Gen 1B|Device: Gen 1","Seno Medical Instruments Inc.","GEN1B-01","February 19, 2019","Seno Medical, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT03845907"
615,"NEOBREADS: Neoadjuvant Breast Diet Study","Recruiting","No Results Available","Breast Cancer","Other: Carbohydrate restricted dietary intervention|Drug: standard of care aromatase inhibitors","Monica Mita|Cedars-Sinai Medical Center","IIT2018-25-MITA-NEOBREADS","January 30, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT03822715"
616,"Demonstration of a Novel Approach Using Surface-Image Guidance to Improve Delivery of Breast Radiotherapy","Recruiting","No Results Available","Breast Cancer","Other: Temporary skin markings|Other: Surface imaging","The University of Texas Health Science Center at San Antonio","CTMS# 18-0135|18-769H","January 10, 2019","UT Health San Antonio Mays Cancer Center, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT03799523"
617,"Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy","Recruiting","No Results Available","Breast Cancer","Drug: Palbociclib|Drug: Letrozole","SOLTI Breast Cancer Research Group|Pfizer","SOLTI-1710|2019-001275-36","October 17, 2019","Hospital General de Catalunya, Barcelona, Spain|ICO Hospitalet, Barcelona, Spain|Hospital 12 de octubre, Madrid, Spain|Hospital Universitario Infanta Sofía, Madrid, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Son Espases, Palma De Mallorca, Spain|Complejo Hospitalario Santiago de Compostela (CHUS), Santiago De Compostela, Spain|Hospital Virgen del Rocío, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT04130152"
618,"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer","Recruiting","No Results Available","Chemotherapy-induced Thrombocytopenia","Drug: Romiplostim|Drug: Placebo","Amgen","20170770","May 3, 2019","Research Site, Jonesboro, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Orange City, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Alexandria, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, Springfield, Missouri, United States|Research Site, Sparta, New Jersey, United States|Research Site, Binghamton, New York, United States|Research Site, Fort Worth, Texas, United States|Research Site, Cordoba, Córdoba, Argentina|Research Site, Viedma, Río Negro, Argentina|Research Site, Curitba, Paraná, Brazil|Research Site, Teresina, Piauí, Brazil|Research Site, Caxias do Sul, Rio Grande Do Sul, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Sofia, Bulgaria|Research Site, Santiago, Chile|Research Site, Cali, Valle Del Cauca, Colombia|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion - Crete, Greece|Research Site, Thessaloniki, Greece|Research Site, Farkasgyepu, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szolnok, Hungary|Research Site, Torokbalint, Hungary|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Oaxaca, Mexico|Research Site, Arequipa, Peru|Research Site, Brzeziny, Poland|Research Site, Poznan, Poland|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Cluj Napoca, Romania|Research Site, Iasi, Romania|Research Site, Ploiesti, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Moscow Region, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, Tambov, Russian Federation|Research Site, Granada, Andalucía, Spain|Research Site, Salamanca, Castilla León, Spain|Research Site, Ourense, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Denizli, Turkey|Research Site, Edirne, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kocaeli, Turkey|Research Site, Malatya, Turkey|Research Site, Tekirdag, Turkey|Research Site, Chernivtsi, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine","https://ClinicalTrials.gov/show/NCT03937154"
619,"Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors","Recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Cancer Fatigue|Cancer Survivor|Complete Remission|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8","Drug: Bupropion Hydrochloride Controlled-release|Other: Placebo|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Gary Morrow|National Cancer Institute (NCI)|University of Rochester","URCC-18007|NCI-2019-01528|R01CA214647|UG1CA189961","June 24, 2019","Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Lakeland Hospital Niles, Niles, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Lakeland Medical Center Saint Joseph, Saint Joseph, Michigan, United States|Marie Yeager Cancer Center, Saint Joseph, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Strecker Cancer Center-Belpre, Belpre, Ohio, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Mount Carmel East Hospital, Columbus, Ohio, United States|Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Grant Medical Center, Columbus, Ohio, United States|The Mark H Zangmeister Center, Columbus, Ohio, United States|Mount Carmel Health Center West, Columbus, Ohio, United States|Doctors Hospital, Columbus, Ohio, United States|Delaware Health Center-Grady Cancer Center, Delaware, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Dublin Methodist Hospital, Dublin, Ohio, United States|Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|OhioHealth Mansfield Hospital, Mansfield, Ohio, United States|Marietta Memorial Hospital, Marietta, Ohio, United States|OhioHealth Marion General Hospital, Marion, Ohio, United States|Knox Community Hospital, Mount Vernon, Ohio, United States|Licking Memorial Hospital, Newark, Ohio, United States|Newark Radiation Oncology, Newark, Ohio, United States|Southern Ohio Medical Center, Portsmouth, Ohio, United States|Saint Ann's Hospital, Westerville, Ohio, United States|Genesis Healthcare System Cancer Care Center, Zanesville, Ohio, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States|Greenville Health System Cancer Institute-Butternut, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Faris, Greenville, South Carolina, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Eastside, Greenville, South Carolina, United States|Greenville Health System Cancer Institute-Greer, Greer, South Carolina, United States|Greenville Health System Cancer Institute-Seneca, Seneca, South Carolina, United States|Greenville Health System Cancer Institute-Spartanburg, Spartanburg, South Carolina, United States|Bon Secours Memorial Regional Medical Center, Mechanicsville, Virginia, United States|Bon Secours Saint Francis Medical Center, Midlothian, Virginia, United States|Bon Secours DePaul Medical Center, Norfolk, Virginia, United States|Bon Secours Maryview Medical Center, Portsmouth, Virginia, United States|Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States|Bon Secours Health Center at Harbour View, Suffolk, Virginia, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03996265"
620,"A Research Study for Latina Women Undergoing Breast Cancer Treatment","Recruiting","No Results Available","Cancer-related Problem/Condition|Quality of Life|Stress, Emotional","Behavioral: My Guide","Northwestern University","STU00201961A","August 21, 2019","Northwestern University, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04064151"
621,"Reconstruction of Partial Mastectomy Defects With Pectoralis Myo-glandular Local Flap.","Recruiting","No Results Available","Breast Cancer","Procedure: Pectoralis myo-glandular flap reconstruction.","Mansoura University","R/19.08.578","September 17, 2019","Mansoura University Oncology Center, Mansourah, DK, Egypt","https://ClinicalTrials.gov/show/NCT04091958"
622,"Prospective Randomized Study of Accelerated Radiation Therapy (PRART)","Recruiting","No Results Available","Breast Cancer","Radiation: Radiation therapy - 3 weeks|Radiation: Radiation therapy - 2 weeks","Weill Medical College of Cornell University","19-07020533","November 22, 2019","New York Presbyterian Hospital at Lower Manhattan Cancer Center, New York, New York, United States|Brooklyn Methodist Hospital - NewYork Presbyterian, New York, New York, United States|New York Presbyterian Hospital - Queens, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04175210"
623,"Trial to Compare the Efficacy and Safety of F-627 and GRAN®","Completed","No Results Available","Breast Cancer","Biological: F-627","Generon (Shanghai) Corporation Ltd.","SP11631","November 22, 2019","Peking University Cancer Hospital, Peking, Beijing, China","https://ClinicalTrials.gov/show/NCT04174599"
624,"The Analgesic Efficacy of the Pectoral Nerves Block Versus Local Anesthetic Infiltration After Mastectomy","Not yet recruiting","No Results Available","Breast Cancer","Other: PECS block|Other: Local infiltration","Hôpital du Valais|University of Lausanne Hospitals","PECS 2019","October 4, 2019",,"https://ClinicalTrials.gov/show/NCT04116021"
625,"Sentinel Node Biopsy Vs Observation After Axillary PET","Recruiting","No Results Available","Breast Cancer","Procedure: SLNB is spared","Fudan University","SCHBCC-SOAPET","August 28, 2019","Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04072653"
626,"Optoacoustic Images Versus Imagio® Ultrasound","Completed","No Results Available","Breast Cancer","Device: Reader Study - Imagio Ultrasound|Device: Reader Study Imagio Ultrasound + Optoacoustic Imaging|Device: Mammography","Seno Medical Instruments Inc.","Reader-02 Study","July 23, 2019","American College of Radiology Center for Research and Innovation, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04030104"
627,"OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment","Recruiting","No Results Available","Breast Cancer","Radiation: Irradiation","Grupo de Investigación Clínica en Oncología Radioterapia","GIC-RAD-2016-01","June 4, 2019","Hospital Universitario de Cruces, Barakaldo, Bilbao, Spain|Hospital Universitario de Araba, Vitoria, Pais Vasco, Spain|Hospital Universitario Sant Joan de Reus, Reus, Tarragona, Spain|Centro Oncológico de Galicia, A Coruña, Spain|Hospital Infanta Cristina, Badajoz, Spain|ICO Badalona, Badalona, Spain|Hospital Universitario Santa Lucía, Cartagena, Spain|Hospital Universitario de Donostia, Donostia, Spain|ICO Girona, Girona, Spain|Hospital Universitari Arnau de Vilanova, Lerida, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Gregrorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT03972696"
628,"A Study of the Use of AirXpanders AeroForm in Patients Undergoing Post-Mastectomy Radiation Therapy","Withdrawn","No Results Available","Breast Cancer","Device: AirXpanders AeroFormtissue expander","Case Comprehensive Cancer Center","CASE2119","April 17, 2019",,"https://ClinicalTrials.gov/show/NCT03918317"
629,"TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol","Recruiting","No Results Available","Breast Cancer","Drug: Carvedilol","Mayo Clinic|National Cancer Institute (NCI)","18-006090|R01CA233610","March 19, 2019","Mayo Clinic, Phoenix, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT03879629"
630,"Acute Effect of Chromatic Environment During Chemotherapy","Recruiting","No Results Available","Breast Cancer","Other: Chromatic Environment|Other: Room Orientation","Universidad Europea de Madrid|Instituto Oncológico Balselga","R-2017/UEM11","March 13, 2019","Hospital Ruber Internacional, Madrid, Spain","https://ClinicalTrials.gov/show/NCT03873519"
631,"Screening CEDM in Intermediate and High-Risk Patient Populations","Recruiting","No Results Available","Breast Cancer","Device: Contrast Enhanced Digital Mammography","Mayo Clinic","18-010602","March 1, 2019","Mayo Clinic in Arizona, Scottsdale, Arizona, United States","https://ClinicalTrials.gov/show/NCT03859492"
632,"Under- and Overdiagnosis in BreastScreen Norway","Active, not recruiting","No Results Available","Breast Cancer","Other: Under- or overdiagnosed cancer|Other: Screening","Cancer Registry of Norway|Extrastiftelsen","17/222|2018/FO201362","February 25, 2019","Cancer Registry of Norway, Oslo, Norway","https://ClinicalTrials.gov/show/NCT03852953"
633,"Analgesia Nociception Index (ANI) After Unilateral Radical Mastectomy as an Evaluation of Paravertebral Block Failure","Recruiting","No Results Available","Breast Cancer","Other: Analgesia Nociception Index","Institut de Cancérologie de Lorraine","2019-A00121-56","February 6, 2019","Institut de Cancérologie de Lorraine (ICL), Vandœuvre-lès-Nancy, France","https://ClinicalTrials.gov/show/NCT03832920"
634,"Food Effect Study of D-0502 Tablet in Healthy Volunteers","Completed","No Results Available","Breast Cancer","Drug: D-0502","InventisBio Inc.","IBIO-302","January 18, 2019","Covance Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States","https://ClinicalTrials.gov/show/NCT03810625"
635,"Satisfaction & Efficacy of Compression Using Surgical Gloves in Chemo-induced Peripheral Neuropathies","Not yet recruiting","No Results Available","Breast Cancer|Colorectal Cancer","Device: Chilled gloves|Device: Surgical gloves","Centre Leon Berard","ET18-262 ELEGANT","March 13, 2019",,"https://ClinicalTrials.gov/show/NCT03872908"
636,"Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer","Not yet recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Chemotherapy-Induced Peripheral Neuropathy|Digestive System Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8","Drug: Lorcaserin|Drug: Lorcaserin Hydrochloride|Other: Questionnaire Administration","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","OSU-19085|NCI-2019-03368|P30CA016058","December 19, 2019","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT04205071"
637,"Abbreviated Breast MRI in Cancer Detection","Recruiting","No Results Available","Breast Cancer Female","Radiation: Breast MRI","Assiut University","Abbreviated Breast MRI","March 12, 2019","Zahraa, Assiut, Egypt","https://ClinicalTrials.gov/show/NCT03870659"
638,"Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer","Recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Invasive Breast Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8","Drug: Docetaxel|Drug: Paclitaxel|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","EAZ171|NCI-2019-00266|ECOG-ACRIN-EAZ171|UG1CA189828","June 28, 2019","Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|IU Health West Hospital, Avon, Indiana, United States|IU Health North Hospital, Carmel, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States|Springmill Medical Center, Indianapolis, Indiana, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lexington Medical Center, West Columbia, South Carolina, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States","https://ClinicalTrials.gov/show/NCT04001829"
639,"Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors","Not yet recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Arthralgia|Postmenopausal|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8","Dietary Supplement: Dietary Intervention|Behavioral: Exercise Intervention|Other: Questionnaire Administration","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","18-001926|NCI-2019-02909|P30CA016042","May 16, 2019","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT03953157"
640,"Reducing Breast Cancer Risk in Korean American Women","Completed","No Results Available","Secondhand Tobacco Smoke Exposure Reduction","Behavioral: Tobacco LHW","University of California, San Francisco|Korean Community Center of the East Bay","CBCRP 23AB-1400","September 6, 2019","Korean Community Center of the East Bay, San Leandro, California, United States","https://ClinicalTrials.gov/show/NCT04079556"
641,"Accessible Cancer Care to Enable Support for Survivors Programme","Recruiting","No Results Available","Survivorship|Breast Cancer|Gynecologic Cancer","Other: Supportive and survivorship care program|Other: Usual care","National University, Singapore|National Cancer Centre, Singapore","CIRB Ref. No: 2019/2090","July 10, 2019","National Cancer Centre Singapore, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT04014309"
642,"Investigation of Cancer Cell Extravasation Through mRNA Analysis of Organ-specific Endothelial Cells and Microfluidics","Completed","No Results Available","Breast Cancer Metastatic","Other: Tissue samples collection and cells isolation","Istituto Ortopedico Galeazzi","BRCP USA","August 6, 2019","IRCCS Galeazzi Orthopedic Hospital, Milan, Italy","https://ClinicalTrials.gov/show/NCT04047459"
643,"Does Chemotherapy Train the Mutation of the Pig-A Gene? (PIGA)","Recruiting","No Results Available","Breast Cancer Female","Biological: Blood collection and Micronuclei assay on binucleate lymphocytes in culture","Assistance Publique Hopitaux De Marseille","2018-63","February 11, 2019",": Service de Gynécologie Obstétrique Hôpital Nord, Marseille, Marseille Cedex 20, France","https://ClinicalTrials.gov/show/NCT03837054"
644,"Understanding Patient Experience and Preferences for the QT Scanner Compared to Mammography","Active, not recruiting","No Results Available","Breast Cancer Screening","Diagnostic Test: QT Scanner","QT Ultrasound LLC|Analysis Group, Inc.","QT MG PRE Phase 1","August 15, 2019","Analysis Group, Inc., Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04057391"
645,"Ultrasonographic Evaluation of Changes After Complex Decongestive Therapy","Not yet recruiting","No Results Available","Lymphedema of Upper Arm","Other: Complex decongestive therapy phase 1","Marmara University","09.2019.866","October 25, 2019","Esra Giray, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04139291"
646,"Impact of Diet and Physical Activity Changes on Body Weight, Biomarkers and Quality of Life in Breast Cancer Survivors","Completed","No Results Available","Body Weight Changes|Mammographic Density|Quality of Life","Behavioral: Motivational Interviewing|Behavioral: Traditional Education","Centro de Investigación en Alimentación y Desarrollo A.C.|National Council of Science and Technology, Mexico","60252|262211","September 19, 2019","Centro de Investigación en Alimentación y Desarrollo, Hermosillo, Sonora, Mexico","https://ClinicalTrials.gov/show/NCT04096469"
647,"Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity","Recruiting","No Results Available","Cardiotoxicity|Cardiac Rehabilitation","Other: Cardiac rehabilitation","Hospital Clinico Universitario de Santiago|Instituto de Salud Carlos III","PI17/01687","May 28, 2019","Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT03964142"
648,"Clinical Trial of Comparative Study of GB221 Pharmacokinetics","Completed","No Results Available","Metastatic Breast Cancer","Drug: Coprelotamab Injection|Drug: Trastuzumab Injection","Genor Biopharma Co., Ltd.","GB221-001","November 22, 2019","Linear Clinical Research Limited, Nedlands, Western Australia, Australia","https://ClinicalTrials.gov/show/NCT04175171"
649,"Study of the Impact of DPD Activity on the Efficacy of Capecitabine","Not yet recruiting","No Results Available","Breast Neoplasm Malignant Female","Other: DPD activity assessment|Drug: Capecitabine","Centre Antoine Lacassagne|Cerbaliance","2017/15","December 13, 2019","Clinique Saint Jean, Cagnes-sur-Mer, France|Centre Azuréen de Cancérologie, Mougins, France|Clinique St Georges, Nice, France|Centre Antoine Lacassagne, Nice, France|Hôpital Princesse Grâce, Monaco, Monaco","https://ClinicalTrials.gov/show/NCT04198727"
650,"Laser vs Hyaluronic Acid for GSM in Breast Cancer","Recruiting","No Results Available","Urogenital Disease","Device: Cikatridina|Device: Juliet Feminine Laser","Medical University of Graz","30-225 ex 17/18","January 25, 2019","Department of Obstetrics, Medical University Graz, Graz, Austria","https://ClinicalTrials.gov/show/NCT03816735"
651,"Combined PECS II and Transversus Plane Blocks Versus Erector Spinae Block in Modified Radical Mastectomy","Not yet recruiting","No Results Available","Breast Cancer|Acute Postoperative Pain","Procedure: Combined Modified Pectoralis and Transversus Plane Blocks|Procedure: Erector Spinae block","Assiut University","Analgesia in breast surgey","April 4, 2019",,"https://ClinicalTrials.gov/show/NCT03903224"
652,"Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC","Not yet recruiting","No Results Available","Breast Cancer Female|HER2-positive Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer|Breast Diseases|Hormone Receptor Positive Tumor","Drug: Pyrotinib|Drug: Trastuzumab|Drug: Aromatase inhibitor","Peking Union Medical College Hospital","BREAST-Pyrotinib","April 10, 2019",,"https://ClinicalTrials.gov/show/NCT03910712"
653,"Comparison of Three Methods for Early Detection of Breast Cancer","Enrolling by invitation","No Results Available","Proliferative Breast Disease","Diagnostic Test: Contrast Enhanced imaging|Drug: Lumason","Mayo Clinic","18-003544","May 17, 2019","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT03954015"
654,"Somatic Acupressure for Symptom Cluster Management in Breast Cancer Patients","Not yet recruiting","No Results Available","Cancer","Other: Somatic Acupressure|Other: Sham acupressure|Other: Usual care","Charles Darwin University|The Affiliated Hospital Of Southwest Medical University","H19017","October 8, 2019",,"https://ClinicalTrials.gov/show/NCT04118140"
655,"Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer","Active, not recruiting","No Results Available","Cognitive Decline|Chemo-brain","Drug: Memantine","UNC Lineberger Comprehensive Cancer Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","LCCC1921|5K12HD001441","July 26, 2019","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04033419"
656,"Feasibility and Accuracy of Nanosensor-based Cancer Diagnosis at the Point-of-care (Chedza)","Recruiting","No Results Available","Breast Neoplasms|Lymphoma","Diagnostic Test: Contrast Microhalography (CEM)","Harvard School of Public Health|National Cancer Institute (NCI)|Botswana Harvard Aids Institute|Massachusetts General Hospital|Brigham and Women's Hospital","BHP0111|UH3CA202637","October 8, 2019","Botswana Harvard AIDS Institute, Gaborone, Botswana","https://ClinicalTrials.gov/show/NCT04119154"
657,"Pectoral Nerve Block and Erector Spine Plane Block in Breast Cancer Surgery","Recruiting","No Results Available","Anesthesia|Analgesia|Acute Pain|Chronic Pain|Pectoralis Nerve Block|Erector Spine Plane Block|Patient Controlled Analgesia","Procedure: Pectoralis nerve block|Procedure: Erector spine plane block|Other: Control","Ondokuz Mayıs University|CENGİZ KAYA (ckaya)","PA191001001","October 22, 2019","Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey","https://ClinicalTrials.gov/show/NCT04135157"
658,"The Technical Operations And Standard Clinical Application Protocol of CBBCT in Diagnostic Process of Breast Cancer","Unknown status","No Results Available","The Clinical Application Guide of Conebeam Breast CT","Device: CBBCT","Tianjin Medical University Cancer Institute and Hospital|Sun Yat-sen University|Chinese PLA General Hospital|The First Affiliated Hospital of Zhengzhou University|Guangxi Medical University|Koning Corporation","CBBCT2018CIH","March 4, 2019","Tianjin Medical University Cancer Institute And Hospital, Tianjin, Tianjin, China","https://ClinicalTrials.gov/show/NCT03861221"
659,"Breaststroke Swimming After Breast Cancer Treatment/Surgery as a Means of Treatment for Seroma, Lymphedema, and Chronic Arm and Chest Pain","Not yet recruiting","No Results Available","Lymphedema|Seroma|Pain, Postoperative|Pain, Chest","Behavioral: Swimming","Ottawa Hospital Research Institute|University of Ottawa|Bruyere Research Institute","20190304-01H","September 6, 2019",,"https://ClinicalTrials.gov/show/NCT04080934"
660,"Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer","Active, not recruiting","No Results Available","Breast","Drug: pegfilgrastim","Julie Fisher, MD|Atrium Health","LCI-BRE-GCSF-001|00037721","November 22, 2019","Levine Cancer Institute, Charlotte, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04174742"
661,"Phase II Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma","Recruiting","No Results Available","Ductal Breast Carcinoma in Situ","Procedure: Lumpectomy|Radiation: Partial breast irradiation prior to surgery","Stanford University","IRB-46373|BRS0096","April 10, 2019","Stanford University, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT03909282"
662,"Effects of a Physical Exercise Intervention During Neoadjuvant Chemotherapy in Women With Breast Cancer","Not yet recruiting","No Results Available","Physical Exercise","Other: Exercise training|Other: Control","Universidad Europea de Madrid","UEM Quirón","October 22, 2019",,"https://ClinicalTrials.gov/show/NCT04135586"
663,"Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients","Active, not recruiting","No Results Available","Radiation Dermatitis","Device: Gelronate|Other: Aloevera","Sheba Medical Center|Ferring Pharmaceuticals","5652-18-SMC","May 8, 2019","Sheba Medical Center, Ramat Gan, Israel","https://ClinicalTrials.gov/show/NCT03941665"
664,"A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies","Recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Solid Tumor|High Grade Glioma","Drug: Poziotinib Hydrochloride","Spectrum Pharmaceuticals, Inc","SPI-POZ-203","November 21, 2019","Pacific Shores Medical Group, Long Beach, California, United States","https://ClinicalTrials.gov/show/NCT04172597"
665,"A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer","Active, not recruiting","No Results Available","Prostate Cancer","Drug: enzalutamide|Drug: enzalutamide Placebo|Drug: digoxin|Drug: rosuvastatin","Astellas Pharma Global Development, Inc.|Pfizer|Astellas Pharma Inc","9785-CL-0018","September 19, 2019","Site MD37301, Chisinau, Moldova, Republic of","https://ClinicalTrials.gov/show/NCT04094519"
666,"The Effect Of Ultrasound-guided Modified Pectoral Nerves Block Versus Ketamine Plus Magnesium Infusion On Analgesic Profile In Breast Cancer Surgeries","Recruiting","No Results Available","Postoperative Pain","Procedure: pectoral nerves block group|Drug: Ketamine plus magnesium group|Drug: Control group","National Cancer Institute, Egypt","N10-2017","September 19, 2019","National Cancer Institute, Al haram, Giza, Egypt","https://ClinicalTrials.gov/show/NCT04095455"
667,"Guided Imagery & Music in Cancer","Recruiting","No Results Available","Cancer, Breast|Cancer, Metastatic|Cancer Ovaries|Cancer Uterus Cervix","Behavioral: the Guided Imagery and Music method|Behavioral: standard care and verbal counselling","Aalborg University|Aretaieion University Hospital|SONORA Organisation for Music Therapy and Research","62/19-06-18","May 3, 2019","Aretaieion University Hospital, Athens, Attiki, Greece","https://ClinicalTrials.gov/show/NCT03936075"
668,"Temperature and Injury in Radiotherapy Radiation Skin Injury","Enrolling by invitation","No Results Available","Breast Neoplasm Female|Radiation Toxicity","Device: a digital Infrared thermography (FLIR E5 Serial No.63985976）","Shandong Cancer Hospital and Institute","FIR-2015","August 7, 2019",,"https://ClinicalTrials.gov/show/NCT04047823"
669,"Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study","Recruiting","No Results Available","Breast Neoplasm Female|Lymphoma|Cardiotoxicity|Anthracyclines|Physical Activity","Other: Exercise Training","University Hospital Inselspital, Berne|Spital STS AG|Bürgerspital Solothurn|Lindenhofspital|University of Bern","CAPRICE","February 21, 2019","Lindenhofgruppe, Bern, Switzerland|University Clinic for Cardiology, Bern, Switzerland|Bürgerspital Solothurn, Solothurn, Switzerland|Spital STS AG, Thun, Switzerland","https://ClinicalTrials.gov/show/NCT03850171"
670,"Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction","Recruiting","No Results Available","Anthracycline Related Cardiotoxicity in Breast Cancer","Drug: sulforaphane|Drug: Placebo Oral Tablet","Texas Tech University Health Sciences Center","L19-065","May 2, 2019","Texas Tech University Health Sciences Center, Lubbock, Texas, United States","https://ClinicalTrials.gov/show/NCT03934905"
671,"ConquerFear-Group: A Psychological Intervention for Fear of Cancer Recurrence","Recruiting","No Results Available","Fear of Cancer Recurrence|Breast Cancer Female","Behavioral: ConquerFear-Group|Behavioral: Relaxation Training","Aarhus University Hospital|University of Aarhus","NINTAU","October 24, 2019","Aarhus University Hospital, Aarhus, Denmark","https://ClinicalTrials.gov/show/NCT04137575"
672,"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","Recruiting","No Results Available","Breast Cancer|Non-small Cell Lung Carcinoma","Drug: Trastuzumab deruxtecan (DS-8201a)|Drug: Pembrolizumab","Daiichi Sankyo, Inc.|AstraZeneca UK Limited|Merck Sharp & Dohme Corp.","DS8201-A-U106|2018-002489-38","August 2, 2019","Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University du Cancer de Toulouse, Toulouse, France","https://ClinicalTrials.gov/show/NCT04042701"
673,"Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the ""Massive Parallel Sequencing"" on Circulating Tumor DNA","Recruiting","No Results Available","Breast Cancer|Colo-rectal Cancer","Procedure: Blood samples","Centre Hospitalier Henri Duffaut - Avignon","DEGENCA","September 26, 2019","Centre Hospitalier Henri Duffaut, Avignon, France","https://ClinicalTrials.gov/show/NCT04104633"
674,"3-D Super Resolution Ultrasound Microvascular Imaging","Not yet recruiting","No Results Available","Breast Cancer|Thyroid Cancer","Drug: Definity|Device: Acoustic Angiography","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","LCCC1915|R01CA220681","October 23, 2019","Univeristy of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04136912"
675,"LOL: It's All Improv After Cancer!™","Recruiting","No Results Available","Breast Cancer|Psychological Distress","Behavioral: Improvisational comedy classes|Behavioral: Waitlist control","Arash Asher, MD|Tower Cancer Research Foundation|Cedars-Sinai Medical Center","IIT2018-05-ASHER-IMPROV2","January 31, 2019","Cedars Sinai Medical Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT03824132"
676,"Southeast Asian Women's Health Project","Not yet recruiting","No Results Available","Breast Cancer|Cervical Cancer","Behavioral: Navigation|Other: Information only","Ohio State University|University of South Florida|American Cancer Society, Inc.","2018B0521","September 12, 2019","The Ohio State University, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT04086771"
677,"Management of Perioperative Anxiety by the Cardiac Coherence Technique Coupled With a Hypnosis Session","Recruiting","No Results Available","Breast Cancer|Gynecologic Cancer","Other: Cardiac coherence","Institut du Cancer de Montpellier - Val d'Aurelle","PROICM 2019-06 COH","June 11, 2019","Institut régional du cancer de Montpellier, Montpellier, Hérault, France","https://ClinicalTrials.gov/show/NCT03981731"
678,"Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients","Completed","No Results Available","Breast Cancer|Necrosis","Diagnostic Test: ICG microangiography","University of Wisconsin, Madison","2019-0557|SMPH/SURGERY/SURGTRAMA|A539714|UW19043","October 30, 2019","University of Wisconsin, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT04145323"
679,"Immediate Breast Reconstruction With Acellular Dermal Matrix","Completed","No Results Available","Breast Cancer|Breast Carcinoma in Situ|Mammaplasty|Acellular Dermis","Procedure: one-stage technique","Aarhus University Hospital|Danish Cancer Society|The Korning foundation|Foundation of the Kjaersgaard Family|King Christian X foundation|Foundation of architect Holger Hjortenberg|LifeCell Corporation (Branchburg, NJ, USA)","VEK 1-10-72-572-12","December 23, 2019",,"https://ClinicalTrials.gov/show/NCT04209010"
680,"Evaluation of a Novel Axillary Lymph Node Ink Localization Technique: A Feasibility Study","Recruiting","No Results Available","Breast Cancer|Axillary Lymphadenitis","Device: Black-Eye Ink","The Ottawa Hospital","20180569-01H","October 23, 2019","The Ottawa Hospital, Ottawa, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04136496"
681,"Karolinska Interventional Study of Mammograhic Density (Karisma-1)","Completed","No Results Available","Breast Cancer|Mammographic Density","Drug: Tamoxifen","Karolinska Institutet","2015-000345|2014-005005-20","September 6, 2019",,"https://ClinicalTrials.gov/show/NCT04079517"
682,"Pilot Usability and Feasibility Testing on Kinect-Enhanced Training System for Lymphatic Exercises","Recruiting","No Results Available","Breast Cancer|Lymphedema","Behavioral: Kinect-TOLF Training System","NYU Langone Health|National Cancer Institute (NCI)","19-00222|1R01CA214085","June 26, 2019","NYU Langone Health, New York, New York, United States","https://ClinicalTrials.gov/show/NCT03999177"
683,"In Vivo Smart Biopsy Device Protocol In Radiology","Active, not recruiting","No Results Available","Breast Cancer|Image Guided Biopsy","Device: Smart Biopsy Device","Dune Medical Devices","CP-10-001","April 16, 2019","Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center Campus Beilinson, Petah Tikva, Israel","https://ClinicalTrials.gov/show/NCT03914911"
684,"Pre Pectoral Implant for Immediate Breast Reconstruction Using Single Port Endoscopy","Recruiting","No Results Available","Genetic Predisposition|Breast Cancer","Procedure: Prophylactic mastectomy with immediate breast reconstruction","University Hospital, Montpellier|association la montpellier reine a du coeur","RECHMPL18_0244 UF 7672","February 12, 2019","Montpellier University Hospital, Montpellier, Hérault, France","https://ClinicalTrials.gov/show/NCT03838549"
685,"Pre-pectoral Versus Sub-pectoral Implant Placement in Immediate Breast Reconstruction","Recruiting","No Results Available","Mastectomy|Breast Cancer","Procedure: immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.|Procedure: Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement","Ottawa Hospital Research Institute","1449","May 22, 2019","The Ottawa Hospital, Ottawa, Ontario, Canada","https://ClinicalTrials.gov/show/NCT03959709"
686,"Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung","Recruiting","No Results Available","TNBC - Triple-Negative Breast Cancer|Triple Negative Breast Cancer|NSCLC|NSCLC Stage IV|Non Small Cell Lung Cancer|Non Small Cell Lung Cancer Metastatic|NSCLC Stage IV Without EGFR/ALK Mutation","Radiation: Sterotactic Body Radiotherapy/SBRT|Drug: Standard of care","Memorial Sloan Kettering Cancer Center","18-431","January 17, 2019","Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|New York Presbyterian Hospital-Weill Medical College of Cornell University (Specimen Analysis), New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States","https://ClinicalTrials.gov/show/NCT03808662"
687,"Self-compression Mammography in Clinical Practice","Active, not recruiting","No Results Available","Mammography|Breast Cancer","Other: Self compression arm","Arcispedale Santa Maria Nuova-IRCCS","RCT Pristina 2/TR","July 5, 2019","Laura Canovi, Reggio Emilia, RE, Italy","https://ClinicalTrials.gov/show/NCT04009278"
688,"Using Bupivacaine Locally in the Mastectomy Drains to Control Postoperative Pain","Completed","No Results Available","Pain, Postoperative|Breast Cancer","Drug: 40ml of 0.25% bupivacaine|Drug: 40ml of 0.9% normal saline","Alexandria University","malhussini001","January 10, 2019","Faculty of Medicine, Main Univeristy Hospital, Alexandria, Egypt","https://ClinicalTrials.gov/show/NCT03799757"
689,"Quality of Life, Aesthetic Result and Health Economy in Breast Reconstruction","Active, not recruiting","No Results Available","Breast Cancer Female|Surgery--Complications","Procedure: Breast reconstruction","Vastra Gotaland Region","Bröst-07:2-4","May 24, 2019",,"https://ClinicalTrials.gov/show/NCT03963427"
690,"Quantitative Evaluation of the Breast's Morphological Variations During Radiotherapy: MorphoBreast3D","Recruiting","No Results Available","Breast Cancer Female|Adjuvant Radiotherapy","Device: 3D surface scan","Centre Paul Strauss","2018-01|2017-A02489-44","January 14, 2019","Centre paul Strauss, Strasbourg, France","https://ClinicalTrials.gov/show/NCT03801850"
691,"Health and QoL in Oncological Patients: Management of Bone Pathology in Italian Citbl Population","Recruiting","No Results Available","Breast Cancer Female|Osteoporosis","Behavioral: Observational Analysis","Fondazione Policlinico Universitario Agostino Gemelli IRCCS","VIL-HEQ-17-014","August 14, 2019","Policlinico Agostino Gemelli, Roma, RM, Italy","https://ClinicalTrials.gov/show/NCT04055805"
692,"A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia","Recruiting","No Results Available","Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia","Procedure: Biopsy|Drug: ABIRATERONE|Drug: ENZALUTAMIDE|Drug: VENETOCLAX|Drug: PALBOCICLIB|Drug: All-trans Retinoic Acid|Drug: BORTEZOMIB|Drug: CABAZITAXEL|Drug: OXALIPLATIN|Drug: FLUOROURACIL|Drug: FOLINIC ACID|Drug: CARBOPLATIN|Drug: PANOBINOSTAT|Drug: VORINOSTAT|Drug: PEMBROLIZUMAB|Drug: BEVACIZUMAB|Drug: IPILIMUMAB|Drug: NIVOLUMAB|Drug: EVEROLIMUS|Drug: SIROLIMUS|Drug: CELECOXIB|Drug: OLAPARIB|Drug: AFATINIB|Drug: CABOZANTINIB|Drug: SORAFENIB|Drug: DASATINIB|Drug: ERLOTINIB|Drug: IDELALISIB|Drug: IMATINIB|Drug: LENVATINIB|Drug: PERTUZUMAB|Drug: PONATINIB|Drug: RUXOLITINIB|Drug: SUNITINIB|Drug: TRAMETINIB|Drug: VEMURAFENIB","OHSU Knight Cancer Institute|Oregon Health and Science University","STUDY00015588","March 18, 2019","OHSU Knight Cancer Institute, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT03878524"
693,"Hair-Safe Study: Scalp Cooling for Hair Saving in Women Undergoing Chemotherapy","Recruiting","No Results Available","Breast Cancer Female|Alopecia","Device: Paxman Scalp Cooling System|Other: Alopecia Assessments","Medical University Innsbruck","1049/2018","October 7, 2019","Medical University Innsbruck, Department of Gynaecology and Obstetrics, Innsbruck, Tyrol, Austria","https://ClinicalTrials.gov/show/NCT04117815"
694,"Fathers and Mothers Invested in Lives of Their Youth (FAMILY) Study: A Pilot Intervention","Recruiting","No Results Available","Metastatic Breast Cancer|Parenting","Behavioral: FAMILY Intervention","UNC Lineberger Comprehensive Cancer Center|National Cancer Institute (NCI)","LCCC1920|5K07CA218167-02","September 17, 2019","Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04092816"
695,"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease","Recruiting","No Results Available","Triple Negative Breast Cancer|Non Small Cell Lung Cancer|Metastatic Breast Cancer|Metastatic Non-Small Cell Lung Carcinoma","Radiation: Stereotactic Body Radiotherapy/SBRT|Drug: Systemic Therapy/Standard of Care","Memorial Sloan Kettering Cancer Center","18-486","January 17, 2019","Miami Cancer Institute, Miami, Florida, United States|Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States|Memoral Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan - Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03808337"
696,"A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR)","Recruiting","No Results Available","Ovarian Cancer|Triple-negative Breast Cancer|Urothelial Carcinoma|Solid Tumor","Drug: Rucaparib|Drug: Lucitanib|Drug: Sacituzumab govitecan","Clovis Oncology, Inc.|Immunomedics, Inc.","CO-338-098","June 20, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03992131"
697,"Intraoperative Molecular Diagnosis of Sentinel Lymph Node In Breast Cancer Patients","Recruiting","No Results Available","Sentinel Lymph Node Biopsy","Device: The OSNA assay","Shandong Cancer Hospital and Institute","OSNA","May 3, 2019","Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China","https://ClinicalTrials.gov/show/NCT03937414"
698,"Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy","Completed","No Results Available","Breast Carcinoma|Head and Neck Carcinoma|Sarcoma","Other: Survey|Other: Survey Administration|Behavioral: Telephone-Based Intervention","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","2016-0300|NCI-2019-02651|P30CA016672","May 28, 2019","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03964896"
699,"Dibenzyl Trisulphide (GUINEAHEN WEED) for Stage IV Cancer","Recruiting","No Results Available","Stage IV Prostate Cancer|Stage IV Colon Cancer|Stage IV Breast Cancer|Stage IV Cancer of the Cervix","Drug: Dibenzyl trisulphide capsules|Drug: Stage IV Breast Cancer Placebo|Drug: Stage IV: Colon Cancer Placebo|Drug: Cervical Cancer Stage IV Placebo|Drug: Cancer of the Prostate Placebo","The University of The West Indies","ECP 250 - 15/16","October 2, 2019","Faculty of Medial Sciences, Kingston, Jamaica","https://ClinicalTrials.gov/show/NCT04113096"
700,"Plant Sterol INtervention for Cancer Prevention (PINC)","Recruiting","No Results Available","Hypercholesterolemia|Breast Cancer|Obesity","Dietary Supplement: Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)|Dietary Supplement: Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)","University of Leeds|The Leeds Teaching Hospitals NHS Trust|University of Oslo","RD19/123502","November 1, 2019","University of Leeds, Leeds, West Yorkshire, United Kingdom","https://ClinicalTrials.gov/show/NCT04147767"
701,"A Study of Serum Folate Levels in Patients Treated With Olaparib","Not yet recruiting","No Results Available","Ovarian Cancer|Breast Cancer|Folic Acid Deficiency","Drug: Folic Acid Tablet","Rush University Medical Center","ESR-18-13807","July 18, 2019",,"https://ClinicalTrials.gov/show/NCT04024254"
702,"Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women","Recruiting","No Results Available","Chemotherapy-induced Peripheral Neuropathy|Breast Cancer Female|Gynecologic Cancer","Device: Acupuncture","University of Utah","107709","August 26, 2019","Huntsman Cancer Institute, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT04067544"
703,"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","Recruiting","No Results Available","Non Small Cell Lung Cancer|Ovarian Cancer|Triple Negative Breast Cancer|Gastric Cancer|Pancreatic Cancer|Urothelial Cancer","Drug: BT5528|Drug: Nivolumab","Bicycle Tx Limited","BT5528-100","November 27, 2019","Florida Cancer Specialists, Sarasota, Florida, United States|Stephenson Cancer Center (Oklahoma University), Oklahoma City, Oklahoma, United States|Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT04180371"
704,"Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery","Recruiting","No Results Available","Body Mass Index Greater Than or Equal to 30|Malignant Breast Neoplasm|Mammoplasty Patient|Obesity","Procedure: Negative Pressure Wound Therapy|Procedure: Wound Care Management","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","2018-0004|NCI-2019-02777|P30CA016672","July 1, 2019","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04003038"
705,"Opera® for Aromatase Inhibitor-related Arthralgia Management (AIA)","Completed","No Results Available","Breast Cancer|Hormone Receptor Positive Tumor|Arthralgia","Dietary Supplement: OPERA","Azienda Ospedaliero-Universitaria Careggi","OPERA2","November 13, 2019","Azienda Ospedaliero Universitaria Careggi, Florence, Italy","https://ClinicalTrials.gov/show/NCT04161833"
706,"Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Melanoma|Nasopharyngeal Carcinoma|Microsatellite Stable Colorectal Cancer|Triple Negative Breast Cancer","Drug: DKY709|Drug: PDR001","Novartis Pharmaceuticals|Novartis","CDKY709A12101C","March 27, 2019","Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Chuo ku, Tokyo, Japan","https://ClinicalTrials.gov/show/NCT03891953"
707,"Vaccine Response With NT-I7","Not yet recruiting","No Results Available","Breast Carcinoma|Colorectal Adenocarcinoma|Bladder Carcinoma","Biological: Recombinant human IL-7-hyFc (NT-I7)|Biological: Vaccine sequence 1|Biological: Vaccine sequence 2","National Cancer Institute (NCI)|NeoImmuneTech, Inc.|National Institutes of Health Clinical Center (CC)","190134|19-C-0134","August 13, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04054752"
708,"Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Removal of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors","Recruiting","No Results Available","Stage IV Non-small Cell Lung Cancer|Stage IV Melanoma|Triple Negative Breast Cancer|Renal Cell Carcinoma Stage IV","Combination Product: ImmunicomAIAC","Prof. Gal Markel|Sheba Medical Center","SHEBA-19-6136-GM-CTIL","October 29, 2019","Sheba Medical Center, Ramat Gan, Israel","https://ClinicalTrials.gov/show/NCT04142931"
709,"Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization","Not yet recruiting","No Results Available","Breast Carcinoma|Cervical Carcinoma|Colorectal Carcinoma","Other: Training|Other: Cancer Screening intervention","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","RG1006143|NCI-2019-08033|P30CA015704","December 23, 2019","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04208724"
710,"The Effect of Acupuncture on Cancer-Related Cognitive Difficulties","Recruiting","No Results Available","Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|Stage I Colorectal Cancer|Stage II Colorectal Cancer|Stage III Colorectal Cancer|Gynecologic Cancer|Stage I Gynecologic Cancer|Stage II Gynecologic Cancer|Stage III Gynecologic Cancer","Other: Acupuncture|Other: Sham Acupuncture|Other: 8 week waiting period + optional Acupuncture","Memorial Sloan Kettering Cancer Center","19-179","July 5, 2019","Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States","https://ClinicalTrials.gov/show/NCT04007770"
711,"Anthracycline Induced Cardiotoxicity - Early Detection by Combination of Diastolic Strain and T2-mapping","Recruiting","No Results Available","Breast Cancer|Myocardial Damage|Cardiotoxicity","Diagnostic Test: Cardiac MRI and echocardiography, laboratory parameters","Heinrich-Heine University, Duesseldorf","15-002","May 7, 2019","Division of Cardiology, Pulmonary Disease and Vascular Medicine, Dusseldorf, Germany","https://ClinicalTrials.gov/show/NCT03940625"
712,"A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ","Recruiting","No Results Available","Ductal Breast Carcinoma In Situ|HER2/Neu Positive","Biological: Granulocyte-Macrophage Colony-Stimulating Factor|Biological: Multi-epitope HER2 Peptide Vaccine H2NVAC|Procedure: Therapeutic Conventional Surgery","Mayo Clinic|National Cancer Institute (NCI)","MC1713|NCI-2019-07002|P30CA015083","October 30, 2019","Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT04144023"
713,"Atezolizumab Combined With Intratumoral G100 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors","Not yet recruiting","No Results Available","Solid Tumor, Adult|Pancreatic Cancer|Virus-associated Tumors|Non Small Cell Lung Cancer|Melanoma|Bladder Cancer|Triple Negative Breast Cancer","Drug: Association atezolizumab + G100 + RT","Institut Bergonié|Roche Pharma AG|National Cancer Institute, France|Immune Design","IB 2019-01|2019-000850-78","April 16, 2019","Institut Bergonié, Bordeaux, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille Cedex, France|Centre Léon Bérard, Lyon Cedex 08, France|Institut Paoli Calmettes, Marseille, France|Institut du Cancer de Montpellier, Montpellier, France|Institut Curie, Paris, France|Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, France|IUCT Oncopôle, Toulouse, France|Institut Gustave Roussy, Villejuif Cedex, France","https://ClinicalTrials.gov/show/NCT03915678"
714,"A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors","Active, not recruiting","No Results Available","Solid Tumors|Advanced Triple Negative Breast Cancer|Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer|Advanced Metastatic Castration-Resistant Prostate Cancer|Advanced Platinum-Resistant Ovarian Cancer","Drug: TRX518|Drug: Cyclophosphamide|Drug: Avelumab","Leap Therapeutics, Inc.|Pfizer|Merck KGaA, Darmstadt, Germany","TRX518-004","March 4, 2019","Horizon Oncology Research, Lafayette, Indiana, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Virginia, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT03861403"
715,"Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors","Active, not recruiting","No Results Available","Metastatic Colorectal Cancer|Triple Negative Breast Cancer|Prostate Adenocarcinoma|Stomach Adenocarcinoma|Esophageal Adenocarcinoma","Drug: Tremelimumab|Drug: Durvalumab","Gustave Roussy, Cancer Campus, Grand Paris","2018-003115-21|2018/2798","June 11, 2019","Gustave Roussy, Villejuif, Val De Marne, France","https://ClinicalTrials.gov/show/NCT03982173"
716,"A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.","Recruiting","No Results Available","Breast Cancer|Prostate Cancer|Ovarian Cancer","Drug: Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib|Drug: Part 1, Dose level 2b and dose level 3: Ipatasertib|Drug: Part 1, Dose Level 1 and Dose Level 2b: Rucaparib|Drug: Part 1, Dose Level 2a and Dose Level 3: Rucaparib","Hoffmann-La Roche","BO40933","February 15, 2019","California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States|Regional Cancer Care Associates LLC, Central Jersey Division, East Brunswick, New Jersey, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Mary Crowley Medical Research Center; Oncology, Dallas, Texas, United States|Kinghorn Cancer Centre; St Vincents Hospital, Darlinghurst, New South Wales, Australia|Macquarie University Hospital, Sydney, New South Wales, Australia|Cabrini Hospital Malvern, Malvern, Victoria, Australia|Istituto Nazionale Tumori Regina Elena IRCCS, Roma, Lazio, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori; S. C. Oncologia Medica 2, Milano, Lombardia, Italy|Azienda Ospedaliera Santa Maria di Terni, Terni, Umbria, Italy|Istituto Oncologico Veneto IRCCS, Padova, Veneto, Italy|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain","https://ClinicalTrials.gov/show/NCT03840200"
717,"A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors","Recruiting","No Results Available","Cancer|Advanced Solid Tumors|Triple-Negative Breast Cancer (TNBC)|Non-small-cell-lung-cancer (NSCLC)|Metastatic Solid Tumors","Drug: ABBV-927|Drug: ABBV-368|Drug: ABBV-181|Drug: Carboplatin|Drug: Nab-paclitaxel","AbbVie","M19-037|2019-000478-45","March 28, 2019","St Jude Hospital dba St Joseph /ID# 211130, Santa Rosa, California, United States|Yale University /ID# 210678, New Haven, Connecticut, United States|Carolina BioOncology Institute /ID# 210664, Huntersville, North Carolina, United States|Mary Crowley Cancer Research /ID# 210716, Dallas, Texas, United States|NEXT Oncology /ID# 210717, San Antonio, Texas, United States|Virginia Cancer Specialists /ID# 210671, Fairfax, Virginia, United States|Gustave Roussy /ID# 213052, Villejuif, Ile-de-France, France|Institut de Cancer de l'Ouest /ID# 212880, Angers, France|Hopital Bichat-Claude Bernard /ID# 212869, Paris, France|Sheba Medical Center /ID# 211699, Ramat Gan, Israel|Hospital Vall d'Hebron /ID# 212804, Barcelona, Spain|Hospital Universitario Fundacion Jimenez Diaz /ID# 212806, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 212805, Madrid, Spain|National Cheng Kung University Hospital /ID# 210994, Tainan City, Tainan, Taiwan|National Taiwan University Hospital /ID# 210993, Taipei City, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT03893955"
718,"Physical Activity Intervention for Young Cancer Survivors","Active, not recruiting","No Results Available","Breast Cancer|Quality of Life|Physical Activity","Behavioral: Exercise Intervention","University of California, San Diego|Haus of Volta","181367","August 22, 2019","University of California, San Diego, La Jolla, California, United States","https://ClinicalTrials.gov/show/NCT04064892"
719,"HeartPhone Cancer Survivors Trial 2019","Recruiting","No Results Available","Breast Cancer|Leukemia|Lymphoma","Behavioral: HeartPhone app|Drug: Acetylcholine|Drug: Sodium Nitroprusside|Drug: L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester","Penn State University","00011271","May 16, 2019","The Pennsylvania State University, University Park, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03953326"
720,"Assessment of Outpatient Digital Follow-up of Patients Over 70 Years of Age Undergoing Chemotherapy Treatment","Not yet recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Lung Cancer","Device: IPC NET","Institut Paoli-Calmettes","E-SN@P PROJECT-IPC 2017-029","May 22, 2019","Institut Sainte Catherine, Avignon, France|CHI des Alpes du Sud, Gap, France|Institut Paoli-Calmettes, Marseille, France|CHU Nice, Nice, France","https://ClinicalTrials.gov/show/NCT03959774"
721,"A Digimed Oncology PharmacoTherapy Registry","Active, not recruiting","No Results Available","Colon Cancer|Breast Cancer|Rectal Cancer","Other: DigiMeds","Proteus Digital Health, Inc.","PRO 1676","September 13, 2019","Carolina Blood and Cancer Care, Rock Hill, South Carolina, United States","https://ClinicalTrials.gov/show/NCT04088955"
722,"PBMT for the Management of CIA ( HAIRLASER )","Not yet recruiting","No Results Available","Breast Cancer|Chemotherapy-induced Alopecia|Alopecia","Device: Photobiomodulation therapy|Device: Sham photobiomodulation therapy","Hasselt University|Jessa Hospital","19.58/ONCO19.08","July 30, 2019","Jessa Ziekenhuis, Hasselt, Belgium","https://ClinicalTrials.gov/show/NCT04036994"
723,"Involvement of SK3 Calcium Channel in Taxane Neuropathy","Recruiting","No Results Available","Breast Cancer|Chemotherapy-induced Peripheral Neuropathy|Prostate Cancer","Other: Blood samples","University Hospital, Tours","RIPH3-RNI18/NEUROTAX|2018-A02884-51","January 25, 2019","Department of Oncology, Hospital, Chinon, Chinon, France|Department of Medical Oncology, University Hospital, Tours, Tours, France","https://ClinicalTrials.gov/show/NCT03816904"
724,"Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment","Recruiting","No Results Available","Breast Cancer|Pre Diabetes|Diabetes",,"Memorial Sloan Kettering Cancer Center","19-315","December 24, 2019","Memorial Sloan Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04210128"
725,"Comparison of pCR Rate After Neadjuvant Chemotherapy Guided by Result of in Vitro Cell Culture Drug Sensitivity or Physician's Choice","Not yet recruiting","No Results Available","Breast Cancer|Neoadjuvant Chemotherapy|Drug Effect","Combination Product: treatment of drug screening","Peking University People's Hospital","PKUPH10B001","October 17, 2019","Peking University People'S Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04130750"
726,"Seroma Reduction and Drain Free Mastectomy","Not yet recruiting","No Results Available","Breast Cancer|Seroma|Wound Complication","Procedure: No drain|Procedure: With drain","Zuyderland Medisch Centrum","METCZ2019016","July 29, 2019","Zuyderland Medisch Centrum, Sittard, Limburg, Netherlands","https://ClinicalTrials.gov/show/NCT04035590"
727,"Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion","Not yet recruiting","No Results Available","Lung Cancer|Breast Cancer|Malignant Pleural Effusion","Drug: microparticles packaging methotrexate (MPs-MTX)|Drug: recombinant human interleukin-2(rhIL-2)","Peking Union Medical College","NCC20180327","October 18, 2019",,"https://ClinicalTrials.gov/show/NCT04131231"
728,"EHR-embedded OCDT in Breast or GI Cancer","Recruiting","No Results Available","Oral Cancer Directed Therapy|Breast Cancer|Gastrointestinal Cancer|Oral Chemotherapy","Other: Active Care Team Alert|Other: Passive Care Team Alert","Dana-Farber Cancer Institute","18-571","March 1, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT03858712"
729,"BReast CAncer Genes(BRCA) Expressions in Metastatic Gastric Cancer","Recruiting","No Results Available","BRCA Gene Rearrangement","Genetic: BRCA 1|Drug: Chemotherapy","Chung-Ang University","1771-001-287","February 12, 2019","Chung-Ang University College of Medicine, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT03838406"
730,"Evolution of the Physical Condition in Treated Cancer Patients","Recruiting","No Results Available","Non-small Cell Lung Cancer Metastatic|Breast Cancer Female|Colon Cancer","Other: Adaptated Physical Activity","Centre Paul Strauss","2019-001|2019-A00848-49","May 21, 2019","Centre Paul Strauss, Strasbourg, France","https://ClinicalTrials.gov/show/NCT03956641"
731,"SLNB After Neoadjuvant Treatment in Node Positive Patients","Completed","No Results Available","Sentinel Lymph Node Biopsy|Locoregional Neoplasm Recurrence|Progression, Disease",,"Clinical Hospital Center Rijeka","SLNBvsALND","February 7, 2019",,"https://ClinicalTrials.gov/show/NCT03833960"
732,"Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour","Not yet recruiting","No Results Available","Colorectal Cancer|Triple Negative Breast Cancer|Sarcoma|Nasopharyngeal Carcinoma|Prostate Cancer|Gastric Cancer","Biological: Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell","CytoMed Therapeutics Pte Ltd","CTM-N2D","September 27, 2019","Landmark Medical Centre, Johor Bahru, Johor, Malaysia","https://ClinicalTrials.gov/show/NCT04107142"
733,"Direct Information to At-risk Relatives","Enrolling by invitation","No Results Available","Familial Breast Cancer|Familial Colorectal Cancer|Hereditary Breast and Ovarian Cancer Syndrome|Hereditary Breast Cancer|Lynch Syndrome","Other: Standard care encouraging family-mediated disclosure of hereditary cancer risk|Other: Offer of health-care assisted disclosure by sending direct letters to at-risk relatives","Umeå University|Göteborg University|Lund University|Karolinska Institutet","The Swedish DIRECT study|Ref. no: 2018-00964","December 13, 2019","Cancergenetisk mottagning, Umeå, Sweden","https://ClinicalTrials.gov/show/NCT04197856"
734,"Tumoral Bone Strength Assessment by Numerical Simulation Using Quantitative CT : the MEKANOS Study","Recruiting","No Results Available","Metastases to Bone|Metastatic Breast Cancer|Metastatic NSCLC","Other: Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation","Hospices Civils de Lyon","69HCL17_0642","November 20, 2019","Service de rhumatologie, CHU d'Angers, Angers, France|Service de radiothérapie, Institut Jean-Perrin, Clermont-Ferrand, France|Service de rhumatologie, CH Annemasse, Contamine-sur-Arve, France|Service de rhumatologie, CHU de Grenoble, La Tronche, France|Service d'onco-rhumatologie, Centre Oscar Lombret, Lille, France|Service de Radiothérapie, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, Lyon, France|Service d'oncologie médicale, Institut Curie, 26 rue d'Ulm, Paris, France|Service de Radiologie, Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France|Service de Rhumatologie, Hospices Civils de Lyon, Groupement Hospitalier Lyon Sud, Pierre-Bénite, France|Service de rhumatologie, CHU de Poitiers, Poitiers, France|Service de rhumatologie, CHU de Saint Etienne, Saint-Priest-en-Jarez, France","https://ClinicalTrials.gov/show/NCT04170634"
735,"Pain Phenotyping of Patients With Bone Cancer Pain","Recruiting","No Results Available","Pain|Bone Metastases|Metastatic Breast Cancer",,"University of Copenhagen|The Novo Nordic Foundation","H-18041465","April 9, 2019","Department of Oncology, Rigshospitalet, Copenhagen, Denmark|The Department of Oncology, Herlev Hospital, Herlev, Denmark","https://ClinicalTrials.gov/show/NCT03908853"
736,"Development and Validation of a qPCR Cell Free DNA Assay as a Potential Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer","Active, not recruiting","No Results Available","Metastatic Non-Small Cell Lung Carcinoma|Metastatic Colorectal Cancer|Metastatic Breast Cancer","Diagnostic Test: Blood-based cell-free cfDNA qPCR assay","Cadex Genomics","CADEX-0001","March 27, 2019","CARTI Cancer Center, Little Rock, Arkansas, United States|Sutter Health - Palo Alto Medical Foundation, Sunnyvale, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|IACT Health, Columbus, Georgia, United States|University Medical Center, New Orleans, Louisiana, United States|Southeast Louisiana Veterans Health Care System, New Orleans, Louisiana, United States|Nebraska Cancer Center, Omaha, Nebraska, United States|National Translational Research Group LLC, Port Jefferson Station, New York, United States|Waverly Hematology Oncology, Cary, North Carolina, United States|Advent Health, Hendersonville, North Carolina, United States|Greenville Health System - Prisma Health, Greenville, South Carolina, United States|West Cancer Center and Research Institute, Germantown, Tennessee, United States|McGill University, Montréal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT03892096"
737,"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies","Recruiting","No Results Available","Ovarian Epithelial Cancer|Gastric Adenocarcinoma|Pancreas Adenocarcinoma|Triple Negative Breast Cancer|Bladder Cancer","Drug: SKB264","Klus Pharma Inc.","KL264-01","November 5, 2019","University of California Los Angeles, Los Angeles, California, United States|Georgetown University, Washington, District of Columbia, United States|Florida Cancer Specialists and Research Institute, Sarasota, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|START MidWest, Grand Rapids, Michigan, United States|The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Providence Cancer Institute, Franz Clinic, Portland, Oregon, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States","https://ClinicalTrials.gov/show/NCT04152499"
738,"Ultrasound Guided Costotransverse Block for Breast Cancer Surgery","Completed","No Results Available","Postoperative Pain","Other: costotransverse block","Cigli Regional Training Hospital","CTB in Breast surgery","December 13, 2019","Cigli regional research hospital, İzmir, Turkey","https://ClinicalTrials.gov/show/NCT04197206"
739,"Evaluation of Perforator Phase Contrast Angiography in Developing Surgery Plans for Patients With Breast Cancer Undergoing Breast Reconstruction With Free-Flap Methods After Mastectomy","Not yet recruiting","No Results Available","Mammoplasty Patient","Procedure: Angiography|Procedure: MRI-Based Angiogram|Other: Quality-of-Life Assessment","Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI)","OSU-18094|NCI-2018-03417|P30CA016058","August 21, 2019","Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT04063410"
740,"Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors","Recruiting","No Results Available","Solid Tumor|Clear Cell Renal Cell Carcinoma|TNBC - Triple-Negative Breast Cancer|Colorectal Cancer|CRC|RCC|ccRCC","Drug: CB-839|Drug: Talazoparib","Calithera Biosciences, Inc","CX-839-011","March 14, 2019","University of Alabama, Birmingham, Alabama, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Columbia University, New York, New York, United States|MD Anderson, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Wisconsin, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03875313"
741,"A Study of SGN-CD228A in Advanced Solid Tumors","Recruiting","No Results Available","Cutaneous Melanoma|Pleural Mesothelioma|Breast Cancer|Non-small Cell Lung Cancer|Colorectal Cancer|Pancreatic Ductal Adenocarcinoma","Drug: SGN-CD228A","Seattle Genetics, Inc.","SGN228-001","August 2, 2019","Angeles Clinic and Research Institute, The, Santa Monica, California, United States|Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT04042480"
742,"Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction","Enrolling by invitation","No Results Available","Postoperative Complications|Recurrence|Breast Neoplasms|Breast Cancer|BRCA1 Mutation|BRCA2 Mutation|Surgery|Surgery--Complications","Procedure: Robotic nipple sparing mastectomy","Severance Hospital|European Institute of Oncology|Changhua Christian Hospital|Gustave Roussy, Cancer Campus, Grand Paris","4-2019-0834","September 27, 2019","Yonsei University College of Medicine, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04108117"
743,"Prevention of Obesity-related Cancers: Setting up of a Multi-Cancer Education and Prevention Program in Hong Kong","Recruiting","No Results Available","Obesity|Colorectal Cancer|Prostate Cancer|Breast Cancer","Diagnostic Test: Faecal Immunochemical Test|Diagnostic Test: Prostate-Specific Antigen Test|Diagnostic Test: Mammogram","Chinese University of Hong Kong","MCP Study_Protocol_20190226","July 29, 2019","Lek Yuen Health Centre, Hong Kong, Hong Kong","https://ClinicalTrials.gov/show/NCT04034953"
744,"Multicentric Risk Evaluation of Autologous Fat Grafting Procedure","Active, not recruiting","No Results Available","Pain, Postoperative","Procedure: Autologous fat grafting procedure|Procedure: Breast reconstruction","Humanitas Clinical and Research Center","1955K","October 17, 2019","Istituto Clinico Humanitas, Rozzano, Milan, Italy","https://ClinicalTrials.gov/show/NCT04130373"
745,"Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane","Not yet recruiting","No Results Available","Healthy","Drug: Dexrazoxane","Hui-Ming Chang|University of Missouri-Columbia","2014006","April 29, 2019",,"https://ClinicalTrials.gov/show/NCT03930680"
746,"Recurrence Risk Evaluation by 21-gene Detection","Completed","No Results Available","Relationship and Consistency Analysis","Diagnostic Test: recurrence risk evaluation","Xijing Hospital","KY2019","February 15, 2019","Xijing hoapital, Xi'an, China","https://ClinicalTrials.gov/show/NCT03841266"
747,"The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL","Recruiting","No Results Available","CIPN - Chemotherapy-Induced Peripheral Neuropathy","Device: Cryotherapy|Device: Compression Therapy|Device: Loose glove/sock","Columbia University","AAAR9515","March 13, 2019","Columbia University Medical Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT03873272"
748,"Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families","Recruiting","No Results Available","Hereditary Breast Carcinoma|Hereditary Ovarian Carcinoma|Lynch Syndrome|Mutation Carrier","Behavioral: Behavioral Dietary Intervention|Other: E-mail|Behavioral: Exercise Intervention|Other: Internet-Based Intervention|Other: Questionnaire Administration|Behavioral: Telephone-Based Intervention|Other: Text Message","M.D. Anderson Cancer Center|National Cancer Institute (NCI)","2016-0775|NCI-2019-02453|P30CA016672","October 14, 2019","M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04125914"
749,"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)","Active, not recruiting","No Results Available","Advanced Solid Tumors|Triple Negative Breast Cancer|Ovarian Cancer|Gastric Cancer|Colorectal Cancer|Glioblastoma|Biliary Tract Cancers","Biological: Pembrolizumab|Drug: Lenvatinib","Merck Sharp & Dohme Corp.|Eisai Inc.","7902-005|2018-003747-37|MK-7902-005|E7080-G000-224|LEAP-005","January 9, 2019","City of Hope ( Site 0002), Duarte, California, United States|Cedars Sinai Medical Center ( Site 0003), Los Angeles, California, United States|University of California Davis Comprehensive Cancer Center ( Site 0005), Sacramento, California, United States|University of Colorado, Anschutz Cancer Pavilion ( Site 0007), Aurora, Colorado, United States|University of Florida-Health Cancer Center-Orlando ( Site 0015), Orlando, Florida, United States|Rutgers Cancer Institute of New Jersey ( Site 0009), New Brunswick, New Jersey, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0023), New York, New York, United States|West Cancer Center - East Campus ( Site 0018), Germantown, Tennessee, United States|Swedish Medical Center ( Site 0021), Seattle, Washington, United States|University of Wisconsin Carbone Cancer Center ( Site 0017), Madison, Wisconsin, United States|Royal Brisbane and Women s Hospital ( Site 0901), Herston, Queensland, Australia|Alfred Health ( Site 0902), Melbourne, Victoria, Australia|BC Cancer - Abbotsford ( Site 0200), Abbotsford, British Columbia, Canada|CancerCare Manitoba ( Site 0201), Winnipeg, Manitoba, Canada|Juravinski Cancer Centre ( Site 0208), Hamilton, Ontario, Canada|Sunnybrook Research Institute ( Site 0207), Toronto, Ontario, Canada|Princess Margaret Cancer Centre ( Site 0202), Toronto, Ontario, Canada|CHU de Quebec Universite de Laval ( Site 0206), Quebec, Canada|Fundacion Arturo Lopez Perez ( Site 1201), Santiago, Chile|Pontificia Universidad Catolica de Chile ( Site 1202), Santiago, Chile|Hospital Clinico Universidad de Chile ( Site 1200), Santiago, Chile|Instituto Clinico Oncologico del Sur ( Site 1203), Temuco, Chile|Centre Oscar Lambret ( Site 0401), Lille, France|Centre Leon Berard ( Site 0405), Lyon, France|Centre Antoine Lacassagne ( Site 0404), Nice, France|Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0402), Saint-Herblain, France|Institut Claudius Regaud IUCT Oncopole ( Site 0403), Toulouse, France|Institut Gustave Roussy ( Site 0400), Villejuif, France|Universitaetsklinikum Frankfurt ( Site 0306), Frankfurt am Main, Germany|Universitaetsklinikum Jena ( Site 0302), Jena, Germany|Universitaetsklinikum Regensburg ( Site 0304), Regensburg, Germany|HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 0301), Wiesbaden, Germany|Soroka Medical Center ( Site 0601), Beer Sheva, Israel|Rambam Medical Center ( Site 0602), Haifa, Israel|Chaim Sheba Medical Center ( Site 0600), Ramat Gan, Israel|Sourasky Medical Center ( Site 0603), Tel Aviv, Israel|Seoul National University Hospital ( Site 1000), Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System ( Site 1001), Seoul, Korea, Republic of|Asan Medical Center ( Site 1002), Seoul, Korea, Republic of|Hospital Clinic i Provincial ( Site 0703), Barcelona, Spain|Hospital Universitario Gregorio Maranon ( Site 0701), Madrid, Spain|Clinica Universitaria de Navarra ( Site 0704), Madrid, Spain|Hospital Ramon y Cajal ( Site 0702), Madrid, Spain|Cambridge University Hospitals NHS Trust ( Site 0803), Cambridge, Cambridgeshire, United Kingdom|University Hospitals of Leicester NHS Trust ( Site 0804), Leicester, United Kingdom|Guy's Hospital ( Site 0806), London, United Kingdom|The Royal Marsden Foundation Trust ( Site 0800), London, United Kingdom|Christie NHS Foundation Trust ( Site 0805), Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT03797326"
750,"GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma","Recruiting","No Results Available","Pancreatic Adenocarcinoma|Esophageal Adenocarcinoma|Esophageal Squamous Cell Carcinoma|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Triple Negative Breast Cancer|Castration-resistant Prostate Cancer|Microsatellite Stable Colorectal Cancer","Drug: GB1275|Drug: nab-paclitaxel and gemcitabine|Drug: pembrolizumab","GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.|MSD International GmbH (Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc.)|Gossamer Bio Inc.","GB1275-1101 (KEYNOTE-A36)","August 19, 2019","University of Colorado Hospital, Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, United States|South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|The Royals Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","https://ClinicalTrials.gov/show/NCT04060342"
751,"Living Well After Breast Surgery","Active, not recruiting","No Results Available","Breast Cancer Female|Stage I Breast Cancer|Stage II Breast Cancer|Stage III Breast Cancer|Ductal Carcinoma in Situ|Ductal Breast Carcinoma|Lobular Breast Carcinoma","Other: Breast reconstruction decision aid|Other: Educational website","University of Texas at Austin|Ohio State University|Washington University School of Medicine","2018-05-0009","February 8, 2019","Texas Oncology, Austin, Texas, United States","https://ClinicalTrials.gov/show/NCT03834532"
752,"OPTimizing Treatment Focused Genetic Testing IN Cancer","Recruiting","No Results Available","Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Prostate Cancer","Other: Chatbot|Other: Video Education","Dana-Farber Cancer Institute","19-068","August 26, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04066361"
753,"Effect of Dexmedetomidine on the Duration of Pain Control in ESP Block for Breast Surgery","Recruiting","No Results Available","Breast Cancer|Mastectomy|Axillary Lymph Node Dissection|Pain, Postoperative","Drug: Dexmedetomidine","Lebanese American University","LAUMCRH.YJ1.16/Jul/2019","July 23, 2019","Lebanese American University Medical Center-Rizk Hospital, Beirut, Lebanon","https://ClinicalTrials.gov/show/NCT04029467"
754,"Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker","Recruiting","No Results Available","Non-small Cell Lung Cancer|Breast Cancer|Pancreatic Cancer|Urogenital Cancer","Drug: GEM3PSCA","GEMoaB Monoclonals GmbH|GCP-Service International Ltd. & Co. KG","GEM3PSCA-01","April 25, 2019","Klinikum rechts der Isar der TU München, Munich, Bayern, Germany|Universitätsklinikum Würzburg, Würzburg, Bayern, Germany|Universitätsklinikum Dresden, Dresden, Sachsen, Germany","https://ClinicalTrials.gov/show/NCT03927573"
755,"The Clinical Study of Modern Therapies on Flora in Body Fluids and Blood of Malignant Tumor Patients","Not yet recruiting","No Results Available","Lung Cancer|Breast Cancer|Gastrointestinal Cancer|Malignant Neoplasms","Diagnostic Test: Flora analysis","The First Affiliated Hospital of Dalian Medical University","PJ-KS-KY-2019-134","December 18, 2019","The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China","https://ClinicalTrials.gov/show/NCT04202848"
756,"Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT","Recruiting","No Results Available","Malignant Solid Tumor|Breast Cancer|Head and Neck Cancer|Melanoma (Skin)","Drug: 68GaNOTA-Anti-MMR-VHH2","Universitair Ziekenhuis Brussel|Kom Op Tegen Kanker","UZBRU_VHH2_1|2017-001471-23","November 19, 2019","Uz Brussel, Brussels, Belgium","https://ClinicalTrials.gov/show/NCT04168528"
757,"PECS Block in Partial Mastectomy for Postoperative Pain Control","Recruiting","No Results Available","Breast Cancer|Postoperative Pain|Opioid Use|Local Anesthesia","Procedure: Pectoral Nerve Block|Procedure: Surgery without Nerve Block","Main Line Health","R20-3896L","September 11, 2019","Kaitlyn Kennard, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04086394"
758,"Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy","Not yet recruiting","No Results Available","Breast Cancer|Mastectomy|Anesthesia, Local|Narcotic Use","Drug: regional nerve block with local anesthesia of bupivacaine with steroid|Other: Placebo regional nerveblock with normal saline","University of Alabama at Birmingham","IRB-300003680","July 15, 2019",,"https://ClinicalTrials.gov/show/NCT04019834"
759,"Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases","Recruiting","No Results Available","Brain Metastases|Melanoma|Lung Cancer|Breast Cancer","Drug: Dexamethasone|Drug: Metformin","Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|University of Milan","INT31/19|B43C17000350001|2019-000105-73","June 28, 2019","Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy","https://ClinicalTrials.gov/show/NCT04001725"
760,"Sexual Health Empowerment for Women's Health","Recruiting","No Results Available","Cervical Cancer|Breast Cancer|Contraceptive Usage|Sexually Transmitted Diseases","Behavioral: SHE-WOMEN","University of Kansas Medical Center","STUDY00143316","June 13, 2019","Jackson County Correctional Facility, Kansas City, Missouri, United States","https://ClinicalTrials.gov/show/NCT03984695"
761,"Virtual Reality Versus Proprioceptive Neuromuscular Facilitation on Postmastectomy Lymphedema","Completed","No Results Available","Postmastectomy Lymphedema","Other: virtual reality|Other: proprioceptive neuromuscular facilitation|Other: complete decogestive therapy","doaa atef|Cairo University","Doaa Atef","December 4, 2019","faculty of physical therapy, Cairo university, Giza, Egypt","https://ClinicalTrials.gov/show/NCT04185181"
762,"Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting","Recruiting","No Results Available","Breast Carcinoma|Colorectal Carcinoma|Community Practice|Lung Carcinoma|Melanoma|Solid Neoplasm","Other: Survey Administration","ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group","EAQ161CD|NCI-2018-01707|ECOG-ACRIN-EAQ161CD|UG1CA189828","January 15, 2019","Northwestern University, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT03804255"
763,"TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers","Recruiting","No Results Available","Hepatocellular Carcinoma|Metastatic Castration Resistant Prostate Cancer|Renal Cell Carcinoma|Non-small Cell Lung Cancer|Colorectal Cancer|Squamous Cell Carcinoma of Head and Neck|Triple-Negative Breast Cancer|Urothelial Carcinoma|Cholangiocarcinoma|GastroEsophageal Cancer|Pancreatic Cancer|Sarcoma","Drug: Part 1 TPST-1120|Drug: Part 2a TPST-1120 + nivolumab|Drug: Part 2b TPST-1120 + docetaxel|Drug: Part 2c TPST-1120 + cetuximab|Drug: Part 3 TPST-1120|Drug: Part 4a TPST-1120 + nivolumab|Drug: Part 4b TPST-1120 + docetaxel|Drug: Part 4c TPST-1120 + cetuximab","Tempest Therapeutics","TPST-1120-001","February 4, 2019","Miami Cancer Institute, Miami, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Sarah Cannon Research Institute - TN, Nashville, Tennessee, United States|Mary Crowley Cancer Research, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT03829436"
764,"Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study","Enrolling by invitation","No Results Available","Breast Carcinoma|Colorectal Carcinoma|Lung Carcinoma|Lymphoma|Prostate Carcinoma","Other: Survivorship Care Plan|Other: Educational Intervention|Other: Questionnaire Administration","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","RG1005815|NCI-2019-05726|P30CA015704","September 9, 2019","Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04081779"
765,"Diagnostic Power Comparison Between VOCs and CTCs","Not yet recruiting","No Results Available","Circulating Tumor Cell|Volatile Organic Chemicals|Breast Cancer|Gastric Cancer|Diagnoses Disease","Diagnostic Test: Circulating tumor cells, Volatile organic compounds","Anhui Medical University|Technion, Israel Institute of Technology","DPCVC","May 22, 2019",,"https://ClinicalTrials.gov/show/NCT03958812"
766,"A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers","Active, not recruiting","No Results Available","Non-Small Cell Lung Cancer|Ovarian Cancer|Fallopian Tube Cancer|Triple Negative Breast Cancer|Multiple Myeloma|Pancreatic Ductal Adenocarcinoma","Biological: CART-TnMUC1|Drug: Cyclophosphamide|Drug: Fludarabine","Tmunity Therapeutics","CART-TnMUC1-01","July 18, 2019","The Angeles Clinic and Research Institute, Los Angeles, California, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04025216"
767,"Feasibility of a New Technology for Isolating Circulating Tumour Cells","Not yet recruiting","No Results Available","HER2-positive Metastatic Breast Cancer|Ovarian Cancer|Hormone-resistant Prostate Cancer|Circulating Tumor Cell","Procedure: Blood sample collection","Centre Oscar Lambret","CTC-SMMiL-E-1901|2019-A01187-50","June 7, 2019","Centre Oscar Lambret, Lille, France","https://ClinicalTrials.gov/show/NCT03979339"
768,"A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors","Recruiting","No Results Available","Melanoma|Cervical Carcinoma|Pancreatic Carcinoma|Triple Negative Breast Cancer|Hepatocellular Carcinoma|Urothelial Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Nasopharyngeal Carcinoma|Renal Cell Carcinoma|Non-small Cell Lung Carcinoma|Small Cell Lung Carcinoma|Gastric or Gastroesophageal Junction Adenocarcinoma|Advanced or Metastatic Solid Tumors|Prostate Carcinoma|MSI-H|Mismatch Repair Deficiency|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Intrahepatic Cholangiocarcinoma","Biological: XmAb®22841|Biological: Pembrolizumab (Keytruda®)","Xencor, Inc.|ICON Clinical Research","XmAb22841-01|DUET-4","February 21, 2019","UCLA Hematology & Oncology Clinic, Los Angeles, California, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Brigham and Women's Health Care Center, Chestnut Hill, Chestnut Hill, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, United States|Siteman Cancer Center - North County, Saint Louis, Missouri, United States|Siteman Cancer Center - St. Peters, Saint Peters, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Hospital of the University of Pennsylvania - Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|UPMC Shadyside Hospital, Pittsburgh, Pennsylvania, United States|Mary Crowley Cancer Research - Medical City, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT03849469"
769,"Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer","Recruiting","No Results Available","Anatomic Stage I Breast Cancer AJCC v8|Anatomic Stage IA Breast Cancer AJCC v8|Anatomic Stage IB Breast Cancer AJCC v8|Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage IIA Breast Cancer AJCC v8|Anatomic Stage IIB Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Lung Non-Small Cell Carcinoma|Prognostic Stage I Breast Cancer AJCC v8|Prognostic Stage IA Breast Cancer AJCC v8|Prognostic Stage IB Breast Cancer AJCC v8|Prognostic Stage II Breast Cancer AJCC v8|Prognostic Stage IIA Breast Cancer AJCC v8|Prognostic Stage IIB Breast Cancer AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Stage I Lung Cancer AJCC v8|Stage I Ovarian Cancer AJCC v8|Stage IA Ovarian Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage IB Ovarian Cancer AJCC v8|Stage IC Ovarian Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage II Ovarian Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIA Ovarian Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage IIB Ovarian Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA1 Ovarian Cancer AJCC v8|Stage IIIA2 Ovarian Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8","Drug: Chemotherapy|Other: Functional Assessment|Other: Questionnaire Administration","Southwest Oncology Group|National Cancer Institute (NCI)","S1714|NCI-2018-01568|SWOG-S1714|UG1CA189974","May 6, 2019","Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Hawaii Cancer Care - Savio, 'Aiea, Hawaii, United States|Pali Momi Medical Center, 'Aiea, Hawaii, United States|Hawaii Cancer Care Inc-POB II, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Little Company of Mary Hospital, Evergreen Park, Illinois, United States|Edward Hines Jr VA Hospital, Hines, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Salina Regional Health Center, Salina, Kansas, United States|Associates In Womens Health, Wichita, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Louisiana State University Health Science Center, New Orleans, Louisiana, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Winchester Hospital, Winchester, Massachusetts, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Saint Joseph Hospital, Nashua, New Hampshire, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|CaroMont Regional Medical Center, Gastonia, North Carolina, United States|CarolinaEast Medical Center, New Bern, North Carolina, United States|Trinity Cancer Care Center, Minot, North Dakota, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Gibbs Cancer Center-Gaffney, Gaffney, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Butternut, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Gibbs Cancer Center-Pelham, Greer, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Prisma Health Cancer Institute - Spartanburg, Spartanburg, South Carolina, United States|MGC Hematology Oncology-Union, Union, South Carolina, United States|Cookeville Regional Medical Center, Cookeville, Tennessee, United States|UMC Cancer Center / UMC Health System, Lubbock, Texas, United States|Texas Tech University Health Sciences Center-Lubbock, Lubbock, Texas, United States|University of Virginia Cancer Center, Charlottesville, Virginia, United States|Bon Secours Memorial Regional Medical Center, Mechanicsville, Virginia, United States|Bon Secours Saint Francis Medical Center, Midlothian, Virginia, United States|Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States","https://ClinicalTrials.gov/show/NCT03939481"
770,"GEN1046 Safety Trial in Patients With Malignant Solid Tumors","Recruiting","No Results Available","Solid Tumors|Non-small Cell Lung Cancer|Urothelial Carcinoma|Endometrial Carcinoma|Triple Negative Breast Cancer|Squamous Cell Carcinoma of the Head and Neck|Cervical Cancer","Biological: GEN1046","Genmab|Biontech SE","GCT1046-01","April 17, 2019","Yale University Cancer Center, New Haven, Connecticut, United States|START Midwest, Grand Rapids, Michigan, United States|Rambam Health Care Campus RHCC - Rambam Medical Center, Haifa, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Sheba Medical Center, Ramat Gan, Tel HaShomer, Israel|Hospital Universitario Vall dHebron, Barcelona, Spain|START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain|START Madrid-CIOCC, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Spain","https://ClinicalTrials.gov/show/NCT03917381"
771,"Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer","Recruiting","No Results Available","Squamous Cell Carcinoma of Head and Neck|Non-small Cell Lung Cancer|Hepatocellular Carcinoma|Esophageal Cancer|Gastric Cancer|Melanoma|Renal Cell Carcinoma|Pancreatic Cancer|Cervical Cancer|Triple Negative Breast Cancer|Advanced Cancer","Drug: KY1044|Drug: KY1044 and atezolizumab","Kymab Limited","KY1044-CT01","February 4, 2019","Kymab investigational site 1102, New Haven, Connecticut, United States|Kymab investigational site 1104, Sarasota, Florida, United States|Kymab investigational site 1103, Nashville, Tennessee, United States|Kymab investigator site 1101, Houston, Texas, United States|Kymab investigational site 3901, Milano, Italy|Kymab investigational site 3903, Milano, Italy|Kymab investigational site 3902, Napoli, Italy|Kymab investigational site 8802, Tainan, Taiwan|Kymab investigational site 8801, Taipei, Taiwan|Kymab investigational site 4402, Manchester, United Kingdom|Kymab investigational site 4401, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT03829501"
772,"Paclitaxel Therapeutic Drug Monitoring in Cancer Patients","Recruiting","No Results Available","Solid Tumor, Adult|Metastatic Nonsmall Cell Lung Cancer|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic Cervical Carcinoma|Metastatic Ovarian Carcinoma|Malignant Uterine Neoplasm|Vulvar Cancer|Invasive Breast Cancer|Metastatic Breast Carcinoma|Prognostic Stage IV Breast Cancer AJCC v8|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Lung Non-Small Cell Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Vulvar Carcinoma|Stage IV Cervical Cancer AJCC v8|Stage IV Lung Cancer AJCC v8|Stage IV Vulvar Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IVA Cervical Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Vulvar Cancer AJCC v8|Stage IVB Cervical Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Vulvar Cancer AJCC v8|Vulva Squamous Cell Carcinoma","Other: Blood draws|Other: QLQ-CIPN20 Survey|Other: PR-CTCAE Survey","Wake Forest University Health Sciences|National Cancer Institute (NCI)","IRB00058758|WFBCCC 01319|P30CA012197|NCI-2019-05616","June 17, 2019","Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT03987555"
773,"Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer","Recruiting","No Results Available","Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Clinical Stage III Cutaneous Melanoma AJCC v8|Clinical Stage IV Cutaneous Melanoma AJCC v8|Health Care Provider|Malignant Brain Neoplasm|Malignant Genitourinary System Neoplasm|Pathologic Stage III Cutaneous Melanoma AJCC v8|Pathologic Stage IIIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIIC Cutaneous Melanoma AJCC v8|Pathologic Stage IV Cutaneous Melanoma AJCC v8|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Prognostic Stage IV Breast Cancer AJCC v8|Stage III Colorectal Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Pancreatic Cancer|Stage IVA Prostate Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Pancreatic Cancer|Stage IVB Prostate Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8","Procedure: Biospecimen Collection|Other: Genetic Testing|Other: Quality-of-Life Assessment|Other: Questionnaire Administration","Mayo Clinic|National Cancer Institute (NCI)","19-002006|NCI-2019-04725|P30CA015083","August 28, 2019","Mayo Clinic in Arizona, Scottsdale, Arizona, United States","https://ClinicalTrials.gov/show/NCT04067960"
774,"Delphinus SoftVue™ ROC Reader Study","Completed","No Results Available","Breast Cancer Detection|Dense Breast Parenchyma|Benign Breast Findings|Normal Breast Screening|Abnormal Breast Screening","Device: Reading of Automated Breast Ultrasound in conjunction with Screening Mammography","Delphinus Medical Technologies, Inc.|University of Chicago|Boston Biomedical Associates LLC|Reed Technical Associates, LLC","DMT-2019.001","June 3, 2019","Cobo Center, Detroit, Michigan, United States","https://ClinicalTrials.gov/show/NCT03972605"
775,"A Study of ZN-c3 in Participants With Solid Tumors","Recruiting","No Results Available","Solid Tumor|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer|Triple Negative Breast Cancer|Small Cell Lung Cancer|Metastatic Breast Cancer|Malignant Melanoma|Non Small Cell Lung Cancer|Urothelial Carcinoma","Drug: ZN-c3|Drug: Talazoparib|Drug: Pembrolizumab","K-Group Beta|IQVIA Biotech","ZN-c3-001","November 8, 2019","Site 0102, Tucson, Arizona, United States|Site 0101, Detroit, Michigan, United States|Site 0103, Houston, Texas, United States|Site 0100, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT04158336"
776,"Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study","Recruiting","No Results Available","Cancer, Breast|Cancer Colorectal|Cancer Prostate|Cancer, Lung|Cancer Melanoma Skin|Cancer, Other","Drug: Propofol|Drug: isoflurane, sevoflurane or desflurane","Peter MacCallum Cancer Centre, Australia|M.D. Anderson Cancer Center|Melbourne Health|The Alfred","16/144","August 30, 2019","Peter MacCallum Cancer Centre, Melbourne, Australia","https://ClinicalTrials.gov/show/NCT04074460"
777,"A Study of LY3435151 in Participants With Solid Tumors","Terminated","No Results Available","Solid Tumor|Triple-negative Breast Cancer|Gastric Adenocarcinoma|Head and Neck Squamous Cell Carcinoma|Cervical Carcinoma|High Grade Serous Ovarian Carcinoma|Hepatocellular Carcinoma|Undifferentiated Pleomorphic Sarcoma|Leiomyosarcoma","Drug: LY3435151|Drug: Pembrolizumab","Eli Lilly and Company","17364|J1Q-MC-JZIA","September 23, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan","https://ClinicalTrials.gov/show/NCT04099277"
778,"A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors","Not yet recruiting","No Results Available","Breast Cancer|Endometrial Cancer|Lung Cancer|Colo-rectal Cancer|Head and Neck Cancer","Drug: Serabelisib|Drug: Canagliflozin 300mg","Petra Pharma","PT06-01","August 29, 2019",,"https://ClinicalTrials.gov/show/NCT04073680"
779,"Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast","Suspended","No Results Available","DCIS|Breast Cancer|Low Risk DCIS|Breast Conserving Surgery|Radiotherapy Omission","Radiation: Radiotherapy|Other: No Radiotherapy","UNICANCER|National Cancer Institute, France","UC-0107/1803","March 18, 2019","Institut de Cancérologie de l'Ouest -Site Paul Papin, Angers, France|Institut Sainte Catherine, Avignon, France|Institut Bergonie, Bordeaux, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges Francois Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Hospitalier Bretagne Sud, Lorient, France|Centre Léon Berard, Lyon, France|Institut Regional Du Cancer Montpellier Val D Aurelle, Montpellier, France|Institut CURIE, Paris, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Institut De Cancerologie De Lorraine Alexis Vautrin, Vandœuvre-lès-Nancy, France","https://ClinicalTrials.gov/show/NCT03878342"
780,"The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","Recruiting","No Results Available","Oncology|Breast Cancer|Prostate Cancer|Gynecologic Cancer|Brain Tumor|Brain Cancer|Gynecologic Tumor|Prostate Tumor|Prostate Neoplasm|Breast Tumor|Radiation Toxicity|Quality of Life|Rectal Cancer|Rectal Tumor|Rectal Neoplasms|Lung Cancer|Lung Tumor|Lung Neoplasm|Esophageal Cancer|Esophagus Cancer|Esophageal Tumor|Esophageal Neoplasm|Esophagus Tumor|Esophagus Neoplasm|Pancreatic Cancer|Pancreatic Tumor|Pancreatic Neoplasms|Head and Neck Cancer|Head and Neck Neoplasms|Head and Neck Tumor|Tumor|Neoplasms|Bladder Cancer|Bladder Neoplasm|Liver Cancer|Liver Neoplasms|Liver Metastases|Oligometastases","Radiation: Radiation therapy","UMC Utrecht|The Netherlands Cancer Institute|Sunnybrook Health Sciences Centre|M.D. Anderson Cancer Center|The Christie NHS Foundation Trust|Royal Marsden NHS Foundation Trust|Medical College of Wisconsin|Elekta","NL63674.041.18","August 30, 2019","University Medical Center Utrecht, Utrecht, Netherlands","https://ClinicalTrials.gov/show/NCT04075305"
781,"The Risk of Postoperative Wound Complications Following the Use of Negative Pressure Wound Therapy in Patients Undergoing Mastectomy","Recruiting","No Results Available","Breast Cancer|Wound Complication|Wound Infection|Wound Dehiscence|Wound Necrosis","Device: Negative pressure wound therapy","Zuyderland Medisch Centrum","METCZ20190024","May 8, 2019","Zuyderland Medisch Centrum, Sittard, Limburg, Netherlands","https://ClinicalTrials.gov/show/NCT03942575"
782,"Measuring and Improving the Safety of Test Result Follow-Up","Active, not recruiting","No Results Available","Lung Cancer|Breast Cancer|Colon Cancer|Bladder Cancer|Hepatocellular Cancer","Behavioral: SAFER TRACKS Intervention","VA Office of Research and Development|White River Junction Veterans Affairs Medical Center|Michael Debakey Veterans Affairs Medical Center|Baylor College of Medicine","IIR 17-127|H-45450","November 18, 2019","Michael E. DeBakey VA Medical Center, Houston, TX, Houston, Texas, United States|White River Junction VA Medical Center, White River Junction, VT, White River Junction, Vermont, United States","https://ClinicalTrials.gov/show/NCT04166240"
783,"Memory Perception Assessment in Central/Non-central Nervous System Cancers and HIV","Recruiting","No Results Available","Glioblastoma|Glioma|Breast Cancer|Hiv|Healthy","Other: QMRP questionnaire","Institut du Cancer de Montpellier - Val d'Aurelle","PROICM 2018-07 BPR","June 5, 2019","Icm Val D'Aurelle, Montpellier, Herault, France","https://ClinicalTrials.gov/show/NCT03975959"
784,"Non-Viral TCR Gene Therapy","Recruiting","No Results Available","Glioblastoma|Non-Small Cell Lung Cancer|Breast Cancer|Gastrointestinal/Genitourinary Cancer|Ovarian Cancer","Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Aldesleukin|Biological: Sleeping Beauty Transposed PBL","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","190143|19-C-0143","September 25, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04102436"
785,"Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy","Recruiting","No Results Available","Gastrointestinal Cancer|Head and Neck Cancer|Breast Cancer|Chemotherapy Effect|5-Fluorouracil Toxicity","Other: Arterial blood pressure|Other: Skin microcirculatory blood flow|Other: Brachial artery blood flow|Other: Venous blood draw","Kansas State University","Pro9646","August 1, 2019","Lafene Health Center, Manhattan, Kansas, United States","https://ClinicalTrials.gov/show/NCT04042298"
786,"Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy","Recruiting","No Results Available","Breast Cancer|Surgery--Complications|Genetic Predisposition to Disease|Surgery|BRCA1 Mutation|BRCA2 Mutation|Breast Diseases","Procedure: Robotic Nipple-Sparing Mastectomy (RNSM)","University Health Network, Toronto","19-5250.0","November 5, 2019","University Health Network, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04151368"
787,"A Randomized Clinical Trial","Completed","No Results Available","Regional Anesthesia","Procedure: PECS block","Shaukat Khanum Memorial Cancer Hospital & Research Centre","IRB-15-03","May 13, 2019","Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Punjab, Pakistan","https://ClinicalTrials.gov/show/NCT03947463"
788,"Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors","Enrolling by invitation","No Results Available","Breast Neoplasm|Prostatic Neoplasm|Colorectal Neoplasms|Endometrial Neoplasms|Hodgkin Disease|Non Hodgkin Lymphoma","Other: AH-HA Tool in the EPIC EHR","Wake Forest University Health Sciences|National Cancer Institute (NCI)|Washington University School of Medicine|University of Texas Southwestern Medical Center","IRB00056774|NCI-2019-01362","May 2, 2019","Wake Forest School of Medicine, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT03935282"
789,"Plan to Thrive: Extending Cancer Survivorship Care Beyond the Clinic","Recruiting","No Results Available","Cancer, Breast|Cancer of Colon|Cancer of Rectum|Cancer","Device: Plan to Thrive smartphone application","Northwestern University|Vignet, Inc.","STU00209558","June 24, 2019","Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT03996031"
790,"Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions","Not yet recruiting","No Results Available","Breast Fibroadenoma|Atypical Ductal Hyperplasia|Atypical Lobular Hyperplasia|Lobular Carcinoma in Situ|Flat Epithelial Atypia|Phyllodes; Fibroadenoma|Phyllodes Breast Tumor|Radial Scar|Breast Papilloma|Complex Sclerosing Papillary Lesion of the Breast","Procedure: Vacuum-assisted percutaneous excision|Procedure: Open surgical excision","Lawson Health Research Institute","1","March 11, 2019",,"https://ClinicalTrials.gov/show/NCT03868475"
791,"Calming Alternatives Learned During MRI-Guided Breast Biopsy","Completed","No Results Available","Breast Cancer|Breast Pain|Pain, Acute|Anxiety|Coping Skills|Self Efficacy","Behavioral: Controlled Breathing Intervention","Duke University","Pro00100029","March 15, 2019","Duke Cancer Institute, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT03877146"
792,"A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study","Active, not recruiting","No Results Available","Solid Neoplasms|Carcinoma, Non-Small-Cell Lung|Prostatic Neoplasms|Head and Neck Neoplasms|Triple Negative Breast Neoplasms|Microsatellite Instability High Solid Tumors|Melanoma|Pancreatic Ductal Adenocarcinoma|Microsatellite-stable Colon Cancer","Drug: TAK-573","Millennium Pharmaceuticals, Inc.|Takeda","TAK-573-1001|U1111-1238-9163","November 8, 2019","Levine Cancer Institute, Charlotte, North Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Mary Crowley Cancer Research, Dallas, Texas, United States|NEXT Oncology, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT04157517"
793,"Family History Study on Cancer Risk","Not yet recruiting","No Results Available","Lynch Syndrome|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Family Characteristics|Genetic Predisposition","Other: online cancer risk assessment|Other: Usual care","Kaiser Permanente|Patient-Centered Outcomes Research Institute","1407426","October 30, 2019","Division of Research, Kaiser Permanente Northern California, Oakland, California, United States","https://ClinicalTrials.gov/show/NCT04145388"
794,"FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors","Recruiting","No Results Available","Advanced Solid Tumors|Lymphoma|Gastric Cancer|Colorectal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|EGFR Positive Solid Tumor|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreas Cancer|Melanoma|NSCLC|Urothelial Carcinoma|Cervical Cancer|Microsatellite Instability|Merkel Cell Carcinoma","Drug: FT500|Drug: Nivolumab|Drug: Pembrolizumab|Drug: Atezolizumab|Drug: Cyclophosphamide|Drug: Fludarabine","Fate Therapeutics","FT500-101","February 15, 2019","UCSD Moores Cancer Center, San Diego, California, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03841110"
795,"Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues","Recruiting","No Results Available","Breast Carcinoma|Colon Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Head and Neck Carcinoma|Kidney Carcinoma|Lung Carcinoma|Ovarian Carcinoma|Pancreatic Carcinoma|Solid Neoplasm|Uterine Corpus Cancer","Procedure: Computed Tomography|Radiation: Gallium Ga 68 FAPi-46|Radiation: Gallium Ga 68-labeled PSMA-11|Procedure: Positron Emission Tomography","Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","19-000756|NCI-2019-07265|P30CA016042","November 1, 2019","UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT04147494"
796,"Education Intervention in Patients With Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment.","Active, not recruiting","No Results Available","Consent Form|Lung Cancer|Colon Cancer|Pancreas Cancer|Head and Neck Cancer|Breast Cancer","Other: EDUCATION","Cyprus University of Technology","0000-0001-5580-7256","June 20, 2019","Eleni Papoui, Larnaca, Athienou, Cyprus","https://ClinicalTrials.gov/show/NCT03992664"
797,"A Safety Study of SGN-CD47M in Patients With Solid Tumors","Recruiting","No Results Available","Soft Tissue Sarcoma|Colorectal Cancer|Head and Neck Squamous Cell Carcinoma|Non-small Cell Lung Carcinoma|Breast Carcinoma|Ovarian Carcinoma|Exocrine Pancreatic Carcinoma|Gastric Carcinoma|Melanoma","Drug: SGN-CD47M","Seattle Genetics, Inc.","SGN47M-001","May 21, 2019","Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|NEXT Oncology, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT03957096"
798,"Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health","Not yet recruiting","No Results Available","Breast Cancer|Colorectal Cancer|Endometrial Cancer|Kidney Cancer|Multiple Myeloma|Ovary Cancer|Prostate Cancer","Behavioral: Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|Other: Diet-Exercise|Other: Exercise-Diet|Other: Wait-list Control- Combined Diet and Exercise","University of Alabama at Birmingham|University of Tennessee Health Science Center|National Cancer Institute (NCI)","IRB-300002068|1P01CA229997","June 27, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Tennessee Health Science Center, Memphis, Tennessee, United States","https://ClinicalTrials.gov/show/NCT04000880"
799,"Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors","Recruiting","No Results Available","Breast Cancer|Epithelial Ovarian Cancer|Cervical Cancer|Pancreatic Cancer|Endometrial Cancer|Renal Cancer|Urothelial Cancer|Head and Neck Cancer|Mesothelioma|Melanoma|Hepatic Carcinoma|Prostate Cancer|NSCLC","Combination Product: Naptumomab estafenatox (ABR-217620; Nap) with durvalumab (IMFINZI; MEDI4736)","NeoTX Therapeutics Ltd.|AstraZeneca Pharmaceuticals PLC","127-CL-01","June 12, 2019","Rambam Medical Center, Haifa, Israel|Sheba Medical Center, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel","https://ClinicalTrials.gov/show/NCT03983954"
800,"Gene Expression, Meditative Movement, and Emotional Distress (GME)","Active, not recruiting","No Results Available","Cognitive Impairment","Behavioral: Meditative Movement","Arizona State University|Pomona Valley Hospital Medical Center|Children's Hospital Los Angeles","GME Study","December 30, 2019","Robert and Beverly Lewis Family Cancer Care Center, Pomona, California, United States","https://ClinicalTrials.gov/show/NCT04213872"
801,"MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour","Recruiting","No Results Available","Melanoma|Breast Cancer|Uterine Cancer|Ovarian Cancer|Prostate Cancer|Urethral Cancer|Bladder Cancer|Renal Cancer|Lung Cancer|Head and Neck Cancer","Drug: MRx0518 Capsules|Drug: MRx0518/placebo Capsules","Imperial College London|4D pharma plc","C/35/2017","May 2, 2019","Imperial College Healthcare NHS Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT03934827"
802,"Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors","Recruiting","No Results Available","Melanoma|Breast Cancer|Merkel Cell Carcinoma|Squamous Cell Cancer|Non Small Cell Lung Cancer|Cervical Cancer|Urothelial Carcinoma|Ovarian Cancer|Hepatocellular Carcinoma|Small-cell Lung Cancer|Microsatellite Instability High|Gastric Cancer|Esophageal Cancer","Device: Echopulse|Drug: Imiquimod|Drug: Standard of Care PD-1 Therapy","Craig L Slingluff, Jr|Theraclion|University of Virginia","21850","October 4, 2019","University of Virginia, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT04116320"
803,"Study to Evaluate the Safety of Nanoxel M Inj.","Recruiting","No Results Available","Breast Cancer|Non-small Cell Lung Cancer|Prostate Cancer|Ovarian Cancer|Head and Neck Cancer|Gastric Cancer|Esophageal Cancer",,"Samyang Biopharmaceuticals Corporation","DPM401","August 26, 2019","Samyang Biopharmaceuticals, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04066335"
804,"A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation","Not yet recruiting","No Results Available","Neoplasms|Hiv|Cervical Cancer|Breast Cancer|HNSCC|Vulvar Cancer|Anal Cancer|Cancer Suspect","Other: Potlako intervention|Other: Enhanced care","Brigham and Women's Hospital|Botswana Harvard Aids Institute|Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|University of Oxford","BHP0120|R01CA236546","October 28, 2019","Botswana Harvard AIDS Institute, Gaborone, Botswana","https://ClinicalTrials.gov/show/NCT04141449"
805,"Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation","Available","No Results Available","Non Small Cell Lung Cancer|Medullary Thyroid Cancer|Colon Cancer|Breast Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Other Solid Tumors With Evidence of Activating RET Alteration","Drug: Selpercatinib","Loxo Oncology, Inc.|Eli Lilly and Company","Selpercatinib EAP","April 8, 2019","Cancer Treatment Centers of America, Goodyear, Arizona, United States|Mayo Clinic Hospital, Scottsdale, Arizona, United States|City of Hope, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UCI Health - Chao Family Comprehensive Cancer Center, Orange, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mayo Clinic Hospital, Jacksonville, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Tallahassee Memorial Hospital, Tallahassee, Florida, United States|University Cancer and Blood Center, Athens, Georgia, United States|Emory University, Atlanta, Georgia, United States|Cancer Treatment Centers of America, Chicago, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|START Midwest, Grand Rapids, Michigan, United States|Mayo Clinic Hospital, Rochester, Minnesota, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|JamesCare at Martha Morehouse Medical Plaza, Columbus, Ohio, United States|Cancer Treatment Centers of America, Tulsa, Oklahoma, United States|University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, United States|Cancer Treatment Centers of American, Philadelphia, Philadelphia, Pennsylvania, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Oncology Consultants, Houston, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Linear Clinical Research, Nedlands, Western Australia, Australia|Universitatsklinikum Würzburg, Würzburg, Germany|Prince of Wales Hospital, Shatin, Hong Kong|Soroka University Medical Center, Be'er Sheva, Israel|Sheba Medical Center, Ramat Gan, Israel|University of Pisa, Pisa, Italy|Osaka City General Hospital, Miyakojima-Ku, Osaka, Japan|National Cancer Centre, Singapore, Singapore|Hospital Universitari de la Vall d'Hebron, Barcelona, Spain|START Madrid, Hospital Universitario HM Sanchinarro, Madrid, Spain|Luzerner Kantonsspital, Spitalstrasse, Switzerland","https://ClinicalTrials.gov/show/NCT03906331"
806,"PROactive Evaluation of Function to Avoid CardioToxicity","Recruiting","No Results Available","Cardiotoxicity|Breast Cancer|Lymphoma|Sarcoma|Leukemia|Myeloma|Lung Cancer","Device: MyoStrain®","Washington University School of Medicine|Myocardial Solutions","201809177","March 5, 2019","Yale, New Haven, Connecticut, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Texas Southwestern, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT03862131"
807,"A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors","Recruiting","No Results Available","Malignancy|Non-hodgkin Lymphoma|Multiple Myeloma|Breast Cancer|Ovarian Cancer|Soft Tissue Sarcoma|Squamous Cell Carcinoma|Head and Neck Cancer|DLBCL|Mantle Cell Lymphoma|Follicular Lymphoma|Leiomyosarcoma|Pancreatic Cancer|Sarcoma|CLL","Drug: CYT-0851","Cyteir Therapeutics, Inc.","CYT-0851-01","June 25, 2019","Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Florida Cancer Specialists and Research Institute, Sarasota, Florida, United States|John Theurer Cancer Center at HUMC, Hackensack, New Jersey, United States|Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Washington Seattle Cancer Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03997968"
808,"Hypertension Management in Cancer Patients","Recruiting","No Results Available","Blood Pressure|Hypertension|Cancer|Cancer, Breast|Cancer of Prostate|CLL|Hematopoietic Malignancy","Other: Automated Messaging","Duke University|Duke Institute for Health Innovation","Pro00102260","April 18, 2019","Duke University Medical Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT03919214"
809,"A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China","Not yet recruiting","No Results Available","Non-small Cell Lung Cancer|Colorectal Cancer|Pancreatic Ductal Carcinoma|Esophageal Squamous Cell Carcinoma|Head and Neck Squamous Cell Carcinoma|Breast Cancer|Other Solid Tumors","Drug: JAB-3312","Jacobio Pharmaceuticals Co., Ltd.","JAB-3312-1002","October 9, 2019","Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04121286"
810,"A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors","Recruiting","No Results Available","Non-small Cell Lung Cancer|Colorectal Cancer|Pancreatic Ductal Carcinoma|Esophageal Squamous Cell Carcinoma|Head and Neck Squamous Cell Carcinoma|Breast Cancer|Other Solid Tumors","Drug: JAB-3312","Jacobio Pharmaceuticals Co., Ltd.","JAB-3312-1001","August 5, 2019","HealthONE Clinic Services Oncology-Hematology, Denver, Colorado, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States|Washington University School of Medicine, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04045496"
811,"Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac","Recruiting","No Results Available","Rectal Cancer|Head and Neck Cancer|Liver Cancer|Breast Cancer|Prostate Cancer|Oligometastasis|Esophageal Cancer","Radiation: Radiotherapy on the MR-Linac|Diagnostic Test: Imaging on the MR Linac","University Hospital Tuebingen","659/2017BO1","November 21, 2019","University Hospital Tübingen, Department of Radiation Oncology, Tübingen, Baden-Württemberg, Germany","https://ClinicalTrials.gov/show/NCT04172753"
812,"The Master Registry of Oncology Outcomes Associated With Testing and Treatment","Not yet recruiting","No Results Available","Adenocarcinoma|Adenocystic Carcinoma|Anal Cancer|Appendix Cancer|Brain Tumor|Glioblastoma|Astrocytoma|Bile Duct Cancer|Cholangiocarcinoma|Bladder Cancer|Bone Cancer|Synovial Sarcoma|Chondrosarcoma|Liposarcoma|Sarcoma, Kaposi|Sarcoma,Soft Tissue|Sarcoma|Osteosarcoma|CNS Cancer|Brain Stem Neoplasms|Breast Cancer|Cervical Cancer|Colorectal Cancer|Rectal Cancer|Colon Cancer|Esophageal Cancer|Esophagus Cancer|Cancer of Colon|Pancreatic Cancer|Cancer of Pancreas|Testis Cancer|Testicular Cancer|Ureter Cancer|Renal Cell Carcinoma|Kidney Cancer|Gestational Trophoblastic Tumor|Head and Neck Neoplasms|Parotid Tumor|Larynx Cancer|Tongue Cancer|Pharynx Cancer|Salivary Gland Cancer|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Lymphoblastic Leukemia|Multiple Myeloma|Non Hodgkin Lymphoma|Carcinoid Tumor|Lung Cancer|Neuroendocrine Tumors|Mesothelioma|Thyroid Cancer|Parathyroid Neoplasms|Adrenal Cancer|Small Bowel Cancer|Stomach Cancer|Liver Cancer|Hepatic Cancer|Melanoma|Skin Cancer|Unknown Primary Tumors|Uterine Cancer|Fallopian Tube Cancer|Ovarian Cancer|Prostate Cancer|Vaginal Cancer|Penile Cancer|Vulvar Cancer|Waldenstrom Macroglobulinemia|Cancer, Advanced|Thymus Cancer|Nasopharyngeal Carcinoma|Multiple Endocrine Neoplasia|Pheochromocytoma|Small Cell Carcinoma|Pulmonary Carcinoma","Diagnostic Test: Biomarker Testing (L)|Drug: Systemic Treatment (T)|Other: Patient Reported Outcomes (P)","Taproot Health","ROOT","July 22, 2019",,"https://ClinicalTrials.gov/show/NCT04028479"
813,"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","Recruiting","No Results Available","Cancer, All Types|Cancer of Liver|Cancer of Stomach|Cancer of Head and Neck|Cancer of Rectum|Cancer of Kidney|Cancer of Esophagus|Cancer of Colon|Cancer Skin|Cancer of Cervix|Cancer, Metastatic|Cancer of Larynx|Cancer of Neck|Cancer of Lung|Cancer of Brain and Nervous System|Cancer of Vulva, Disseminated|Cancer of Pancreas|Sarcoma|GIST|Small-cell Lung Cancer|Adenocarcinoma Lung|Cancer of Prostate|Cancer, Advanced|Adrenal Cancer|Testicular Cancer|Uterine Cancer|Bronchoalveolar Cell Lung Cancer|Cancer Unknown Primary|Glioblastoma Multiforme|Oligodendroglioma|Breast Cancer|Renal Cell Carcinoma|Hepatocellular Carcinoma|Cholangiocarcinoma|Squamous Cell Carcinoma|Transitional Cell Carcinoma|Cancer, Other|Cancer, Anal|Melanoma|Cancer, Bile Duct|Cancer, Bladder|Cancer Cords Vocal|Cancers Cell Neuroendocrine|Cancer Differentiated Poorly|Cancer, Anaplastic Thyroid",,"SpeciCare|Dana-Farber Cancer Institute|Kalispell Regional Medical Center|Georgia Institute of Technology|Ontario Institute for Cancer Research|SEngine Precision Medicine|Helomics","MYCT001","April 1, 2019","Specicare, Gainesville, Georgia, United States","https://ClinicalTrials.gov/show/NCT03896958"
814,"EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds","Recruiting","No Results Available","Surgical Wound|Diabetes|Amputation Wound|Incision Wound|Peripheral Arterial Disease|Breast Cancer|Diabetic Foot","Device: Transcu O2®","Baylor College of Medicine|Electrochemical Oxygen Concepts, Inc.","H-41361","May 23, 2019","Baylor College of Medicine, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT03960463"
815,"Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy","Recruiting","No Results Available","Advanced Solid Tumor|Lymphoma|Gastric Cancer|Colorectal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|EGFR Positive Solid Tumor|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Small-cell Lung Cancer|Renal Cell Carcinoma|Pancreas Cancer|Melanoma|NSCLC|Urothelial Carcinoma|Cervical Cancer|Microsatellite Instability|Merkel Cell Carcinoma","Genetic: Allogeneic natural killer (NK) cell","Fate Therapeutics","FT-003","September 26, 2019","UCSD Moores Cancer Center, San Diego, California, United States|University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States|MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04106167"
816,"Evaluation of the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB)","Recruiting","No Results Available","Vacuum-assisted Biopsy","Diagnostic Test: Vacuum-assisted biopsy","Centre Georges Francois Leclerc","NeoVAB","March 15, 2019","Centre Georges François Leclerc, Dijon, France","https://ClinicalTrials.gov/show/NCT03876951"
817,"Magnesium and Ketamine in Postoperative Analgesia","Recruiting","No Results Available","Postoperative Analgesia","Drug: Ketamine|Drug: ketamine and magnesium","National Cancer Institute, Egypt","AP1904-50102","October 1, 2019","National Cancer Institute, Cairo, Egypt","https://ClinicalTrials.gov/show/NCT04111848"
818,"Study on Skin Microbiome of HFS","Recruiting","No Results Available","Microbiota","Drug: Capecitabine 150Mg Oral Tablet","First Affiliated Hospital of Harbin Medical University|Sponsor GmbH","Yunwei Wei 2019-09-12","October 21, 2019","First affiliated hospital of Harbin medical university, Harbin, Heilongjiang, China","https://ClinicalTrials.gov/show/NCT04132713"
819,"Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome","Recruiting","No Results Available","BRCA-Mutated Ovarian Carcinoma|BRIP1 Gene Mutation|MSH2 A636P|MLH1 Gene Mutation|MSH6 Gene Mutation|PMS2 Gene Mutation|EPCAM|RAD51C Gene Mutation","Other: CASCADE genetic screening","NYU Langone Health","17-01135","July 5, 2019","NYU Langone Health, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04009148"
820,"Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ","Recruiting","No Results Available","Breast Ductal Carcinoma in Situ","Drug: Low-dose tamoxifen|Radiation: Whole breast radiotherapy","National Taiwan University Hospital|Tri-Service General Hospital|Koo Foundation Sun Yat-Sen Cancer Center|Kaohsiung Medical University|Kyoto University|Mackay Memorial Hospital","201902048MINC","August 6, 2019","National Taiwan University Hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT04046159"
821,"Evaluation of the Adhesion to the GENEPY Network","Not yet recruiting","No Results Available","Hereditary Cancer Syndrome|Hereditary Breast and Ovarian Cancer|Hereditary Colorectal Endometrial Cancer Syndrome","Genetic: inclusion of subjects in the GENEPY network","Institut Claudius Regaud","18HLGENE03","June 7, 2019","Institut Claudius Regaud - IUCT-Oncopole, Toulouse, Occitanie, France","https://ClinicalTrials.gov/show/NCT03979612"
822,"Study of DF1001 in Patients With Advanced Solid Tumors","Recruiting","No Results Available","Solid Tumor, Adult","Drug: DF1001|Drug: Pembrolizumab","Dragonfly Therapeutics","DF1001-001","October 29, 2019","Rhode Island Hospital, Providence, Rhode Island, United States|MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04143711"
823,"Pediatric Reporting of Adult-Onset Genomic Results","Recruiting","No Results Available","Hereditary Breast and Ovarian Cancer Syndrome|Lynch Syndrome|Familial Hypercholesterolemia","Genetic: Receive an adult-onset result|Genetic: Receive a pediatric-onset result|Genetic: Control - No Result","Geisinger Clinic|National Human Genome Research Institute (NHGRI)","2018-0419|1R01HG009671-01A1","February 6, 2019","Geisinger, Danville, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03832985"
824,"A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors","Recruiting","No Results Available","Medullary Thyroid Cancer|Infantile Myofibromatosis|Infantile Fibrosarcoma|Papillary Thyroid Cancer|Soft Tissue Sarcoma","Drug: LOXO-292","Loxo Oncology, Inc.","LOXO-RET-18036|2019‐000212‐28","April 2, 2019","Children's Hospital Los Angeles, Los Angeles, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Inc., Memphis, Tennessee, United States|University of Texas, Southwestern Medical Center, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT03899792"
825,"RANKL Inhibition and Mammographic Breast Density","Recruiting","No Results Available","Dense Breasts","Drug: Denosumab|Drug: Placebo|Drug: Calcium|Drug: Vitamin D3|Procedure: Core needle biopsy|Procedure: Blood draw","Washington University School of Medicine|National Institutes of Health (NIH)","201907039","August 26, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT04067726"
826,"Discomfort Assessment of Senographe Pristina Patient-assisted Versus Standard Compression Mode and Quality Assessment of Screening Mammograms","Recruiting","No Results Available","Mammography Related Discomfort","Device: bilateral two-view (CC and MLO) FFDM (full field digital mammography) using patient-assisted compression mode|Device: bilateral two-view (CC and MLO) FFDM (full field digital mammography) using standard compression mode","Parc de Salut Mar|GE Healthcare","2017-7631","April 26, 2019","Hospital del Mar - Parc de Salut Mar, Barcelona, Catalonia, Spain","https://ClinicalTrials.gov/show/NCT03928886"
827,"Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis","Not yet recruiting","No Results Available","Oral Mucositis Due to Radiation|Radiation Dermatitis","Device: Photobiomodulation using CareMin650 at 6 Joules (curative intent)|Device: Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)","NeoMedLight|Qualissima","ID-RCB: 2018-A03356-49","June 17, 2019","Institut de Cancérologie de l'ouest - Paul Papin, Angers, France|Centre Oscar Lambret, Lille, France|Centre de Haute Energie, Nice, France|Institut Curie, Paris, France|Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France","https://ClinicalTrials.gov/show/NCT03988556"
828,"Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors","Recruiting","No Results Available","Advanced/Metastatic Solid Tumors","Drug: NMS-03305293","Nerviano Medical Sciences","PARPA-293-001|2018-003918-40","December 2, 2019","MD Anderson Cancer Center, Houston, Texas, United States|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy|Istituto Oncologico Veneto IRCCS, Padova, Italy|Centro Ricerche Cliniche di Verona Srl, Verona, Italy","https://ClinicalTrials.gov/show/NCT04182516"
829,"Breast Density Measurements in Digital Mammography and Breast Tomosynthesis Systems of Different Pixel Size","Recruiting","No Results Available","Mammographic Breast Density","Device: Volpara","Corporacion Parc Tauli|University of Barcelona|Universitat de Girona","2019/629","October 15, 2019","Radiology Breast Unit, Hospital Parc Taulí, Sabadell, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04127175"
830,"A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes","Recruiting","No Results Available","Solid Tumor","Drug: Rucaparib","Clovis Oncology, Inc.","CO-338-100","November 21, 2019","Innovative Clinical Research Institute, Glendale, California, United States|UCLA Medicine Hematology and Oncology, Los Angeles, California, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|New York Cancer And Blood Specialists, Bronx, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|New York Cancer and Blood Specialists, Port Jefferson Station, New York, United States|Mayo Clinic, Rochester, New York, United States|Ohio State University, Columbus, Ohio, United States|Stephenson Cancer Center - The University of Oklahoma, Oklahoma City, Oklahoma, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|SCRI/Tennessee Oncology - Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|The University of Texas Health Center at Tyler, Tyler, Texas, United States|Seattle Cancer Care Alliance/University of Washington, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04171700"
831,"A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers","Recruiting","No Results Available","HER2-expressing Cancers","Drug: ZW49","Zymeworks Inc.","ZWI-ZW49-101","January 29, 2019","City of Hope, Duarte, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago Medicine, Chicago, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|NEXT Oncology, San Antonio, Texas, United States|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT03821233"
832,"A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.","Recruiting","No Results Available","Solid Tumor","Drug: BDTX-189","Black Diamond Therapeutics, Inc.","BDTX-189-01","December 24, 2019","Florida Cancer Specialists, Lake Mary, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04209465"
833,"Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101","Recruiting","No Results Available","Lymphoma|Advanced Solid Tumors","Drug: E7766","Eisai Inc.|H3 Biomedicine Inc.","E7766-G000-101|2019-000160-17","October 30, 2019","Yale, New Haven, Connecticut, United States|Sylvester Cancer Center, Miami, Florida, United States|MGH, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Center for Immuno-Oncology , DFCI, Boston, Massachusetts, United States|UPMC, Pittsburgh, Pennsylvania, United States|Institut Gustave Roussy, Villejuif, France|Imperial College Healthcare NHS Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04144140"
834,"Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety","Enrolling by invitation","No Results Available","Cancer","Drug: Rogaratinib (BAY1163877)|Drug: Combination drug","Bayer","20252|2019-000808-15","October 14, 2019","Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland","https://ClinicalTrials.gov/show/NCT04125693"
835,"A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer","Recruiting","No Results Available","Advanced Cancer","Drug: LY3475070|Drug: Pembrolizumab","Eli Lilly and Company|Merck Sharp & Dohme Corp.","17504|J2I-MC-JZMA|2019-003270-64|Keynote A57","November 4, 2019","Cedars Sinai Medical Center, Los Angeles, California, United States|Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States|Florida Cancer Specialists ORLANDO/DDU, Lake Mary, Florida, United States|Washington University Medical School, Saint Louis, Missouri, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Marsden Hospital, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT04148937"
836,"A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors","Recruiting","No Results Available","Solid Tumor","Biological: NeoTCR-P1 adoptive cell therapy|Biological: nivolumab","PACT Pharma, Inc.","PACT-0101","May 31, 2019","City of Hope, Duarte, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, Irvine Medical Center, Orange, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Diego, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT03970382"
837,"Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors","Recruiting","No Results Available","Advanced Solid Tumors Cancer","Drug: ABBV-151|Drug: ABBV-181","AbbVie","M19-345|2018-004303-40","January 30, 2019","Yale University /ID# 208356, New Haven, Connecticut, United States|Indiana Univ School Medicine /ID# 208384, Indianapolis, Indiana, United States|Univ Michigan Med Ctr /ID# 221129, Ann Arbor, Michigan, United States|NYU Langone Medical Center /ID# 209822, New York, New York, United States|Carolina BioOncology Institute /ID# 208358, Huntersville, North Carolina, United States|The Ohio State University - The James /ID# 217611, Columbus, Ohio, United States|NEXT Oncology /ID# 208930, San Antonio, Texas, United States|Chris O'Brien Lifehouse /ID# 213236, Camperdown, New South Wales, Australia|Princess Margaret Cancer Centre /ID# 209423, Toronto, Ontario, Canada|Hopital Universitaire Purpan /ID# 218667, Toulouse, Haute-Garonne, France|Centre Leon Berard /ID# 218515, Lyon CEDEX 08, Rhone, France|Institut Gustave Roussy /ID# 218668, Villejuif, Val-de-Marne, France|Rambam Health Care Campus /ID# 222198, Haifa, Israel|Sheba Medical Center /ID# 209037, Ramat Gan, Israel|Tel Aviv Sourasky Medical Center /ID# 222199, Tel Aviv-Yafo, Israel|National Cancer Center Hospital /ID# 209421, Chuo-ku, Tokyo, Japan|Seoul National University Hospital /ID# 218513, Seoul, Korea, Republic of|Severance Hospital /ID# 218512, Seoul, Korea, Republic of|Hospital Clinic de Barcelona /ID# 221106, Barcelona, Spain|Hospital Fundacion Jimenez Dia /ID# 220928, Madrid, Spain|Hosp Clin Univ de Valencia /ID# 221107, València, Spain|China Medical University Hosp /ID# 218492, Taichung City, Taichung, Taiwan|National Taiwan University Hospital /ID# 218490, Taipei City, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT03821935"
838,"Association Between Maternal Metabolic Disturbances During the First Pregnancy and Breast Density","Recruiting","No Results Available","Breast Density","Other: Altered metabolic milieu during first full term pregnancy","Instituto de Nutrición y Tecnología de los Alimentos|Pontificia Universidad Catolica de Chile|Servicio de Salud Metropolitano Sur Oriente","1190532","April 18, 2019","Corporación de Salud Municipal de Puente Alto, Santiago de Chile, Puente Alto, Chile","https://ClinicalTrials.gov/show/NCT03920098"
839,"A Web-based Tailored Health Behavior Intervention for Breast and Colon Cancer Survivors (eWellness)","Completed","No Results Available","Nutrition|Physical Activity","Behavioral: Intervention Physical Activity|Other: Usual Care","University of North Carolina, Chapel Hill|University of Texas","16-1897","December 5, 2019","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04188002"
